Polyunsaturated fatty acids, genetic susceptibility, and breast cancer incidence and survival by Khankari, Nikhil
  
POLYUNSATURATED FATTY ACIDS, GENETIC SUSCEPTIBILITY, AND BREAST 
CANCER INCIDENCE AND SURVIVAL 
 
Nikhil K. Khankari 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Epidemiology in the Gillings School of Global Public Health. 
 
Chapel Hill 
2014 
 
 Approved by: 
 Marilie D. Gammon 
 Patrick T. Bradshaw 
 Andrew F. Olshan 
 Regina M. Santella 
 Susan E. Steck 
ii 
© 2014 
Nikhil K. Khankari 
ALL RIGHTS RESERVED 
 
iii 
 
ABSTRACT 
 
Nikhil K. Khankari: Polyunsaturated Fatty Acids, Genetic Susceptibility, and Breast Cancer 
Incidence and Survival 
(Under the direction of Marilie D. Gammon) 
 
 Laboratory studies have demonstrated that ω-3 polyunsaturated fatty acids (PUFAs) 
inhibit inflammatory eicosanoids generated by ω-6 PUFAs metabolism. Additionally, ω-3 
PUFAs have been shown to induce a cytotoxic environment thereby increasing apoptosis and 
reducing cell growth in breast cancer cells. Despite this biologic plausibility, epidemiologic 
investigations of dietary PUFA intake and breast cancer are inconclusive among Western 
populations. This ancillary study examined the impact of dietary PUFA and fish (a primary 
source of beneficial long-chain (LC) ω-3 PUFAs) intake, and genetic susceptibility in 
biologically relevant pathways (i.e., inflammation, oxidative stress, and estrogen metabolism) 
on: the risk of breast cancer (Aim 1); and survival following a first, primary breast cancer 
diagnosis (Aim 2).  To address these aims, resources from the Long Island Breast Cancer 
Study Project (LIBCSP), a case-control study of 1463 breast cancer cases and 1500 controls 
were utilized. Additionally, vital status for the population-based cases was determined 
through 2011, yielding a median follow-up time of 14.7 years and 485 deaths. Adjusted odds 
ratios (ORs) and hazard ratios (HRs), and corresponding 95% confidence intervals (CIs), 
were estimated using unconditional logistic regression and Cox-proportional hazards 
regression, respectively. We observed a super-additive interaction (Relative Excess Risk Due 
to Interaction=0.43; 95% CI=0.09, 0.78) between ω-3 and ω-6 intake in association with 
iv 
breast cancer risk, though the CIs for the joint exposure of low ω-3 and high ω-6 compared to 
high ω-3 and low ω-6 intake were imprecise (OR=1.21; 95% CI=0.86, 1.70). No interactions 
were observed with polymorphisms considered, but odds were elevated for low ω-3/ω-6 ratio 
across genotypes. All-cause mortality was reduced by 25-29% among women with breast 
cancer reporting the highest quartile of intake (compared to never) for: tuna (HR=0.71, 95% 
CI=0.55, 0.92); other baked/broiled fish (HR=0.75, 95% CI=0.58, 0.97); and dietary long-
chain ω-3 PUFAs docosahexanoic (DHA, HR=0.71, 95% CI=0.55, 0.92) and 
eicosapentanoic (EPA, HR=0.75, 95% CI=0.58, 0.97) acid. Breast cancer risk reduction may 
be possible for U.S. women with dietary consumption of both higher ω-3 and lower ω-6. 
Additionally, LC ω-3 PUFA intake from fish and other dietary sources may provide a 
potential strategy to improve survival after breast cancer. 
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CHAPTER 1:  
BACKGROUND AND INTRODUCTION 
 
 This dissertation examines the association between polyunsaturated fatty acids 
(PUFAs) and the risk of breast cancer incidence and mortality, and explores whether these 
associations vary by PUFA class (ω-3, ω-6, the relative balance of ω-3 and ω-6, and ω-3 and 
ω-6 subtypes), or by fish (the major source of long-chain ω-3), or by genetic polymorphisms 
in biologically related pathways (inflammation, oxidative stress, and estrogen metabolism). 
This first chapter provides the rationale for the dissertation aims, including a review of: the 
descriptive and analytic epidemiology of breast cancer incidence and mortality; the biologic 
and epidemiologic characteristics of the primary study exposure, PUFAs, as well as the 
primary group of effect modifiers of interest, polymorphisms in biologically related 
pathways; and critically evaluates the previously reported epidemiologic studies that have 
examined the putative PUFA-breast cancer association to underscore the novel aspects of the 
dissertation aims. 
 
1.1 Epidemiology of Breast Cancer Incidence and Mortality 
 Breast cancer is the second most common cancer among women in the United States 
(U.S.), and accounts for nearly one third of all cancer diagnoses in the U.S. [1, 2].  It is also 
the second leading cause of cancer mortality among women in the U.S. [1].  Nearly 230,500 
women were expected to be diagnosed with invasive breast cancer and roughly 40,000 
women will die from breast cancer in 2013 [2].  In the U.S., breast cancer incidence rates are 
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highest among Caucasian white women, followed by African American, Asian/Pacific 
Islanders, American Indian/Alaska Native, and lowest among Hispanic women [1].  
 Majority of breast cancers are invasive, where the tumor spreads past the lobules and 
ducts into the surrounding tissue.  In situ breast cancer occurs when the tumor is contained 
within either the duct (ductal carcinoma in situ, DCIS) or the lobule (lobular carcinoma in 
situ, LCIS).  It is estimated that about 58,000 new cases of in situ breast cancer were 
diagnosed in 2013, and approximately 83% of these were DCIS [2]. 
 Breast cancer rates are much lower among Asian populations than among Western 
populations (see Figure 1.1 below).  Among Western populations, breast cancer incidence 
increases with age, with rate of increase slowing around age fifty, but continuing to increase 
after age fifty [2].  However, among Asian women, the incidence rate of breast cancer 
increases with age until fifty, and then stabilizes (Figure 1.1).  This distinct pattern seen 
among Western and Asian populations points to the direct role of reproductive factors in 
breast cancer etiology [3].  Reproductive risk factors for breast cancer include: early age at 
menarche; late age at menopause; nulliparity; late age at first full-term pregnancy; no 
lactation; and use of hormone replacement therapy.  Also, migration studies of Asian 
immigrants have shown that the breast cancer incidence patterns begin to reach those of 
Western countries after only a few generations after migration [4-7], suggesting a role for 
other environmental risk factors for breast cancer.  As discussed in more detail below, other 
risk factors for breast cancer include: post-menopausal obesity; alcohol use; physical 
inactivity; and family history of breast cancer [8]. 
 Five-year relative survival rates for breast cancer were lower among women who 
were diagnosed prior to 40 years of age (84%) compared to women diagnosed at 40 years or 
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older (90%) [2].  Five-year relative survival rates are highest for women whose tumors are 
localized (99%) compared to regional (84%) and distant tumors (23%).  Mortality rates are 
highest and 5-year survival rates are lowest among African American women [1].  As 
discussed below, prognostic factors for breast cancer include: tumor size; tumor stage; breast 
cancer treatment; breast cancer subtypes; and obesity at diagnosis [9]. 
 
1.2 Breast Cancer Risk Factors 
1.2.1 Reproductive risk factors 
 There are several established breast cancer risk factors that are associated with 
reproduction, including early age at menarche, late age at menopause, late age at first full-
term pregnancy, nulliparity, lack of or short duration of breast-feeding, and hormone 
replacement therapy.  Many of these reproductive risk factors are thought to affect breast 
cancer via regulation of long-term exposure to endogenous hormones, including estrogen and 
progesterone, which are thought to play an important role in breast cancer etiology [8].  The 
tumor inducing and promoting potential of estrogens has been demonstrated [10, 11], and 
removal of the ovaries or administration of an anti-estrogenic drug can prevent this effect 
[12].  Early age at menarche and late age at menopause maximizes a women’s lifetime 
exposure to estrogen, and this prolonged exposure to estrogen has been shown to increase 
breast cancer risk among many different populations [13-18]. 
 Additionally, later age at first and last full-term pregnancy is thought to increase 
breast cancer risk and has been reported in different studies across different populations [14-
16, 18].  An earlier first-full term pregnancy is thought to reduce the likelihood that cells 
could become initiated due to the terminal differentiation of breast tissue during pregnancy, 
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and these terminally differentiated cells have been shown to have lower proliferation due to 
longer cell cycles and increased time spent in the resting phase (G1) of the cell cycle [19].  A 
similar mechanism has been proposed for the risk reductions observed among women who 
have increased duration of lactation, which has been reported in a number of studies [15, 16, 
18, 20, 21]. This risk reduction conferred by breastfeeding may be due to the increase in 
terminal differentiation of the breast epithelium, as well as the delay in the restoration of the 
ovulatory cycle post-pregnancy [14]. 
 Many women are prescribed hormone replacement therapy in order to help ameliorate 
the symptoms associated with menopause.  However, the use of hormone replacement 
therapy has been demonstrated to affect breast cancer risk, and is dependent upon the type of 
hormones that are prescribed.  In 2001, among participants in the Women’s Health Initiative 
trial, there was a reported 26% (95% CI = 1.00, 1.59) increased hazard for breast cancer 
among postmenopausal women on estrogen and progestin replacement therapy compared to 
those taking placebo [22].  Increased risks also were observed among the Million Women 
Study in the United Kingdom, where breast cancer risk was doubled for estrogen-progestin 
replacement therapy [23]. 
 In sum, examination of the reproductive risk factors for breast cancer has helped to 
elucidate an important role of endogenous and exogenous estrogen and progesterone in breast 
cancer carcinogenesis. 
 
1.2.2 Family History 
 Another established risk factor includes inherited susceptibility for breast cancer.  
Family history of breast cancer in a first-degree relative has been shown to increase breast 
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cancer risk.  Women, whose mothers or sisters have breast cancer, are 1.5 to 3 times as likely 
to have breast cancer compared to other first-degree relatives without breast cancer [24].  A 
meta-analysis reported the risk for breast cancer was nearly double for women with any 
relative, first-degree relative, mother, or sister with breast cancer [25].  The highest risk was 
observed for women who had a mother and sister with breast cancer (RR = 3.6; 95% CI = 
2.5, 5.0). 
 In the mid-1990s, breast cancer gene 1 (BRCA1) on chromosome 17q21 and breast 
cancer gene 2 (BRCA2) on chromosome 13q12-13 were identified [26].  These two genes are 
suggested to act as tumor suppressors, and mutations in these genes are highly penetrant and 
account for 2-5% of breast cancer risk [24].  In the general population, estimated prevalence 
of BRCA1 and BRCA2 mutation carriers range from 0.1- 0.2% [26, 27], and these mutations 
may be responsible for early-onset breast cancer among high risk families [27]. 
 However, family history cannot solely explain geographic variation in breast cancer 
rates.  Studies conducted among Asian immigrants have shown that the breast cancer 
incidence patterns for these populations mimic those of Western countries only a few 
generations after migration [4-7].  Therefore, other environmental risk factors, for which the 
prevalence varies by geographic residence, may help to explain this observed geographic 
variation in breast cancer rates. 
 
1.2.3 Obesity and Physical Activity 
 Obesity is another source for endogenous estrogen production.  Adipose tissue and 
visceral fat has been shown to be metabolically active [28].  Androgens present in adipose 
tissue can be converted to estradiol via aromatase, resulting in an additional source of 
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metabolically active estrogen that is not produced by the ovaries [28, 29].  These laboratory 
findings are supported by epidemiologic results.  For example, a pooled analysis based on 
data collected primarily among women of European descent examined the effect of body 
mass index (BMI) on breast cancer risk and reported that increasing BMI among 
postmenopausal women (BMI exceeding 28 kg/m
2
) was associated with an increase in breast 
cancer risk of 26% (95% CI = 1.09, 1.46) [30].  Changes in weight (greater than 15 kg since 
age 20) compared to maintaining weight, has been reported to increase risk for 
postmenopausal breast cancer (OR = 1.6; 95% CI = 1.11, 2.26) [31], and this increased risk 
has been consistently reported among several other studies [32-34].  Asian studies also 
reported a similar increased risk for postmenopausal breast cancer with increases in body 
weight [35] or BMI [36, 37]. 
 In contrast, the association between obesity and premenopausal breast cancer appears 
to be more complex.  Estrogen production via metabolism of adipose tissue is not the primary 
production source for estradiol among premenopausal women, for whom ovarian production 
remains active; therefore the potential for increased risk for breast cancer due to excess 
adipose tissue may be reserved for postmenopausal women only.  For example, in the pooled 
analysis discussed above, a risk reduction (RR = 0.54; 95% CI = 0.34, 0.85) was observed for 
premenopausal women with higher BMI (BMI exceeding 31 kg/m
2
 versus BMI less than 21 
kg/m
2
) [30].  Further, only one Asian study reported a risk reduction for increased BMI and 
premenopausal breast cancer [36].  Other studies have similarly reported breast cancer risk 
reductions among premenopausal women for increasing weight [33, 38-40]; however, one of 
these studies reported that this risk reduction was limited only to those with early-stage, 
lower grade breast cancer [38].  Some theories have been postulated for the risk reductions 
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seen among premenopausal women, and include obesity-triggered anovulation [41], which 
can result in lower levels of exposure to both progesterone and estradiol [42]. 
 Physical activity also is thought to reduce breast cancer risk via a variety of 
mechanisms, including lower levels of estrogens and increased levels of sex hormone 
binding globulin (SHBG) resulting from reduced adipose tissue and visceral fat [43, 44], 
improved immune response [45], and lower inflammatory markers [46, 47].  A systematic 
review reported risk reductions ranging from 20-80% were observed for postmenopausal 
breast cancer with increasing levels of physical activity [48].  A smaller risk reduction (15-
20%) was observed for premenopausal women [48-50].  Similar risk reductions were 
observed for recreational physical activity among Chinese women [51].  A recent study 
examined the joint effects of physical activity, weight gain, and body size on breast cancer 
risk, and reported risk reductions for breast cancer and recreational physical activity during 
both reproductive years and postmenopausal [52].  However, it also was reported that 
excessive weight gain during postmenopausal years may negate any of the beneficial effects 
of any physical activity. 
 In summary, physical activity, obesity, and weight maintenance provide a potential 
opportunity for breast cancer risk reduction.  However, increasing physical activity, reducing 
obesity or maintaining weight may not be an easily implemented option for all women.  
Therefore, other opportunities for breast cancer risk reduction need to be explored, including 
nutritional factors. 
 
1.2.4 Non-Steroidal Anti-inflammatory Drugs 
 Another potential risk reduction strategy for breast cancer is non-steroidal anti-
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inflammatory drugs (NSAIDs), such as aspirin and ibuprofen.  NSAIDs are drugs that inhibit 
cyclooxygenase (COX) activity and thereby result in reduced levels of prostaglandins, which 
have been implicated in breast carcinogenesis [53].  There is evidence from animal studies 
that NSAIDs may also have an inhibitory effect that is independent of prostaglandin 
synthesis.  Animal and laboratory studies suggest that NSAIDs may inhibit the effects of 
estrogen in the pituitary gland [54] and may inhibit binding of estradiol to the estrogen 
receptor [55].  Observational studies have reported a modest risk reduction (10-20%) for 
NSAID use and breast cancer risk [56], though this inverse association is not consistently 
reported across all studies [56, 57].  Risk reductions were slightly stronger among case-
control studies compared to cohort studies, which may reflect differential recall bias present 
in case-control studies resulting in exaggerated effect estimates.  Recent studies have been 
inconsistent regarding NSAID use and breast cancer, with one reporting risk reduction [58], 
another reporting null effects [59], and yet another reporting increased risk [60].  NSAID use 
was reported to decrease breast cancer risk by 20% among postmenopausal women [58], but 
had no effect among premenopausal women [61].  A recent study reported stronger risk 
reductions for NSAIDs that were selective COX-2 inhibitors (e.g., celecoxib, rofecoxib, and 
valdecoxib) in comparison to non-specific NSAIDs [62].  Inconsistencies in the literature 
may arise from differences in control selection (e.g., population- versus hospital-based), 
differences in exposure assessments (e.g., questionnaire versus health care prescription data), 
or differential recall in case-control studies versus cohort studies. 
 Considering genetic susceptibility in NSAID metabolism may help to clarify the 
NSAID breast cancer association.  For example, Brasky et al. [63] examined the interaction 
between NSAID use and genetic polymorphisms in COX-2, and reported strongest risk 
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reductions for aspirin use among those with the variant allele rs4648261 (C-to-T base pair 
change), a single nucleotide polymorphism (SNP) in COX-2.  In the Long Island Breast 
Cancer Study Population (LIBCSP), risk reductions were reported for regular use of aspirin 
and breast cancer [64], but largely no interactions were seen for COX-2 polymorphisms and 
NSAID use [65]. 
 In sum, although many studies have reported risk reductions for NSAID use and 
breast cancer, the results are not conclusive.  NSAIDs inhibit cyclooxygenase activity 
thereby reducing levels of inflammatory prostaglandins.  It has also been noted that long-
term use of NSAIDs could have potentially adverse outcomes on health [66, 67].  Similar to 
NSAIDs, ω-3 PUFAs are also known to competitively inhibit binding of ω-6 PUFAs to 
cyclooxygenase enzyme (see below), thereby reducing levels of inflammatory prostaglandins 
[68].  Thus, dietary intake of ω-3 PUFAs may provide a safer alternative for breast cancer 
risk reduction compared to NSAIDs. 
 
1.2.5 Alcohol 
 Alcohol is thought to affect breast carcinogenesis via multiple mechanisms, including 
increasing levels of endogenous estrogen, production of acetaldehyde and reactive oxygen 
species resulting from alcohol metabolism, and interference with absorption of essential 
nutrients [69].  An early meta-analysis [70] reported a 24% increased risk (95% CI = 1.15, 
1.34) for women consuming two drinks per day compared to non-drinkers.  Women 
consuming three drinks per day had nearly a 40% increase in risk (95% CI = 1.23, 1.55) [70].  
A 1998 pooled analysis reported 10% (95% CI = 1.04, 1.13) and 41% (95% CI = 1.18, 1.69) 
increases in breast cancer risk for 10-gram and 30-60 gram increase in alcohol consumption 
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per day, respectively [71].  More recent studies examining alcohol intake and breast cancer 
have reported similar effect estimates.  The Million Women Study reported a 12% increase in 
breast cancer risk for a 10-gram increase [72]. The Nurses’ Health Study reported a 15% 
increase in breast cancer risk for 5-10 gram increase in alcohol consumption [73], and the 
American Cancer Society Nutrition Cohort reported a 26% increase for 15 gram per day 
increase in alcohol consumption [74].  However, among the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort, no effects were observed for 10-gram 
per day increase in alcohol intake and breast cancer risk [75]. 
 In sum, alcohol is an established breast cancer risk factor which acts via multiple 
mechanisms to affect breast cancer risk, including increased estrogen production.  Thus, 
epidemiologic and supporting laboratory evidence has demonstrated that an ingested 
compound can influence estrogen levels among adult women and increase breast cancer risk. 
 
1.2.6 Dietary Fat 
 Dietary fat and breast cancer risk has been extensively examined, however, there is 
limited evidence suggesting an association between total fat intake and breast cancer.  
Dietary fat is known to increase endogenous estrogen production [76].  Also, dietary fat can 
increase levels of serum-free fatty acids thereby displacing estradiol from serum albumin, 
and thus resulting in increased levels of free estradiol [77].  A null association has been 
reported for total fat intake among all ages or premenopausal breast cancer [78].  Numerous 
studies have examined the effect of total fat on postmenopausal breast cancer, where 
prospective cohort studies tend to report inconsistent associations and case-control studies 
tend to report modest increases in risk.  Seven cohort studies reported increased risks for 
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postmenopausal breast cancer [79-82, 82-85], whereas two other studies reported risk 
reductions [86, 87].  The majority of case-control studies report an increased risk for 
postmenopausal breast cancer with total fat intake [88-100], with a relatively fewer number 
of studies reporting a decrease in risk [89, 101-104].  A summary estimate was derived from 
seven case-control studies reporting a modest 11% increase in risk for total fat intake [78].  
This difference in effect estimates derived from the case-control and prospective studies may 
reflect differential recall bias of total fat intake, which would exaggerate effects in case-
control studies.  Therefore, there is limited evidence regarding total fat intake and breast 
cancer, with no associations reported for premenopausal women, and a suggested increase in 
risk for postmenopausal breast cancer.  However, conclusions regarding total fat and breast 
cancer risk are still unclear.   
 The inconsistent reported effects of the association between breast cancer incidence 
and fat intake may be due to type of dietary fat consumed.  A pooling project reported 
differential effects for different types of fat, where saturated and monounsaturated fats 
increased risks by 9% and 5%, respectively [105].  Modest risk reductions (2-13%) were 
reported when substituting either saturated or monounsaturated fats with PUFAs [105].  In 
order to better understand the effects of fat on breast cancer risk, it may be important to 
examine the different types of fat in relation to breast cancer, such as PUFAs. 
 
1.2.7 Summary 
 A number of breast cancer risk factors have been identified.  Reproductive risk 
factors include: reproductive history; menstrual history; and exogenous hormone use.  Other 
risk factors include: family history of breast cancer, such as inherited genetic susceptibility; 
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and select nutritional factors such as obesity, physical activity, and alcohol. With the 
exception of these select nutritional factors, few risk factors are easily modifiable.  
Identification of other potentially modifiable nutritional factors, such as dietary intake of 
PUFAs, may be warranted in order to provide additional avenues for breast cancer 
prevention. 
 
1.3 Prognostic Factors for Breast Cancer 
1.3.1 Age, Socioeconomic Status, and Race 
 A few established prognostic factors for breast cancer survival include age at 
diagnosis, socioeconomic status, and race.  Women with younger age at diagnosis have been 
reported to have reduced survival and increased relapse compared to women who are 
diagnosed at older ages [106-108].  Younger women at diagnosis have been reported to have 
more aggressive tumors, consisting of worse histopathology (e.g., higher stage, larger tumor 
size), thus contributing to their lower survival rates [106].  In addition to age at diagnosis, 
African American women are more likely to have reduced survival compared to Caucasian 
women [108].  It has also been reported that African American women tend to have a higher 
prevalence of basal-like breast cancer, which is reported to have poor prognosis [109].  
Although, basal-like breast cancer has poor prognosis, it is not an inherently more aggressive 
disease among African American women compared to Caucasian women [110].  This racial 
difference in survival also could be attributed to differences in screening rates resulting in 
more African American women presenting at older ages with higher tumor grade and stage 
[108].  It is possible that socioeconomic status is associated with many of the factors relating 
to differences in survival, since it has been observed that women with low socioeconomic 
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status have poor prognosis, irrespective of race [111]. 
 
1.3.2 Tumor Size and Stage at Diagnosis 
 The size of the tumor is known to predict survival. Women with larger tumors have 
worse prognosis than those with smaller tumors [107, 112].  Women with tumors greater than 
two centimeters are more likely to die from breast cancer five years post diagnosis [107], and 
are more likely to have distant metastatic disease [113].  Metastases to regional lymph nodes 
are a strong prognostic indicator, among whom women with greater number of lymph nodes 
with worse survival than those with negative lymph nodes [112, 114].  Tumor stage is also a 
strong indicator of disease survival, where women with higher stage have poor prognosis 
compared to those with lower stage [114, 115].  Thus, tumor size and stage are established 
breast cancer prognostic factors. 
 
1.3.3 Breast Cancer Subtypes 
 The estrogen receptor plays a vital role in breast cancer survival, with approximately 
60% to 65% of breast cancers being estrogen receptor-positive (ER+) [116].  The ER+ 
subtype of breast cancer is an important indicator for treatment, as those with this tumor type 
can be more effectively treated with anti-estrogenic drugs, such as tamoxifen and raloxifene.  
In addition to the possibility for more effective treatment, ER+ tumors are more likely to be 
better differentiated and are known to have better prognosis [117], whereas as estrogen 
receptor-negative (ER-) tumors tend to have worse histologic characteristics (e.g., tumor size, 
tumor grade, regional spread) resulting in lower survival [118, 119].  Women with ER+ 
tumors and progesterone receptor-positive (PR+) tumors are reported to have better five-year 
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relative survival rates than women with ER- or PR- tumors [120]. 
 Gene expression analysis has documented multiple intrinsic subtypes, in addition to 
the ER/PR subtypes.  The ER+/ER- subtypes can be further classified into separate groups, 
which include: (1) luminal A: ER+ and/or PR+, human epidermal growth factor receptor-2 
negative (HER2-); (2) luminal B: ER+ and/or PR+, HER2+; (3) HER2+/ER-: ER-, PR-, 
(HER2+); and (4) basal-like: ER-, PR-, HER2-, cytokeratin 5/6+, and/or HER1+ [109].  
Basal-like tumors are more prevalent among African American women (premenopausal), and 
both basal-like and HER2+/ER- tumors were more likely to be of higher grade, greater 
mitotic index, higher prevalence of p53 mutations, and more likely to be poorly differentiated 
[109].  These factors may account for the poor prognosis observed among women with basal-
like and HER2+/ER- tumors [109].  Understanding the prognostic influence of breast cancer 
subtypes is not only important for identifying successful treatments for women diagnosed 
with breast cancer, but also could help to identify women who would benefit from additional 
interventions to help improve survival. 
 
1.3.4 Treatment 
 Treatment for breast cancer is often dependent upon the subtype of cancer.  For 
example, tamoxifen treatment has been shown to improve survival among women with ER+ 
tumors, and provide modest improvement for ER- tumors [121-124].  Chemotherapy also 
reduced the annual breast cancer death rate by nearly 40% for women younger than 50 years 
of age, and about 20% for women 50-69 years of age at diagnosis [121].  Among patients 
treated with radical mastectomy, combined radiation and chemotherapy treatment was shown 
to improve recurrence, relapse-free survival, and breast cancer-specific survival when 
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compared to chemotherapy alone [125].  Supplementary treatment strategies, that are both 
cost-effective and easily-implemented, need to be considered to further improve survival for 
women diagnosed with breast cancer. Nutritional factors that enhance treatment efficacy, 
such as PUFAs, should be considered as they may provide an additional means for improving 
survival among women diagnosed with breast cancer.    
 
1.3.5 Obesity and Physical Activity 
 There is a strong indication that obesity and physical activity play a role in breast 
cancer prognosis, though they are not considered established breast cancer prognostic factors.  
A recently published pooling project reported increased hazards for overall mortality and 
breast cancer mortality for underweight (BMI < 18.5 kg/m
2
) and morbidly obese women 
(BMI ≥ 40 kg/m2) [126].  More recently, Cleveland et al. also reported increased mortality 
among women who were obese at diagnosis among both pre- and post-menopausal women 
[127].  Also, among premenopausal women, those who gained greater than 16 kg between 
age 20 and one year prior to diagnosis had more than double the hazard for mortality when 
compared to those who maintained a stable weight (± 3 kg) [127].  Post-diagnosis 
maintenance of weight is also important for improving survival [128].  Bradshaw et al. 
reported more than two-fold increase in mortality for those who gained more than 10% after 
diagnosis, and this effect was more pronounced in the first two years after diagnosis [128].  
Thus, maintenance of weight, whether it is prior to diagnosis or after, is suggested to improve 
breast cancer survival for both premenopausal and postmenopausal breast cancer patients. 
 Physical activity prior to breast cancer diagnosis is reported to improve survival after 
breast cancer.  Cleveland et al. reported a nearly 50% reduction in all-cause mortality for 
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women who engaged in nine or more metabolic equivalent task hour (MET-hour) per week 
of lifetime recreational physical activity from menarche to diagnosis compared to women 
who did not exercise [129].  Similar results were reported among the California Teachers 
Study [130].  Additionally, exercise within three years of diagnosis was inversely associated 
with both overall and relapse/disease-specific mortality [131, 132].  Similarly, Bradshaw et 
al. reported improved survival among women who were highly active (>9 weekly MET-
hours) post-diagnosis [133]. Studies suggest that both pre-diagnostic and timely post-
diagnostic engagement in exercise may help to improve survival among women diagnosed 
with breast cancer. 
 
1.3.6 Dietary Fat and NSAIDs 
 The relation between dietary fat intake and breast cancer survival has been 
increasingly reported by a number of investigators.  The majority of studies regarding dietary 
fat and survival showed an increased risk of dying with higher fat intake [134-137], with the 
exception of one study showing a risk reduction [138].  An early study examined the relation 
between dietary fat and breast cancer survival among both Caucasian and Japanese women 
with breast cancer diagnoses in Hawaii [139].  The study reported more than triple the risk of 
death for high versus low total fat intake for Caucasian women.  In comparison, nearly 40% 
mortality risk reduction was reported among women of Japanese ancestry for high versus low 
total fat intake.  Though both estimates were imprecise, this difference in the direction of the 
reported associations among Caucasian and Japanese women may highlight the importance 
of examining different types of fat on breast cancer, such as ω-3 and ω-6 PUFA. 
 The majority of epidemiologic studies have reported poor prognosis for total dietary 
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fat intake.  Two large randomized trials were conducted in the mid-1990s in order to examine 
the effect of reductions in dietary fat intake on prognosis among breast cancer survivors in 
the U.S.  The Women’s Intervention Nutrition Study (WINS) was focused primarily on the 
efficacy of reduction in dietary fat intake [140].  The WINS study included approximately 
2,400 postmenopausal women who had completed primary treatment and had been diagnosed 
with stage one breast cancer in the previous year.  Study participants were randomized to 
receive an intervention targeted to reduce fat intake.  The study reported slight reductions in 
the hazard for overall survival (HR = 0.89; 95% CI = 0.65, 1.21) [140].  In contrast, the 
Women’s Healthy Eating and Living (WHEL) trial focused on the efficacy of changes in 
dietary pattern, which included reduction in dietary fat intake [141].  The WHEL study 
included approximately 3,000 women, among whom nearly 80% were postmenopausal, and 
had been diagnosed with stage one breast cancer within the previous four years. The 
intervention focused on implementing a dietary pattern with high fruit, vegetable, and fiber 
intake and low total fat intake.  The WHEL study reported null associations for the dietary 
pattern intervention on overall survival (HR = 0.97; 95% CI = 0.78, 1.22) [142].  A modest 
reduction in the hazard for recurrence was reported in the WINS study (HR = 0.76; 95% CI = 
0.60, 0.98), but not for the WHEL study (HR = 0.99; 95% CI = 0.83, 1.17). 
 It is important to note the differences in assessment methods used in these two trials.  
The focus of the WHEL study was on dietary pattern changes, which included reduction in 
dietary fat intake.  Whereas, the WINS study’s primary focus was on reduction of dietary fat 
intake.  Also, the studies differ with regards to the time between breast cancer diagnosis and 
enrollment.  The WINS study enrolled women within one year of diagnosis, whereas the 
WHEL study enrolled women within four years of breast cancer diagnosis.  Thus, the WINS 
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study would focus on more short-term prognosis, or women who could have a breast cancer 
event within five years of diagnosis.  In contrast, the WHEL study under sampled women 
who had a breast cancer event within four years of the diagnosis, and therefore are unable to 
examine the effect of the intervention on early recurrence and death.  This may explain the 
differences in the reported HRs for breast cancer recurrence in the two studies. 
 These previous studies on breast cancer progression and mortality focused on 
reductions in total fat intake without any consideration given to the type of fat.  It is possible 
that ω-3 and ω-6 PUFAs will have differential effects on survival, and that reduction in 
dietary intake of the unfavorable ω-6 fatty acids and increases in the more favorable ω-3 fatty 
acid could improve breast cancer survival.  Therefore, examination of these different types of 
PUFAs and their relative balance could further elucidate the relation between dietary fat and 
breast cancer survival. 
 Non-steroidal anti-inflammatory drugs could also improve survival by reducing 
inflammatory metabolites resulting from metabolism of arachidonic acid via cyclooxygenase 
enzymes.  However, only two studies on NSAID use in relation to survival from breast 
cancer have been reported to date, and results were conflicting  [143, 144].  Thus, other 
avenues for improving breast cancer survival should be considered. 
 
1.3.7 Summary 
 There are many established clinical indictors of breast cancer prognosis, including 
late age at diagnosis, low socioeconomic status, African American race, ER- tumor subtype 
including triple negative and basal-like breast cancer, and inadequate treatment, which have 
been demonstrated to worsen prognosis among breast cancer patients.  Additionally, there is 
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growing evidence that lifestyle factors such as weight maintenance, increased physical 
activity, and reduced fat intake before and after diagnosis improve survival. The promising 
findings for nutritional factors underscore the hypothesis that some factors may be modified 
in an effort to improve survival, and support the examination of other possible nutritional 
factors that could influence breast cancer survival. One possibility is dietary PUFA intake, 
which may help to provide an opportunity for improving survival among women diagnosed 
with breast cancer. 
 
1.4 PUFAs 
1.4.1 Structure 
 Fatty acids are long-chain lipids containing primarily two groups: a carboxylic acid; 
long carbon chain; and methyl end.  PUFAs are lipids that contain at least two double bonds 
resulting in the cis configuration [145].  There are two primary classes of PUFAs, ω-6 and ω-
3.  Omega-6 fatty acids refers to the position of the first double bond in the carbon-chain 
from the methyl group found at the end of the carbon-chain; whereas, ω-3 fatty acids have 
the first double bond at the third position from the methyl group.  The ω-6 PUFA subtypes 
include: linoleic acid (LA) and arachidonic acid (AA); and the ω-3 PUFA subtypes include: 
alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and 
docosapentaenoic acid (DPA).  The total number of double bonds present in the carbon-chain 
differentiates between the individual subtypes of ω-3 fatty acids or ω-6 fatty acids.  Please 
refer to Table 1.1 (see below) for details regarding the carbon chain length and total number 
of double bonds for the different ω-3 and ω-6 PUFA subtypes. 
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1.4.2 PUFA Sources and Biosynthesis 
Mammalian cells are unable to endogenously produce ω-3 and ω-6 PUFAs and, thus 
the primary source of PUFAs in humans is diet.  As shown in Table 1.1 (see below), fatty 
fish (e.g., halibut, mackerel, herring, and salmon) are the primary source of long-chain ω-3 
(LC ω-3) PUFAs. Vegetable oils are the major source of ALA [146].  Other sources 
contribute only minor quantities of ω-3 to the diet and include nuts and seeds, vegetables and 
some fruit, egg yolk, poultry and meat [146].  Different cooking methods (e.g., deep frying) 
have been shown to substantially reduce LC ω-3 PUFA content [147].  Vegetable oils are 
major sources of ω-6 fatty acids.  Corn oil, peanut oil, sunflower oil, safflower oil, 
margarine, lard, bacon, ham, nuts are sources of LA [145, 148]. 
In addition to these exogenous sources of PUFAs, it is also important to consider in 
vivo metabolism of ω-3 and ω-6 fatty acids, respectively.  Humans do not possess the 
enzymes necessary to desaturate LA to ALA, thus conversion from one PUFA class to 
another (e.g., ω-6 to ω-3) is impossible [148].  However, through a series of desaturations 
(removal of hydrogen and introduction of double bond) and elongations (extension of the 
fatty acid chain by two carbons), formation of different subtypes of ω-3 and ω-6 fatty acids 
are possible in vivo.  For example, desaturation (via δ-5-desaturase and δ-6-desaturase) and 
elongation of LA (ω-6) and ALA (ω-3) would lead to AA and EPA, respectively [148].  
Further elongation of EPA leads to DPA, which subsequently can be elongated (via acetyl-
CoA), then desaturated (via δ-6-desaturase), and transported to the peroxisome for β-
oxidation forming DHA [148].  Deficiency in ALA can lead to reduced levels of DHA and 
enhanced levels of ω-6 fatty acids in tissue membranes [149].  This conversion process for 
certain PUFA subtypes is important to consider since it could affect the availability of other 
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subtypes in vivo.  For example, low intake of ω-3 PUFAs that are precursors (e.g., ALA) in 
fatty acid biosynthesis may affect the bioavailability of downstream LC ω-3 PUFAs (e.g., 
EPA, DPA, DHA) [150].  Therefore, in addition to considering dietary intake of specific 
subtypes of ω-3 and ω-6 PUFAs separately, it may be equally important to consider total 
dietary intake of ω-3, ω-6, and the relative balance of ω-3 and ω-6 PUFAs.  Figure 1.2 
shown below provides an overview PUFA biosynthesis. 
It is suggested that human beings evolved on an ω-3:ω-6 ratio approximately 
equivalent to one, and since then our diets have evolved to include more sources of ω-6 fatty 
acids [151].  This increased consumption of ω-6 fatty acids was due in large part to the 
development of technology during the early 1900s marking the beginning of the vegetable oil 
industry, and modern agriculture with the emphasis on feeding domestic livestock with 
grains rich in ω-6 fatty acids [151].  During the 20th century, the consumption of soybean oil 
increased dramatically [152]. Thus, the availability of LA (as a percentage of total energy) 
has increased dramatically in Western populations; whereas, the availability of LC ω-3 
PUFA has remained stable [152]. The relative intake of ω-3 and ω-6 PUFA varies 
geographically, with western diets having an intake ratio of ω-3:ω-6 of 1:15-20, compared to 
the ratio of 1:5-6 in India and 1:4 in Japan [153].  Also, it has been reported that serum levels 
of LCω3-PUFA are lower among U.S. Whites when compared to other Asian populations 
[154].  Since ω-3 and ω-6 fatty acids compete for the same enzymes, it is important to 
consider the relative balance of the two when considering their effects on chronic disease. 
In summary, examination of the relative balance of ω-3 and ω-6 fatty acid intake may 
be vital to understanding the effects of PUFA on breast cancer, and for identifying an 
unfavorable ratio that may increase breast cancer risk and reduce survival. 
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1.5 Metabolism of PUFAs  
PUFAs are incorporated into the cellular membrane.  After incorporation within this 
lipid bilayer, PUFAs are then available for metabolism which occurs via the cyclooxygenase, 
lipoxygenase, and cytochrome p450 pathways.  Both ω-6 and ω-3 fatty acids are metabolized 
via these pathways and compete with one another for the same enzymes, and they have 
demonstrated effects on the hallmarks of cancer [155].  The differential effect of ω-6 and ω-3 
fatty acids on breast cancer etiology has been well demonstrated in animal and laboratory 
studies. Figure 1.3 shown below provides an overview of the biologic pathways involved in 
arachidonic acid metabolism. 
 
1.5.1 Cyclooxygenase pathway 
Metabolism of AA via the cyclooxygenase pathway results in the formation of 
inflammatory intermediates, known as eicosanoids.  A key metabolic enzyme in this pathway 
is prostaglandin synthase 2, or COX-2.  Aberrant upregulation of COX-2 expression has been 
reported in breast tumors [156-158].  COX-2 is known to be overexpressed in most human 
epithelial cancers, and is overexpressed in 40-50% of human invasive breast cancers [159-
166].  Additionally, local COX-2 expression in the mammary gland of mice has been 
suggested to be sufficient for in situ tumor initiation and progression [167].  COX-2 
overexpression has been shown to enhance lymphatic invasion of breast cells [168], increase 
metastasis [165, 166, 169], inhibit apoptosis and differentiation [170], and has been 
suggested to enhance aromatase [171] in breast cancer cells. COX-2 specific inhibitors have 
been shown to prevent breast cancer metastasis, tumor growth, and angiogenesis [166, 172-
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176]. 
A key prostaglandin resulting from the cyclooxygenase pathway includes 
prostaglandin E2 (PGE2), which has been implicated in breast cancer etiology in animal and 
laboratory studies.  Prostaglandin E2 is known to be a primary eicosanoid of COX-2 derived 
AA metabolism [177, 178], and is known to have tumorigenic properties [177].  Overall, 
PGE2 has been shown to influence Hanahan and Weinberg’s hallmarks of cancer [179], 
which include the following: evasion of apoptosis; autonomy in growth signals; promotion of 
angiogenesis; and increased cell migration eventually leading to tissue invasion and 
metastasis. 
Specifically, in breast tissue and breast cancer cell lines, PGE2 has been shown to 
increase angiogenesis, metastasis, and invasiveness.  Chang et al. [180] demonstrated the 
harmful effects of COX-2 derived PGE2 on mammary gland tumor progression by inducing 
mammary gland angiogenesis in mouse models.  Similar metastatic effects of PGE2 in breast 
cancer have been demonstrated in human breast cancer cell lines [181].  A proposed 
mechanism for PGE2’s contribution to enhanced metastatic activity in breast cells is via the 
suppression of natural killer cell function.  Increasing concentrations of PGE2 resulted in 
inhibition of natural killer cell function in mouse models [182].  In breast cancer cells, PGE2 
was also shown to increase Id-1 gene expression leading to increased invasiveness [183].  
Thus, inhibition of COX-2 enzyme, and resulting PGE2 production, may help to inhibit the 
tumorigenic effects of this metabolic pathway. 
 
1.5.2 Lipoxygenase pathway 
 Another pathway for ω-6 fatty acid metabolism is via the lipoxygenase pathway. The 
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enzymes involved in the lipoxygenase pathway include 15-lipoxygenase-1 and -2 (15-LOX-1 
and 15-LOX-2), 5-lipoxygenase (5-LOX), and 12-lipoxygenase (12-LOX).  12-LOX has 
been shown to be overexpressed in breast tumors [163, 184, 185] and both animal and 
laboratory studies have observed the tumorigenic and metastatic potential of ω-6 fatty acids 
such as AA. These enzymes metabolize either LA or AA, both ω-6 fatty acids, and result in 
different sets of inflammatory eicosanoids. 15-LOX-1 metabolizes LA into the mitogenic 
metabolite, 13S-hydroxyoctadeca-9Z, 11E-dienoic acid (13-S-HODE).  The potential 
mitogenic activity of 13-S-HODE is considered to be epidermal growth factor (EGF) 
dependent.  Increasing formation of 13-S-HODE has been observed to augment the EGF 
receptor signaling pathway, and thus increase cellular proliferation in breast cells [186].  
Therefore, reduction in LA may help to reduce the tumorigenic effects of 13-S-HODE in 
breast cells.  In addition to increased cellular proliferation, 13-S-HODE has been shown to 
influence metastasis by decreasing E-cadherin expression in breast cancer cells [187]. 
The lipoxygenase pathway also has enzymes that metabolize AA, including, 15-LOX-
2, 5-LOX, and 12-LOX.  The eicosanoids resulting from these enzymes include the 
hydroxyeicosatetraenoic acids (HETEs), which then are converted to leukotrienes (LKs), 
lipoxins (LOs), and hepoxilins (HOs) [53].  The 12-LOX-2 metabolite of AA metabolism 
(12-S-HETE) has been suggested to increase tumor invasiveness in breast cancer cell lines 
via increased secretion of cathepsin B, a collagen responsible for basement membrane 
digestion [188].  In addition to 12-S-HETE, the 15-LOX-2 metabolite 15-S-HETE also 
promotes metastasis by stimulating the adhesion of metastatic breast cancer tumor cells to the 
extracellular matrix, a key component of the metastatic process [189].  Inhibitors of the LOX 
metabolism enzymes have demonstrated reductions in HETE production and resulting 
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mammary tumorigenesis [190]. 
 
1.5.3 Cytochrome p450 pathway 
 In addition to the production of prostaglandins and leukotrienes via the 
cyclooxygenase and lipoxygenase pathways, respectively, AA can also be metabolized via 
the cytochrome p450 pathway.  The eicosanoids produced via the cytochrome p450 pathway 
include HETEs and epoxyeicosatrienoic acids (EETs) [191].  The principal pro-inflammatory 
product derived from arachidonic acid via the cytochrome p450 pathway is 20-HETE [192].  
This metabolite has been implicated in cardiovascular disease [192-194] and renal cell 
carcinoma proliferation and growth [195, 196].  However, the effects of 20-HETE has not 
been elucidated in animal and laboratory studies with respect to breast cancer. 
 Another process by which cytochrome p450 enzymes could be involved in breast 
cancer etiology is via estrogen biosynthesis.  Cytochrome aromatase enzymes are involved in 
endogenous production of estrogen, and these enzymes include CYP19 and CYP17.  PGE2, 
the primary cyclooxygenase-derived AA eicosanoid, increases aromatase expression in breast 
tissue [197-202].  Studies have shown strong correlations between COX2 expression and 
aromatase expression in human breast cancer cells [171, 203].  Additionally, COX-2 
selective-inhibitors suppress aromatase expression in breast cancer cells [204].  Thus, 
increased levels of PGE2 resulting from AA metabolism via the cyclooxygenase pathway 
could increase aromatase activity within breast tissue leading to increased estrogen levels 
thus contributing to breast growth. 
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1.5.4 Inflammation 
 AA metabolism is influenced by different inflammatory enzymes, in addition to the 
enzymes involved in the cyclooxygenase, lipoxygenase, and cytochrome p450 pathways.  
The primary cytokines and receptors that influence AA metabolism include: tumor necrosis 
factor alpha (TNF-α) and peroxisome proliferator-activated receptors (PPAR-α, PPAR-γ).  
Phospholipase A2 (PLA2) is responsible for releasing the membrane bound-form of AA into 
the cytosol, and therefore making it available for metabolism via the different pathways [53].  
TNF-α has been shown to indirectly influence AA release by inducing PLA2 activity in 
human tumor cells [205, 206].  In human breast adipose cells, TNF-α was also shown to 
increase expression of COX-2 and production of PGE2 [207].  FAS and FAS-L, a ligand-
receptor system part of the TNF family, is known to increase apoptosis; however, increased 
production of FAS-L is seen in many cancer types, including breast cancer [208-211].  
PGE2, the cyclooxygenase-derived metabolite resulting from AA metabolism, has 
demonstrated effects on increasing FAS-L production [212], which may lead to the aberrant 
regulation of apoptosis in cancer cells.  FAS/FAS-L expression may provide an advantage for 
tumor cells (both late and early in the carcinogenic process) by facilitating tumor immune 
escape [209, 211, 212].  Thus, in addition to its apoptotic properties, TNF-α and family 
members, could potentially influence carcinogenesis by increasing cytosolic levels of AA, or 
increasing expression of FAS/FAS-L thus giving tumor cells the ability to evade immune 
response. 
 PPARs are transcriptional factors that belong to the nuclear hormone receptor family 
[213].  There are three different PPARs, including PPAR-α, PPAR-β, PPAR-γ.  There is 
evidence that PPAR-γ is often up-regulated in breast cancer cells [214].  Activation of 
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PPAR-γ can inhibit breast cancer growth [215], promote apoptosis [216], and invasion of 
human breast cancer cells [213].  Ligands required for PPAR-γ activation include 
eicosanoids from AA metabolism, namely 15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) derived 
from the cyclooxygenase pathway, and leukotriene B4 derived from the lipoxygenase 
pathway [217]. Also, long-chain fatty acids are known ligands for PPAR-activation, which 
inhibits vascular inflammation and induces apoptosis via NFkb and AP1 signaling [218, 
219]. 
 
1.5.5 Beneficial effects of ω-3 fatty acids 
 Animal models have demonstrated the beneficial effects of cyclooxygenase inhibition 
on mammary tumorigenesis by reducing cell migration, invasiveness, cell proliferation, and 
angiogenesis [220].  Similarly, reducing LA intake, an ω-6 fatty acid and precursor to AA, 
induced tumor apoptosis in mouse models [221].  Also, in the same study conducted by 
Connolly et al. increasing intake of DHA in combination with reduction of LA induced 
greater levels of apoptosis then reducing LA intake alone.  Other animal studies regarding ω-
3 supplementation (EPA, DHA, alone or combination of the two) have echoed these results 
regarding reduced tumor growth [222, 223], prevention of human breast cancer cell 
metastasis [224], and suppression of human breast cancer cell proliferation [225]. The 
beneficial effects of ω-3 intake within the cyclooxygenase pathway occur via the decreased 
production of the harmful COX-2 derived metabolite, PGE2 [68].  Thus, ω-3 fatty acids can 
competitively inhibit metabolism of AA via COX-2, and potentially reduce the tumorigenic 
effects of harmful COX-2 derived metabolites. 
Laboratory studies have shown inhibition of the lipoxygenase pathway via 
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nordihydroguaiaretic acid (NDGA) can reduce 13-S-HODE production, and thus, reduce 13-
S-HODE induced cellular proliferation in breast cells [226]. Specifically, ω-3 fatty acids 
have been shown to reduce 13-S-HODE production in liver cancer cells [227] and breast 
cancer cell lines [225].  Similarly, inhibition of the 5-LOX and 12-LOX enzymes has been 
shown to inhibit apoptosis and thereby reduce human mammary cancer growth [228-230].  
DHA has been shown to inhibit linoleic acid-derived 12-S-HETE and 15-S-HETE production 
in mice [68].  Also, ω-3 fatty acids have been demonstrated to suppress human breast cancer 
cell line growth by reducing leukotriene B production in vitro [222]. Thus, ω-3 fatty acids 
have been shown to reduce production of harmful eicosanoids resulting from the 
lipoxygenase pathway, namely 13-S-HODE, 12-S-HETE, and 15-S-HETE. 
 Animal and laboratory studies have also examined the beneficial effects of fish oil, a 
major source of ω-3 PUFAs, on breast cancer tumorigenesis.  Studies conducted in animals 
have shown that fish oil can have beneficial effects on breast cancer via multiple 
mechanisms, including: inhibition of breast cancer growth [231-233]; increased apoptosis 
[234]; down-regulation of anti-apoptotic gene activity [235]; increased expression of tumor 
suppressor molecule (syndecan-1) [216]; decreased cell proliferation [234]; and prevention of 
metastasis [232, 236, 237].  Other dietary supplements high in ω-3 fatty acid content 
(including walnuts, flaxseed oil, seal oil) have been shown to inhibit breast cancer growth, 
induce apoptosis, and prevent metastasis as well [238-241]. 
 Animal and laboratory studies have also directly examined the effect of ω-3 fatty 
acids on breast cancer.  Similar to the fish oil literature, these studies have demonstrated the 
ability for ω-3 fatty acids to reduce breast cancer growth [68, 223, 225, 242-249] and prevent 
metastasis [224, 250]. 
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 The beneficial effects of ω-3 fatty acids are not limited to the prostaglandin and 
leukotriene pathways.  Omega-3 fatty acids have been shown to differentially activate 
PPARs in human breast cancer cells compared to ω-6 fatty acids.  Omega-3 PUFAs were 
shown to inhibit transactivation of PPAR-γ, whereas ω-6 PUFAs were shown to stimulate 
activity in breast cancer cells [251].  Also, ω-3 fatty acids have been shown to inhibit 
progestin-driven invasiveness in human breast cancer cells [252].  Additionally, ω-3 
supplementation was also shown to suppress the synthesis of interleukin-1 (IL-1) and TNF, 
inflammatory proteins that promote cell growth and differentiation [253]. 
 
1.5.6 Cytotoxic environment induced by ω-3 fatty acids 
The beneficial effects of ω-3 fatty acids occur via a number of mechanisms 
mentioned previously, and they include the following: inhibition of cell proliferation; 
increased apoptosis; reduced angiogenesis; and prevention of metastasis.  In addition to these 
mechanisms, lipid peroxidation has also been suggested to contribute to the beneficial effects 
of ω-3 fatty acids.  Apoptosis in mammary cancer cells involves lipid peroxidation of both ω-
3 and ω-6 fatty acids [254].  However, the level of lipid peroxidation and resulting cellular 
oxidative stress depends upon the number of double bonds within the fatty acids chain [255].  
The number of double bonds found in ω-3 fatty acids, particularly in EPA and DHA, are 
greater than those found in ω-6 fatty acids, such as AA.  This cytotoxic environment induced 
by lipid peroxidation of PUFAs can inhibit breast cancer growth [254, 256-258], and 
therefore could prove beneficial for breast cancer prevention and survival.  DHA and fish oil 
supplementation has been suggested to increase ROS-initiated apoptosis in breast cancer 
cells in vitro and in vivo [259].  Genetic variation in oxidative stress enzymes conferring 
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greater reactive oxygen species (ROS) scavenging capabilities may lead to reduced levels of 
oxidative stress within the cell, and thus remove the potential benefit of this cytotoxic 
cellular environment on breast cancer [254, 256, 260]. 
The beneficial effect of ω-3 fatty acids on increasing apoptosis via lipid peroxidation 
may be limited to women with early stages of breast cancer.  It has been previously reported 
that the ω-3 induced cytotoxicity was significantly less in normal cells compared to tumor 
cells [261].  It is possible that dietary supplementation of ω-3 fatty acids could increase lipid 
peroxidation resulting apoptosis in transformed or malignant mammary cells [262].  Thus, ω-
3 fatty acid intake could have an impact on late stage promotion of breast cancer among 
women at high risk for breast cancer.   
Additionally, the beneficial effects of inducing a cytotoxic environment could also 
prove beneficial for survival among women already diagnosed with breast cancer and who 
are receiving treatment.  Studies have examined the effect of polyunsaturated fatty acid 
supplementation on enhancing treatment efficacy.  DHA supplementation in addition to 
doxorubicin treatment significantly reduced cell viability in human breast cancer cell lines 
[255].  Another study examined the effect of fish oil supplementation on the cytotoxicity of 
breast cancer tumor cells in mice [263].  Fish oil supplementation was shown to increase the 
efficacy of doxorubicin therapy as evidenced by reduced tumor growth after initiation of 
doxorubicin treatment.  Additionally, dietary DHA was able to sensitize resistant rodent 
malignant mammary tumors to chemotherapy [264] and radiation [265].  In addition to 
chemotherapy and radiation therapies, dietary EPA has also been demonstrated to restore 
tamoxifen sensitivity in breast cancer cell lines via inhibition of Akt signaling (involved in 
tamoxifen resistance) [266].   In addition to these laboratory studies, two clinical studies 
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suggested greater chemotherapy efficacy among those with high levels of DHA [267, 268]. 
Thus, lipid peroxidation via ω-3 fatty acids could potentially enhance the cytotoxic 
environment induced by breast cancer treatment, regardless of type of treatment (e.g., 
chemotherapy, radiation, and hormone therapy). 
 
1.5.7 Summary 
 Metabolism of AA can occur via three different pathways, including cyclooxygenase, 
lipoxygenase, and cytochrome p450, as illustrated in Figure 1.2 (see below).  The resulting 
eicosanoids produced via AA metabolism have been demonstrated to influence breast 
carcinogenesis in experimental studies, and include: 13-S-HODE, 12-S-HETE, 15-S-HETE, 
PGE2, and 20-HETE.  These AA-derived eicosanoids have been demonstrated to increase 
cell proliferation, metastatic potential, aromatase activity, angiogenesis, and cell 
proliferation.  At the same time, these harmful eicosanoids can also reduce apoptosis and cell 
differentiation.  Omega-3 fatty acids also bind to the same enzymes utilized in AA 
metabolism, however, the production of the harmful eicosanoids are reduced.  In addition to 
the reduction of inflammatory eicosanoids, ω-3 fatty acids are also known to induce a 
cytotoxic environment within the cell by increasing levels of lipid peroxidation within the 
cell, and inducing apoptosis.  Thus, intake of ω-3 fatty acids may provide a means for 
reducing breast carcinogenesis which could affect both incidence and survival. 
 
1.6 PUFA Assessment in Epidemiologic Studies of Breast Cancer  
1.6.1 Issues to Consider in the Evaluation of the PUFA-Breast Cancer Studies  
 A number of issues affect clear interpretation of findings drawn from epidemiologic 
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studies undertaken to address the potential link between PUFAs and breast cancer.  Key 
issues include: (1) the distribution of PUFA classes varies by geography, and biologic effects 
are likely to vary by PUFA subtype – thus epidemiologic study results are likely to vary by 
geographic location; (2) methods used to assess PUFA subtype exposures (self-reports of 
dietary intake or biomarker levels) provide estimates of individual level exposures that reflect 
different time periods, and thus findings from epidemiologic studies are likely to vary by the 
PUFA assessment method; and (3) the epidemiologic study design employed affects the 
timing of the exposure assessment relative to the diagnosis of the disease, which in turn 
influences the underlying assumptions regarding the timing of the exposure –and thus 
epidemiologic findings are likely to vary by study type. These issues will be discussed in 
more detail below. 
 
1.6.2 Geographic Variation in PUFA Intake 
 As previously discussed, the distribution of dietary intake of the classes of PUFA 
varies widely by country.  Thus, the relative intake of ω-3 and ω-6 PUFA varies 
geographically, with western diets having an intake ratio of ω-3:ω-6 of 1:15-20, compared to 
the ratio of 1:5-6 in India and 1:4 in Japan [153].  Also, previous investigators have reported 
that serum levels of LC ω3 PUFA are lower among U.S. Whites when compared to other 
Asian populations [154].  Thus, if the association between PUFA subtypes and breast cancer 
varies by exposure dose, then studies conducted in different geographic populations with 
varying exposure doses could yield varying results. Thus, consideration of the geographic 
location of the population under study is critical. 
 Animal and laboratory evidence shows that ω-3 and ω-6 fatty acids have differential 
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effects on breast cancer.  Thus, it is important to examine the different subtypes of PUFA 
intake since the laboratory evidence suggests that the association between PUFA and breast 
cancer is complex.  A comprehensive examination of PUFA intake, including ω-3 subtypes, 
ω-6 subtypes, and the relative balance of ω-3 and ω-6 classes, is warranted and may help to 
capture this complexity and help elucidate the PUFA-breast cancer association.  However, 
given this biologic complexity, few studies [269, 270] have comprehensively examined 
PUFA intake.   
Therefore, consideration of the geographic location of the study population and 
whether assessment of PUFA intake was comprehensive (including ω-3 subtypes, ω-6 
subtypes, and the relative balance of ω-3 and ω-6 fatty acids) are both important 
considerations when evaluating epidemiologic studies that address the PUFA-breast cancer 
association. 
 
1.6.3 Self-reported Dietary Assessment of PUFAs 
 The majority of studies to date have relied upon self-reported measures of dietary 
PUFA intake.  Among those studies using self-reported measures of dietary PUFA intake, the 
majority used food frequency questionnaires (FFQ) to measure usual dietary intake.  Other 
alternative methods of dietary assessment include short-term recall (e.g., 24-hour recall) and 
diet records.  Short-term 24-hour recall, which reflects foods eaten the day prior to the 
assessment only, has its limitation as it does not account for day-to-day variations, 
seasonality of dietary intake, or long-term patterns of intake.  Multiple 24-hour recalls 
throughout the year could help deal with day-to-day variation in dietary intake; however, this 
approach is costly, inefficient, and a burden to the participants.  While diet records consider 
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daily variations, this assessment method still fails to address seasonal intake, variations in 
intake that take place throughout the year, and long-term patterns of intake.   
The FFQ is the most commonly used measure for assessment of usual dietary intake, 
since it provides an inexpensive method for assessing usual patterns of long-term intake.  The 
FFQ typically assesses consumption of foods in the past year.  This exposure assessment 
provides estimates of usual intake while accounting for seasonal dietary influences.  
Shortcomings of this approach, however, include difficulties in recalling patterns in the 
previous year or in accurately measuring energy intake.  However, as reviewed by Willett 
[271], this instrument type is most useful for relative ranking of individual takes, rather than 
trying to estimate precise intake levels.  
 In addition to the type of dietary assessment, it is equally important to consider the 
potential for misclassification that can occur with self-reported dietary data.  For example, in 
a case-control study of PUFA intake, it is possible that cases and controls may differentially 
recall dietary exposure, thus biasing effect estimates away from the null.  Also, dietary 
exposures measured via questionnaires are subject to non-differential measurement error, 
which could attenuate effect estimates towards the null value. Dietary exposures measured 
via questionnaires fail to consider the impact of biologic processes involved in the body, and 
therefore, may not provide the estimates of bioavailability.  Additionally, nutrient intakes 
derived from an FFQ may provide biased assessments due to subject assessments of portion 
size, frequency of intake, and differences in recipes and cooking methods. 
 The FFQ generally includes assessment of dietary intake in the past year, although for 
some instruments the assessment period can be for up to 5 to 10 year prior to the interview. 
Regardless of the number of years assessed, the intake estimates from the FFQ are assumed 
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to reflect usual diet – in other words, long-term patterns. The accuracy of this assumption has 
not been definitely demonstrated.  
In sum, the FFQ is the most frequently used dietary intake assessment used in studies 
of PUFA and breast cancer. This approach is an inexpensive and efficient method for 
epidemiologists to estimate usual dietary intake in the past year, which possibly reflects long-
term dietary intake. 
 
1.6.4 Biochemical Markers of PUFAs 
 Biochemical markers, or biomarkers, of PUFAs provide an alternative way to 
measure dietary intake reflecting both dietary intake and the biologic processes involved in 
metabolism of the nutrient [272].  The hope is that these biomarkers would provide an 
alternative, unbiased assessment of dietary PUFA assessment.  However, there are many 
limitations of using biomarker measurements of PUFAs that require consideration. 
 It is important to consider the type of biomarker measured and what exposure 
window is being measured. There are primarily three biomarkers for PUFA intake and 
include: serum, erythrocyte membrane, and adipose tissue biomarkers.  Each of these 
different biomarkers reflects a different exposure window for PUFA intake.  Serum fatty acid 
biomarkers reflect the shortest window of exposure of all the three fatty acid biomarkers.  
Most serum or plasma biomarkers reflect fatty acid intake over the past few meals or days 
[273].  The next biomarker level, erythrocyte-membrane bound biomarker tends to reflect a 
longer term of intake than serum and contains a high proportion of long-chain PUFAs.  
Erythrocyte-membrane bound PUFA biomarkers reflect dietary intake spanning the life cycle 
of a red blood cell, which is approximately 120 days [273].  Thus, erythrocyte-membrane 
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biomarkers will likely reflect PUFA intake over the past few months.  However, it is 
important that samples for erythrocyte-membrane biomarker testing are stored pretreated, 
which would protect the membranes from degrading due to oxidation, and that samples are 
stored at -80°C in order to maintain stability up to five years [273].  Finally, adipose tissue 
biomarkers can be measured in order to reflect long-term dietary intake.  The samples can be 
obtained from gluteal, abdominal, subscapular, pectoral, or from another site [273].  In 
general, fatty acids concentrations obtained from these different sites are similar [272].  
However, adipose tissue biomarkers are subject to measurement error in the presence of 
weight loss [273]. 
 There are numerous factors that are known to influence measured fatty acid 
biomarker levels and include the following: dietary intake, relative amounts of other fatty 
acids in media, supplement use, genetic polymorphisms of elongase and desaturase enzymes, 
tissue sampling site, tissue sampling procedure, amount sampled, handling and storage of 
samples, analytic method, lipolysis and fasting, nutritional status (e.g., iron, zinc, copper, and 
magnesium sufficiency), lipogenesis, diseases (e.g., cystic fibrosis, malabsorption, liver 
cirrhosis, diabetes, Zellweger Syndrome), and oxidation [273].   
 Therefore, there are many opportunities for measurement error even with a more 
objective measure of PUFA intake, and the time-period of the exposure reflected by the 
biomarker may not be relevant to the carcinogenic process, which is up to at least several 
decades [274]. 
 
1.6.5 Study Design and Timing of Exposure Assessment 
 The majority of studies that have examined the association between PUFAs and 
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breast cancer incidence have been case-control in study design [99, 104, 269, 275-287].  
Some case-control studies were nested within a fully enumerated cohort [85, 288] and others 
were cohort studies [80, 100, 270, 289-298].  The issue of the type of study design is 
important because it often determines the timing of the PUFA assessment, which is likely to 
influence the observed associations that are reported in the different study designs found in 
the epidemiologic literature.   
In case-control studies, subjects are typically interviewed to assess dietary intake at 
the time of diagnosis (for the cases) and at the time of interview (for the controls).  In 
contrast, for cohort studies dietary assessment is made at the time of interview at the 
beginning of the study.  It is possible that dietary assessment captured at diagnosis or 
interview (for case-control studies) and at enrollment (for cohort studies) does not adequately 
assess intake during the etiologically relevant time period.  Thus, the estimated association 
for these study designs may be attenuated if the exposure does not reflect intake during the 
etiologically relevant time period [274].   
Given a long enough period of follow-up (e.g., more than ten years), it is possible that 
assessment of dietary intake in cohort studies may capture intake closer to the etiologically 
relevant time period for breast cancer.  If this is the case, then estimates derived from cohort 
studies may be stronger than those estimated from case-control designs. If, however, dietary 
intake patterns change over time, then neither the case-control nor the cohort study design 
will provide valid measures of association. 
With regard to PUFA biomarkers, again effect estimates derived from case-control 
vs. cohort (or nested case-control studies) may not reflect the true PUFA breast cancer 
association.  The PUFA biomarker obtained years prior to the outcome, as is the case for the 
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cohort or nested case-control study, may not reflect usual PUFA exposure levels in the time 
period relevant to carcinogenesis. The problem is similar for case-control studies – where the 
biomarker levels assessed closer to diagnosis also do not reflect usual exposure levels in the 
time period relevant to carcinogenesis.    
In sum, regardless of the study design, the underlying assumption is that the dietary 
data estimate, or the biomarker levels, reflects long-term usual exposure levels, which may 
not be a valid assumption -- for any epidemiologic study design type or exposure assessment 
method used.   Thus, in interpreting findings from epidemiologic studies, it is important to 
carefully consider the timing of the exposure assessments which is inherent to each of the 
different study designs when evaluating the epidemiologic literature. 
 
1.6.6 Summary 
 A variety of issues could affect the estimated associations derived from previous 
epidemiologic studies undertaken to examine PUFA intake and breast cancer.  The main 
issues include: geographic variation (e.g., study population); the assessment of PUFA intake 
(FFQ versus biomarker measurements); types of PUFA examined (e.g., ω-3 subtypes only, 
ω-6 subtypes only, or a more comprehensive measure including both classes and the relative 
balance); and study design (e.g., case-control versus cohort) as it affects the timing of the 
exposure assessment.   
The evaluation of the epidemiologic literature is presented below for both incidence 
and survival.  A summary of the literature examining the association between self-reported 
PUFA intake and breast cancer incidence is presented in Tables 1.2 and 1.3 for case-control 
and cohort studies, respectively.  The subsequent sections regarding the epidemiologic 
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literature examining self-reported PUFA intake is assessed separately for each study design, 
then by study population, and assessment of PUFA.  A separate section is devoted to 
epidemiologic literature utilizing PUFA biomarkers and those studies examining dietary fish 
intake.  
 
1.7 Epidemiology of PUFAs and Breast Cancer 
1.7.1 PUFAs Assessed using Dietary Intake Measures and Incidence 
 As shown below in Tables 1.4 and 1.5, over two dozen observational studies have 
been published examining the relation between self-reported dietary PUFA intake and breast 
cancer incidence. However, as reviewed in more detail below, results remain inconclusive.  
The studies addressing the issue have utilized both case-control and cohort study designs, 
have been conducted among different international populations, and the PUFA measures 
assessed also vary across studies.  Details of the existing evidence published to date, and the 
potential reasons for the lack of consistency across studies, are reviewed in more detail 
below.  Results from the case-control studies are considered first, followed by those from the 
cohort studies. 
 
1.7.1.1  Case-Control Studies 
 As shown in Table 1.4, sixteen case-control studies examining the effect of PUFA on 
breast cancer incidence have been conducted in populations across the globe, including Asian 
(n=3) [275-277], European (n=7) [99, 104, 269, 278-281], the U.S. (n=3) [285-287], Latin 
American (n=2) [283, 284], and Saudi Arabian (n=1) [282] populations. 
 Three case-control studies were conducted among Asian populations [275-277].  The 
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two earlier case-control studies conducted among Asians [275, 276] reported results for only 
total PUFA intake without considering the different classes (e.g., ω-3 and ω-6).  Shun-Zhang 
et al. reported increased breast cancer risks for women with higher intakes of total 
polyunsaturated fatty acids, and the effect was stronger when polyunsaturated fatty acids 
were considered as a continuous variable (13 grams/day increase) versus tertiled [275].  Lee 
et al. reported increased breast cancer risk for total PUFA intake among postmenopausal 
women, but a risk reduction for premenopausal women [276].  However, both these earlier 
case-control studies included small sample sizes resulting in imprecise estimates of the 
PUFA and breast cancer association. 
 A third Asian case-control study, which was larger and conducted among a Korean 
population, examined the effects of total ω-3 fatty acid intake and LC ω-3 PUFAs [277].  The 
study reported risk reductions for all three exposures (e.g., total ω-3, DHA, and EPA), with 
stronger risk reductions seen among postmenopausal women consuming higher quantities of 
EPA and DHA.  However, Kim et al. failed to estimate effects for ω-6 fatty acids and the 
relative intake of ω-3 and ω-6 PUFA intake in this Korean population.  While Kim et al. had 
a larger sample size (N=718) than the earlier Asian studies, the effect estimates were still 
imprecise, even more so when stratified by menopausal status.  Additionally, Kim et al. 
sampled controls from patients who attended the same hospital as the cases and received 
health check-ups and/or cancer screening [277].  This selection of hospital-based controls has 
the potential to bias the effect estimates if the distribution of ω-3 fatty acid intake differs 
between those attending the hospital versus the source population, and thus limiting the 
external validity of the study findings.  Therefore, the conclusions from Asian case-control 
studies that examined the effects of PUFA intake and incidence of breast cancer are limited 
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due to a variety of reasons, including the lack of examination of all PUFAs, relative intake of 
ω-3 and ω-6 fatty acids, and issues with internal and external validity.  However, among the 
few that have considered ω-3 alone, breast cancer risk reductions are apparent, but 
information on ω-6 and the relative balance are not well studied. 
 Seven European case-control studies have been conducted regarding PUFA intake 
and breast cancer incidence [99, 104, 269, 278-281].  Results for total PUFA intake are 
inconsistent, with some reporting risk reductions [99, 104, 279] and two reporting an 
increased risk [278, 280].  One European study examined the effect of only LA intake, and 
reported increased risk for breast cancer for women consuming high intakes of LA (Quartile 
4 versus 1 OR = 1.22; 95% CI = 0.89, 1.68) [280].  The estimate was stronger among 
premenopausal women (Quartile 4 versus 1 OR = 1.46; 95% CI = (0.86, 2.49). Another 
European study reported a 20% breast cancer risk reduction for total ω-3 fatty acid intake 
(Quintile 5 versus 1 OR = 0.8; 95% CI = 0.7, 1.0) [281].  However, both of these studies did 
not examine the effect of the relative intake of ω-3 and ω-6 PUFAs within their respective 
European populations.  These differences in reported results could reflect differences in 
intake of different polyunsaturated fatty acids across different populations (e.g., ω-3 versus 
ω-6), differences in control sampling methods (e.g., hospital-based versus population-based 
controls), and differences in covariate adjustment sets.   
 One European case-control study comprehensively examined (including ω-3 
subtypes, ω-6 subtypes, and the relative balance of ω-3 and ω-6 fatty acids) the effect of 
PUFA on breast cancer incidence [269].  Another comprehensive case-control study 
examined the effect of ω-6 (LA, AA, total ω-6 intake) and ω-3 (ALA, DPA, EPA, DHA, 
total ω-3) fatty acids on breast cancer incidence among a French-Canadian population in 
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Montreal [269].  However, the reported effect estimates were not consistent with the biologic 
plausibility of ω-3 and ω-6 fatty acids.  Nkondjock et al. reported increased risks for ω-3 
fatty acids and risk reductions for ω-6 fatty acids [269].  Also, a 26% increase in breast 
cancer risk was observed for the highest quantile of ω-3:ω-6 intake (Quartile 4 versus 1 OR = 
1.26; 95% CI = 0.86, 1.86) [269].  In comparison, a 58% increase in breast cancer risk was 
observed for the third quartile of intake ω-3:ω-6.  It is possible that in this population the 
consumption of ω-3 fatty acids is not enough, and that the dietary habits of this French-
Canadian population resemble those of other North American populations where intake of ω-
6 fatty acid dominates.  This may explain why the reported associations are not consistent 
with the animal and laboratory studies. 
 A few other case-control studies were conducted among Uruguayan [283], Saudi 
Arabian [282], and Mexican [284] populations.  De Stefani et al. reported effects that are not 
consistent with the biology in their Urugauyan population, with increased risks for ALA, a 
long-chain ω-3 fatty acid and risk reduction for LA, a ω-6 fatty acid [283].  Aloithameen et 
al. reported only effects for total PUFA intake in a Saudi Arabian population [282].  The only 
comprehensive assessment of PUFA intake was conducted among a Mexican population and 
reported risk reduction for total ω-3 intake, increased risk for total ω-6 intake, and risk 
reduction for the favorable ratio of ω-3:ω-6 intake.  The estimated increased risk and risk 
reductions reported were even stronger when examined among only premenopausal women 
[284]. 
 In the U.S., only three studies examined the association between PUFAs assessed 
using dietary intake measures and breast cancer incidence [285-287].  However, two of these 
studies reported opposite effect estimates for LA intake, with one reporting increased risks 
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[287], and another reporting a risk reduction [285].  Another study conducted in Connecticut 
[286] reported risk reductions for LCω-3 fatty acids (EPA and DHA) among premenopausal 
women only.  However, a nearly 20% risk reduction was observed when examining the effect 
of the ratio of ω-3:ω-6 fatty acids on breast cancer risk among all women, and this risk 
reduction for the ratio was more pronounced among premenopausal women (Quartile 4 
versus 1 OR = 0.59; 95% CI = 0.29, 1.19).  However, the study lacked a comprehensive 
measure of PUFA intake (including ω-3 subtypes, ω-6 subtypes, and ratio of ω-3:ω-6 fatty 
acids).  Inconsistent effect estimates are observed among case-control studies conducted in 
the U.S. for the estimate of LA on breast cancer risk.  Also, the studies conducted in the U.S. 
could benefit from a comprehensive assessment of PUFA intake utilizing a large population-
based study. 
 In sum, numerous case-control studies have been conducted examining the 
association between PUFA and breast cancer, though inconsistencies in the estimated 
association exist.  Among the sixteen case-control studies, only one examined the PUFA 
exposure comprehensively by subtypes and relative balance [269].  However, the reported 
associations are not consistent with the biology of ω-3 and ω-6 fatty acids [269].  Only three 
studies were conducted in the U.S. [285-287], of which only one examined the relative 
balance of ω-3 and ω-6 fatty acid intake [286]. 
 
1.7.1.2  Cohort Studies 
 As shown below in Table 1.5, fifteen cohort studies examining the effect of PUFA 
intake and breast cancer incidence have been conducted among various populations, 
including Asian [100, 289, 290], European [85, 291-294], and U.S. [80, 270, 288, 295-298].  
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Three Asian cohort studies [100, 289, 290] present consistent results with respect to long-
chain ω-3 PUFAs and the relative balance of ω-3 and ω-6 fatty acid intake in relation to 
breast cancer risk.  The Singapore Chinese Health Study reported the greatest breast cancer 
risk reduction for marine-derived ω-3 PUFA intake with a nearly 30% decrease in risk 
(Quartile 4 versus 1 RR = 0.72; 95% CI = 0.53, 0.98), and this effect was even greater among 
postmenopausal women (Quartile 4 versus 1 RR = 0.68; 95% CI = 0.47, 0.97) [289].  Also, 
the Singapore Chinese Health study reported an 87% increase in risk (OR = 1.87; 95% CI = 
1.06, 3.27) when examining the joint effects of highest quartile of ω-6 PUFA intake and 
lowest quartile of ω-3 intake [289].  Similar effects were seen in the Japan Collaborative 
Cohort Study [100], where a 30% risk reduction for ω-3 fatty acid intake was reported and 
this risk reduction was more pronounced for long-chain ω-3 PUFA intake (Quartile 4 versus 
1, RR = 0.50; 95% CI = 0.30, 0.85). Wakai et al. also reported an increase in breast cancer 
risk for the unfavorable ratio (ω-6:ω-3) of PUFAs (Quartile 4 versus 1, RR = 1.31; 95% CI = 
0.78, 2.19).  These findings were echoed in a recently published cohort study utilizing the 
Shanghai Women’s Health Study [290].  Similar to the other Asian cohort studies, a 25% risk 
reduction was observed for long-chain ω-3 PUFAs (Quintile 5 versus 1, RR = 0.74; 95% CI 
= 0.52, 1.06) and a nearly 30% increase in risk was observed for unfavorable ratio of ω-6:ω3 
fatty acid intake (Quintile 5 versus 1, RR = 1.29; 95% CI = 0.95, 1.75).  Among Asian cohort 
studies, the effect of long-chain ω-3 fatty acids is consistently reported to reduce risk of 
breast cancer by approximately 30%.  All three Asian cohorts also examined the ratio of ω-6 
to ω-3 fatty acids and reported increases in risk ranging from 30% for all women [100, 290] 
to nearly 90% among postmenopausal women [289]. Thus, the Asian cohort studies are 
consistent with regard to breast cancer risk reduction conferred among those women 
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consuming long-chain ω-3 PUFA, and the increased breast cancer risks attributed to high 
intake of the unfavorable ratio of ω-6 to ω-3 PUFA. 
 While Asian cohort studies are consistent with regards to PUFAs assessed using self-
reported dietary intake data and breast cancer risk, the associations reported among European 
and U.S. populations are not.  A few European cohort studies reported inconsistent effects for 
total PUFA intake and breast cancer incidence, with one reporting an increased risk among a 
Finnish cohort [291] in comparison to other cohorts reporting risk reductions among Dutch 
and Swedish cohorts [292, 293].  This inconsistency between the studies could be due to 
differences in the model covariates. The Finnish cohort study reported effects adjusted for 
only age and total energy intake, the Dutch study reported effects adjusted for only age 
(energy did not influence the effect estimates), whereas the Swedish study reported effects 
that were adjusted for other potential confounders in addition to energy intake. 
 Another European study, utilizing a nested case-control study design within a well-
defined Swedish cohort, comprehensively examined PUFA intake and reported the effect of 
total ω-3, total ω-6, and the effect of relative intake of ω-3 and ω-6 fatty acids (ω-3:ω-6 
ratio).  They reported increased risks for both total ω-3 intake (Quintile 5 versus 1 OR = 
1.81; 95% CI = 1.09, 2.99; p for trend = 0.026) and total ω-6 intake (Quintile 5 versus 1 OR 
= 3.02; 95% CI = 1.78, 5.13; p for trend = 0.0002) [85].  However, a risk reduction was 
observed for the ω-3:ω-6 ratio on breast cancer incidence (Quintile 5 versus 1 OR = 0.66; 
95% CI = 0.41, 1.08; p for trend = 0.137). 
 Other European cohort studies also examined the associations of PUFA subtypes and 
breast cancer incidence.  In contrast to the Asian cohort studies, the results reported for 
LCω3 fatty acid intake and breast cancer risk are null.  While a substantial risk reduction was 
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observed for ALA, null effects for were observed for LCω3 fatty acids in the Netherlands 
Cohort Study [292].  An essentially null effect was observed for LCω3 fatty acids intake and 
breast cancer incidence even though a slight risk reduction was reported among a French 
cohort [Quintile 5 versus 1, RR = 0.94; 95% CI = 0.80, 1.10) [294].  Only two European 
cohort studies examined the relative balance of ω-6 and ω-3 PUFAs [85, 294] and a null 
association was reported for the unfavorable ratio of ω-6 to ω-3 PUFA among the Swedish 
cohort (Quintile 5 versus 1, RR = 0.97; 95% CI = 0.83, 1.14) [294][299] and a stronger risk 
reduction was observed among the French cohort for the favorable ratio of ω-3 to ω-6 PUFA 
(Quintile 5 versus 1, RR = 0.66; 95% CI = 0.41, 1.08) [85]. 
 Overall, the beneficial effects of long-chain ω-3 fatty acids and the deleterious effects 
of an unfavorable ratio of ω-6 to ω-3 fatty acids observed among Asian cohort studies was 
not replicated among European cohorts.  Also, studies that assessed PUFA subtype intake 
primarily reported null estimates for subtypes of ω-3 and ω-6 fatty acids [292, 294], with the 
possible exception of ALA intake in the Netherlands Cohort. Thus, the estimates of PUFA 
intake and breast cancer risk among European populations are either inconsistent or null, and 
require further investigation. 
 Few cohort studies among U.S. populations have comprehensively examined the 
association of PUFA on breast cancer incidence.  An early cohort study reported increasing 
age-adjusted breast cancer incidence rates incidence with each increasing tertile of total 
PUFA, LA, and ALA intake [295].  Two other cohort studies reported inconsistent effects for 
LA intake among postmenopausal women, with one reporting a nearly 30% increase breast 
cancer risk (Quintile 5 versus 1, RR = 1.29; 95% CI = 0.78, 2.13) [297] and the other 
reporting a slight risk reduction among Nurses’ Health Study cohort (Quintile 5 versus 1, RR 
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= 0.93; 95% CI = 0.74, 1.16) [80].  This inconsistency between the two studies could be due 
to differences in exposure assessment methods.  The Nurses’ Health Study assessed changes 
in dietary intake via multiple assessments of the food frequency questionnaire during follow-
up [80, 296].  While repeated questionnaires may help to provide changes in diet over time, it 
is possible that this cumulatively averaged LA intake used in the Nurses’ Health Study may 
not accurately reflect the relevant exposure window for breast cancer etiology, and thus 
would result in a biased effect estimate towards the null [274].  Whereas, the Velie et al. 
paper assessed LA intake at baseline and reported increased risk for breast cancer which is 
concordant with the known biology of ω-6 fatty acids. The assessment made by Velie et al. 
may reflect LA intake during an etiologically relevant time period for breast cancer more 
accurately than cumulatively averaged intake presented in the Nurses’ Health Cohort [80].  
This may explain the differences in effect estimates obtained by the two studies. 
 Finally, only the Nurses’ Health Study and the VITAL cohort study comprehensively 
examined the association between total PUFAs, ω-3 subtypes, and ω-6 subtypes on breast 
cancer risk among U.S. populations [270, 296].  Predominantly null effect estimates were 
reported among the Nurses’ Health cohort, with the exception of ALA (RR for 1% increase 
in energy = 0.75; 95% CI = 0.54, 1.03) and total PUFA intake among postmenopausal 
women (RR for 5% increase in energy = 0.88; 95% CI = 0.74, 1.04) [296].  Risk reductions 
were observed among postmenopausal women in the VITAL cohort for LCω-3 PUFAs, 
including EPA (Quintile 5 versus Quintile 1 HR = 0.70; 95% CI = 0.54, 0.90) and DHA 
(Quintile 5 versus Quintile 1 HR = 0.67; 95% CI = 0.52, 0.87); whereas, a modest increase in 
breast cancer risk was reported for LA (Quintile 5 versus Quintile 1 HR = 1.18; 95% CI = 
0.84, 1.66) [270]. In addition to the examination of ω-3 and ω-6 subtypes, the VITAL cohort 
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also reported modest risk reduction for relative intake of ω3 to ω6 (Quintile 5 versus Quintile 
1 HR = 0.84; 95% CI = 0.65, 1.09) [270].  Therefore, the association between PUFAs and 
breast cancer risk is not clear among U.S. cohort studies, with studies reporting inconsistent 
results for ω-3 and ω-6 subtypes, and only one study [270] suggesting a modest risk 
reduction with favorable ω-3:ω-6 ratio. 
 In sum, fifteen cohort studies have estimated the potential association between PUFA 
and breast cancer incidence.  Among the Asian cohort studies, consistency was observed 
with regard to LCω3 intake and breast cancer risk reduction [100, 289, 290].  Inconsistencies 
regarding the potential association between PUFAs and breast cancer incidence remain 
among the European and U.S. cohort studies.  Among the five cohort studies conducted 
among U.S. populations, only one [270] examined the relative balance of ω-3 to ω-6 intake. 
 
1.7.2 PUFAs Assessed using Dietary Intake Measures and Survival 
 Epidemiologic studies regarding self-reported PUFA intake and breast cancer risk are 
severely lacking, despite the demonstrated biologic plausibility in animal and laboratory 
studies.  Only ecologic studies have been conducted regarding PUFA intake and survival 
after breast cancer diagnosis.  One study [300] used age-specific breast cancer mortality rates 
from the World Health Organization (WHO) for 30 industrialized countries.  PUFA intake 
was derived from 47 published dietary surveys from 17 different countries.  The study 
reported high correlations between PUFA intake and breast cancer mortality rates, with high 
correlation coefficients from 0.53, 0.84, to 0.87 for age groups 50-54, 60-64, and 70-74 
years, respectively.  Another ecologic study was conducted to examine the relation between 
breast cancer mortality and dietary factors in Japanese women [301].  The study reported 
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high correlation coefficients for PUFAs and age-adjusted breast cancer mortality, with a 
correlation coefficient nearly 0.20.  A higher correlation coefficient was reported for ω-3 
fatty acids (0.22) than for ω-6 fatty acids (0.17).  However, temporality between PUFAs and 
breast cancer mortality cannot be assessed since both these studies are ecological in design. 
 
1.7.3 Summary 
 While there have been many studies that have examined the association between 
PUFAs and breast cancer risk, the studies have reported inconsistent results.  Many of the 
earlier studies focused only on examination of total PUFA intake [99, 104, 275, 276, 278, 
279, 282, 291], without considering the potentially opposite effects of ω-3 and ω-6 fatty 
acids.  Other studies only considered one PUFA subtype, either ω-3 or ω-6 [80, 277, 280, 
281, 287, 288, 297, 298, 302].  Few studies examined the relative intake of ω-3 and ω-6 fatty 
acids [85, 100, 269, 270, 284, 286, 289, 290, 294].  Among these studies examining the 
relative balance of ω-3 and ω-6 fatty acids, only two were conducted using a U.S. population 
[270, 286].  While Asian cohort studies have suggested a risk reduction for long-chain ω-3 
PUFA and an increased risk with high ω-6 to ω-3 fatty acid ratio, the results from studies 
conducted among European and U.S. populations are still inconsistent. These latter 
populations could benefit from a comprehensive assessment of PUFA intake, including ω-3 
and ω-6 subtypes and the relative intake of ω-3 and ω-6 fatty acids, and their effects on 
breast cancer incidence.  Finally, the epidemiologic evidence on the association between 
PUFA intake and survival among women with breast cancer is limited to ecologic analyses, 
and thus additional research for this plausible association is needed. 
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1.8 PUFA Biomarkers 
1.8.1 Epidemiology of PUFA Biomarkers and Breast Cancer 
 Several studies have been conducted examining PUFA biomarkers.  Previous studies 
have been conducted regarding fatty acid biomarkers and breast cancer incidence [94, 303-
317].  One examined the effect of fatty acid biomarkers on survival [318].  Many of these 
studies measured adipose tissue biomarkers [94, 303-305, 313, 314].  However, most of these 
studies were conducted among European populations, and interpretation of the results is 
limited by the reduced sample sizes or hospital-based study designs.  Only three studies were 
conducted among U.S. populations [94, 317, 318].  One of the three studies [94] included 
only postmenopausal women diagnosed with stage 1 or 3 breast cancer in a hospital-based 
case-control study design.  The study reported 40% risk reduction (95% CI = 0.4, 1.0) when 
comparing the third quartile of long-chain ω-3 fatty acids to the lowest quartile.  No effects 
were seen for total PUFAs, and ω-6 fatty acids were not reported.  The second study 
examined the effect of an adipose tissue biomarker on breast cancer survival [318].  
However, only 16 of 161 women comprising the cohort died of breast cancer, thus, resulting 
in imprecise effect estimates and limiting the interpretation of the results.  The third study 
examined adipose tissue levels of PUFAs and breast cancer incidence using a hospital-based 
case-control design [317].  The study included a total of 147 subjects and reported null 
estimates for ω-6 adipose tissue levels and breast cancer.  However, the study reported 
approximately 8% risk reduction for long-chain ω-3 fatty acids (OR = 0.92; 95% CI = 0.84, 
1.01), and 40% risk reduction for a unit increase in the ratio of long-chain ω-3 fatty acids to 
ω-6 fatty acids (OR = 0.60; 95% CI = 0.32, 1.10).  However, the limited sample size for this 
study and the hospital-based design limits the inference of the study results to other 
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populations. 
 Although, there have been five studies that examined erythrocyte membrane fatty 
acids and breast cancer incidence, all of these studies were conducted among either Asian 
[306, 308] or European populations [307, 311, 312].  One of the studies selected the cases 
and controls from women who were formerly employed at the Shanghai Textile Industry 
Bureau, thus limiting inferences of the study results to other populations [308].  Among 
Japanese women, a higher ratio of ω-6 to ω-3 erythrocyte membrane biomarker resulted in 
increased risk for breast cancer (OR for highest tertile versus lowest = 1.51; 95% CI = 0.81, 
2.81) [306].  Another study examining the ω-3 to ω-6 ratio reported a 4% risk reduction 
(95% CI = 0.78, 1.18) for postmenopausal breast cancer among a Swedish cohort [311]. 
 Only four previous studies examined serum biomarkers of fatty acid intake on breast 
cancer incidence.  A cohort study conducted among New York women reported nearly 30% 
reduction in breast cancer risk among those women with the highest quartile of serum ω-3 
levels in fat compared to the lowest [309].  A similar risk reduction was observed for total ω-
6, which is not consistent with the biologic mechanism of ω-6 fatty acid metabolism and 
breast carcinogenesis.  Additionally, the study did not examine the relative levels of ω-3 to 
ω-6 fatty acids.  The second study of serum biomarkers and breast cancer derived their study 
participants from a previous randomized trial and was comprised of women who were heavy 
smokers [310].  The final two European studies utilized a case-control study design 
conducted among Finnish [316] and French populations [315].   The Finnish study reported 
nearly 70% risk reduction for the highest tertile of total serum PUFAs to the lowest tertile 
[316].  The French study reported a slight breast cancer risk reduction for the highest quartile 
of serum ω-6 compared to the lowest (OR = 0.91; 95% CI = 0.40-2.06) and an approximately 
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40% risk reduction for the highest quartile of serum ω-3 compared to the lowest (OR = 0.58; 
95% CI = 0.27, 1.28).  In summary, few previous studies examined the relative balance of ω-
3 and ω-6 PUFA biomarkers on breast cancer incidence in a large population-based sample. 
 
1.8.2 Summary 
 Few studies have considered PUFA biomarkers using U.S. populations, but 
interpretation is limited due to small samples and failure to examine the relative balance of 
ω-3 and ω-6 fatty acids.  Also, PUFA biomarkers, though an objective measurement of fatty 
acid intake, may not reflect a relevant time period of exposure for breast cancer etiology.  
Most importantly, PUFA biomarkers may reflect dietary intake from a few hours (serum), 
months (erythrocyte membrane), or years (adipose tissue) of intake.  While adipose tissue 
biomarkers provide an appealing option for epidemiologic studies of diet and breast cancer, it 
is likely to result in selection bias due to the invasive procedure involved.  Also, adipose 
tissue biomarkers may not accurately reflect exposure during the etiologically relevant time 
period due to changes in weight.  In a situation with unlimited resources, repeated biomarker 
measurements would be ideal for examining the effects of PUFA levels on both breast cancer 
incidence and survival. 
 
1.9 Epidemiology of Fish Intake and Breast Cancer  
1.9.1 Fish Intake and Incidence 
 Twenty-two studies have been conducted regarding fish intake and breast cancer 
incidence.  The majority of studies have been conducted among either European (n=9) [89, 
279, 319-325] or Asian populations (n=7) [277, 326-331].  Comparatively, fewer studies 
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(n=5) have been conducted among U.S. populations [288, 298, 332-334], and one study was 
conducted among a Mexican population [335].  The literature regarding dietary fish intake 
and breast cancer incidence is assessed separately for case-control (n=15) and cohort studies 
(n=7), as the study design influences the timing of the exposure assessment. 
1.9.1.1 Case-Control Studies 
 As shown below in Table 1.6, results from case-control studies of fish intake and 
breast cancer among European populations consistently show risk reduction for breast cancer 
incidence.  The results are typically presented for total fish intake [89, 279, 321-323].  
European case-control studies estimated associations for total fish intake and breast cancer 
ranging from approximately 30% risk reduction (when comparing highest quantile to lowest) 
[321-323] to a 65% risk reduction [279].  One study reported a more pronounced risk 
reduction for total fish intake among postmenopausal (OR = 0.76; 95% CI = 0.70, 0.90) than 
among premenopausal women (OR = 0.88; 95% CI = 0.70, 1.10) [89].  Another European 
case-control study presented results for types of fish in addition to total fish intake.  Terry et 
al. [319] reported a modest risk reduction for total fish intake (OR = 0.88; 95% CI = 0.60, 
1.29) among a Swedish population.  However, when considering fatty fish intake, the 
primary source for LCω3 fatty acids, the association was stronger (OR = 0.70; 95% CI = 
0.45, 1.10).  Overall, European case-control studies tend to report risk reductions for fish 
intake.  However, none of these studies took into account fish preparation methods, which 
could affect the PUFA content in the food, and potentially reduce its benefit. 
 Similar to European populations, Asian case-control studies are also consistent with 
respect to fish intake.  The majority of Asian case-control studies report risk reductions for 
total fish intake [277, 326, 328, 330].  A Korean study reported stronger estimated 
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association between fatty fish and breast cancer incidence (OR=0.23; 95% CI = 0.13, 0.42) 
compared to total fish intake (OR=0.55; 95% CI = 0.32, 0.96), though estimates are 
imprecise [277].  More pronounced associations were also reported for total fish intake 
among postmenopausal women compared to premenopausal women [328, 329]. 
 While the majority of Asian studies report a risk reduction for fish intake, the 
Shanghai Breast Cancer Study population seems to be an exception.  Dai et al. [327] reported 
a nearly 50% increased risk of breast cancer for women in the highest quintile of intake for 
freshwater fish (OR = 1.48; 95% CI = 1.16, 1.89) and a modest increase in risk for marine 
fish (OR = 1.14; 95% CI = 0.90, 1.45).  A recently published study using the Shanghai Breast 
Cancer Study population also reported similar results for freshwater (OR = 1.39; 95% CI = 
1.23, 1.56; p for trend < 0.001) and marine fish (OR = 1.19; 95% CI = 1.02, 1.39) [331].  No 
differences were seen across ER/PR subtypes.  The results from the Shanghai Breast Cancer 
studies are not consistent with other Asian studies with regard to fish intake.  This increase in 
risk associated with freshwater and marine fish intake has been reported for other cancer sites 
as well, including endometrial [336] and colon [337] cancers.  The authors suggest that this 
unexpected increase in risk for fish intake in this Shanghai population may be due to the high 
levels of chemical exposures, including methylmercury, dibenzofurans, and organochlorine 
residues [331]. 
 Food science literature has demonstrated that different cooking methods could reduce 
the LCω-3 content in the food [147].  Also different food preparation methods (e.g., deep-
fried fish) could introduce ω-6 PUFA, and thus reduce the potential benefits of fish intake by 
unfavorably tipping the relative balance of ω-3/ω-6 PUFAs towards high ω-6 intake [147].  
Therefore, it is important to consider preparation methods when examining the potential 
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association between dietary fish intake and breast cancer.  Cancer epidemiologic studies 
examining fish cooking method have reported differences in risk [338]; however, this topic 
remains understudied with respect to breast cancer.  A few Asian studies also reported effect 
estimates for different type of fish cooking or preparation methods.  One hospital-based case-
control study conducted in Japan also attempted to examine the effect of cooking methods on 
breast cancer incidence [328].  However, the categorization of cooking methods was crude, 
where the authors had only two categories of preparation methods: (1) cooked/raw fish 
consumption; and (2) dried/salted fish consumption.  Comparing the highest level of intake 
frequency (greater than 3 times per week) versus the lowest (almost never), the authors 
reported a risk reductions for cooked/raw fish intake and dried/salted fish among 
postmenopausal women only.  The Shanghai Breast Cancer Study population [327] took into 
account different levels of deep-fried cooking (including never deep-fried, ever deep-fried, 
and well-done) and reported a 50% increased breast cancer risk for deep-fried freshwater fish 
and approximately 30% increased risk for deep-fried marine fish [327].  There was a 
suggestion of a potential U-shaped relation between consumption of ever deep-fried marine 
fish and well-done marine fish and breast cancer, with the second, third, and fourth quintiles 
of intake conferring a reduction in breast cancer risk.  In comparison, an early Japanese 
hospital-based case-control study [326], examined the effects of boiled (or broiled) fish and 
sashimi intake on breast cancer incidence.  Compared to those who consumed less than or 
equal to 3 servings per month, a 12% risk reduction was observed among premenopausal 
women who consumed 1-2 servings per week, and this effect was stronger among 
postmenopausal women (OR = 0.82; 95% CI = 0.63, 1.07). 
 Overall, Asian studies (with the exception of Shanghai populations) report consistent 
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risk reductions with respect to total fish intake and breast cancer incidence.  Stronger 
associations were estimated for fatty fish intake and among postmenopausal women. 
 One Mexican study also examined the effect of total fish intake on breast cancer 
incidence [335], using a hospital-based case-control study of a total of approximately 400 
subjects.  Comparing highest consumption of fish intake (greater than 1.5 portions per week) 
to never, the authors reported a nearly 35% risk reduction (OR = 0.67; 95% CI = 0.26, 1.72).  
Risk reductions were also observed for those women consuming less than 1 portion per week 
(OR = 0.72; 95% CI = 0.29, 1.79) and 1-1.5 portions per week of total fish intake (OR = 
0.89; 95% CI = 0.34, 2.30). 
 While many case-control studies regarding fish consumption and breast cancer 
incidence have been conducted among European and Asian populations, only one case-
control study was conducted using a U.S. population.  McElroy et al. conducted a population-
based case-control study in Wisconsin, examining the effects of sport-caught fish on breast 
cancer risk [334].  The exposure was determined using the following questions: (1) “How 
often did you eat sport-caught fish?”; and (2) “Was any of this sport-caught fish from the 
Great Lakes?”  In addition to these questions, recent consumption of trout or salmon from the 
Great Lakes was also assessed.  The authors reported a modest risk reduction to null effects 
for any recent sport-caught fish consumption and any recent Great Lakes trout or salmon 
consumption. 
 In sum, several case-control studies have been conducted among both European and 
Asian populations examining dietary fish intake and breast cancer incidence.  Consistent risk 
reductions were reported among both European and Asian populations for total fish intake 
and breast cancer risk.  In both of these populations, more pronounced associations were 
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estimated for fatty fish intake and among postmenopausal women.  While numerous case-
control studies were conducted among both European and Asian populations, only one case-
control study was conducted among a U.S. population.  However, the exposure assessment 
utilized in this study is not ideal for considered dietary intake, thus limiting the interpretation 
of the study results. 
 
1.9.1.2 Cohort Studies 
 As shown below in Table 1.7, all cohort studies examining the association of fish 
intake and breast cancer incidence have been conducted among either European [320, 324, 
325] or U.S. populations [288, 298, 332, 333].  The European cohort studies examining the 
effect of fish intake and breast cancer report increased risks overall.   However, among a 
Norwegian cohort of 14,500 women who were followed for 11 to 14 years, poached fish 
reduced breast cancer risk for both women who consumed 2-4 times per week (RR = 0.8; 
95% CI = 0.5, 1.1) and those who consumed greater than or equal to 5 times per week (RR = 
0.7; 95% CI = 0.4, 1.0), when compared to women consuming less than twice per month 
[320]. 
 Cohort studies conducted among U.S. populations are also inconsistent, with most 
studies reporting a null [288, 332] or very modest reduction [298].  An increased incidence of 
breast cancer among premenopausal women was suggested among the Nurses’ Health Study 
(RR = 1.17; 95% CI = 0.92, 1.50) [296].  In contrast, a modest risk reduction (approximately 
10%) was reported for total fish intake on breast cancer incidence in the Iowa Women’s 
Health Study, a cohort comprised of nearly 42,000 women aged 55-69 years [298].  While 
most U.S. studies report null results for fish intake and breast cancer, the VITamins And 
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Lifestyle (VITAL) Cohort reported a statistically significant 30% risk reduction for current 
users of fish oil supplements and breast cancer risk (HR = 0.68; 95% CI = 0.50, 0.98).  
Results on former users of fish oil supplements and breast cancer risk were null, and 10-year 
average use of fish oil supplements prior to baseline were reported to reduce risk by 20-25%, 
though no evidence of a trend was observed [333].  The authors suggest that current use may 
be a better measure of exposure during the etiologically relevant time period for breast cancer 
(0-7.3 years after baseline), and that former use of fish oil supplements may not represent a 
relevant exposure window for breast cancer etiology.  While Brasky et al. reported a breast 
cancer risk reduction for current users of fish oil supplements, the effect of fish intake on 
breast cancer remains unresolved in the U.S.  No recommendations regarding fish or fish oil 
supplementation should be made without further investigation into this topic. 
 In sum, European cohort studies examining fish intake and breast cancer incidence 
report increased risks, with the exception for poached fish, where a risk reduction was 
suggested.  The potential association between fish intake and breast cancer incidence among 
U.S. cohort studies remains inconsistent across studies.  However, a potential risk reduction 
was reported among the VITAL cohort for fish oil supplementation. 
 
1.9.2 Fish Intake and Survival & Mortality 
 Unlike breast cancer incidence, the observational studies of dietary fish intake and 
breast cancer survival are limited.  As shown in Table 1.8, three studies have been conducted 
examining the effect of fish intake on survival from breast cancer [339-341].  The earliest 
study was conducted in 1992 among a Japanese population following 213 breast cancer cases 
starting in 1975-1978 until 1987 [340].  A total of 47 breast cancer deaths occurred.  
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Compared to those in the lowest quartile of intake, women who had the highest quartile of fat 
consumption from fish origin (including fat from fresh fish, shell fish, and processed fish) 
were 40% more likely to die from breast cancer (HR = 1.4; 95% CI = 0.5, 1.7) [340].  
Another study conducted among a Norwegian population followed 533, 276 women aged 35-
54 from 1970 to 1985 [341].  Those women who were married to a fisherman were 33% less 
likely to die from breast cancer (RR = 0.67; 95% CI = 0.47, 0.94) compared to wives of 
unskilled workers.  The results from this study are difficult to interpret with regards to fish 
intake and breast cancer mortality due to the exposure assessment for fish intake.  It is 
assumed that wives of fisherman are likely to consume more fish than wives of unskilled 
workers, which may not be a valid assumption. 
 Only one of the three cohort studies on fish intake in relation to breast cancer survival 
was conducted using a U.S. population [339].  This study was conducted using the Women’s 
Healthy Eating and Living (WHEL) study and followed more than 3,000 women with breast 
cancer for a median of 7.3 years.  Marine sources of both EPA and DHA were assessed using 
multiple 24-hour dietary recalls.  The study found that those women consuming the highest 
tertile of marine sources of EPA and DHA compared those women in the lowest tertile were 
less likely to have a breast cancer recurrence (HR = 0.72; 95% CI = 0.57, 0.90) and less 
likely to die (all-cause mortality HR = 0.59; 95% CI = 0.43, 0.82) [339].  An eligibility 
criterion for inclusion into the WHEL study was diagnosis of primary operable invasive stage 
breast carcinoma within the past 4 years.  While Patterson et al. adjusted for time between 
diagnosis and study entry in their statistical models, it is still likely that assessment of fish 
intake occurred at different time periods after breast cancer diagnosis for different women.  
Thus, it is difficult to understand whether dietary intake early in diagnosis (versus later) 
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would prove to be more beneficial for survival.  This information would be important for 
survivors regarding at what point to incorporate fish intake into dietary habits after breast 
cancer diagnosis and treatment. 
 
1.9.3 Summary 
 The small number of studies, both case-control and cohort, that have examined the 
effects of fish intake on breast cancer incidence are not consistent among U.S. populations.  
No studies conducted among U.S. populations examined the effect of cooking or preparation 
methods.  A consistent risk reduction for fish intake was observed among the majority of 
Asian case-control studies.  However, an exception is the Shanghai Breast Cancer Study 
population, where studies have consistently reported increased risks for breast cancer for 
both freshwater and marine fish.  European case-control studies reported a risk reduction for 
overall fish intake, whereas cohort studies reported increased risks for fish intake.  Neither 
case-control nor cohort studies conducted among European populations examined cooking or 
preparation methods.  The consistency observed among Asian populations may be due to 
differences in fish intake.  Asian populations are known to consume large quantities of fish 
compared to other populations, and this may explain consistency observed among this 
population.  Differences seen among European case-control and cohort studies may reflect 
differential recall of dietary intake.  It is possible that differential recall was causing the 
European case-control studies to have risk reductions for overall fish intake.  Overall, the 
effect of fish on breast cancer risk remains unresolved in Europe and the U.S. 
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1.10 Epidemiology of PUFA-Gene Interactions and Breast Cancer 
 Only two studies have been conducted examining the effect of PUFA-gene 
interaction and breast cancer incidence [287, 342].  First, using data from the Singapore 
Chinese Health Study, Gago-Dominguez et al. [342] examined the effect of marine ω-3 fatty 
acid intake, glutathione S-transferase polymorphisms and breast cancer incidence among 
postmenopausal women.  Gago-Dominguez utilized a nested case-control study design 
including 258 women with incident breast cancer and a sample of 670 cohort controls.  The 
study reported effect estimates stratified by genotype (e.g., GSTM1 null, GSTM1 positive, 
GSTT1 null, etc.) and comparing quartiles 2-4 to quartile 1 of dietary marine ω-3 intake.  
Large risk reductions were reported for postmenopausal women consuming dietary marine 
ω-3 fatty acid intake in quartiles 2-4 compared to quartile 1 when stratified by the following 
genotypes: GSTM1 null (OR = 0.66; 95% CI 0.37, 1.16); GSTM1 positive (OR = 0.83; 95% 
CI = 0.48, 1.42), GSTT1 null (OR = 0.54; 95% CI = 0.29, 1.00); GSTP1 (A-to-G transition at 
base 1578 and C-to-T transition at base 2293) AB/BB genotypes (OR = 0.49; 95% CI = 0.26, 
0.93), where GSTP1*A genotypes possess both AA (base 1578) and CC (base 2293), 
GSTP1*B genotypes possess both AG/GG (base 1578) and CC (base 2293) [342].  The 
strongest effects for marine ω-3 fatty acid intake were seen among those carrying genotypes 
conferring lower glutathione S-transferase activity, which is consistent with the biologic 
mechanism of PUFAs inducing a cytotoxic environment via lipid peroxidation. 
 The second PUFA-gene interaction study examined the effect of dietary LA and 
genetic polymorphisms in 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein 
(ALOX5AP) on breast cancer risk utilizing a the San Francisco Bay Area Breast Cancer 
Study, a population-based case-control study including Latina, African American, and White 
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women [287].  A total of three polymorphisms (one microsatellite and two SNPs) were 
examined for ALOX5AP, including: (1) -169 to -146 poly(A) microsatellite; (2) -4900 A>G 
rs4076128; and (3) -3472 A>G rs4073259.  Three polymorphisms were also selected for 
ALOX5: (1) -176 to -147 Sp1-binding site 6-bp (-GGGCGG-) variable number of tandem 
repeat; (2) -1279 G>T rs6593482, and (3) 760 G>A rs2228065. 
 When examining the joint effects of the ALOX5AP -4900 A>G polymorphism and 
dietary LA intake, the largest risk for breast cancer was observed among women with the 
highest intake of LA (quartile 4) and AA genotype (OR = 1.8; 95% CI = 1.2, 2.9), and this 
increased risk among this grouping was consistent among Whites and Latinas [287].  
However, the authors did note that the results from this nutrient-gene interaction paper were 
not consistent with the biology of ω-6 metabolism via the lipoxygenase pathway.  They 
expected variant alleles for ALOX5 transcription to have a reduced risk for breast cancer due 
to the reduced production of the inflammatory metabolite 5-hydroxy-6,8,11,14-
eicosatetrenoic acid (5S-HpETE). 
 Only these two studies have examined the effect of genetic polymorphisms and 
dietary PUFA intake on breast cancer incidence.  No studies have examined the effect of 
PUFA-gene interactions for breast cancer survival.  Examining PUFA-gene interactions are 
important for identifying subgroups of women who may be susceptible to the beneficial 
effects of ω-3 fatty acids for both preventing breast cancer incidence and improving survival 
from breast cancer. 
 
1.11 Background and Introduction Summary 
 Breast cancer is the second most common cancer among women and is the second 
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leading cause of cancer mortality in the U.S. [1, 2].  Despite this high burden of breast cancer 
in the U.S., few easily modifiable breast cancer risk reduction strategies or strategies to 
improve survival after diagnosis are available.  Laboratory and animal evidence suggest that 
ω-3 fatty acids competitively inhibit ω-6 fatty acids, and thus help reduce inflammatory 
eicosanoids resulting from ω-6 metabolism.  Despite this biologic plausibility, the results 
from epidemiologic studies of dietary PUFA intake and breast cancer incidence are 
inconsistent, especially among European and U.S. populations.  Examination of the relative 
balance of ω-3 and ω-6 intake and the interaction of PUFAs with genes involved in 
biologically related pathways, may help to elucidate the potential association between dietary 
PUFA intake and breast cancer in the U.S.  However, few studies have examined the 
association between the relative balance of ω-3 and ω-6 intake on breast cancer incidence 
[270, 286], and the interaction between PUFA intake and genes [287], among U.S. 
populations.  Studies regarding dietary PUFA intake and survival from breast cancer are 
limited to ecologic analyses [300, 301], thus limiting inference regarding the potential benefit 
of ω-3 intake on improving survival from breast cancer.  Therefore, comprehensive 
examination of dietary PUFA intake (including ω-3 subtypes, ω-6 subtypes, and the relative 
balance of ω-3 and ω-6), along with interaction with biologically plausible genes may help to 
elucidate the potential association between PUFA intake and breast cancer incidence and 
survival in the U.S.  
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Table 1.1 Polyunsaturated Fatty Acids and Sources 
PUFA 
Category 
Name 
Carbon  
Chain  
length 
# of 
double  
bonds 
Examples of foods rich in 
PUFAs 
ω-3 
Alpha-linolenic acid 
(ALA) 
18 3 
Canola oil, linseed oil, mackerel, 
herring, salmon,  
trout, tuna, cod, flaxseed, 
soybeans 
Eicosapentaenoic acid 
(EPA) 
20 5 
Docosahexaenoic acid 
(DHA) 
22 6 
Docosapentaenoic acid 
(DPA) 
22 5 
ω-6 
Linoleic acid (LA) 18 2 Corn oil, sunflower oil, 
margarine, lard, egg,  
bacon, ham, maize, almond,  
brazil nut, peanut, walnut 
Arachidonic acid (AA) 20 4 
 
Source: [145, 146, 148] 
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Table 1.2 Summary of Case-Control Studies of Self-reported PUFA Intake and Breast Cancer Incidence 
 
No. Study, Year [Ref.] Population 
Study N 
PUFA ω3 
Subtypes 
ω6 
Subtypes ω3 
ω6 Case Cont. ALA EPA DHA DPA LA AA 
1 Shun-Zhang, 1990 [275] Shanghai 186 186 ↑          
2 Lee, 1992 [276] Singapore 200 420 ↔          
3 Kim, 2009 [277] Korea 358 360  ↓  ↓ ↓      
4 Zaridze, 1991 [104] Russia 139 139 ↓          
5 Van’t Veer, 1991 [99] Netherlands 168 548 ↓          
6 Katsouyanni, 1994 [278] Greece 820 1547 ↑          
7 Landa, 1994 [279] Spain 100 100 ↓          
8 Martin-Moreno, 1994 [280] Spain 762 988 ↑       ↑   
9 Nkondjock, 2003 [269] Montreal 414 429  ↑ ↑ ↑ ↔ ↑ ↔ ↓ ↓ ↑ 
10 Tavani, 2003 [281] Italy, Switz. 2900 3122  ↓         
11 Alothaimeen, 2004 [282] Saudi Arab. 499 498 ↑          
12 De Stefani, 1998 [283] Uruguay 365 397 ↔  ↑     ↓   
13 Chajes, 2012 [284] Mexico 1000 1074  ↓     ↑   ↓ 
14 Witte, 1997 [285] USA 140 220 ↓       ↓   
15 Goodstine, 2003 [286] USA 565 554 ↑   ↓ ↔     ↓ 
16 Wang, 2008 [287] USA 1788 2129        ↑   
Note: 
↑ indicates an effect estimate > 1.  ↓ indicates an effect estimate < 1.  ↔ indicates a null effect estimate. 
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Table 1.3 Summary of Cohort Studies of Self-reported PUFA Intake and Breast Cancer Incidence 
 
No. Study, Year [Ref.] Population 
N 
Events 
PUFA ω3 
Subtypes 
ω6 
Subtypes 
ω3 
ω6 
ω6 
ω3 
ω6 
LCω3 ALA EPA DHA DPA 
LC 
ω3 
LA AA 
1 
Gago-Dominguez, 
2003 [289] 
Singapore 314 ↑ ↓     ↓ ↑   ↔ ↑  
2 Wakai, 2005 [100] Japan 79 ↑ ↓     ↓ ↔    ↑  
3 Murff, 2010 [290] Shanghai 712   ↑    ↓  ↑ ↑  ↔ ↑
a
 
4 Knekt, 1990 [291] Finland 54 ↑             
5 Voorrips, 2002 [292] Netherlands 941 ↓  ↓ ↔ ↔    ↓ ↔    
6 Lof, 2007 [293] Sweden 974 ↓             
7 Wirfalt, 2002 [85] Sweden 237
b
 ↑ ↑      ↑   ↓   
8 Thiebaut, 2009 [294] France 1650  ↔ ↑    ↓ ↓ ↓ ↔  ↔  
9 Toniolo, 1994 [288] USA 180
c
         ↑     
10 
Barrett-Connor, 1993 
[295] 
USA 15 ↑  ↑      ↑     
11 Holmes, 1999 [296] USA 2956 ↔ ↑ ↓ ↑ ↑    ↓ ↑    
12 Velie, 2000 [297] USA 996         ↑     
13 Byrne, 2002 [80] USA 1071         ↓     
14 Folsom, 2004 [298] USA 1885  ↓            
15 
Sczaniecka, 2012 
[270] 
USA 772 ↔  ↔ ↓ ↓    ↑ ↔ ↓   
Note: 
↑ indicates an effect estimate > 1.  ↓ indicates an effect estimate < 1.  ↔ indicates a null effect estimate. 
a Estimates presented as interactions (e.g., high ω-3 intake, low ω-6, etc.), not ratio of ω-3 and ω-6 intake. 
b Nested case-control study of 237 cases and 673 controls. 
c Nested case-control study of 180 cases and 900 controls. 
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Table 1.4 Case-Control Studies of PUFA and Breast Cancer Incidence 
Author, Year Population 
Cases/Controls & 
Control Sampling 
Exposure 
Assessment & 
Categorization 
Results, Adjusted OR (95% CI), & Covariates 
Shun-Zhang, et 
al. 1990 [275] 
Shanghai 
186/186 
Population-based 
68-item FFQ 
Continuous, Tertiles 
PUFA 13g/day increase: 1.24 (0.75, 2.05) 
PUFA Q3 vs. Q1: 1.06 (95% CI Not reported) 
 
Covariates: Other sources of calories, education, BMI 
Zaridze, et al. 
1991 [104] 
Russia 
139/139 
Clinic-based 
 
145-item FFQ 
Quartiles 
Q4 vs. Q1 PUFA: Post-menopausal women only 
Model 1: 0.28 (0.08, 0.87); p for trend = 0.045 
Model 2: 0.14 (0.03, 0.69); p for trend = 0.008 
 
Covariates: 
Model 1: Energy intake 
Model 2: Energy intake, age at menarche, education 
Van’t Veer, et 
al. 1991 [99] 
Netherlands 
168/548 
Population-based 
236-item FFQ 
Referent: 
PUFA ≤ 16% of 
total fat 
PUFA high vs. low: 
Model 1: 0.85 (0.56, 1.29) 
Model 2: 0.84 (0.55, 1.27) 
 
Covariates: 
Model 1: Age 
Model 2: Age and fat 
Lee, et al. 1992 
[276] 
Singapore 
200/420 
Hospital-based 
FFQ 
Tertiles 
  Premen.  Postmen. 
PUFA T3 vs. T1: 0.4 (0.2, 0.7) 1.7 (0.8, 3.6) 
p for trend: 0.004  0.05 
 
Covariates: 
Pre: Age, Age at first birth 
Post: Age, nulliparity, height, education, family history 
Katsouyanni, et 
al. 1994 [278] 
Greece 
820/(795, 753) 
Orthapaedic patients & 
hospital visitors 
 
115-item FFQ 
Quintiles analyzed 
as continuous 
variable 
PUFA unit-increase per quintile: 1.04 (0.97, 1.12) 
 
Covariates: Age, place of birth, age at first pregnancy, age at 
menarche, menopausal status, Quetelet’s index, total energy 
intake 
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Table 1.4 (cont.) Case-Control Studies of PUFA and Breast Cancer Incidence 
Author, Year Population 
Cases/Controls & 
Control Sampling 
Exposure 
Assessment & 
Categorization 
Results, Adjusted OR (95% CI), & Covariates 
 
Landa, et al. 
1994 [279] 
 
Spain 
100/100 
Hospital-based 
99-item FFQ 
Tertiles of monthly 
consumption 
PUFA T3 vs. T1: 0.42 (0.1, 1.1) 
Covariates: calories 
Martin-Moreno, 
et al. 1994 [280] 
Spain 
762/988 
Population-based 
118-item FFQ 
Quartiles 
Q4 vs. Q1 
 Pre  Post  All women 
PUFA: 1.58 (0.93, 2.71) 1.08 (0.73, 1.59) 1.34 (0.98, 1.84) 
LA: 1.46 (0.86, 2.49) 1.20 (0.81, 1.71) 1.22 (0.89, 1.68) 
Covariates: Age, geographical region (province), SES, 
Quetelet’s index, total energy intake 
Witte, et al. 
1997 [285] 
USA & Canada: 
California, 
Connecticut, and 
Quebec 
140: Premenopausal 
bilateral breast cancer 
220: Unaffected sisters 
Semi-quantitative 
FFQ 
Quartiles 
Q4 vs. Q1 
PUFA: 0.3 (0.1, 0.7); p for trend < 0.01 
LA: 0.3 (0.1, 0.7); p for trend < 0.01 
 
Covariates: Age, age at menarche, parity, oral contraceptive 
use, alcohol consumption, BMI, energy (residual method) 
De Stefani, et al. 
1998 [283] 
Uruguay 
365/397 
Hospital-based 
64-item FFQ 
Quartiles 
Q4 vs. Q1 
PUFA: 0.99 (0.59, 1.64); p for trend = 0.70 
LA: 0.72 (0.44, 1.19); p for trend = 0.25 
ALA: 3.24 (1.89, 5.58); p for trend = 0.01 
Covariates: Age, residence, urban/rural status, family history, 
BMI, age at menarche, parity, alcohol, total energy, dietary 
fiber, folate 
Goodstine, et al. 
2003 [286] 
USA: 
Connecticut 
565/554 
Hospital-based (New 
Haven) & Population-
based (Tolland county) 
Semi-quantitative 
FFQ 
Quartiles 
Q4 vs. Q1 
 Overall  Pre  Post 
PUFA: 1.06 (0.68, 1.64) n/a  n/a 
EPA: 0.94 (0.66, 1.34) 0.79 (0.38, 1.64) 0.97 (0.64, 1.47) 
DHA: 1.00 (0.70, 1.44) 0.82 (0.40, 1.68) 1.06 (0.70, 1.62) 
ω3/ω6: 0.82 (0.58, 1.15) 0.59 (0.29, 1.19) 0.89 (0.60, 1.34) 
Covariates: Age, age at menarche, age at first birth, number of 
live births, lactation history, BMI, menopausal status, race, 
family history, income 
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Table 1.4 (cont.) Case-Control Studies of PUFA and Breast Cancer Incidence 
Author, Year Population 
Cases/Controls & 
Control Sampling 
Exposure 
Assessment & 
Categorization 
Results, Adjusted OR (95% CI), & Covariates 
Nkondjock, et al. 
2003 [269] 
Montreal 
414/429 
Population-based 
200-item FFQ 
Quartiles 
Q4 vs. Q1 
LA: 0.90 (0.61, 1.34) 
AA: 0.86 (0.58, 1.30)  ω-6:  1.03 (0.70, 1.53) 
ALA: 1.27 (0.85, 1.89)  ω-3:  1.11 (0.74, 1.65) 
DPA: 1.33 (0.89, 1.99)  ω3/ω6:  1.26 (0.86, 1.86) 
EPA: 1.23 (0.82, 1.83) 
DHA: 0.98 (0.66, 1.46) 
Covariates: Age at first full-term pregnancy, history of breast 
cancer, history of benign breast disease, number of full-term 
pregnancies, smoking, marital status, and total energy intake 
Tavani, et al. 
2003 [281] 
Italy, Switzerland 
2,900/3,122 
Hospital-based 
78-item FFQ 
Quintiles, 
Continuous 
ω-3 Q5 vs. Q1: 0.8 (0.7, 1.0) 
Continuous (1 gram/week increase): 0.90 (0.84, 0.95) 
 
Covariates: Age, study center, education, BMI, energy intake, 
parity 
 
Alothaimeen, et 
al. 2004 [282] 
 
Saudi Arabia 
499/498 
Hospital-based 
FFQ 
Quartiles 
PUFA Q4 vs. Q1: 2.12 (95% CI not reported) 
Covariates: Not reported 
Wang, et al. 
2008 [287] 
USA: San Francisco 
1,788/2,129 
Population-based 
106-item Block FFQ 
Quartiles 
LA Q4 vs. Q1: 
Model 1: 1.27 (1.04, 1.54) 
Model 2: 1.10 (0.88, 1.37) 
 
Covariates: 
Model 1: Age, race/ethnicity, menopausal status, country of 
birth, education, family history, history of benign breast 
disease, age at menarche, parity, breast feeding, BMI, height, 
alcohol intake, total energy intake 
Model 2: Model 1 covariates plus saturated fat and oleic acid 
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Table 1.4 (cont.) Case-Control Studies of PUFA and Breast Cancer Incidence 
Author, Year Population 
Cases/Controls & 
Control Sampling 
Exposure 
Assessment & 
Categorization 
Results, Adjusted OR (95% CI), & Covariates 
Kim, et al. 2009 
[277] 
Korea 
358/360 
Hospital-based 
103-item FFQ 
Quartiles 
Q4 vs. Q1 
 Overall  Pre  Post 
ω-3: 0.47 (0.27, 0.80) 0.46 (0.22, 0.96) 0.51 (0.22, 1.13) 
EPA: 0.50 (0.28, 0.91) 0.67 (0.54, 2.33) 0.38 (0.15, 0.96) 
DHA: 0.44 (0.24, 0.79) 0.54 (0.24, 1.20) 0.32 (0.13, 0.82) 
All p for trend < 0.05, except for EPA (Pre) and DHA (Pre) 
 
Covariates: Age, BMI, family history, supplement use, 
education level, occupation, alcohol consumption, smoking 
status, physical activity, parity, total energy intake, menopausal 
status, age at menarche 
Chajes, et al. 
2012 [284] 
Mexico 
1,000/1,074 
Population-based 
FFQ 
Tertiles 
T3 vs. T1  
 Overall  Pre  Post 
ω-3: 0.87 (0.68, 1.13) 0.80 (0.54, 1.19) 0.87 (0.61, 1.22) 
ω-6: 1.45 (1.03, 2.04) 1.92 (1.13, 3.26) 1.04 (0.65, 1.68) 
ω3/ω6: 0.82 (0.64, 1.05) 0.71 (0.48, 1.05) 0.89 (0.64, 1.25) 
Only ω-6 (overall) and ω-6 (pre) with p for trend < 0.05 
 
Covariates: BMI, height, family history, age at first menses, age 
at first full-term pregnancy, number of full-term pregnancies, 
breast feeding, age at menopause, SES, hormone use, OC use, 
physical activity, energy intake, alcohol consumption 
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Table 1.5 Cohort Studies of PUFA and Breast Cancer Incidence 
Author, Year Population 
Sample size, Median 
Length of Follow-up 
Exposure 
Assessment 
(Categorization) 
Results, Adjusted HR, RR (95% CI), & Covariates 
Knekt, et al. 
1990 [291] 
Finland 
3,988 total cohort 
54 outcomes 
20 years (1967-1986) 
Diet history at 
baseline (Tertiles) 
  Model 1   Model 2 
PUFA T3 vs. T1: 0.86 (0.44, 1.68)  1.23 (0.55, 2.75) 
 
Covariates: age (Model 1), age and energy (Model 2)  
 
Barrett-Connor, 
et al. 1993 [295] 
 
USA: Rancho 
Bernardo, California 
590 total cohort 
15 outcomes 
24-hour dietary 
recall (Tertiles) 
Age-adjusted rates of incident breast cancer increase with 
increasing tertiles (values obtained from visual inspection of 
graphs) 
 Tertile 1  Tertile 2  Tertile 3 
PUFA: 5/1000py 15/1000py 55/1000py 
LA: 5/1000py 15/1000py 65/1000py 
ALA: 10/1000py 20/1000py 50/1000py 
Toniolo, et al. 
1994 [288] 
USA: New York 
University Women’s 
Health Study 
 
180/900 
Nested case-control study 
 
71-item modified 
Block FFQ 
Quintiles 
LA Q5 vs. Q1: 1.13 (0.65, 1.98) 
Higher risks seen for Q2 (1.21), Q3 (1.66), and Q4 (1.49) 
Covariates: energy 
Holmes, et al. 
1999 [296] 
 
USA: Nurses’ 
Health Study 
 
88,795 total cohort 
2,956 outcomes 
14 years 
Repeated FFQs, 
cumulatively 
averaged intake 
reported in 1980, 
1984, 1986, and 
1990 (continuous) 
 Overall  Pre  Post 
PUFA
a
: 0.91 (0.79, 1.04) 0.99 (0.77, 1.27) 0.88 (0.74, 1.04) 
ω-3b: 1.09 (1.03, 1.16) 1.10 (0.96, 1.26) 1.09 (1.02, 1.17) 
PUFA
c
: 0.97 (0.81, 1.16) 
LA
d
: 0.95 (0.92, 0.98) 
ALA
d
: 0.75 (0.54, 1.03) 
AA
d
: 1.05 (1.00, 1.10) 
EPA
d
: 1.06 (1.02, 1.10) 
DHA
d
: 1.04 (1.01, 1.06) 
a
5% of energy, 
bω-3 from fish (0.1% of energy), c5% of energy 
adjusted for other fats, 
d
1% of energy 
Covariates: energy, age, energy-adjusted vitamin A intake, 
alcohol intake, time period, height, parity, age at first birth, 
weight change since age 18 years, BMI at 18 years, age at 
menopause, menopausal status, HRT use, family history, benign 
breast disease, age at menarche 
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Table 1.5 (cont.) Cohort Studies of PUFA and Breast Cancer Incidence 
Author, Year Population 
Sample size, Median 
Length of Follow-up 
Exposure 
Assessment 
(Categorization) 
Results, Adjusted HR, RR* (95% CI), & Covariates 
Velie, et al. 2000 
[297] 
 
USA: Breast Cancer 
Detection 
Demonstration 
Project 
 
40,022 post-menopausal 
women 
996 breast cancer cases 
5.3 years average follow-
up 
Block 60-item FFQ 
(Quintiles) 
Postmenopausal women (N=40,022) 
LA Q5 vs. Q1: 1.05 (0.82, 1.34) 
Postmenopausal women with history of BBD (N=13,707) 
LA Q5 vs. Q1: 1.29 (0.78, 2.13) 
 
Covariates: total energy, BMI, height, family history, parity, 
age at first birth, educational level, alcohol use, age at 
menarche, history of BBD (for first model only) 
Byrne, et al. 
2002 [80] 
USA: Nurses’ 
Health Study 
44,697 post-menopausal 
women 
1,071 breast cancer cases 
Repeated FFQs: 
61-item FFQ (1980) 
131-item FFQ 
(1984, 1986, 1990) 
Cumulative 
averaged dietary 
intake 
(Quintiles) 
Replicate of Velie, et al., (2000) analysis 
Postmenopausal women (N=44,697) 
LA Q5 vs. Q1: 0.93 (0.74, 1.16) 
Q4, Q3, Q2 all consistent with RRs approx. 0.83 
 
Covariates: age, height, age at menarche, age at menopause, use 
of postmenopausal hormones, parity, age at first birth, BMI, 
weight change since age 18, total energy, alcohol, family 
history, vitamin A intake. 
Voorrips, et al. 
2002 [292] 
The Netherlands 
Cohort Study 
 
Case-cohort study: 
1,598 sub-cohort 
941 cases 
6.3 years average follow-
up 
 
150-item semi-
quantitative FFQ 
(Quartiles) 
Q5 vs. Q1  
PUFA: 0.88 (0.67, 1.15)   
ALA: 0.68 (0.51, 0.91)  LA: 0.95 (0.72, 1.24)  
EPA: 1.03 (0.78, 1.37)  AA: 1.01 (0.77, 1.33) 
DHA: 1.02 (0.77, 1.36) 
Note: 
Q4 vs. Q1 (EPA) = 1.23 (0.93, 1.62) 
Q4 vs. Q1 (DHA) = 1.20 (0.91, 1.58) 
 
Age-adjusted (adjustment for other covariates including total 
energy intake didn’t make a difference) 
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Table 1.5 (cont.) Cohort Studies of PUFA and Breast Cancer Incidence 
Author, Year Population 
Sample size, Median 
Length of Follow-up 
Exposure 
Assessment 
(Categorization) 
Results, Adjusted HR, RR* (95% CI), & Covariates 
 
Wirfalt, et al. 
2002 [85] 
 
Sweden 
237/673 
Population-based nested 
case-control study 
7-day diet history & 
FFQ 
Quintiles 
Q5 vs. Q1 
PUFA: 3.02 (1.75, 5.21); p for trend = 0.0007 
ω-3: 1.81 (1.09, 2.99); p for trend = 0.026 
ω-6: 3.02 (1.78, 5.13); p for trend = 0.0002 
ω3/ω6: 0.66 (0.41, 1.08); p for trend = 0.137 
 
Covariates: Past food habit change, energy intake, BMI, height, 
waist circumference, age at first birth, current hormone therapy, 
alcohol habits, and educational status 
Gago-
Dominguez, et 
al. 2003 [289] 
 
The Singapore 
Chinese Health 
Study 
 
35,298 women aged 45-74 
years old 
314 breast cancer cases 
5.3 years average follow-
up 
165-item semi-
quantitative FFQ 
Quartiles 
Q4 vs. Q1 
PUFA:  1.27 (0.92, 1.74) Note: Q3 0.83 (0.59, 1.18) 
ω-6:  1.22 (0.89, 1.67) Note: Q3 0.90 (0.64, 1.26) 
ω-3:  0.87 (0.64, 1.18)  
ω-3, marine: 0.72 (0.53, 0.98) 
ω-3, other: 1.00 (0.73, 1.36) Note: Q2 thru Q3 ↓ risk 
   
  Pre   Post 
ω-3, marine: 0.90 (0.49, 1.65)  0.68 (0.47, 0.97) 
 
High ω-6 intake (Q4), low ω-3 intake (Q1): 1.87 (1.06, 3.27) 
Low ω-6 intake (Q2), high ω-3 intake (Q2-4): 1.03 (0.69, 1.53)  
 
Covariates: age, year of recruitment, dialect group, education, 
daily alcohol drinker, family history, age at menarche, parity 
 
Folsom, et al. 
2004 [298] 
 
USA: The Iowa 
Women’s Health 
Study cohort 
41,836 women aged 55-69 
years 
1,885 breast cancer cases 
127-item FFQ 
Quintiles 
ω-3 Q5 vs. Q1: 0.91 (0.77, 1.08) 
 
Covariates: age, energy intake, education, alcohol, smoking, 
pack-years of cigarette smoking, age at first birth, estrogen use, 
vitamin use, BMI, waist/hip ratio, diabetes, hypertension, intake 
of whole grains, fruit and vegetables, red meat, cholesterol, and 
saturated fat 
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Table 1.5 (cont.) Cohort Studies of PUFA and Breast Cancer Incidence 
Author, Year Population 
Sample size, Median 
Length of Follow-up 
Exposure 
Assessment 
(Categorization) 
Results, Adjusted HR, RR* (95% CI), & Covariates 
 
Wakai, et al. 
2005 [100] 
 
Japan Collaborative 
Cohort Study 
(JACC) 
26, 291 women aged 40-
79 years 
129 breast cancer cases 
40-item FFQ 
Quartiles 
Q5 vs. Q1  
 Age-adjusted  Multivariate-adjusted 
PUFA: 0.85 (0.52, 1.40)  1.10 (0.63, 1.90) 
ω-3: 0.62 (0.37, 1.03)  0.69 (0.40, 1.18) 
ω-6: 0.80 (0.49, 1.30)  1.02 (0.59, 1.74) 
ω6/ω3: 1.20 (0.73, 1.99)  1.31 (0.78, 2.19) 
LC ω-3: 0.50 (0.30, 0.83)  0.50 (0.30, 0.85) 
Higher risks reported among postmenopausal women at 
baseline for total PUFA, ω-3, and ω-6. 
 
Covariates: age, study area, educational level, family history of 
breast cancer, age at menarche, age at menopause, age at first 
birth, parity, use of exogenous female hormones, alcohol 
consumption, smoking, consumption of green leafy vegetables, 
daily walking, height, body mass index, and total energy intake. 
Lof, et al. 2007 
[293] 
Sweden 
 
49,261 women 30-49 
years of age 
974 breast cancer cases 
 
80-item FFQ 
Quintiles 
Q5 vs. Q1 
 Overall  BC < 50 yrs BC > 50 yrs 
PUFA: 0.72 (0.52, 1.00) 1.06 (0.64, 1.75) 0.54 (0.35, 0.85) 
 
Covariates: education, parity, age at menarche, use of oral 
contraceptives, age at first birth, first-degree relative with breast 
cancer, non-alcohol total energy intake, total fat intake, BMI, 
and alcohol intake 
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Table 1.5 (cont.) Cohort Studies of PUFA and Breast Cancer Incidence 
Author, Year Population 
Sample size, Median 
Length of Follow-up 
Exposure 
Assessment 
(Categorization) 
Results, Adjusted HR, RR* (95% CI), & Covariates 
Thiebaut, et al. 
2009 [294] 
France 
 
56,007 women 
1,650 breast cancer cases 
 
208-item diet history 
questionnaire 
Quintiles 
Q5 vs. Q1 
ω-6: 0.93 (0.80, 1.09) ω-3: 0.99 (0.84, 1.15) 
LA: 0.92 (0.79, 1.07) ALA: 1.05 (0.90, 1.23) 
AA: 0.99 (0.85, 1.16) LC ω-3: 0.94 (0.80, 1.10) 
 
ω6/ω3: 0.97 (0.83, 1.14) 
 
Covariates: age, non-alcohol energy, ethanol intake, smoking 
history, history of BBD, history of breast cancer in first-degree 
relative, age at menarche, parity, BMI, menopausal status, age 
at menopause, use of hormone treatment 
Murff, et al. 
2010 [290] 
 
Shanghai Women’s 
Health Study 
 
72,571 women 
712 breast cancer cases 
FFQ 
Quintiles 
Q5 vs. Q1 
LA: 1.13 (0.82, 1.54)  ALA: 1.07 (0.76, 1.50) 
AA: 1.06 (0.78, 1.45)  LC ω-3: 0.74 (0.52, 1.06) 
 
ω6/ω3:  1.02 (0.77, 1.34) 
ω6/ LC ω3: 1.29 (0.95, 1.75) 
 
Covariates: age, BMI, total energy, family history of breast 
cancer, alcohol use, tobacco use, education, use of hormone 
replacement therapy, personal history of diabetes, menopausal 
status, age at menopause, age at menarche, parity, age at first 
pregnancy, level of physical activity, red meat intake, fish 
intake, vitamin E intake 
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Table 1.5 (cont.) Cohort Studies of PUFA and Breast Cancer Incidence 
Author, Year Population 
Sample size, Median 
Length of Follow-up 
Exposure 
Assessment 
(Categorization) 
Results, Adjusted HR, RR* (95% CI), & Covariates 
Sczaniecka, et 
al. 2012 [270] 
 
USA: VITamins 
And Lifestyle  
(VITAL) Cohort 
 
 
30,252 postmenopausal 
women 
772 invasive breast cancer 
cases 
Mean follow-up time = 6 
years 
 
FFQ 
Quintiles 
Q5 vs. Q1 
PUFA: 1.07 (0.76, 1.52) 
ALA: 0.97 (0.71, 1.32)  LA: 1.18 (0.84, 1.66) 
EPA: 0.70 (0.54, 0.90)  AA: 0.97 (0.74, 1.29) 
DHA: 0.67 (0.52, 0.87)  ω3/ω6: 0.84 (0.65, 1.09) 
 
Covariates: age, race, education, height, BMI, age at menarche, 
age at first birth, age at menopause, history of hysterectomy, 
years of combined hormone therapy, years of estrogen hormone 
therapy, family history, mammography, history of benign breast 
biopsy, regular use of NSAIDs, exercise, alcohol consumption, 
vegetable intake, fruit intake, and total energy 
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Table 1.6 Case-Control Studies of Dietary Fish Intake and Breast Cancer 
Author, Year Population 
Cases/Controls & 
Control Sampling 
Exposure 
Assessment & 
Categorization 
Results, Adjusted OR* (95% CI), & Covariates 
 
Landa et al. 
1994 [279] 
 
Spain 
100/100 
Hospital-based 
99-item FFQ 
Tertiles of monthly 
consumption 
Fish: T2: 0.55, T3:0.34 (95% CI not reported) 
Covariates: Age 
 
Franceschi et al. 
1995 [321] 
 
Italy 
2,569/2,588 
Hospital-based 
79-item FFQ 
Quintiles 
Fish: 0.69 (0.56, 0.84); p for trend < 0.01 
Covariates: age, center, education, parity, energy, alcohol 
 
Hirose et al. 
1995 [326] 
 
Japan 
1,052/23,163 
Hospital-based 
FFQ 
≤ 3/month 
1-2/wk 
≥ 3/wk 
Boiled, or broiled fish, sashimi: ≤ 3/month (reference) 
  Premenopausal  Postmenopausal 
1-2/wk:  0.88 (0.71, 1.09)  0.82 (0.63, 1.07) 
≥ 3/wk: 0.98 (0.78, 1.24)  0.75 (0.57, 0.98) 
 
Covariates: age, first-visit year 
 
Braga et al. 1997 
[89] 
 
Italy 
2,569/2,588 
Hospital-based 
78-item FFQ 
Quintiles 
Fish (incl. boiled and roasted fish; fried fish, tinned tuna and 
sardines) 
 Premenopausal  Postmenopausal 
OR: 0.88 (0.7, 1.1)  0.76 (0.7, 0.9) 
 
Covariates: age, center, education, parity/age at 1
st
 birth, and 
energy 
 
 
Favero et al. 
1998 [322] 
 
Italy 
2,569/2,588 
Hospital-based 
78-item FFQ 
Quintiles 
Fish: 0.69 (0.6, 0.8); p for trend < 0.01 
Covariates: age, center, education, parity, energy and alcohol 
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Table 1.6 (cont.) Case-Control Studies of Dietary Fish Intake and Breast Cancer 
Author, Year Population 
Cases/Controls & 
Control Sampling 
Exposure 
Assessment & 
Categorization 
Results, Adjusted OR* (95% CI), & Covariates 
 
Torres-Sanchez 
et al. 2000 [335] 
 
Mexico 
198/198 
Hospital-based 
95-item FFQ 
Portions per week 
Fish portion/wk (never = reference) 
<1 0.72 (0.29, 1.79) 
1-1.5 0.89 (0.34, 2.30) 
> 1.5 0.67 (0.26, 1.72) 
Covariates: total energy intake, age at menarche, number of 
children and age at first birth, lifetime lactation, family history 
of breast cancer, menopausal status, and Quetelet index 
 
Dai et al. 2002 
[327] 
 
The Shanghai Breast 
Cancer Study 
1,459/1,556 
Population-based 
76-item FFQ 
Quintiles 
Freshwater fish: 1.48 (1.16, 1.89) 
Marine fish: 1.14 (0.90, 1.45) 
(F) Freshwater fish Deep-fried (Q5 vs. Q1; >20.7 g/d vs. ≤ 2.9) 
(M) Marine fish Deep-fried (Q5 vs. Q1)  
 Never  Ever  Well-done 
F: 1.46 (1.03, 2.07) 1.50 (1.05, 2.13) 1.52 (1.05, 2.22) 
M: 0.94 (0.67, 1.33) 1.29 (0.91, 1.84)* 1.32 (0.91, 1.93)* 
*potential U-shape 
 
Covariates: age, education, family history of breast cancer, 
family history of breast fibroadenoma, WHR, age at menarche, 
physical activity, ever had live birth, age at first live birth, 
menopausal status, age at menopause, total energy 
 
Terry et al. 2002 
[319] 
 
Sweden 
2,085/2,000 
Population-based 
34-item FFQ 
Servings per week 
>3.5 servings/week vs. 0 to ≤0.5 servings/week   
  Age-adjusted  Multivariate 
Total fish: 0.99 (0.68, 1.43)  0.88 (0.60, 1.29) 
Fatty fish: 0.67 (0.44, 1.03)  0.70 (0.45, 1.10) 
Other fish: 0.81 (0.54, 1.21)  0.76 (0.49, 1.16) 
 
Covariates for multivariate model: age, BMI, height, smoking, 
leisure-time physical activity between 18 and 30 yrs of age, 
alcohol, consumption of Brassica vegetables, history of benign 
breast disease, menopause type (surgical or natural), parity, 
duration of hormone replacement therapy use, age at menarche, 
age at menopause, age at first birth 
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Table 1.6 (cont.) Case-Control Studies of Dietary Fish Intake and Breast Cancer 
Author, Year Population 
Cases/Controls & 
Control Sampling 
Exposure 
Assessment & 
Categorization 
Results, Adjusted OR* (95% CI), & Covariates 
 
Hirose et al. 
2003 [328] 
 
Japan 
2,385/19,013 
Hospital-based 
18-item FFQ 
Categories 
 
4 Categories (Almost never, 1-3 times/month, 1-2 times/week, 
3+ times/week) 
ORs presented comparing highest vs. lowest category 
  Premenopausal  Postmenopausal 
Cooked/raw fish: 0.95 (0.70, 1.28)  0.75 (0.57, 0.98) 
Dried/salted fish: 1.15 (0.89, 1.49)  0.78 (0.60, 1.01) 
Covariates: age, visit year, family history, age at menarche, 
parity, age at first full-term pregnancy, and BMI (for 
postmenopausal ORs) 
 
McElroy et al. 
2004 [334] 
 
USA: Wisconsin 
1,481/1,301 
Population-based 
2 questions: 
How often did you 
eat sport-caught 
fish? Was any of this 
sport-caught fish 
from the Great 
Lakes (GL)? 
Recent sport-caught fish consumption: 1.00 (0.86, 1.17) 
Recent GL fish consumption:  1.06 (0.84, 1.33) 
Recent GL trout/salmon:   1.00 (0.78, 1.28) 
Recent meals per year (≥24 vs. 1-3): 0.94 (0.75, 1.18) 
Recent GL trout/salmon meals (≥7 vs. 1-2): 0.98 (0.62, 1.54) 
Stronger effects seen for premenopausal women for both 
questions. 
 
Covariates: age, family history of breast cancer, recent alcohol 
consumption, parity, age at first full-term pregnancy, lactation, 
menopausal status, age at menopause, weight at age 18, age at 
menarche, and education 
 
 
Hirose et al. 
2005 [329] 
 
Japan 
167/854 
Hospital-based 
119-item FFQ 
Tertiles 
Fish/fish products:  
 Premenopausal  Postmenopausal 
T2: 1.53 (0.74, 3.18)  1.42 (0.75, 2.66) 
T3: 1.36 (0.65, 2.88)  0.77 (0.39, 1.52) 
Covariates: age, motives for consultation, smoking, drinking, 
exercise, energy, family history, age at menarche, parity, age at 
first full-term pregnancy, BMI, and age at menopause (for 
postmenopausal women only) 
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Table 1.6 (cont.) Case-Control Studies of Dietary Fish Intake and Breast Cancer 
Author, Year Population 
Cases/Controls & 
Control Sampling 
Exposure 
Assessment & 
Categorization 
Results, Adjusted OR* (95% CI), & Covariates 
 
Bessaoud et al. 
2008 [323] 
 
France 
437/922 
Population-based 
FFQ 
Quartiles 
  Age-adjusted  Multivariate 
Fish & seafood: 0.69 (0.49, 0.97)  0.79 (0.54, 1.16) 
Covariates: total energy intake, education, parity, breast-
feeding, age at first full-term pregnancy, duration of ovulatory 
activity, BMI, physical activity, and first-degree family history 
of breast cancer 
 
 
Kim et al. 2009 
[277] 
 
Korea 
358/360 
Hospital-based 
103-item FFQ 
Quartiles 
  Age-adjusted  Multivariate 
Total fish: 0.62 (0.41, 0.93)  0.55 (0.32, 0.96)* 
Lean fish: 1.20 (0.81, 1.79)  1.21 (0.72, 2.04)* 
Fatty fish: 0.27 (0.17, 0.44)  0.23 (0.13, 0.42) 
*potential U-shape 
No difference by menopausal status for total fish and fatty fish. 
Increased risks (ORs = 1.34 – age-adjusted, 1.22 – multivariate) 
seen for lean fish intake in premenopausal women. 
 
Covariates: age, BMI, family history of breast cancer, 
supplement use, education level, occupation, alcohol 
consumption, smoking status, physical activity, parity, total 
energy intake, menopausal status, age at menarche 
 
 
Zhang et al. 
2009 [330] 
 
China 
438/438 
Hospital-based 
81-item FFQ 
Quartiles 
 Model 1   Model 2 
Fish: 0.56 (0.38, 0.85)  0.72 (0.46, 1.10) 
Model 1 Covariates: age at menarche, live birth and age at first 
live birth, BMI, history of benign breast disease, 
mother/sister/daughter with breast cancer, physical activity, 
passive smoking, use of deep-fried cooking method, and total 
energy intake 
 
Model 2 Covariates: all Model 1 covariates, vegetable, fruit, 
and soy food intake 
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Table 1.6 (cont.) Case-Control Studies of Dietary Fish Intake and Breast Cancer 
Author, Year Population 
Cases/Controls & 
Control Sampling 
Exposure 
Assessment & 
Categorization 
Results, Adjusted OR* (95% CI), & Covariates 
 
Bao, et al. 2012 
[331] 
 
Shanghai Breast 
Cancer Study 
3,443/3,474 
Population-based 
FFQ 
Tertiles (Freshwater) 
Quintiles (Marine) 
Freshwater fish:  Marine fish: 
T2: 1.17 (1.03, 1.32) Q5: 1.19 (1.02, 1.39)  
T3: 1.39 (1.23, 1.56) 
 
No differences seen when stratified by ER/PR status. 
 
Covariates: total energy, age, education, benign breast disease, 
family history, participation in regular exercise, body mass 
index, study phase, age at menarche, menopausal status, parity, 
total vegetable intake, total fruit intake 
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Table 1.7 Cohort Studies of Dietary Fish Intake and Breast Cancer 
 
Author, Year Population 
Sample size, Median 
Length of Follow-up 
Exposure 
Assessment 
(Categorization) 
Results, Adjusted HR, RR* (95% CI), & Covariates 
 
Vatten et al. 
1990 [320] 
 
Norway 
14,500 total cohort 
152 breast cancer cases 
11-14 years of follow-up 
60-item FFQ 
Servings per week 
 
Overall fish (> 2 times/week versus ≤ 2 times/week): 
Crude IRR = 1.2 (0.8, 1.7) 
Poached fish (< 2times/month = reference category) 
2-4 times/week crude IRR: 0.8 (0.5, 1.1) 
≥ 5 times/week crude IRR: 0.7 (0.4, 1.0) 
 
 
Toniolo et al. 
1994 [288] 
 
USA: New York 
University Women’s 
Health Study 
14,291 women 
180 breast cancer cases 
71-item modified 
Block FFQ 
Quintiles 
RR Q5: 1.02 (0.61, 1.71) 
Largest risk seen among Q2 (RR = 1.32) 
 
Covariates: energy 
 
Holmes et al. 
2003 [332] 
 
USA: Nurses’ 
Health Study 
88,647 women 
4,107 breast cancer cases 
18 year follow-up 
61-item FFQ 
answered in 1980 
baseline 
Quintiles 
Fish intake 
Overall RR: 1.04 (0.93, 1.14) 
Premenopausal: 1.17 (0.92, 1.50) 
Postmenopausal: 1.00 (0.89, 1.12) 
 
Covariates: age, 2 year time period, total energy intake, alcohol 
intake, parity and age at first birth, BMI at age 18, weight 
change since age 18, height, family history of breast cancer, 
history of benign breast disease, age at menarche, menopausal 
status, age at menopause, hormone replacement therapy, 
duration of menopause 
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Table 1.7 (cont.) Cohort Studies of Dietary Fish Intake and Breast Cancer 
 
Author, Year Population 
Sample size, Median 
Length of Follow-up 
Exposure 
Assessment 
(Categorization) 
Results, Adjusted HR, RR* (95% CI), & Covariates 
 
Stripp et al. 2003 
[324] 
 
Denmark 
 
23,693 postmenopausal 
women 
424 breast cancer cases 
Median length of follow-
up = 4.8 years 
 
192-item FFQ 
(Quartiles and 
Continuous) 
    IRR 
Total fish intake (Continuous): 1.13 (1.03, 1.23) 
Fatty fish (Continuous):  1.11 (0.91, 1.34) 
Lean fish (Continuous):  1.13 (0.99, 1.29) 
Fried fish (Continuous):  1.09 (0.95, 1.25) 
Boiled fish (Continuous):  1.09 (0.85, 1.42) 
Processed fish (Continuous): 1.12 (0.93, 1.34) 
Total Fish (Q4 vs. Q1):  1.54 (1.18, 2.02) 
Approx. 14% increased incidence seen for total fish intake 
(continuous) for ER+ breast cancers. 
 
Covariates: parity (parous/nulliparous, number of births and age 
at first birth), benign breast tumor, years of school, use of 
hormone replacement therapy, duration of HRT use, BMI, and 
alcohol 
    
 
Folsom et al. 
2004 [298] 
 
USA: The Iowa 
Women’s Health 
Study 
 
41,836 women aged 55-69 
years 
1,885 breast cancer cases 
14 years of follow-up 
 
127-item FFQ 
(Quintiles) 
 
RR for breast cancer incidence = 0.92 (0.76, 1.12) 
 
Covariates: age, energy intake, educational level, physical 
activity, alcohol consumption, smoking status, pack-years of 
cigarette smoking, age at first live birth, estrogen use, vitamin 
use, body mass index, waist/hip ratio, diabetes, hypertension, 
intake of whole grains, fruit and vegetables, red meat, 
cholesterol, and saturated fat 
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Table 1.7 (cont.) Cohort Studies of Dietary Fish Intake and Breast Cancer 
 
Author, Year Population 
Sample size, Median 
Length of Follow-up 
Exposure 
Assessment 
(Categorization) 
Results, Adjusted HR, RR* (95% CI), & Covariates 
 
Engeset et al. 
2006 [325] 
 
 
The European 
Prospective 
Investigation into 
Cancer and Nutrition 
(EPIC) 
 
310,671 women aged 25-
70 years 
4,776 breast cancer cases 
Median follow-up = 6.4 
years 
FFQ 
Quintiles 
Total fish:   1.07 (0.95, 1.20) 
Total fish (premenopausal): 1.11 (0.84, 1.45) 
Total fish (postmenopausal): 1.10 (0.95, 1.28) 
Lean fish:   1.07 (0.95, 1.21) 
Fatty fish:   1.13 (1.01, 1.26) 
 
Covariates: center, adjusted for time of follow-up, energy 
intake, height, weight, age at menarche, number of full-term 
pregnancies, age at first full-term pregnancy, current use of 
hormone replacement therapy, current use of oral 
contraceptives, menopausal status (excluded for pre- and post 
RRs) 
 
Brasky et al. 
2010 [333] 
 
USA: VITamins 
And Lifestyle  
(VITAL) Cohort 
 
35,016 women aged 50-76 
years 
880 breast cancer cases 
Mean follow-up time = 6 
years 
 
Detailed 
questionnaire of 
supplement use 
Fish oil supplements 
(Nonuser, former, 
current) 
HR Current fish oil users (compared to nonusers): 
0.68 (0.50, 0.92) 
 
Covariates: age, race, education, BMI, height, fruit 
consumption, vegetable consumption, alcohol consumption, 
physical activity, age at menarche, age at menopause, age at 
first birth, history of hysterectomy, years of combined hormone 
therapy, family history, benign breast biopsy, mammography, 
low-dose aspirin use, regular aspirin use, ibuprofen use, 
naproxen use, and use of multivitamins 
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Table 1.8 Studies of Fish Intake and Breast Cancer Survival and Mortality  
 
Author, Year Population 
Sample size, Median 
Length of Follow-up 
Exposure 
Assessment 
(Categorization) 
Results, Adjusted HR, RR* (95% CI), & Covariates 
 
Kyogoku et al. 
1992 [340] 
 
Japan 
 
213 breast cancer cases 
(from case-control study) 
47 breast cancer deaths 
Follow-up from 1975-
1978 through 1987 
 
FFQ 
(Quartiles) 
Fat from fish origin (includes fresh fish, shell fish, and 
processed fish) 
HR = 1.4 (0.5, 4.3) 
 
Covariates: clinical stage, BMI, age at menarche, age at first 
birth, age at operation, radiation therapy, chemotherapy, 
endocrine therapy, operative procedure, and each of the 
nutrients 
 
Lund et al. 1993 
[341] 
 
Norway 
 
533,276 women aged 35-
54 years 
Follow-up from 1970 
through 1985 
 
Married to a 
fisherman 
RR for breast cancer mortality = 0.67 (0.47, 0.94) compared to 
wives of unskilled workers 
Covariates: age and number of children 
 
Patterson et al. 
2010 [339] 
 
 
USA: Women’s 
Healthy Eating and 
Living (WHEL) 
Study 
 
3,081 breast cancer cases 
Median follow-up time = 
7.3 years 
Repeated 24-hour 
recalls 
Multiple dietary 
assessments 
(Tertiles) 
HR for additional breast cancer events 
Marine sources of EPA/DHA: 0.72 (0.57. 0.90) 
No differences for food adjusted for supplements, food plus 
supplements 
 
HR for all-cause mortality 
Marine sources of EPA/DHA: 0.59 (0.43, 0.82) 
Reduced hazard (HR = 0.68) for food plus supplements 
 
Covariates: tumor stage, grade, and time between diagnosis and 
study entry (additional adjustments for obesity, age, physical 
activity, intervention group and entry cohort did not change the 
statistical significance of results) 
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Figure 1.1 Age-specific breast cancer incidence rates (per 100,000) for Western and 
Asian populations in 2002 
 
 
Graph generated from online resource Ferlay et al. [343] 
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Figure 1.2 PUFA Biosynthesis 
 
Adapted from [148] 
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Figure 1.3 Metabolism of Arachidonic Acid 
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CHAPTER 2:  
METHODS 
 
2.1 Study Overview 
2.1.1 Specific Aims 
 Among American women, breast cancer is the leading incident cancer, with an 
estimated 207,100 incident cases, and the second leading cause of cancer mortality, with an 
estimated 40,000 breast cancer deaths in 2013 [1].  Laboratory studies indicate that high 
intakes of ω-6 fatty acids increase cancer risk whereas intakes of ω-3 fatty acids reduce risk 
via the differential production of inflammatory eicosanoids resulting from arachidonic acid 
metabolism [53].  However, the epidemiologic studies regarding dietary intake of PUFAs and 
breast cancer are inconsistent. 
Both ω-6 and ω-3 fatty acids are metabolized via the cyclooxygenase and 
lipoxygenase pathways [163, 344].  However, the eicosanoids resulting from ω-6 and ω-3 
fatty acid metabolism differ, with ω-3 fatty acids resulting in fewer inflammatory eicosanoids 
than ω-6 fatty acids [345]. PUFAs have also been implicated in the regulation of additional 
inflammation and oxidative stress factors involved in carcinogenesis, including 
cyclooxygenase (PTGS-2) [53], peroxisome proliferator-activated receptors (PPARs) [345, 
346], tumor-necrosis factor-alpha (TNF-α) [347], FAS/FASL [212, 348], and cytochrome 
aromatase enzymes (CYP17, CYP19) [199]. Additionally, PUFAs can induce a cytotoxic 
environment via lipid peroxidation, consequently inhibiting breast cancer growth [254, 256, 
257]. 
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Previous population studies on prostate [349, 350] and colorectal cancer [351-354] 
have considered potential interactions between PUFA intake and genetic polymorphisms 
associated with PUFA metabolism via the inflammation pathway. Despite evidence from 
animal studies, only two previous epidemiologic studies of breast cancer have considered 
potential PUFA-gene interactions, and examined only genetic variants in the leukotriene 
pathway [287] and with glutathione S-transferases (GSTs) [342].  
The hypotheses examined in this dissertation are that higher intake of ω-6 will 
interact with genetic polymorphisms in the inflammation, oxidative stress, and estrogen 
metabolism pathways to increase the risk of developing breast cancer, which may be less 
pronounced when combined with higher intakes of ω-3 fatty acids.  Further, among women 
diagnosed with breast cancer, higher intakes of ω-3 PUFA will enhance survival, but among 
those with variant polymorphisms in oxidative stress enzymes (conferring greater efficiency 
in ROS scavenging) will have reduced survival. 
To evaluate these hypotheses, existing Long Island Breast Cancer Study Project 
(LIBCSP) data were used, including: self-reported dietary intake of PUFA food sources; 
other potential breast cancer risk factors; and select functional genetic polymorphisms in 
pathways biologically related to PUFA metabolism. The LIBCSP is a population-based 
study, which includes a case-control component (cases = 1,508; controls = 1,556) and a 
follow-up cohort of the case women to determine vital status. This dissertation addresses the 
following specific aims. 
 
Aim 1: Investigate the potential association of dietary PUFA and fish intake, genetic 
susceptibility and breast cancer incidence. 
 91 
1a. Estimate ω-3 and ω-6 intake among LIBCSP participants in order to estimate 
potential association between PUFA intake [ω-3, ω-6, and (ω-3/ω-6) ratio; PUFA subtypes] 
and fish intake [by cooking method] and breast cancer incidence. 
1b. Utilize existing data on genetic variants in the cyclooxygenase (PTGS-2), 
inflammation (PPAR-α, TNF- α, and FAS/FASL), oxidative stress (MnSOD, MPO, CAT, 
GPx, COMT, GSTs), and estrogen metabolism (CYP17) pathways to estimate the joint effects 
of PUFAs (mentioned in Aim 1a) and genetic polymorphisms on breast cancer incidence. 
 
Aim 2: Investigate the potential association of dietary PUFA intake and fish intake, 
genetic susceptibility and breast cancer survival. 
 2a. Estimate all-cause and breast cancer specific mortality associated with PUFA 
intake [ω-3, ω-6, and (ω-3/ω-6) ratio; PUFA subtypes] and fish intake [by cooking method].  
2b. Estimate the effects of genetic variants (mentioned in Aim 1b) in inflammation, 
estrogen, and oxidative stress pathways on breast cancer survival. 
2c. Explore joint effects of PUFAs (mentioned in Aim 2a) and genetic variants 
(mentioned in Aim 1b) on breast cancer survival. 
 
2.1.2 Importance of Knowledge to be gained 
Despite recent downward trends in breast cancer rates, the burden of breast cancer in 
the U.S. remains high [1].  Thus, identification of an individually tailored, low-cost 
chemoprevention strategy to reduce the burden of breast cancer will potentially benefit large 
numbers of women. Findings from this dissertation will enhance our understanding of the 
relation between dietary PUFA and breast carcinogenesis, by identifying potential subgroups 
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of women who may be genetically susceptible to their effects.  This analysis will be the first 
to examine the role of genetic variations in the inflammation, estrogen metabolism, and 
oxidative stress pathways and PUFA measures (ω-3, ω-6, PUFA subtypes, and relative 
balance) in relation to breast cancer incidence and survival.  Finally, the analysis is cost- and 
time- efficient, because it builds upon the existing resources of a large, population-based 
study of breast cancer. 
 
2.2. Long Island Breast Cancer Study Project (LIBCSP) 
2.2.1 Case-Control Study 
The LIBCSP was a federally mandated, population-based study that was initiated as a 
case-control study to determine whether breast cancer risk was associated with 
environmental exposures [355].  The case-control study was conducted among adult women 
of Nassau and Suffolk counties on Long Island, New York.  Cases and controls were 
identified over a 12-month period starting in 1996.  Cases were English-speaking adult 
women with a first primary in situ or invasive breast cancer between August 1, 1996 and July 
31, 1997.  Potential cases were identified from 28 hospitals on Long Island as well as three 
large tertiary care hospitals in New York City.  Eligible controls were sampled at a 
continuous rate using 8 waves of random digit dialing for those less than 65 years of age, and 
twice using the Health Care Finance Administration (HCFA) rosters to identify those older 
than 65 years.  Controls were frequency matched to cases by 5-year age group. There were 
no race or age restrictions.  The final LIBCSP study sample includes a total of 1,508 cases 
(83%) and 1,556 controls (68%) of eligible subjects who completed the case-control 
interview. 
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The 100-minute case-control interviewer-administered, in-person structured 
questionnaires were administered shortly after diagnosis for cases (average within 3 months).  
The main case-control interview obtained information regarding various environmental and 
occupational histories; medical history, including co-morbidities, medication use, and family 
history of cancer; life course changes in body size, physical activity, smoking, alcohol use, 
and hormone use; menstrual and reproductive history; and demographic characteristics. 
Immediately following the main questionnaire, a validated 101-item Block food frequency 
questionnaire (FFQ) was self-completed by 98% of respondents to assess usual eating habits 
in the year prior to diagnosis for cases and the previous year for controls. Blood samples 
were obtained by 1,102 cases and 1,141 controls (73% of respondents) among those 
completing the main questionnaire, with a lower proportion of older control women donating 
blood.  As part of the case-control study, cases were asked to sign a medical record release 
form and medical records were abstracted to determine stage of disease and hormone 
receptor status. 
  
2.2.2 Follow-up Study 
The LIBCSP was later expanded to follow-up the cohort of case women to determine 
vital status and first course of treatment for the first primary breast cancer [127, 356].  
Potentially eligible subjects for the LIBCSP follow-up study were breast cancer cases who 
gave permission to be re-contacted at the end of the LIBCSP case-control interview (N = 
1,414).  The eligible cases were first re-contacted via mail five years post-diagnosis, and then 
a second time via telephone to schedule an interviewer-administered telephone interview.  A 
total of 1,098 interviews (93 of which were proxies) were conducted.  The follow-up 
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interview was used to determine first course of treatment for the first primary breast cancer 
diagnosis.  Cases were asked about procedures that they may have completed, including: 
surgery (needle biopsies, tumor biopsies, modified mastectomy, radical mastectomy, node 
removal); radiation; chemotherapy; and hormonal treatments.  Medical records were re-
abstracted as part of the follow-up study to ascertain first course of treatment for the first 
primary breast cancer.  Complete medical records were abstracted for 598 breast cancer 
cases.  Comparison of the self-reported responses versus information recorded in the medical 
records showed excellent correspondence between the two sources of information (kappa 
coefficients were 0.97 for radiation, 0.96 for chemotherapy, and 0.92 for hormonal therapy) 
[127]. 
The National Death Index (NDI) was utilized for ascertaining vital status for all cases.  
The NDI includes death records from 1979 to the present and is updated yearly [357].  The 
NDI is a gold standard for vital statistics in the U.S., providing a high sensitivity cause of 
death field [358].  The following case information was created, encrypted, and sent to NDI 
via for potential matches:  first and last name; city; state; date of birth; Social Security 
number; gender; race; and marital status.  Previous NDI linkages were conducted in 2002, 
2005, and 2009.  The latest NDI linkage was conducted for follow-up through 2011. 
 
2.2.3 Characteristics of LIBCSP Population 
The LIBSCP study population was predominantly Caucasian (cases = 94%, controls 
= 92%), which reflects the underlying racial distribution of the two study counties on Long 
Island [355].  Women were more likely to be 45-74 years old of age and postmenopausal 
(67%), which reflects the age- and menopausal-distribution of breast cancer among white 
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women in the U.S [355].  Also, the population was well educated with more than half of 
cases (52%) and controls (56%) attended college, graduating from college, or received any 
post college education.  The population was also less likely to be poor with approximately 
two-thirds of both cases (66%) and controls (69%) reporting a household income of greater 
than $35,000.  This primarily white, well-educated older-age sample of women is not 
generalizable to all women in the U.S., but is generalizable to those who are at highest risk of 
developing breast cancer in the U.S.  Also, the geographic location of this American study 
population offers a unique opportunity for higher fish consumption, the largest source of ω-3 
fatty acids. 
 
2.3 Outcome and Exposure Assessments 
2.3.1 Outcome Assessment 
 For the follow-up cohort of the 1,508 women newly diagnosed with breast cancer 
(participant cases from the LIBCSP parent case-control study) (required for Aim 2), 
identification of deaths, both all-cause and breast-cancer specific, were obtained via the NDI, 
as described above.  Participants were followed from diagnosis until December 31, 2011, for 
a median follow-up of 14.7 years (range 0.2 to 15.4 years).  Among the 1,508 women 
diagnosed with breast cancer, 506 died (34%), of which 219 were due to breast cancer (43%).  
Women who died from all-causes (death from any cause), and those whose deaths were 
breast cancer-related (breast cancer-specific mortality) were identified.  Breast cancer-related 
deaths were determined using the International Classification of Disease (codes 174.9 or C-
50.9). 
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2.3.2 Dietary Assessment 
The majority of epidemiologic studies estimating the association between dietary 
factors and breast cancer utilize dietary assessment via FFQ.  Dietary intake assessed by FFQ 
is thought to reflect usual dietary intake, which is more likely to reflect intake during the 
relevant etiologic window of exposure for breast cancer.  In the LIBCSP, diet history was 
assessed using a self-administered modified 101-item Block FFQ which had been previously 
validated [359].  The FFQ was completed by approximately 98% of cases and controls who 
completed the main questionnaire.  The Block FFQ was used to assess usual dietary intake in 
the previous year for the controls and the year prior to diagnosis in cases.  To help reduce 
misclassification of exposure assessments, including usual diet, cases were interviewed on 
average three months after diagnosis.  To facilitate completion of the interview as quickly as 
possible after diagnosis, a “super-rapid” identification was implemented [355].  This 
included contacting pathology departments of 28 hospitals on Long Island and three tertiary 
care hospitals in New York City two to three times a week, of which seven hospitals (those 
servicing the largest number of Long Island residents with breast cancer) were contacted 
daily. 
While use of dietary food records and recall (i.e. 7-day food records, 24-hour dietary 
recall) may be considered the “gold standard” for dietary assessment, it is difficult for food 
records and recalls to assess usual intake, unless applied multiple times in order to account 
for variation in food intake [360].  Additionally, food records and recalls may induce 
reporting error among participants due to high burden.  FFQs are subject to both systematic 
and random error.  Nevertheless, individual nutrient intake obtained from FFQs can be 
ranked using quantiles allowing comparisons across different levels of nutrient intake [360].  
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Assessment of usual diet from FFQs will better represent diet during the etiologically 
relevant induction period for breast cancer, whereas dietary intake assessed using food 
records and recalls will likely reflect highly variable current diet, which may be an 
inappropriate window of exposure for a case-control study of breast cancer incidence. 
 
2.3.3 PUFA Exposure Assessment 
 Dietary PUFA intake -- both ω-3 and ω-6 fatty acids -- were estimated for this 
ancillary study using responses from the modified FFQ and the nutrient quantities from the 
U.S. Department of Agriculture (USDA) database (Aim 1a).  The modified Block FFQ used 
in the LIBCSP assessed both frequency and portion size.  For example, participants were 
asked: “Over the last 12 months, how often did you eat the following foods? (Ignore any 
recent changes)”.  Frequency of intake during the past 12 months was categorized into the 
following groups: never; <1 per month; 1 per month; 2-3 per month; 1-2 per week; 3-4 per 
week; 5-6 per week; 1 per day; 2+ per day.  Portion size was assessed in comparison to the 
average portion size of a particular food item.  For example, the average serving size for shell 
fish on the FFQ is 5 pieces, ¼ cup, or 3 ounces, and participants were asked if they consumed 
less than, equal to, or more than the average intake for shell fish.  PUFA intake was estimated 
using FFQ responses of food intake (grams per day) over the past 12 months, and the average 
nutrient composition of PUFAs in foods ascertained from the USDA National Nutrient 
Database for Standard Reference, Release 23 (example calculation provided in Table 2.1).  
In addition to total ω-3 and ω-6 PUFAs, specific ω-3 and ω-6 subtypes were also estimated 
for this ancillary study, including ALA, EPA, DHA, DPA, LA, and AA. 
 Fish intake and cooking methods were also examined in addition to the derived 
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PUFA exposure assessment explained above.  Fish intake was assessed for: (1) tuna, tuna 
salad, tuna casserole; (2) shell fish (e.g., shrimp, lobster, crab, oysters, etc.); and (3) other 
fish (broiled or baked).  A more detailed examination of consumption of different cooking 
methods of fish was also examined and included the following: (1) grilled or barbequed; (2) 
pan-fried (not deep-fat-fried); (3) oven-broiled; (4) oven-baked; and (5) microwaved. 
 
2.3.4 Genotyping 
The interaction between PUFA intake and genetic variants involved in relevant 
biologic pathways were examined for incidence (Aim 1a) and survival (Aim 2c).  The 
following biologically relevant putatively functional genetic variants were selected: PTGS-2 
(rs20417 and rs5275); PPAR-α (rs1800206); FAS (rs2234767); FASL (rs763110); TNF-α 
(rs1800629); MnSOD (rs4880); MPO (rs2333227); CAT (rs1001179); COMT (rs4680 and 
rs737865); GPX1 (rs1050450); GSTM1 (deletion); GSTP1 (rs1695); GSTT1 (deletion); 
GSTA1 (rs3957356); CYP17 (rs743572).  Proposed functionality for each variant was 
identified using NIEHS SNPInfo web server [361].  Variants affecting polyphen prediction 
(GPX1), transcription factor binding prediction (PTGS-2 rs20417, FAS, FASL, TNF-α, MPO, 
CAT, GSTA1, COMT rs737865, CYP17), miRNA binding (PTGS-2 rs5275, GPX1), 3D 
conformation (PPAR-α, COMT rs4680), or splicing regulation (PPAR-α, FAS rs2234767, 
GPX1, GSTP1, COMT rs4680) were considered as putatively functional variants.  
Additionally, variants resulting in base pair changes that were non-synonymous were also 
classified as potentially functional (PPAR-α, MnSOD, GPX1, GSTP1, COMT rs4680).  
Please refer to Table 2.2 for a detailed summary regarding the chosen putatively functional 
genetic variants. 
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Blood samples were collected from subjects at the time of case-control interview, 
which occurred shortly after the time of diagnosis.  Study interviewers for the LIBCSP, who 
were also certified nurses or phlebotomists, obtained non-fasting 40ml blood samples from 
participants.  A pre-chemotherapy blood sample was obtained from approximately 77% of 
the cases who donated a blood sample.  Blood samples were shipped overnight at room 
temperature to a single laboratory, and processed within 24 hours of collection by lab 
personnel who were masked regarding the case-control status of the samples.  DNA was 
extracted in the laboratory of Dr. Regina Santella at Columbia University.  Processed and 
aliquoted samples were stored at -80°C.  Using the banked DNA, the LIBCSP has previously 
genotyped several variants involved in inflammation (PTGS-2, PPARs, TNF-α, FAS, FASL), 
oxidative stress (MnSOD, MPO, CAT, GPx, GSTs, COMT), and estrogen metabolism 
(CYP17). 
Genotyping methods for existing oxidative stress genes (CAT, MPO, MnSOD, GPx, 
GSTs, COMT) have been published elsewhere [362-366], but briefly, DNA was extracted 
from mononuclear cells in whole blood which was separated by Ficoll (Sigma Chemical Co., 
St. Louis, Missouri).  DNA was isolated using standard phenol, and chloroform isoamyl 
alcohol extraction and RNase treatment. BioServe Biotechnologies (Laurel, Maryland) 
performed the genotyping using high-throughput, matrix assisted, laser desorption/ionization 
time-of-flight mass spectrometry of Sequenom, Inc. (San Diego, California).  Gene deletions 
for GSTM1 and GSTT1 were determined by a multiplex polymerase chain reaction method, 
with the constitutively present gene β-globulin as an internal positive control [366].  For 
inflammation genes, namely FAS, FASL, PPARs, COX-2, the following assays were used: 
Taqman 5’-Nuclease Assay (Applied Biosystems, Foster City, CA) and AcycloPrime™-FP 
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SNP Detection Kit obtained from Perkin Elmer Life Sciences (Boston, Massachusetts, USA) 
[65, 367, 368].  For the aromatase enzyme (CYP17), the following assay was used: 
AcycloPrime™-FP SNP Detection Kit obtained from Perkin Elmer Life Sciences (Boston, 
Massachusetts, USA) with 10 µM probe [369, 370].  The following procedures were used for 
quality control: (i) genotyping results were reviewed manually; (ii) cases and two 
nontemplate controls were included on each plate; (iii) 8% of blinded duplications were 
distributed throughout the DNA samples; and (iv) laboratory personnel were blinded to the 
case/control status of the samples.   
 
2.4 Results from Previous Analyses 
2.4.1 Inflammation genes and breast cancer risk in LIBCSP 
 Investigators of the LIBCSP have previously conducted a study regarding genetic 
polymorphisms in PTGS-2 (also known as COX-2) and breast cancer risk [65]. In addition to 
the main effects of polymorphisms in PTGS-2, the study authors also examined the 
interactive effects with non-steroidal anti-inflammatory drug use (NSAIDs). No associations 
were seen with regard to variant alleles in PTGS-2 and breast cancer risk, nor was there any 
evidence for an interaction with NSAID use.  However, a slight decrease in breast cancer risk 
was seen among hormone receptor positive women using NSAIDs and possessing a PTGS-2 
variant allele (OR = 0.7, 95% CI = 0.5, 1.0). In 2007, Crew et al. examined the effects of 
genetic polymorphisms in FAS and FAS ligand (FASL) on breast cancer risk [367].  Main 
effects of variant alleles in FAS and FASL did not show any association with breast cancer 
risk. However, an increased risk in breast cancer was observed among those carrying the 
variant alleles in FAS when considering effect measure modification by lactation history 
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(Ever lactating: OR = 1.46, 95% CI = 1.04, 2.06; Never lactating: OR = 0.82, 95% CI = 0.64, 
1.06).  Golembesky et al. also found nearly double the risk for breast cancer among women 
with a variant PPAR-α allele (OR = 1.97; 95% CI = 1.14, 3.43) [368].  These initial studies 
conducted on inflammation genes using the LIBCSP have shown plausibility for differences 
in breast cancer risk by genetic variants in inflammation genes, and this genetic variability 
may be further modified by biologically plausible environmental exposures. 
 
2.4.2 Oxidative stress genes and breast cancer risk in LIBCSP 
 LIBCSP investigators have also examined numerous oxidative stress genes in relation 
to breast cancer risk.  Steck et al. [366] examined the effects of glutathione S-transferases 
(GST), specifically GSTM1, GSTT1, GSTP1, on breast cancer risk.  Null genotypes, or those 
conferring reduced activity in GSTM1, GSTT1, and GSTP1, did not show substantial effects 
on breast cancer when examined individually.  However, when main effects of genes were 
examined in combination (i.e. GSTM1 and GSTT1, GSTM1 and GSTP1, GSTP1 and GSTT1) 
those with polymorphisms conferring reduced activity in both GSTM1 and GSTT1 were at 
increased risk for breast cancer (OR = 1.38; 95% CI = 1.09, 1.31).  Effects of other genetic 
polymorphisms in antioxidant enzymes, such as MnSOD, MPO, CAT, and GPx, were also 
previously examined by LIBCSP investigators [362-366].  No associations were reported for 
the main effects of MnSOD and GPx polymorphisms and breast cancer risk.  A variant allele 
conferring reduced MPO transcriptional activity was associated with a reduced risk for breast 
cancer (OR = 0.87; 95% CI = 0.73, 1.04). The variant allele conferring greater CAT enzyme 
ROS-scavenging capability reduced breast cancer risk by 17% (OR = 0.83; 95% CI = 0.69, 
1.00).  Risk reductions were also observed for variant alleles for both COMT rs4680 and 
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COMT rs737865 [371]. 
 In the LIBCSP, joint effects of dietary exposures and oxidative stress genes on breast 
cancer incidence were also examined.  For example, risk reductions were observed for the 
interactive effects of high fruit and vegetable intake and variant alleles in MnSOD [365], 
MPO [362], CAT [363], GPX1 [364], GSTM1 [366], GSTP1 [366], GSTT1 [366], and GSTA1 
[372].  Overall, polymorphisms in oxidative stress genes conferring reduced enzyme activity 
seem to increase breast cancer risk in the LIBCSP.  It is possible that PUFA intake, in 
combination with polymorphisms in oxidative stress genes may modify breast cancer risk. 
 
2.4.3 Aromatase genes and breast cancer risk in LIBCSP 
 LIBCSP investigators have previously examined the effects of aromatase genes on 
breast cancer incidence.  Chen et al. [369] examined the interaction between the estrogen-
biosynthesis gene CYP17 and reproductive, hormonal, and lifestyle factors on breast cancer 
incidence.  Overall, no associations were reported between the CYP17 genotype and breast 
cancer risk.  A risk reduction (OR = 0.81; 95% CI = 0.52, 1.25) was observed for 
homozygotes for the variant allele (resulting in an increased level of serum estrogen) among 
premenopausal women, whereas a 25% (95% CI = 0.90, 1.73) increased risk was observed 
for homozygotes for the variant CYP17 allele among postmenopausal women.  The joint 
effects of higher BMI (25+) and possessing the variant allele increased breast cancer risk 
among postmenopausal women (OR = 1.93; 95% CI = 1.32, 2.84), whereas a risk reduction 
was reported among premenopausal women (OR = 0.65; 95% CI = 0.39, 1.08).  An increase 
in breast cancer risk was suggested for joint effects of the variant allele and nulliparity, ever 
alcohol drinkers, and oral contraceptive use (ever and ≥6 months) among postmenopausal 
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women.  Talbott et al. [370] reported increased risks for the synonymous CYP19 SNPs 
among premenopausal women.  Strongest effects were suggested for the variant CYP19 allele 
for ER- (OR = 3.89; 95% CI = 1.74, 8.70) and PR- (OR = 2.52; 95% CI = 1.26, 5.05), though 
estimates were imprecise.  Although CYP19 is part of the estrogen metabolism pathway the 
proposed analysis will not examine CYP19 variants, due to the potential lack of functionality 
as determined by the NIEHS SNPInfo web server [361]. 
 
2.5 Data Analysis 
2.5.1 Statistical Methods 
All data analysis was conducted using SAS version 9.2 (Cary, NC).  For all analyses 
considering dietary exposures, cases and controls with implausible values for total energy 
intake (those with log-transformed caloric intake three standard deviations above or below 
the mean) were excluded. 
For Aim 1a, standard unconditional logistic regression was used to estimate odds 
ratios (OR) and 95% confidence intervals (95% CIs) for the association between breast 
cancer incidence and multiple measures of intake of PUFAs (ω-3, ω-6, ratio, and subtypes) 
and fish (by cooking method) [373].  Different exposure variable types (e.g., continuous, 
quadratic, trinomial, splines, and quantiles) were considered, and quartiles were chosen based 
upon the shape of the relation between PUFA intake and the log-odds of breast cancer 
(Figures A.1-A.3).  There was no evidence for a monotonic relation between intake and 
breast cancer incidence, thus a formal linear trend test was not conducted. The most 
appropriate model will be determined using model fit and the likelihood ratio test (LRT) 
using nested models. 
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Interaction between dietary PUFA intake and genotype (Aim 1b) was assessed on 
both multiplicative (Tables 3.7, 3.8) and additive scales (Tables 3.4, 3.5). For the former, a 
multiplicative interaction term was included in the logistic regression model (e.g., ω-3*gene). 
Additionally, PUFA-gene interactions for total PUFA, total ω-3, total ω-6, and subtypes were 
also conducted (Tables A.3-A.11). In order to maximize the sample sizes within subgroups 
of the interaction, PUFA intake was dichotomized at the median (based upon distribution 
among control) and genes were dichotomized using a dominant model (homozygous wild 
type versus variant allele).  Statistically significant multiplicative interactions were assessed 
using LRT using nested models for the interaction term.  Interactions on the additive scale 
were assessed using single-referent coding.  Departures from additivity were assessed using 
Relative Excess Risk due to Interaction (RERI = ORhigh PUFA,variant – ORhigh PUFA – ORvariant + 
1) and corresponding 95% CI for RERI were estimated using Hosmer and Lemeshow’s 
method [374]. 
 For Aim 2, Cox proportional hazards regression were conducted to estimate hazard 
ratios (HR) and corresponding 95% CIs for all-cause and breast cancer-specific mortality.  
The proportional hazards assumption was assessed using exposure interactions with time, and 
also using Martingale residuals [375].  Kaplan-Meier survival curves constructed and log-
rank tests were conducted to test for differences between the survivor functions (Figures 
A.4-A.6).  Hazard ratios and corresponding 95% CIs were estimated for PUFA intake (Aim 
2a), main effects of genes (Aim 2b) and the PUFA-gene interaction (Aim 2c) with respect to 
all-cause and breast-cancer specific mortality. Appropriate exposure variable categorization 
was determined by examining the PUFA exposure in relation to log-hazard of mortality 
(Figures A.7-A.9) using different variables to represent dietary intake (e.g., continuous, 
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quadratic, trinomial, splines, and quantiles). The main effects of genetic polymorphisms 
(Aim 2b) were examined using both dominant and additive models.  For the final aim (Aim 
2c), the joint association between PUFA intake and polymorphisms in biologically relevant 
genes on mortality was assessed similar to methods used for Aim 1b, on both multiplicative 
(Tables A.12-A.13) and additive scales (Tables 4.6, 4.8). Similar to Aim 1, PUFA-gene 
interactions for total PUFA, total ω-3, total ω-6, and subtypes were also conducted in relation 
to all-cause mortality (Tables A.14-A.22). 
 
2.5.2 Multiple Comparisons 
 Basing study conclusions solely on statistically significant p-values remains 
controversial in the field of epidemiology.  It is possible to obtain statistically significant p-
values for nearly null associations that are precise (based upon the width of the 95% 
confidence interval), and for strong associations that are imprecise [376].  However, it is 
difficult to convince peer-reviewers and journals alike of the potential harm of making 
conclusions solely based upon p-values, and researchers are often expected to provide p-
values for all estimated associations. 
 The issue of p-values becomes more complicated when conducting multiple 
comparisons, since the number of false positive results increases with increasing number of 
statistical comparisons. Therefore, in order to prevent large numbers of false-positives in 
studies conducting multiple comparisons, further control of the type 1 error rate is required.  
Since all genetic variants for this analysis were chosen based upon strong biologic rationale it 
is possible that no correction is required, compared to more agnostic approaches (e.g., 
genome-wide association studies).  However, the issue of adjustment for multiple 
 106 
comparisons remains controversial and adjustment for multiple comparisons were considered 
for this analysis even though conclusions were not based solely upon statistically significant 
findings. 
 A number of methods have been proposed for addressing issues concerned with 
multiple comparisons, including: Bonferroni correction; false discovery rate (FDR); and 
empirical methods (false positive report probability (FPRP), Bayesian false discovery 
probability (BFDP), and hierarchical modeling) [302, 377-379]. 
 Bonferroni correction is a commonly used method to adjust for multiple comparisons.  
However, it is possible that many genetic polymorphisms are likely correlated (e.g., 
polymorphisms belonging to the same gene) and thus large test statistics are not as likely 
[377].  Therefore, Bonferroni correction for multiple testing is known to be overly 
conservative [377] and conclusions made based solely on statistically significant Bonferroni 
correction could overlook important associations.  The FDR provides an improvement 
compared to the overly conservative Bonferroni correction since the FDR is based on the 
average value of the proportion of false positive results among all statistically significant 
results [380, 381].  However, the FDR has its limitations since it fails to account for study 
power [381]. 
 Bayesian approaches for controlling multiple comparisons have also been suggested.  
FPRP provides another method and is the probability that the null hypothesis is true given a 
statistically significant result.  The magnitude of the FPRP is based upon the p-value, prior 
probability of alternative hypothesis, and statistical power to detect the alternative hypothesis 
[378].  However, a major limitation of the FPRP approach is the difficulty in assigning a 
range of prior probabilities for the alternative hypothesis [378].  Also, some have suggested 
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that the derivation of the FPRP approach is flawed due to its incorrect probabilistic 
representation of an observation [382].  Similar to the FPRP, the BFDP is used to identify 
statistically significant findings within the context of multiple comparisons.  However, in 
comparison to the FPRP, the BFDP incorporates additional information and defines a 
threshold in terms of false discovery and nondiscovery [379].  Hierarchical modeling has also 
been proposed as another Bayesian approach for control of multiple comparisons by 
incorporating prior knowledge regarding the individual comparisons and how they may be 
correlated [302].  However, the utility of this approach over other methods may be 
questionable for datasets with uncorrelated exposures.  Overall, the advantages of employing 
Bayesian approaches for the multiple comparisons may be hindered by the limited 
availability of well-defined priors. 
 In sum, a variety of methods have been proposed for control of multiple comparisons.  
Each of these methods has their own strengths and limitations, and some are more 
computationally rigorous than others.  Adjustment for multiple comparisons was considered 
using the FDR approach, since it is easily implemented and is suggested to be less 
conservative than standard Bonferroni correction.  A p-value for statistical significance was 
identified when the following expression was met: 
raw p-value(i) ≤ (0.05i)/m 
where, i = p-value rank, and m = total number of statistical comparisons [381].  The FDR-
adjusted p-value to for statistical significance for each Aim was calculated using the 
expression above.  However, none of the comparisons were found to be statistically 
significant after adjusting for multiple comparisons (Tables A.23-A.29).  Also, given all the 
genetic variants for this analysis were chosen based upon biologic plausibility, conclusions 
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were based primarily upon the precision of the estimated associations (95% CIs).  
 
2.5.3 Confounding and Effect Measure Modification 
All analyses were adjusted for the matching factor, five-year age group [373].  
Potential covariates were included in the Directed Acylic Graph (DAG) constructed using 
prior knowledge and existing literature (Figures 2.1-2.2), and confounders were identified 
using DAG rules, and adjustments were not made for variables considered colliders or on the 
causal path due to the potential for biased effect estimates [373].  Confounders, previously 
identified from DAG analysis, were included in the statistical model if inclusion of the 
confounder changed the effect estimate by more than 10% [373]. 
 Risk and prognostic factors for breast cancer often vary across different subgroups of 
women.  Breast cancer incidence rates continue to increase after menopause among Western 
women, whereas the incidence rates tend to stabilize after menopause among Asian women 
(Figure 1.1).  The ER+/PR+ breast cancers are the predominant subtype among 
postmenopausal Caucasian women.  Therefore, it is possible that potential associations 
between PUFA and breast cancer could vary according to both menopausal and hormone 
receptor status.  For example, in the LIBCSP the effect estimates for physical activity and 
obesity differ by menopausal status and by hormone receptor status [128, 129].  Effect 
measure modification by menopausal status and hormone receptor status was also observed 
for dietary exposures in the LIBCSP [383].  Thus, it is possible that similar variations in the 
effect estimates will be observed in relation to the PUFA and/or fish intake measures 
considered.  Therefore, effect modification of the main effect (Aims 1a and 2a) of dietary 
intake-breast cancer association by breast cancer subtype (ER+/PR+ versus other subtypes) 
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and menopausal status (pre- versus post-menopausal) were evaluated by conducting a 
stratified analysis for each proposed effect measure modifier (Tables A.30-A.34).  
Additionally, effect measure modification by each individual treatment (e.g., chemotherapy, 
radiation, and hormone therapy) was explored for survival for each treatment separately 
(Tables A.35-A.37). 
 
2.5.4 Energy Adjustment 
 Energy adjustment is common practice in all nutritional epidemiology studies.  The 
majority of epidemiologic studies of PUFA and/or fish intake and breast cancer incidence 
have controlled for energy intake in the statistical model. Willett has proposed many reasons 
for energy adjustment in nutritional epidemiologic studies, including: (1) control for 
confounding; (2) removal of extraneous variation; and (3) simulation of a dietary intervention 
[384].  However, it is known that PUFA contributes to 7% of total energy intake [146] and 
thus energy intake could be considered on the causal path between PUFA intake and breast 
cancer incidence.  Animal studies support inhibition of mammary tumor development with 
caloric restriction [385].  However for humans, the balance between energy intake and 
energy expenditure (considering energy intake, physical activity, and body size) may be more 
important for breast cancer prevention than caloric restriction itself [386]. 
 Adjustment for total energy intake when examining the potential association between 
intake of PUFAs and breast cancer could lead to biased effect estimates [373], if we consider 
total energy intake as a causal intermediate.  Interestingly, no differences in effect estimates 
were observed when examining different methods of energy adjustment (e.g., standard 
multivariate model without energy adjustment, standard multivariate model with energy-
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adjustment, nutrient residual model, energy-partition model, multivariate nutrient density 
model) when examining the effect of fat on coronary heart disease [387]. 
 Nevertheless, the energy adjustment for this analysis could affect the interpretation of 
the effect estimates and has the potential to reflect very different public health messages.  For 
example, including energy adjustment in the model for main effect could reflect a 
substitution of food sources of PUFA for other components of the diet, which may be 
important when examining the effect of relative balance of PUFA (ω-3:ω-6 ratio) which 
would constitute a change composition of the diet.  However, if effect estimates are presented 
without energy-adjustment, then the estimates could be interpreted as the effect of adding 
food sources of PUFA to the diet (e.g., supplementation of the diet) on breast cancer.  
Therefore, main and interactive effects for Aims 1 and 2 were analyzed and are presented 
with and without energy adjustment since they reflect different public health messages.  
Sensitivity analyses were conducted examining different methods of energy adjustment 
(Table A.38), thus reflecting different interpretations for the estimate of PUFA intake in 
relation to either incidence (Tables A.39-A.40) or survival (Tables A.41-A.42).  
Furthermore, sensitivity analysis examining adjustment for the other PUFA class (either ω-3 
or ω-6) was also conducted for both incidence (Table A.43) and survival (Table A.44).  
However, the results from the sensitivity analyses did not alter our conclusions. 
 
2.6 Study Power 
 Power was calculated for incidence (Aim 1) using National Cancer Institute (NCI) 
Power Version 3.0 [388, 389].  Power was calculated considering the main effect of 
PUFA/fish intake (Aim 1a) as categorical variables (e.g., quartiles, tertiles, dichotomized).  
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The detectable OR represented the comparison of the highest to the lowest category (e.g., 
quartile 4 versus quartile 1, tertile 3 versus tertile 1, etc).  This was accomplished by 
assuming a dichotomous exposure variable with prevalence of exposure 50% (highest 
quartile) and varying the study sample sizes (e.g., ½ total sample for quartiles, ⅔ total sample 
for tertiles, and full sample size for dichotomized exposure).  Interactions (Aim 1b) were 
considered for both super-multiplicative and sub-multiplicative interactions. The following 
values for departure from multiplicative interactions (θ) were considered: 0.32, 0.53, 2, and 
3. Power calculations for Aim 1 are presented in Tables A.45-A.46. 
 A similar approach was employed for survival (Aim 2), except using PROC POWER 
in SAS (Cary, NC).  Among the 1,508 LIBCSP cases, there were 444 total deaths, of which 
203 were due to breast cancer.  The number of deaths used for the power calculations were 
proportional to the total sample size for the exposure.  For example, PUFA intake is available 
for 98% of the cases (n=1,481), therefore only 98% of total deaths (n=436) were used in the 
power calculations.  The event rate was calculated by dividing the estimated number of 
deaths (e.g., 436 deaths) by the total person-years (e.g., 1,481 persons * 12.7 years = 18,800 
person-years).  A similar procedure was used for calculating power related to breast-cancer 
specific mortality, using only 203 breast cancer deaths. Power calculations for Aim 2 are 
presented in Tables A.47-A.48. 
 
2.7 Data Interpretation Issues 
 For Aims 1a and 2a, a decreased breast cancer incidence and improved survival 
among those consuming a higher ratio of ω-3 fatty acids relative to ω-6 fatty acids were 
expected.  Risk reductions were also expected for fish intake, and these estimates were 
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thought to vary by cooking method.  However, differences by cooking methods were not 
observed in this population (Tables A.49-A.50) and may be largely due to low fish intake 
and resulting small cell sizes. This decreased risk of breast cancer incidence among those 
consuming more ω-3 fatty acids may be modified by inflammation, oxidative stress, or 
aromatase genes.  For genetic polymorphisms, effect estimates were expected to vary by 
genotype; those variants conferring greater enzyme activity may increase mortality – 
although possible risk reductions were evident, depending upon the biologic function of the 
gene (e.g., increasing versus lowering levels of oxidative stress) and the variant allele’s 
impact on gene function (Aim 2b).  The findings for the polymorphisms are more likely to be 
favorable when their effects are considered in an environment rich with ω-3 fatty acids. Thus, 
for women with a higher ω-3 to ω-6 ratio and genetic variants conferring greater enzyme 
activity pronounced risk reductions in incidence and mortality were expected (Aims 1b and 
2c).   
 Due to the improved survival observed among women diagnosed with breast cancer 
in the U.S. [1], the number of deaths observed in the LIBCSP cohort is lower than 
anticipated.  Thus, the results were expected to be imprecise, especially for the interaction 
between genes and survival (Aim 2c).  Therefore, results from the PUFA-gene interaction 
analyses, especially with respect to survival were interpreted with caution. 
 Exposure assessment of dietary intake of both PUFAs and fish may not be accurate, 
because of incomplete assessment by the FFQ.  For the case-control analyses, differential 
recall between cases and controls is also a possibility, although this concern would not affect 
the case-only cohort analysis.  It is also possible that dietary assessment may not represent 
the actual diet intake during the induction period for development and/or progression of 
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breast cancer, consequently resulting in underestimation of the effect estimates in relation to 
breast cancer incidence and mortality. 
 The LIBCSP is a population-based study, representing women with breast cancer in a 
proscribed geographic area, Nassau and Suffolk counties on Long Island, NY.  Thus, 
findings are applicable to this group of Long Island women, who are primarily white 
postmenopausal women.  This is the specific sub-population that is at highest risk for breast 
cancer in the U.S.  However, the study is not generalizable to other races or ethnicities, 
although the underlying associations observed in the proposed study are not expected to vary 
widely from other populations with similar intake of PUFA-rich foods and similar genetic 
profiles. 
 
2.8 Study Purpose 
 To the best of my knowledge, this study is the first to comprehensively examine the 
potential interaction between PUFA intake and genetic susceptibility in inflammation, 
oxidative stress, and aromatase enzymes on breast cancer incidence and survival. 
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Table 2.1 Example calculation of PUFA intake using USDA 
Food 
Daily grams 
of intake
*
 
ω-3 (per 100g)**  ω-6 (per 100g)** 
ALA EPA DHA DPA LA AA 
Tuna 200 
na 0.363 1.141 0.160 0.068 0.055 
na 0.726
†
 2.282 0.320 0.136 0.110 
Total ω-3 
intake 
 
= 0.726 + 2.282 + 0.320 
= 3.328 
 
Total ω-6 
intake 
  
= 0.136 + 0.110 
= 0.246 
Note: 
*Generated from participant responses to modified Block FFQ 
** Available from USDA National Nutrient Database for Standard Reference, Release 23 
†
 200 grams of tuna * (0.363 grams of EPA per 100 grams of tuna) = 0.726 grams of EPA 
 
  
1
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Table 2.2 Summary of putatively functional SNPs and LIBCSP results 
Gene [Ref.] rs# Function* 
Allele 
substitution 
Main Effects 
OR (95% CI) 
Interaction Effects with Diet 
OR (95% CI) 
Inflammation 
PTGS-2 [65] 
rs20417 TFBS G > C 
GC/CC genotype: 
0.9 (0.8, 1.1) 
GC/CC genotype & ever aspirin use: 
0.8 (0.6, 1.1) 
rs5275 miRNA T > C 
TC/CC genotype: 
0.9 (0.8, 1.1) 
TC/CC genotype & ever aspirin use: 
0.7 (0.5, 0.9) 
PPAR-α [368] rs1800206 
splicing 
nsSNP 
3D 
C > G None 
G variant allele & aspirin use: 
ICR = 0.16 (-0.59, 0.91) 
FAS [367] 
rs2234767 
TFBS 
splicing 
G > A None None 
rs1800682 TFBS G > A 
AA genotype: 
1.13 (0.89, 1.43) 
None 
FASL [367] rs763110 TFBS C > T None None 
TNF-α rs1800629 TFBS G > A None None 
Oxidative Stress 
MnSOD [365] rs4880 
splicing 
nsSNP 
C > T None 
0.63 (0.41, 0.95) 
variant T allele & high total fruit/vegetable 
MPO [362] rs2333227 TFBS G > A 
AA genotype: 
0.83 (0.58, 1.19) 
0.75 (0.58, 0.97) 
AA genotype & high total fruit/vegetable 
CAT [363] rs1001179 TFBS C > T 
CC genotype: 
0.77 (0.49, 1.22) 
0.69 (0.53, 0.90) 
CC genotype & high total fruit/vegetable 
GPX1 [364] rs1050450 
splicing 
miRNA 
nsSNP 
polyphen 
C > T 
TT genotype: 
1.06 (0.79, 1.42) 
0.73 (0.53, 1.01) 
CC genotype & high total fruit/vegetable 
*Defined as functional in HapMap CEU population using SNPinfo web server; Abbreviations: transcription factor binding site prediction (TFBS), non-
synonymous single nucleotide polymorphism (nsSNP), micro RNA binding (miRNA), splicing regulation (splicing), polyphen prediction (polyphen), 3D 
conformation (3D)
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Table 2.2 (cont.) Summary of putatively functional SNPs and LIBCSP results 
Gene [Ref.] rs# Function* 
Allele 
substitution 
Main Effects 
OR (95% CI) 
Interaction Effects with Diet 
OR (95% CI) 
Oxidative Stress 
GSTM1 [366] deletion deletion deletion None 
0.68 (0.45, 1.03) 
GSMT1 present & high cruciferous vegetable intake 
among postmenopausal women 
GSTP1 [366] rs1695 
splicing 
nsSNP 
A > G None 
0.89 (0.64, 1.25) 
Variant G allele & high cruciferous vegetable 
GSTT1 [366] deletion deletion deletion None 
0.74 (0.53, 1.05) 
GSTT1 present & high cruciferous vegetable intake 
among postmenopausal women 
GSTA1 [372] rs3957356 TFBS G > A 
AA genotype: 
1.20 (0.94, 1.54) 
0.83 (0.51, 1.37) 
AA genotype & high total vegetable intake 
COMT [371] 
rs4680 
splicing 
nsSNP 
3D 
G > A 
AA genotype: 
0.88 (0.69, 1.12) 
None 
rs737865 TFBS C > T 
CC genotype: 
Premenopausal: 
0.84 (0.49, 1.45) 
None 
Estrogen Metabolism 
CYP17 [369] rs743572 TFBS T > C 
CC genotype: 
Premenopausal: 
0.81 (0.52, 1.25) 
Postmenopausal: 
1.25 (0.90, 1.73) 
None 
*Defined as functional in HapMap CEU population using SNPinfo web server; Abbreviations: transcription factor binding site prediction (TFBS), non-
synonymous single nucleotide polymorphism (nsSNP), micro RNA binding (miRNA), splicing regulation (splicing), polyphen prediction (polyphen), 3D 
conformation (3D) 
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Figure 2.1 DAG of potential confounders of the PUFA/Fish intake and breast cancer incidence association 
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Figure 2.2 DAG of potential confounders of the PUFA/Fish intake and breast cancer mortality association
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CHAPTER 3: 
INTERACTION BETWEEN PUFAs, GENETIC POLYMORPHISMS, AND BREAST 
CANCER RISK: A POPULATION-BASED, CASE-CONTROL STUDY ON LONG 
ISLAND, NEW YORK 
 
3.1 Introduction 
 Breast cancer incidence rates are almost two and a half times higher in the United 
States (U.S.) and European countries than in Asian countries, such as China or Japan [2, 
390].  Migration studies conducted among Asian immigrants have shown that the breast 
cancer incidence patterns begin to reach those of Western countries a few generations after 
migration [4-7], suggesting that environmental factors may play a role in the geographic 
variation in incidence rates observed in Asian and Western countries.   
One potential environmental exposure is polyunsaturated fatty acids (PUFAs), of 
which there are two primary classes, ω-3 and ω-6 fatty acids.  Laboratory studies show that 
ω-3 PUFAs competitively inhibit ω-6 fatty acids, thus lowering levels of inflammatory 
eicosanoids resulting from ω-6 metabolism [155].  Asian populations have a substantially 
higher ratio of ω-3/ω-6 intake compared to European and U.S. populations [153, 154].  Fish 
is a major source of long-chain ω-3 PUFAs and is commonly consumed among Asian 
populations [146, 391, 392], which may partially explain the lower risk seen in these 
populations.  
 Experimental evidence suggests that higher ω-3 relative to ω-6 could reduce breast 
cancer through mechanisms related to inflammation, oxidative stress, and estrogen 
metabolism [155, 199, 202, 256]. Despite this biologic plausibility, previous epidemiologic 
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studies that have examined the association between PUFAs and the occurrence of breast 
cancer remain inconsistent among U.S. and European populations [80, 85, 99, 104, 269, 270, 
278-281, 285-288, 292-298].  However, in Asian studies, consistent risk reductions have 
been observed for long-chain ω-3 PUFAs and breast cancer incidence [100, 277, 289, 290]. 
One potential reason for this observed inconsistency could be related to low fish intake.  The 
biologic influence of PUFAs is unlikely to differ across populations; however, low fish 
intake in Western countries may mask important risk reductions.  Also, Western populations 
consume higher levels of ω-6 PUFAs than Asian populations [152].  Thus, we hypothesized 
that consideration of both ω-3 and ω-6 intake, as an interaction or as the relative balance (ω-
3/ω-6 ratio), may help to clarify the potential benefit of ω-3 intake among populations with 
low fish intake. 
 PUFAs affect carcinogenesis via multiple biologic pathways [155, 199, 202, 256], 
thus, it may also be important to examine interaction with biologically relevant genetic 
polymorphisms in relation to breast cancer.  However, only two previous studies [287, 342] 
examined interactions between ω-3 or ω-6 intake and genetic polymorphisms involved in 
PUFA metabolism, and only the glutathione S-transferase (GST) [342] or lipoxygenase 
enzymes [287] were examined. Given the multitude of biologic pathways through which 
PUFAs could potentially affect carcinogenesis, we hypothesized that examination of the 
potential interaction with genetic polymorphisms involved in inflammation, as well as 
oxidative stress, and estrogen metabolism pathways, may help to further clarify the impact of 
PUFA intake on breast cancer development. 
In the study reported here, we examined the interaction between dietary ω-3 and ω-6 
PUFA classes, and the interactions between the ω-3/ω-6 ratio and genetic polymorphisms in 
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three related pathways, in association with breast cancer risk among women on Long Island, 
New York (NY).   
 
3.2 Materials and Methods 
 This study utilizes the population-based case-control component of the Long Island 
Breast Cancer Study Project (LIBCSP).  Details of the parent study have been published 
previously [355].  Institutional Review Board approval was obtained from all participating 
institutions. 
 Study population.  Cases and controls were English-speaking residents of Long 
Island, NY (Nassau and Suffolk counties).  Cases were adult women newly diagnosed with a 
first primary in situ or invasive breast cancer between August 1, 1996 and July 31, 1997, and 
were identified using a “super-rapid” network where study personnel contacted (either 2-3 
times per week or daily) hospital pathology departments.  Controls were identified using 
Waksberg’s method of random digit dialing [393] for women under 65 years of age, and the 
Health Care Finance Administration rosters for women 65 years and older.  Controls were 
frequency matched to the expected age-distribution of the case women. There were no upper 
age or race restrictions for subject eligibility. 
The parent LIBCSP respondents included 1,508 cases and 1,556 controls.  
Respondents ranged in age from 20 to 98 years of age, 67% were postmenopausal, and the 
majority self-reported their race as white (94%), followed by black or African American 
(4%), or other (2%), which is consistent with the racial population distribution of these two 
counties at the time of data collection [355].   
 Assessment of PUFAs and other covariates.  All LIBCSP participants were 
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administered a main questionnaire by a trained interviewer about 3 months after diagnosis for 
cases and 5.5 months after identification for controls.  The questionnaire asked about 
demographic characteristics, pregnancy history, menstrual history, hormone use, medical 
history, family history of cancer, body size changes, alcohol use, active and passive cigarette 
smoking, physical activity, occupational history, and other potential risk factors for breast 
cancer [355].  LIBCSP researchers have previously reported that breast cancer risk in this 
population is associated with known reproductive risk factors (increasing age at first birth, 
few or no children, little or no breastfeeding, late age at menarche) [21], and lifestyle risk 
factors (increasing alcohol intake and, for postmenopausal breast cancer, decreased physical 
activity and increased body size) [52, 394]. 
 Approximately 98% of participants (1,479 cases and 1,520 controls) also completed 
the validated [359, 395, 396] self-administered 101-item modified Block food frequency 
questionnaire (FFQ).  Participants with implausible total energy intake (± 3 standard 
deviations from the mean) were excluded (n = 36). Thus, 1,463 cases and 1,500 controls 
were included in our examination of the association between PUFA intake and breast cancer 
risk. 
 We estimated PUFA intake by linking responses from the FFQ (i.e., grams per day 
for each line item) with nutrient values available in the U.S. Department of Agriculture 
databases for ω-3 and ω-6 PUFAs [397].  The following PUFAs were estimated: (1) ω-3 fatty 
acids, including alpha-linolenic acid (ALA), docosapentanoic acid (DPA), docosahexanoic 
acid (DHA), eicosapentanoic acid (EPA); and (2) ω-6 fatty acids, including linoleic acid 
(LA) and arachidonic acid (AA).  An estimate of total PUFA intake was calculated by 
combining all individual fatty acids.  Additionally, an estimate of total ω-3 and ω-6 fatty 
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acids was obtained by summing each individual fatty acid within category (e.g., total ω-3 = 
ALA + DPA + DHA + EPA).   
Fish and/or seafood intakes were assessed according to the following items recorded 
in the FFQ: (1) tuna, tuna salad, tuna casserole; (2) shell fish (shrimp, lobster, crab, oysters, 
etc.); and (3) other fish (either broiled/baked). 
 Genotyping.  Eighteen polymorphisms (in fifteen genes) were selected for this 
analysis spanning three biologically plausible pathways for PUFA metabolism, including 
inflammation, oxidative stress, and estrogen metabolism pathways.  Variants affecting 
polyphen prediction (GPX1), transcription factor binding prediction (PTGS-2 rs20417, FAS, 
FASL, TNF-α, MPO, CAT, GSTA1, COMT rs737865, CYP17), miRNA binding (PTGS-2 
rs5275, GPX1), 3D conformation (PPAR-α, COMT rs4680), or splicing regulation (PPAR-α, 
FAS rs2234767, GPX1, GSTP1, COMT rs4680) were considered as putatively functional 
variants as defined in the NIEHS SNPInfo WebServer [361]. 
 Blood samples collected from subjects at the time of the case-control interview were 
used as the source of DNA for the genotyping.  Genotyping methods have been previously 
described [65, 366-370, 398].  Briefly, DNA was isolated from mononuclear cells in whole 
blood which was separated by Ficoll (Sigma Chemical Co., St. Louis, Missouri) in the 
laboratory of Dr. Regina Santella at Columbia University using standard phenol and 
chloroform-isoamyl alcohol extraction and RNase treatment [398].  Genotyping for 
inflammation genes (PTGS-2, FAS, FASL, PPAR-α, TNF-α), used the following assays: 
Taqman 5’-Nuclease Assay (Applied Biosystems, Foster City, CA) and AcycloPrimeTM-FP 
SNP Detection Kit obtained from Perkin Elmer Life Sciences (Boston, Massachusetts, USA) 
[65, 367, 368].  The same assay was used for aromatase gene (CYP17) with a 10 µM probe 
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[369, 370].  For oxidative stress genes (CAT, MPO, MnSOD, GPX, GSTA1, GSTP1, COMT), 
BioServe Biotechnologies (Laurel, Maryland) performed the genotyping using high-
throughput, matrix assisted, laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry of Sequenom, Inc. (San Diego, California). Gene deletions for GSTM1 and 
GSTT1 were determined by a multiplex polymerase chain reaction method, with the 
constitutively present gene β-globulin as an internal positive control [366]. 
 Data were missing for some genetic polymorphisms, primarily due to laboratory 
failures. Thus, the final sample sizes for our examination of gene-environment interactions 
are PTGS-2 rs20417 and rs5275 (n = 2,106), PPAR-α rs1800206 (n = 1,815), FAS rs2234767 
(n = 2,106), FAS rs1800682 (n = 2,095) FASL rs763110 (n = 2,110), TNF-α rs1800629 (n = 
2,088), MnSOD rs4880 (n = 2,063), MPO rs2333227 (n = 2,078), CAT rs1001179 (n = 
2,068), GPX1 rs1050450 (n = 2,074), GSTM1 deletion (n = 1,925), GSTP1 rs1695 (n = 
2,040), GSTT1 deletion (n = 1,946), GSTA1 rs3957356 (n = 2,075), COMT rs4680 (n = 
2,084), COMT rs737865 (n = 2,064), and CYP17 rs743572 (n = 2,044). 
 Tests for Hardy-Weinberg equilibrium (HWE) among the controls were conducted.  
Only PTGS-2 rs20417 and MPO polymorphisms deviated significantly from HWE (p < 
0.05).  However, the observer agreement in 8% of the randomly selected was high (PTGS-2 
rs20417 kappa statistic = 0.99, MPO kappa statistic = 0.91), and the failure rate of the assay 
was less than 1% for both polymorphisms. Also, the genotype frequencies for both PTGS-2 
rs20417 and MPO polymorphisms were reported to be similar to those observed in other 
studies [362, 399]. 
Statistical analyses.  All analyses were conducted using SAS version 9.2 (SAS 
Institute, Cary, NC).  Unconditional logistic regression was used to estimate odds ratios 
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(ORs) and 95% confidence intervals (95% CI) for the association between PUFA intake and 
breast cancer risk.  All PUFA intake estimates (i.e., total PUFA, total ω-3, ALA, DPA, DHA, 
EPA, total ω-6, LA, AA, ratio of ω-3/ω-6) were categorized as quartiles, according to the 
distribution among controls.  Quartiles were selected over other possible methods of 
categorization (e.g., tertiles, quintiles, linear, splines) because the shape of the dose-response 
between PUFAs and breast cancer risk was best captured using these cut-points. Similarly, 
fish intake was categorized using quartiles according to the distribution among those controls 
who reported consuming fish (i.e., tuna, shell fish, other fish); non-consumers of fish were 
considered the referent group.  Tests for linear trend were not conducted, since the relation 
between any of the PUFA measures and breast cancer risk was not strictly monotonic [373]. 
Interactions between total ω-3 and total ω-6 intake, and between the ω-3/ω-6 ratio 
and the eighteen genetic polymorphisms, in association with breast cancer risk were assessed 
on the additive (common referent) and multiplicative scales.  Additive interaction was 
evaluated using relative excess risk due to interaction (RERI), with 95% CI estimated using 
the Hosmer and Lemeshow method [374]. Multiplicative interactions were evaluated by 
comparing nested models using the Likelihood Ratio Test (LRT) [373].  Total ω-3, total ω-6, 
and ratio of ω-3/ω-6 were dichotomized at the median for use in the interaction models.  
Similarly, in order to maximize cell sample sizes, genotypes were dichotomized according to 
a dominant model and categorized into “high” and “low” risk groups based upon the function 
of the variant allele, which was determined using the existing literature (see Supplemental 
Table 3.6) [219, 399-412].   
We also considered effect modification of the association between PUFA intake and 
breast cancer risk by: menopausal status (post- vs. pre-menopausal status); and dietary 
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supplement use (yes/no).  However, little or no heterogeneity was observed with either of 
these covariates, and thus the results are not shown.  We also considered potential 
heterogeneity across breast cancer subtypes, defined by hormone receptor status (any 
hormone receptor positive breast cancer vs. no hormone receptor positive breast cancer), by 
constructing polytomous regression models; however, no differences in the association with 
PUFA intake were observed across hormone receptor subtype, and thus the results are not 
shown. 
 All models were adjusted for the frequency matching factor five-year age group.  
Other potential confounders (including total energy intake, non-steroidal anti-inflammatory 
drugs (NSAID), family history of breast cancer, income, body mass index, alcohol use, fruit 
and vegetable intake, and physical activity) were identified using directed acyclic graph 
(DAG) [373].  The only covariates that changed the estimates by more than 10% were total 
energy intake for PUFA intake, and energy intake and NSAID use for fish intake.  It is 
possible that chronic NSAID users experience gastrointestinal problems (e.g., stomach 
ulcers, reflux) which may subsequently influence diet, including fish consumption [413]. 
Thus, all PUFA models were adjusted for age and energy intake, and all fish intake models 
included age, energy intake and NSAID use.   
 
3.3 Results 
 As presented in Table 3.1, the average intake of total ω-3 fatty acids (1.01 grams per 
day (SD = 0.74)) was lower relative to ω-6 intake [7.66 grams per day (SD = 5.68)] among 
the 1,500 control women in this population-based sample of Long Island residents without 
breast cancer. The highest contributor to total ω-3 intake was ALA with an average intake of 
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0.86 grams per day (SD = 0.71), whereas LA was the highest contributor to total ω-6 intake 
with an average intake of 7.59 grams per day (SD = 5.66). Tuna intake was reported at higher 
levels [11.92 grams per day (SD = 15.09)] in our control population compared to shell fish 
intake [7.28 gram per day (SD = 11.88)]. 
As also shown in Table 3.1, fish was a large contributor to high intake of long-chain 
ω-3 PUFAs, including DPA, DHA, and EPA.  In contrast, foods that contributed to high 
ALA intake were biscuits/muffins and other fried foods, which was similar to what was 
observed for LA intake.  High AA intake appeared to be predominantly driven by eggs and 
meats, including fish, chicken, and ham. 
 As presented in Table 3.2, the age-adjusted and multivariate-adjusted odds ratios for 
the associations between all measures of PUFA intake and breast cancer risk were imprecise. 
For example, elevated odds ratios were observed for high intake of total PUFA, total ω-3, 
ALA, ω-6, and LA intakes, but CIs were wide.  No associations were observed for the long-
chain ω-3 PUFA (DPA, DHA, EPA), or AA intake.  Similarly, no associations were 
observed for high intakes of the ratio of ω-3/ω-6 intake and breast cancer risk. 
 As shown in Table 3.3, higher intake of tuna, shell fish, or other fish (broiled/baked) 
was not associated with breast cancer risk in our study.  
 As shown in Table 3.4, we observed an interaction between ω-3 and ω-6 intake, 
which was statistically significant on the additive scale [multivariate-adjusted RERI = 0.41 
(95% CI = 0.06, 0.76)].  The risk reductions for breast cancer were modest for women who 
consumed low levels of both ω-3 and ω-6 [multivariate-adjusted OR = 0.83 (95% CI = 0.63, 
1.09)], compared to women who consumed high ω-3 and low ω-6. For women who 
consumed high levels of ω-3 and ω-6, the odds ratios were close to the null value 
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[multivariate-adjusted OR = 0.95 (95% CI = 0.72, 1.26)].  In contrast, higher intakes of ω-6 
fatty acids in conjunction with lower intake of ω-3 fatty acids was associated with an 
approximately 20% increased risk of breast cancer [multivariate-adjusted OR = 1.20 (95% CI 
= 0.85, 1.69)].  The increased risk observed for this group was super-additive (41% greater) 
compared to the 22% (= 5% + 17%) expected risk reduction, derived from the individual 
ORs for those consuming either high levels (≥ median; 5% risk reduction), or low levels (< 
median; 17% risk reduction) of both ω-3 and ω-6 fatty acids. Similar results were observed 
when we considered interactions between ω-3 and ω-6 on a multiplicative scale (see 
Supplemental Table 3.7). 
 As presented in Table 3.5, when we explored interactions between the ratio of ω-3/ω-
6 intake and genetic polymorphisms in the inflammatory, oxidative stress, and estrogen 
metabolism pathway, we found little evidence to support an additive interaction for most of 
the genes considered.  The strongest and most precise risk estimate for the hypothesized 
highest risk group (low ω-3/ω-6 intake and high risk genotype) was observed for PTGS-2 
rs5275 [OR = 1.29 (95% CI = 1.00, 1.66)] in comparison to the hypothesized lowest risk 
group (high intake of ω-3/ω-6 and low risk genotype). We observed similar, but less precise, 
elevations for the corresponding interactions with GSTP1 [OR = 1.23 (95% CI = 0.86, 1.57)], 
and COMT rs737865 [OR = 1.35 (95% CI = 0.87, 2.11)].  For the majority of interactions we 
examined, breast cancer risk remained elevated for low intake of ω-3/ω-6 ratio regardless of 
genotype, with the exceptions of the FASL rs763110 and COMT rs4680 genes. Similar 
results were observed when we considered interactions between the ω-3/ω-6 ratio and 
polymorphisms on a multiplicative scale (see Supplemental Table 3.8).  
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3.4 Discussion 
 We are the first to report an additive interaction between ω-3 intake and ω-6 intake in 
relation to breast cancer risk in a population-based sample of U.S women. Specifically, we 
observed a 20% increase in the odds of breast cancer among consumers of high levels of ω-6 
and low levels of ω-3 compared to those who consumed low levels of ω-6 and high levels of 
ω-3.  The odds ratio for women consuming high ω-6 and low ω-3 was increased, whereas the 
corresponding estimates for intake of either high levels or low levels, of either PUFA class, 
were reduced. This interaction underscores the importance of considering intake of ω-3 and 
ω-6 simultaneously when examining associations with breast cancer in the U.S. 
 No previous studies in the U.S. have examined the potential interaction between ω-3 
and ω-6 PUFAs and breast cancer risk, and only two have examined the ratio of ω-3 and ω-6 
intakes [270, 286]. Consideration of an interaction may be preferable, given that a ratio 
measure permits only one type of relation between two exposures, whereas an interaction is 
more flexible. One previous study has reported on the interaction between ω-3 and ω-6 intake 
on breast cancer risk among women in Shanghai [290]; the investigators observed a 
significant two-fold increased risk for high ω-6 in combination with low marine-derived ω-3 
intake. The LIBCSP results presented here for the interaction between ω-3 and ω-6 intake are 
in the same direction as those reported in the Shanghai study, but less pronounced. 
Importantly, daily fish consumption in the Shanghai population was almost five times greater 
than the frequency reported among our population-based sample of Long Island residents, 
which could partially explain the weaker association observed in our study. 
 The slight positive association between ω-6 PUFA (total ω-6, LA, AA) and breast 
cancer risk observed here is similar to associations reported in other studies conducted 
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among Western populations [270, 280, 289, 290, 297].  However, our findings for the 
association between long-chain ω-3 (DPA, DHA, EPA) PUFAs are not consistent with 
previous studies conducted among Asian or some European populations [100, 277, 289, 290, 
294], where risk reductions were reported.  Additionally, the increased risk for ALA intake 
we observed is inconsistent with the laboratory evidence for inhibition of breast cancer 
growth [238, 240].  However, in other epidemiologic studies, the association between ALA 
intake and breast cancer risk remains unclear, with some studies reporting increased risks 
[269, 283, 290, 294, 295], and others reporting risk reductions [292, 296].  The variation in 
results across studies may be associated with the different dietary assessment methods used, 
consumption of different food sources of ALA (e.g., biscuits/muffins and fried foods were 
major contributors in our population), or with potential recall bias that can occur in case-
control studies. It is also possible that ALA reduces breast cancer growth only after 
conversion to long-chain ω-3 PUFAs.  The in vivo conversion of ALA to long-chain ω-3 
PUFAs is inefficient in the presence of high ω-6 [150]. Thus, it is possible that in populations 
with high ω-6 intake, benefits of ALA intake are less evident. 
 The slight breast cancer risk reductions we observed in relation to a high ω-3/ω-6 
ratio in our study were modest compared to the estimates reported in several other studies in 
European [85], Mexican [284], and U.S. populations [270, 286].  However, this may be a 
reflection of the relatively low intake of ω-3 and ω-6 in our study population. Very low 
intake of both ω-3 and ω-6 PUFAs could result in a high ratio value for ω-3/ω-6 intake.  
Thus, a high ratio of ω-3/ω-6 derived from low intakes of ω-3 and ω-6 PUFAs may not 
represent a sufficient dose for ω-3 to exert a beneficial response in vivo.  In the U.S., only 
one previous population-based study has considered the PUFA ratio in association with 
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breast cancer risk; utilizing data from the Vitamins and Lifestyle Cohort (VITAL) [270], a 
16% risk reduction was observed in association with high ω-3/ω-6 intake ratio.  This Western 
Washington-based study included marine-derived ω-3 intake from both dietary sources and 
supplements, and thus levels of ω-3 intake were higher than the dietary-derived intake 
estimates observed in our Long Island-based study.  Nonetheless, given the weak results 
reported for the PUFA ratio in both our study and the Western Washington study, examining 
the interaction between ω-3 and ω-6 intake, rather than the ratio, may be a more favorable 
strategy in populations where PUFA intake is relatively low. 
We are the first study to examine PUFA-gene interactions when considering multiple 
genes in several biologically plausible pathways, including inflammation. Nonetheless, we 
found little evidence for an interaction between PUFA intake and the eighteen genetic 
polymorphisms in the three pathways considered, despite the biologic plausibility for these 
interactions to impact breast cancer development. Instead, for all of the interactions with 
genetic polymorphisms, more pronounced associations were observed for those consuming 
low ratio of ω-3/ω-6, regardless of genotype.   
Previously, only two epidemiologic studies have considered potential interactions 
between PUFA intake, genetic polymorphisms, and breast cancer [287, 342].  Given the 
examination of PUFA-gene interactions in previous studies is limited to only one or two 
exposures and one or two genetic polymorphisms, comparison of our results to previous 
studies is challenging.  Additionally, both of these previous studies focused only on one 
PUFA exposure (either marine-derived ω-3 or LA) in isolation, without concurrently 
considering ω-6 PUFAs.  Considering ω-3 and ω-6 PUFA simultaneously is likely to better 
reflect the complexity of this dietary exposure, given the competitive inhibition of ω-3 and 
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ω-6 in PUFA metabolism. 
The strengths of our population-based, case-control study include the examination of 
the interaction between ω-3 and ω-6 on breast cancer development, which has not been 
previously assessed in a U.S. population.  Additionally, we also examined associations with 
fish intake (a dietary source rich in ω-3 fatty acids) among this sample of women who reside 
in a geographic area that is surrounded by water, and for whom the variability of fish intake 
would presumably be greater than for others who reside in more land-locked areas of the U.S 
[391].  In fact, women living in New York City [414] have been reported to consume fish 
greater than the national estimates from NHANES [415], which our study corroborates. 
Finally, we are the first to examine PUFA-gene interactions with consideration given to 
genetic polymorphisms spanning multiple biological pathways relevant to PUFA 
metabolism.  
 This study also has limitations that should be considered. The LIBCSP study 
population includes predominantly Caucasian women, which reflects the racial distribution 
of the residents of the two source counties on Long Island, NY. Consequently, examination 
of racial differences in our study was not possible.  Our results are therefore generalizable to 
only Caucasian-American women, for whom breast cancer risk remains high [1].  Though we 
examined PUFA interactions with multiple polymorphisms spanning several biologic 
pathways, our selected genes are not exhaustive.  For studies with larger sample sizes, it may 
be beneficial to examine additional genetic polymorphisms involved in relevant pathways, 
such as genes involved in the in vivo metabolism of ω-3 and ω-6.  Humans do not possess the 
enzymes necessary to desaturate LA to ALA, thus conversion from ω-6 to ω-3 is impossible 
[148].  However, through a series of desaturations and elongations, formation of long-chain 
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ω-3 PUFAs from ALA, and AA from LA, is possible in vivo.  A recent dietary intervention, 
reported increased levels of EPA, DHA, and DPA, among women who lowered their dietary 
LA intake, suggesting increased efficiency in the conversion of ALA to long-chain ω-3 
PUFAs in vivo [416] among this subgroup.  Therefore, consideration of polymorphisms in 
genes involved in this conversion, in combination with PUFA intake, may be helpful for 
understanding the bioavailability of different PUFA subtypes in vivo. 
 Future studies may also be warranted to evaluate the timing of exposure relative to 
breast cancer development. FFQ responses are assumed to reflect usual adult diet [271], 
although recent changes due to a disease diagnosis or treatment regimens could influence 
those responses. The LIBCSP questionnaires were administered within months of diagnosis, 
and for two-thirds of women this was prior to the onset of chemotherapy [355], which is 
likely to reduce the impact of dietary changes and perhaps recall of diet on the FFQ.  
Estimating PUFA intake via FFQ linkage with the USDA databases, however, could result in 
measurement error. For example, it is possible that the PUFA content measured in the foods 
reported in the USDA database [397] differ from those actually consumed by LIBCSP 
participants due to differences in harvesting, storage, processing, and cooking methods [147, 
417, 418]. Additionally, we were unable to assess the relation between breast cancer and 
consumption of different fish varieties in this study. This is important given the amount of 
long-chain ω-3 content found in fish differs by species [419]. However, we assessed tuna 
intake, which is the most frequently consumed fish variety in the U.S. and is also a major 
source of dietary ω-3s [391].  Biomarkers could provide an objective measure of PUFA 
intake. However, PUFA biomarkers may reflect different time periods of exposure, ranging 
from a few days to one year (depending on the type of biomarker used) [273]. Therefore, use 
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of the PUFA biomarker measurements in a case-control study may not reflect the 
etiologically relevant time period for breast cancer development.  
 In conclusion, we found that among a population-based sample of Long Island 
residents, women who consume high levels of ω-6 and low levels of ω-3 had an increased 
risk for breast cancer, compared to women who consume low levels of ω-6 and high levels of 
ω-3.  For interactions with genetic polymorphisms, increased risks were observed for those 
consuming a low ratio of ω-3/ω-6, regardless of genotype.  Our results suggest that high 
intake of ω-3 PUFA, coupled with low intake of ω-6, may be a potential risk reduction 
strategy for breast cancer among U.S. women. 
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Table 3.1 Characteristics of polyunsaturated fatty acid intake (PUFA) and fish intake 
among the population-based sample of control women (N=1500) in the LIBCSP, 1996-1997  
Nutrient/Food Mean SD 
25
th
 
Pct 
50
th
 
Pct 
75
th
 
Pct 
Major PUFA-rich foods contributing 
to high nutrient intake in the LIBCSP 
Nutrient (g/day)       
Total PUFA
a 
8.67 6.31 4.21 7.27 11.25 
Butter, Mayonnaise/salad dressings, 
safflower/corn oil, margarine, 
peanuts/peanut butter 
Total ω-3b 1.01 0.74 0.49 0.83 1.30 
Biscuits/muffins, butter, 
mayonnaise/salad dressings, fish, 
safflower/corn oil  
 ALA 0.86 0.71 0.35 0.68 1.14 
Biscuits/muffins, French fries/fried 
potatoes, butter, cookies, 
mayonnaise/salad dressings 
 DPA 0.01 0.01 0.01 0.01 0.02 Tuna, fish, chicken, shellfish, beef 
 DHA 0.09 0.09 0.03 0.06 0.12 Tuna, fish, eggs, shellfish, chicken 
 EPA 0.04 0.05 0.01 0.03 0.06 Fish, tuna, shellfish, chicken 
Total ω-6c 7.66 5.68 3.68 6.31 10.10 
Biscuits/muffins, French fries/fried 
potatoes, butter, chips/popcorn, 
mayonnaise/salad dressings 
 LA 7.59 5.66 3.65 6.23 9.99 
Biscuits/muffins, French fries/fried 
potatoes, butter, chips/popcorn, 
mayonnaise/salad dressings 
 AA 0.07 0.06 0.04 0.06 0.09 
Eggs, Fish, chicken, ham/lunch meats, 
shellfish 
ω-3/ω-6 0.15 0.14 0.10 0.14 0.17 N/A  
Fish (g/day)
d
       
Tuna 11.92 15.09 4.77 7.85 12.40 N/A 
Shell fish 7.28 11.88 2.00 4.62 9.23 N/A 
Other 
(broiled/baked) 
11.98 11.35 4.67 6.46 16.80 N/A 
Note: 
a
 Total PUFA = ALA + DPA + DHA + EPA + LA + AA 
b
 Total ω-3 = ALA + DPA + DHA + EPA 
c
 Total ω-6 = LA + AA 
d
 Controls with null values for tuna (N=393), shell fish (N=765), and other (N=592) are included in 
calculations.  
LIBCSP = Long Island Breast Cancer Study Project 
SD = standard deviation 
N/A = not applicable 
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Table 3.2 Age- and multivariate
a
-adjusted ORs and 95% CI for the association between dietary PUFA intake and the risk of 
breast cancer in the LIBCSP, 1996-1997 
PUFA Covariates 
Q1  Q2  Q3  Q4 
Co Ca OR  Co Ca OR 95% CI  Co Ca OR 95% CI  Co Ca OR 95% CI 
Total PUFA 
Age 
375 342 
1.00  
375 392 
1.19 0.97,1.46  
375 386 
1.19 0.97,1.46  
375 343 
1.08 0.87,1.33 
Multivariate 1.00  1.23 1.00,1.52  1.27 1.02,1.59  1.25 0.95,1.63 
Total ω-3 
Age 
375 340 
1.00  
375 403 
1.20 0.98,1.47  
375 377 
1.15 0.93,1.41  
375 343 
1.05 0.85,1.29 
Multivariate 1.00  1.25 1.01,1.54  1.23 0.98,1.54  1.20 0.92,1.58 
ALA 
Age 
375 335 
1.00  
375 390 
1.18 0.96,1.45  
375 389 
1.21 0.98,1.48  
375 349 
1.09 0.88,1.34 
Multivariate 1.00  1.23 0.99,1.51  1.29 1.04,1.61  1.25 0.96,1.62 
DPA 
Age 
375 365 
1.00  
375 354 
0.97 0.79,1.20  
375 375 
1.05 0.85,1.28  
375 369 
1.04 0.84,1.27 
Multivariate 1.00  0.99 0.81,1.22  1.08 0.88,1.33  1.09 0.88,1.36 
DHA 
Age 
375 372 
1.00  
375 336 
0.90 0.74,1.11  
375 369 
1.00 0.82,1.23  
375 386 
1.03 0.84,1.26 
Multivariate 1.00  0.91 0.74,1.13  1.02 0.83,1.26  1.06 0.86,1.31 
EPA 
Age 
375 350 
1.00  
375 359 
1.01 0.82,1.24  
375 365 
1.05 0.86,1.29  
375 389 
1.10 0.90,1.35 
Multivariate 1.00  1.02 0.83,1.25  1.08 0.88,1.33  1.14 0.92,1.40 
Total ω-6 
Age 
375 347 
1.00  
375 374 
1.11 0.91,1.37  
375 405 
1.23 1.00,1.51  
375 337 
1.04 0.84,1.28 
Multivariate 1.00  1.15 0.93,1.42  1.31 1.05,1.63  1.18 0.91,1.55 
LA 
Age 
375 351 
1.00  
375 367 
1.08 0.88,1.33  
375 407 
1.22 1.00,1.50  
375 338 
1.03 0.83,1.27 
Multivariate 1.00  1.12 0.91,1.38  1.30 1.05,1.62  1.18 0.90,1.54 
AA 
Age 
375 371 
1.00  
375 378 
1.03 0.84,1.26  
375 367 
1.00 0.81,1.22  
375 347 
0.97 0.79,1.19 
Multivariate 1.00  1.05 0.85,1.29  1.03 0.83,1.27  1.03 0.81,1.29 
ω-3/ω-6 
Age 
375 360 
1.00  
375 384 
1.08 0.88,1.32  
375 346 
0.94 0.76,1.15  
375 373 
0.99 0.80,1.21 
Multivariate 1.00  1.09 0.89,1.34  0.95 0.77,1.17  0.99 0.80,1.21 
Note: 
Co=Controls, Ca=Cases, LIBCSP=Long Island Breast Cancer Study Project 
a
 Multivariate-adjusted ORs and 95% CI adjusted for matching factor (5-year age group) and total energy intake (kcal/day) 
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Table 3.3 Age- and multivariate
a
-adjusted ORs and 95% CI for the association between fish intake and the risk of breast cancer in 
the LIBCSP, 1996-1997 
PUFA Covariates 
Never Q1 Q2 Q3 Q4 
Co Ca OR Co Ca OR 95% CI Co Ca OR 95% CI Co Ca OR 95% CI Co Ca OR 95% CI 
Tuna 
Age 
393 343 
1.00 
256 241 
1.08 0.86,1.36 
285 320 
1.29 1.04,1.60 
141 141 
1.16 0.88,1.52 
425 418 
1.14 0.94,1.39 
Multivariate 1.00 1.08 0.85,1.37 1.24 0.99,1.55 1.12 0.84,1.49 1.15 0.93,1.42 
                     
Shell fish 
Age 
765 750 
1.00 
126 102 
0.87 0.66,1.15 
227 245 
1.12 0.91,1.38 
178 169 
0.99 0.78,1.25 
204 197 
1.04 0.83,1.30 
Multivariate 1.00 0.78 0.58,1.05 1.10 0.89,1.38 0.99 0.78,1.26 1.09 0.86,1.38 
                     
Other fish 
(broiled/baked) 
Age 
592 505 
1.00 
224 253 
1.32 1.07,1.64 
87 104 
1.40 1.03,1.91 
346 341 
1.15 0.95,1.39 
251 260 
1.18 0.96,1.46 
Multivariate 1.00 1.26 1.00,1.58 1.38 1.00,1.91 1.08 0.88,1.32 1.18 0.94,1.47 
Note: 
Co=Controls, Ca=Cases, LIBCSP = Long Island Breast Cancer Study Project 
a Multivariate-adjusted ORs and 95% CI adjusted for matching factor (5-year age group), total energy intake (kcal/day), and NSAID use. 
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Table 3.4 Age- and multivariate
a
-adjusted ORs and 95% CI for the additive interaction between dietary ω-3 and ω-6 (high and 
low intake) and the risk of breast cancer in the LIBCSP, 1996-1997 
Model 
Low ω-6 
(< median) 
 High ω-6 
(≥ median) 
 
RERI
b
 95% CI
c
 
N OR 95% CI  N OR 95% CI  
Age-adjusted           
High ω-3 (≥ median) 256 1.00   1,214 0.90 0.69, 1.19    
Low ω-3 (< median) 1,215 0.87 0.66, 1.14  278 1.21 0.86, 1.70  0.43 0.09, 0.78 
Multivariate
a
           
High ω-3 (≥ median) 256 1.00   1,214 0.95 0.72, 1.26    
Low ω-3 (< median) 1,215 0.83 0.63, 1.09  278 1.20 0.85, 1.69  0.41 0.06, 0.76 
Note: 
Co=Controls, Ca=Cases, LIBCSP=Long Island Breast Cancer Study Project 
a
 Multivariate ORs and 95% CI adjusted for matching factor (5-year age group) and total energy intake (kcal/day) 
b
 RERI (Relative Excess Risk due to Interaction) = OR11 - OR10 - OR01 +1 
c
 95% CI for RERI estimated using Hosmer & Lemeshow [374] 
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Table 3.5 Multivariate
a
-adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for the risk of breast cancer for the 
hypothesized highest risk additive interaction between ω-3/ω-6 ratio and putatively functional genetic polymorphismsb in the LIBCSP, 
1996-1997 
Gene rs# 
Allele 
Substitution 
Variant 
allele 
function
g
 
High 
risk 
genotype 
High ω-3/ω-6 
(≥ median) 
 
Low ω-3/ω-6 
(< median) 
RERI
e
 95% CI
f
 Low 
risk 
 
High 
risk 
 
Low 
risk 
 High 
risk 
OR
c
  OR 95% CI  OR 95% CI  OR
d
 95% CI 
PTGS-2 rs20417 G > C ↓ Inf  GG 1.00  1.09 0.84, 1.41  1.26 0.95, 1.67  1.23 0.95, 1.59 -0.12 -0.54, 0.30 
PTGS-2 rs5275 T > C ↓ Inf  TT 1.00  1.15 0.89, 1.47  1.23 0.98, 1.55  1.30 1.02, 1.66 -0.08 -0.49, 0.33 
PPAR-α rs1800206 C > G ↓ Inf  CC 1.00  0.77 0.51, 1.18  1.12 0.63, 1.98  0.96 0.63, 1.46 0.06 -0.55, 0.68 
FAS rs2234767 G > A ↓ Inf  GG 1.00  1.19 0.89, 1.58  1.57 1.09, 2.24  1.29 0.97, 1.71 -0.46 -1.06, 0.14 
FAS rs1800682 G > A ↑ Inf  GA/AA 1.00  1.22 0.91, 1.62  1.39 0.99, 1.94  1.39 1.04, 1.84 -0.22 -0.73, 0.28 
FASL rs763110 C > T ↓ Inf  CC 1.00  1.18 0.90, 1.53  1.35 1.09, 1.66  1.06 0.81, 1.38 -0.47 -0.92,-0.02 
TNF-α rs1800629 G > A ↑ Inf  GA/AA 1.00  0.96 0.73, 1.27  1.18 0.96, 1.44  1.12 0.85, 1.48 -0.02 -0.43, 0.40 
MnSOD rs4880 C > T ↓ Os  CT/TT 1.00  0.92 0.68, 1.23  1.07 0.75, 1.51  1.12 0.83, 1.50 0.14 -0.26, 0.53 
MPO rs2333227 G > A ↓ Os  GA/AA 1.00  0.87 0.68, 1.13  1.14 0.91, 1.43  1.08 0.83, 1.39 0.06 -0.30, 0.41 
CAT rs1001179 C > T ↑ Os  CC 1.00  0.80 0.62, 1.04  1.06 0.80, 1.41  1.00 0.77, 1.29 0.14 -0.20, 0.47 
GPX1 rs1050450 C > T ↑ Os  CC 1.00  1.05 0.82, 1.35  1.34 1.05, 1.70  1.08 0.85, 1.37 -0.31 -0.73, 0.10 
GSTM1 deletion deletion ↑ Os  present 1.00  0.77 0.59, 1.00  0.99 0.76, 1.29  1.02 0.79, 1.32 0.26 -0.06, 0.58 
GSTP1 rs1695 A > G ↑ Os  AA 1.00  1.03 0.80, 1.33  1.14 0.89, 1.46  1.23 0.96, 1.57 0.05 -0.33, 0.43 
GSTT1 deletion deletion ↑ Os  present 1.00  0.94 0.68, 1.28  1.02 0.69, 1.50  1.11 0.82, 1.52 0.16 -0.26, 0.57 
GSTA1 rs3957356 G > A ↑ Os  GG 1.00  0.83 0.63, 1.08  1.10 0.89, 1.37  1.10 0.86, 1.42 0.17 -0.18, 0.53 
COMT rs4680 G > A ↑ Os  GG 1.00  1.37 1.02, 1.83  1.28 1.05, 1.57  1.20 0.92, 1.56 -0.45 -0.97, 0.07 
COMT rs737865 C > T ↓ Os  CT/TT 1.00  1.16 0.74, 1.81  1.34 0.77, 2.34  1.35 0.87, 2.11 -0.15 -0.87, 0.58 
CYP17 rs743572 T > C ↑ Es  TC/CC 1.00  1.16 0.89, 1.50  1.34 1.00, 1.81  1.28 1.00, 1.65 -0.22 -0.68, 0.24 
Note: 
Inf = inflammation, Os = oxidative stress, Es = estrogen, LIBCSP = Long Island Breast Cancer Study Project 
a All models adjusted for matching factor, 5-year age group, and total energy intake (kcal/day). 
b Genotypes dichotomized using dominant genetic model. 
c Hypothesized lowest risk group (referent group) - low risk genotype for PUFA-gene interaction, high ω-3/ω-6 ratio. 
d Hypothesized highest risk group - high risk genotype for PUFA-gene interaction, low ω-3/ω-6 ratio. 
e RERI (Relative Excess Risk Due to Interaction) = OR11 - OR10 - OR01 + OR00 (e.g., RERI for PTGS-2 rs20417 = 1.23 - 1.26 - 1.09 + 1.00 = -0.12). 
f 95% CI for RERI estimated using Hosmer & Lemeshow [374] 
g Variant allele function is based upon previous literature.  Please refer to Table 3.6 for references. 
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Table 3.6 Assumed variant allele function based on previous literature 
Gene rs# 
Allele 
Substitution 
Variant 
allele 
function 
Reference 
PTGS-2 rs20417 G > C ↓ Inf  [399] 
PTGS-2 rs5275 T > C ↓ Inf  [399] 
PPAR-α rs1800206 C > G ↓ Inf  [219] 
FAS rs2234767 G > A ↓ Inf [400] 
FAS rs1800682 G > A ↑ Inf  [400] 
FASL rs763110 C > T ↓ Inf  [401] 
TNF-α rs1800629 G > A ↑ Inf  [402] 
MnSOD rs4880 C > T ↓ Os [403] 
MPO rs2333227 G > A ↓ Os  [404] 
CAT rs1001179 C > T ↑ Os  [405] 
GPX1 rs1050450 C > T ↑ Os  [406] 
GSTM1 deletion deletion ↑ Os  [407] 
GSTP1 rs1695 A > G ↑ Os  [408] 
GSTT1 deletion deletion ↑ Os  [407] 
GSTA1 rs3957356 G > A ↑ Os  [409] 
COMT rs4680 G > A ↑ Os [412] 
COMT rs737865 C > T ↓ Os  [410] 
CYP17 rs743572 T > C ↑ Es  [411] 
Note: 
Inf = inflammation, Os = oxidative stress, Es = estrogen 
 
 
 
 
  
1
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Table 3.7 Age- and multivariate
a
-adjusted ORs and 95% CI for the multiplicative interaction between dietary ω-3 and ω-6 (high 
and low intake) and the risk of breast cancer in the LIBCSP, 1996-1997 
Model 
Low ω-6 
(< median) 
 High ω-6 
(≥ median) 
 
LRT 
χ2
b
 
p 
value 
N OR 95% CI  N OR 95% CI  
Age-adjusted           
High ω-3 (≥ median) 256 1.00   1,214 1.00     
Low ω-3 (< median) 1,215 0.87 0.66, 1.14  278 1.33 1.02, 1.73  5.01 0.03 
Multivariate
a
           
High ω-3 (≥ median) 256 1.00   1,214 1.00     
Low ω-3 (< median) 1,215 0.83 0.63, 1.09  278 1.26 0.96, 1.65  4.61 0.03 
Note: 
Co=Controls, Ca=Cases, LIBCSP=Long Island Breast Cancer Study Project, LRT=likelihood ratio test 
a
 Multivariate ORs and 95% CI adjusted for matching factor (5-year age group) and total energy intake (kcal/day) 
b
 LRT χ2 calculated using nested models for the multiplicative interaction. 
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Table 3.8 Multivariate
a
-adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for the risk of breast cancer for the 
hypothesized highest risk multiplicative interaction between ω-3/ω-6 ratio and putatively functional genetic polymorphismsb in the 
LIBCSP, 1996-1997 
Gene rs# 
Allele 
Substitution 
Variant 
allele 
function
d
 
High 
risk 
genotype 
 High ω-3/ω-6 
(≥ median) 
 
Low ω-3/ω-6 
(< median) 
 
LRT 
χ2c 
p 
value 
 Low 
risk 
 
High 
risk 
 
Low 
risk 
 
High 
risk 
 
 OR  OR 95% CI  OR  OR 95% CI  
PTGS-2 rs20417 G > C ↓ Inf GG  1.00  1.09 0.84, 1.41  1.00  0.98 0.77, 1.25  0.36 0.55 
PTGS-2 rs5275 T > C ↓ Inf TT  1.00  1.15 0.89, 1.47  1.00  1.05 0.83, 1.34  0.23 0.64 
PPAR-α rs1800206 C > G ↓ Inf CC  1.00  0.77 0.51, 1.18  1.00  0.86 0.56, 1.32  0.11 0.74 
FAS rs2234767 G > A ↓ Inf GG  1.00  1.19 0.89, 1.58  1.00  0.82 0.61, 1.11  3.03 0.08 
FAS rs1800682 G > A ↑ Inf GA/AA  1.00  1.22 0.91, 1.62  1.00  1.00 0.77, 1.30  1.02 0.31 
FASL rs763110 C > T ↓ Inf CC  1.00  1.18 0.90, 1.53  1.00  0.79 0.61, 1.02  4.63 0.03 
TNF-α rs1800629 G > A ↑ Inf GA/AA  1.00  0.96 0.73, 1.27  1.00  0.95 0.72, 1.26  0.00 0.97 
MnSOD rs4880 C > T ↓ Os CT/TT  1.00  0.92 0.68, 1.23  1.00  1.05 0.80, 1.38  0.42 0.51 
MPO rs2333227 G > A ↓ Os GA/AA  1.00  0.87 0.68, 1.13  1.00  0.94 0.74, 1.21  0.17 0.68 
CAT rs1001179 C > T ↑ Os CC  1.00  0.80 0.62, 1.04  1.00  0.94 0.73, 1.20  0.77 0.38 
GPX1 rs1050450 C > T ↑ Os CC  1.00  1.05 0.82, 1.35  1.00  0.80 0.63, 1.02  2.24 0.13 
GSTM1 deletion deletion ↑ Os present  1.00  0.77 0.59, 1.00  1.00  1.03 0.80, 1.32  2.52 0.11 
GSTP1 rs1695 A > G ↑ Os AA  1.00  1.03 0.80, 1.33  1.00  1.07 0.84, 1.37  0.05 0.82 
GSTT1 deletion deletion ↑ Os present  1.00  0.94 0.68, 1.28  1.00  1.09 0.81, 1.48  0.49 0.49 
GSTA1 rs3957356 G > A ↑ Os GG  1.00  0.83 0.63, 1.08  1.00  1.00 0.78, 1.29  1.03 0.31 
COMT rs4680 G > A ↑ Os GG  1.00  1.37 1.02, 1.83  1.00  0.93 0.71, 1.22  3.60 0.06 
COMT rs737865 C > T ↓ Os CT/TT  1.00  1.16 0.74, 1.81  1.00  1.01 0.69, 1.48  0.21 0.64 
CYP17 rs743572 T > C ↑ Es TC/CC  1.00  1.16 0.89, 1.50  1.00  0.95 0.74, 1.23  1.05 0.31 
Note: 
Inf = inflammation, Os = oxidative stress, Es = estrogen, LIBCSP = Long Island Breast Cancer Study Project, LRT=likelihood ratio test 
a All models adjusted for matching factor, 5-year age group, and total energy intake (kcal/day). 
b Genotypes dichotomized using dominant genetic model. 
c LRT χ2 calculated using nested models for the multiplicative interaction . 
d Variant allele function is based upon previous literature.  Please refer to Table 3.6 for references. 
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CHAPTER 4:  
DIETARY INTAKE OF FISH, PUFAs, AND SURVIVAL AFTER BREAST CANCER: 
A POPULATION-BASED, FOLLOW-UP STUDY ON LONG ISLAND, NEW YORK 
 
4.1 Introduction 
 Breast cancer is the second cause of cancer death among women in the U.S. with 
approximately 40,000 estimated new deaths in 2013 [1].  Clinical and demographic 
indicators of breast cancer prognosis include large tumor size, lymph node involvement, 
hormone receptor-negative subtype, early age at diagnosis, and low socioeconomic status [9].  
Weight maintenance and physical activity may improve survival following breast cancer 
[128, 129].  Because breast cancer is a multi-factorial disease, it is plausible that additional 
strategies, including intake of specific nutritional factors, could also improve survival among 
women diagnosed with breast cancer. 
 One potential nutritional risk reduction strategy is polyunsaturated fatty acids 
(PUFAs), of which ω-3 and ω-6 are the two primary classes.  Inflammatory eicosanoids of 
arachidonic acid (AA), an ω-6 PUFA, have been shown in laboratory studies to: increase cell 
proliferation, metastatic potential, aromatase activity, and angiogenesis; and reduce 
apoptosis, and cellular differentiation [155].  ω-3 fatty acids bind to the same enzymes 
utilized in AA metabolism, thus, potentially lowering levels of inflammatory eicosanoids 
generated by ω-6 metabolism [155].  Also, the cytotoxic environment induced by ω-3 has 
been reported to increase apoptosis and reduce cell growth in transformed and malignant 
breast cancer cells [155, 256].  Long-chain ω-3 PUFA have demonstrated ability to chemo-
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sensitize breast cancer tumors and, thus, potentially improve treatment efficacy [268]. Thus, 
it is plausible that intake of ω-3, for which fish is the major dietary source, could provide an 
opportunity for improving survival among women with breast cancer. 
 Despite this laboratory evidence, few epidemiologic studies have examined the 
association between dietary PUFA intake and survival after breast cancer [300, 301, 318].  
Two [300, 301] utilized cross-sectional study designs, thus, limiting inferences regarding the 
potential association between PUFA intake and breast cancer survival. Another study 
examined the association between adipose tissue biomarkers of PUFA on survival after 
breast cancer [318] and reported no associations; however, interpretation of results was 
limited due to the small number of deaths.  Thus, the epidemiologic evidence for the 
potential association between dietary PUFA intake and survival among women with breast 
cancer is limited. 
  Previous studies examining fish intake and mortality among breast cancer survivors 
are inconsistent [339, 340].  One Japanese investigation followed cases for 9 to 12 years, and 
reported increased breast cancer mortality with high fish consumption [340]; however, the 
study population was based on a small number of deaths. The second study  utilized 
participants from the Women’s Healthy Eating and Living (WHEL) study, a dietary 
intervention aimed to reduce total fat intake, and found that higher intake of ω-3 fatty acids 
(eicosapentanoic acid, EPA; and docosahexanoic acid, DHA) from fish was associated with 
reduced breast cancer recurrence and all-cause mortality [339].  This U.S.-based study, 
however, did not assess short-chain ω-3 PUFA (i.e., alpha-linolenic acid, ALA), which are 
readily obtained in the diet of Western populations. 
For the study reported here, we examined whether higher intake of fish, as well as 
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any other dietary sources of ω-3 PUFAs, are associated with improved survival among 
women diagnosed with breast cancer on Long Island, New York. We also considered 
associations with ω-6 PUFAs and the balance between ω-3 and ω-6 intake. Given that 
PUFAs affect tumor initiation and promotion via multiple biologic pathways, we also 
explored interactions with genes involved in inflammation, oxidative stress, and estrogen 
metabolism pathways.   
 
4.2 Methods 
 This follow-up study utilizes resources from the Long Island Breast Cancer Study 
Project (LIBCSP), a population-based study [128, 129, 355]. Institutional Review Board 
approval was obtained from all participating institutions. 
Study Population. Women eligible for the LIBCSP follow-up study were English-
speaking residents of Long Island, New York (Nassau and Suffolk counties) who were newly 
diagnosed with a first primary in situ or invasive breast cancer between August 1, 1996 and 
July 31, 1997. After obtaining physician approval, study personnel contacted pathology 
departments from participating hospitals (2-3 times per week or daily, for the hospitals with 
large numbers of newly diagnosed cases) to identify potentially eligible subjects.  The final 
LIBCSP follow-up sample consisted of 1,508 women with breast cancer.  Within 
approximately three months of diagnosis, 98% (n=1,479) completed a validated self-
administered 101-item modified Block food frequency questionnaire (FFQ) [359, 395, 396].  
Subjects with implausible total energy intake (±3 standard deviations from the mean) were 
excluded (n=16). Thus, the final analytic cohort for this ancillary study included 1,463 
women with newly diagnosed breast cancer. 
 146 
At diagnosis (baseline) with the first primary breast cancer, participants ranged in age 
from 20-98 years, 67% were postmenopausal, and 94% reported their race as white, 4% as 
black, and 2% as other, which reflects the underlying racial distribution of Nassau and 
Suffolk counties at the time of data collection [128, 129, 355]. 
Outcome Assessment. Vital status through December 31, 2011 for all LIBCSP 
participants was determined via linkage with the National Death Index, a standard 
epidemiologic resource for ascertaining mortality data in the U.S. [358].  We identified 
women who died from all-causes (death from any cause), and those whose deaths were breast 
cancer-related (breast cancer-specific mortality).  Breast cancer-related deaths were 
determined using the International Classification of Disease (codes 174.9 or C-50.9). Among 
the 1,463 participants included in this study, the median follow-up time was 14.7 years after 
breast cancer diagnosis (range=0.2-15.4 years), and we identified 485 total deaths, of which 
210 were breast cancer-specific. 
Assessment of PUFA Intake and Other Prognostic Factors.  LIBCSP participants 
self-completed the FFQ, and were administered a baseline, structured questionnaire by a 
trained interviewer, within three months, on average, after diagnosis.  The FFQ assessed 
dietary intake in the year prior to the interview. Other factors assessed included: demographic 
characteristics; reproductive and menstrual history; exogenous hormone use, family history 
of breast cancer, and other  medical history; body size, physical activity, and alcohol use; 
active and passive cigarette smoking;  occupational history and other environmental 
exposures [355].  Medical records were abstracted to determine tumor characteristics of the 
first primary breast cancer and the first course of treatment for the first primary breast cancer.  
Concordance between the medical record and the self-reported treatment data was high 
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(kappa>90%), and thus, the self-reported data are used here. 
 PUFA intake from any dietary source was estimated by linking participant responses 
from the FFQ (i.e., grams per day for each line item) with nutrient values available in the 
U.S. Department of Agriculture databases for ω-3 and ω-6 PUFAs [397].  The following 
PUFA subtypes were estimated: (1) ω-3 PUFA including, alpha-linolenic acid (ALA), 
docosapentanoic acid (DPA), DHA, EPA; and (2) ω-6 PUFA including, linoleic acid (LA) 
and AA.  An estimate of total ω-3 and ω-6 PUFA intake (henceforth, total PUFA intake) was 
calculated by combining all individual PUFA subtypes. Additionally, an estimate of total ω-3 
and ω-6 PUFA was obtained by summing each individual fatty acid within category (e.g., 
total ω-3=ALA+DPA+DHA+EPA).   
Fish and/or seafood consumption were also assessed by FFQ as: (1) tuna, tuna salad, 
tuna casserole; (2) shell fish (shrimp, lobster, crab, oysters, etc.); and (3) other fish 
(broiled/baked). 
Genotyping.  Eighteen variants in 15 genes were selected for this analysis 
representing three biologically plausible pathways for PUFA metabolism, including 
inflammation, oxidative stress, and estrogen metabolism pathways. Variants affecting 
polyphen prediction (GPX1), transcription factor binding prediction (PTGS-2 rs20417, FAS, 
FASL, TNF-α, MPO, CAT, GSTA1, COMT rs737865, CYP17), miRNA binding (PTGS-2 
rs5275, GPX1), 3D conformation (PPAR-α, COMT rs4680), or splicing regulation (PPAR-α, 
FAS rs2234767, GPX1, GSTP1, COMT rs4680) were considered as putatively functional 
variants as identified using the NIEHS SNPInfo WebServer [361]. 
 Blood samples were collected from participants at the baseline interview.  
Genotyping methods have been previously published [65, 366-370, 398].  Briefly, DNA was 
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isolated from mononuclear cells in whole blood which was separated by Ficoll (Sigma 
Chemical Co., St. Louis, MO) using standard phenol and chloroform-isoamyl alcohol 
extraction and RNase treatment [398].  Genotyping for inflammation genes (PTGS-2, FAS, 
FASL, PPAR-α), were conducted using: Taqman 5’-Nuclease Assay (Applied Biosystems, 
Foster City, CA) and AcycloPrime
TM
-FP SNP Detection Kit obtained from Perkin Elmer Life 
Sciences (Boston, MA) [65, 367, 368].  For CYP17, the same assay was used with a 10 µM 
probe [369, 370].  For oxidative stress genes (CAT, MPO, MnSOD, GPX, GSTA1, GSTP1), 
BioServe Biotechnologies (Laurel, MD) performed the genotyping using high-throughput, 
matrix assisted, laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry 
of Sequenom, Inc. (San Diego, CA). Deletions for GSTM1 and GSTT1 genes were 
determined by a multiplex polymerase chain reaction method, with the constitutively present 
gene β-globulin as an internal positive control [366]. 
 Tests for Hardy-Weinberg equilibrium (HWE) indicated that only PTGS-2 rs20417 
and MPO polymorphisms deviated significantly from HWE (p<0.05). However, for both 
polymorphisms, the observer agreement in 8% of randomly selected samples was high 
(PTGS-2 rs20417 kappa statistic=0.99, MPO kappa statistic=0.91), and the failure rate of the 
assay was low (<1%).  Missing data for the genetic polymorphisms reduced the sample size 
for the gene-PUFA interaction analyses, resulting in total sample sizes ranging from 950 to 
1,035 women with breast cancer.  
Statistical analyses.  Kaplan-Meier survival curves were constructed, and Cox-
proportional hazards regression [375] models were used to estimate hazard ratios (HRs) and 
95% confidence intervals (95% CI), to assess the associations between intake of fish, as well 
as PUFAs from any dietary source, and all-cause and breast cancer-specific mortality for the 
 149 
full 15-years of follow-up. As a sensitivity analysis, we also calculated PUFA effect 
estimates for 5-years of follow-up.  
For regression analyses, the proportional hazards assumption was assessed using 
exposure interactions with time, and also using Martingale residuals [375]. Quartiles were 
created for each PUFA exposure (total PUFA, total ω-3, ALA, DPA, DHA, EPA, total ω-6, 
LA, AA, ratio of ω-3/ω-6) based on the distributions among the 1,463 women with breast 
cancer included in our study. Other exposure cut-points were considered (e.g., tertiles, 
quintiles, linear, splines); however, the shape of the dose-response between PUFAs and the 
log-hazard of mortality was best captured with quartiles. Similarly, quartiles were created for 
exposures related to fish intake (i.e., tuna, shell fish, other fish). Tests for linear trend were 
not conducted, given the relation between continuous PUFA and log-hazard of all-cause 
mortality was not strictly monotonic [373]. 
We also utilized Cox-proportional hazards models to examine the associations 
between genotypes in three biologically plausible pathways and mortality.  To maximize the 
number of events per exposure category, genes were dichotomized according to a dominant 
model, and categorized into “high” and “low” risk groups based upon the function of the 
variant allele, which was determined using the existing literature [219, 399-412].  
In the Cox proportional regression models, we also considered interactions between 
total ω-3 and total ω-6, and between the ω-3/ω-6 ratio and genotypes in association with 
mortality. For these interaction analyses, PUFAs were dichotomized at the median, and a 
dominant genetic model was assumed.  Interaction was evaluated on the additive scale and 
measured using relative excess risk due to interaction (RERI), with corresponding 95% CI 
calculated using the Hosmer and Lemeshow method [374].  Multiplicative interactions were 
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also assessed using the Likelihood Ratio Test; however, the conclusions did not change (data 
not shown).  The relatively low number of breast-cancer specific deaths resulted in imprecise 
estimates for the ω-3 and ω-6 interaction, and the PUFA-genotype interactions with this 
outcome. Thus, only the interaction results for all-cause mortality are shown. 
 Effect modification of the PUFA-mortality associations by menopausal status (post- 
vs. pre-menopausal); hormone receptor status (hormone receptor-positive breast cancer vs. 
negative), dietary supplement use (yes/no), and treatment (chemotherapy, radiation, hormone 
therapy) were also examined in the PUFA regression models. After stratification, however, 
little or no heterogeneity was observed, thus these results are not shown. 
Potential confounders for the PUFA-mortality regression models were identified 
using a directed acyclic graph (DAG) [373], and included age (5-year age group), total 
energy intake (kcal/day), non-steroidal anti-inflammatory drugs (NSAID), family history of 
breast cancer, income, body mass index, alcohol use, fruit and vegetable intake, physical 
activity, and race. However, only age and total energy intake changed the HR estimates by 
more than 10%, and thus all PUFA-mortality regression models were adjusted for these two 
confounders only. 
 All statistical analyses were conducted using PROC PHREG (Cox proportional 
hazards regression models) and PROC LIFETEST (Kaplan-Meier survival curves) in SAS 
version 9.2 (SAS Institute, Cary, NC). 
 
4.3 Results 
 PUFA and Fish Intake. As shown in Table 4.1, among our population-based sample 
of women with breast cancer (n = 1,463) intake at baseline of total ω-3 fatty acids from any 
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dietary source (average total ω-3 intake 0.99 grams per day, SD = 0.69) was lower relative to 
ω-6 intake (average total ω-6 intake of 7.51 grams per day, SD = 5.26). ALA intake was the 
highest contributor to total ω-3 intake with an average intake of 0.85 grams per day (SD = 
0.67), whereas LA was the highest contributor to total ω-6 intake with an average intake of 
7.44 grams per day (SD = 5.24). Tuna intake was higher (8.13 grams per day, SD = 10.61) 
compared to shell fish intake (3.30 grams per day, SD = 6.01).  As also shown in Table 4.1, 
fish was a primary contributor to high intake of long-chain ω-3 PUFAs, including DPA, 
DHA, and EPA.  In contrast, foods that contributed to high ALA intake were biscuits/muffins 
and other fried foods.  Additionally, high AA intake appeared to be driven by eggs and 
meats, including fish, chicken, and ham. 
 PUFAs and Mortality. The Kaplan-Meir curves shown in Figure 4.1 indicate survival 
was improved among our population-based sample of women with breast cancer reporting 
higher intake (quartiles (Q) 3 and 4) of the long-chain ω-3 fatty acids DPA, DHA, and EPA.  
As presented in Table 4.2, reductions of 16-34% in all-cause mortality were observed for 
higher intake of long-chain ω-3 fatty acids.  Specifically, lower death rates were observed for 
the highest two quartiles of intake (Q3 or Q4), compared to the lowest quartile (Q1), of DHA 
(HRQ3vs.Q1=0.73, 95%CI=0.56,0.94; and HRQ4vs.Q1=0.71, 95% CI=0.55,0.92), EPA 
(HRQ3vs.Q1=0.70, 95% CI=0.54,0.91; and HRQ4vs.Q1=0.75, 95% CI=0.58,0.97); and DPA 
(HRQ3vs.Q1=0.66, 95%CI=0.51,0.86; and HRQ4vs.Q1=0.84, 95%CI=0.64,1.10). The 
corresponding hazard for ω-3/ω-6 ratio was modestly decreased by 15%, but the confidence 
interval included the null value. As also shown in Table 4.2, adjusted hazards for all-cause 
mortality were increased by 14-30% for higher intakes of total ω-6, LA, AA, and ALA but 
confidence intervals were wide.  Patterns were similar, but less precise, for PUFA intake 
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from all dietary sources in relation to breast cancer-specific mortality after 15 years of 
follow-up (Supplemental Table 4.4), and when we considered all-cause mortality after 5-
years of follow-up (Supplemental Table 4.5).  
 We also considered an interaction between ω-3 and ω-6, and all-cause mortality; 
however, as shown in Supplemental Table 4.6, no interaction on an additive scale was 
observed.   
 Fish and Mortality. As shown in Table 4.3, fish intake was associated with a 25-34% 
reduction in all-cause mortality.  Specifically, lower rates of death were observed for: the 
highest quartile of intake for those in the highest quartile of tuna intake, compared to the 
lowest quartile (HR = 0.71, 95% CI = 0.55, 0.92); and the highest two quartiles for other fish 
(broiled/baked) (HRQ3vs.Q1 = 0.66, 95% CI = 0.51, 0.85; and HRQ4vs.Q1 = 0.75, 95% CI = 0.58, 
0.97). There was little or no evidence of an association between all-cause mortality and shell 
fish intake.  Adjusted estimates for breast cancer-specific mortality showed pronounced but 
imprecise reductions when we considered tuna and other fish in relation to 5 years of follow-
up (Supplemental Table 4.5). Estimates, however, were closer to the null when we 
considered 15 years of follow up [tuna (HRQ4vs.Q1 = 0.81, 95% CI = 0.54, 1.21) and other 
baked/broiled fish (HRQ4vs.Q1 = 1.04, 95% CI = 0.71, 1.52)]. 
 Genotypes and Mortality.  As presented in Supplemental Table 4.7, the association 
between polymorphisms involved in inflammation, oxidative stress, and estrogen metabolism 
and all-cause mortality using a dominant model were largely consistent with no association. 
When we explored the interactions on an additive scale between ω-3/ω-6 ratio and 
polymorphisms in multiple biologic pathways on overall mortality (Supplemental Table 4.8), 
we observed a 19% increase in the rate of death (HR = 1.19, 95% CI = 0.85, 1.68) for low 
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intake of the favorable ratio of ω-3/ω-6 and high risk TNF-α rs1800682 genotype.  This 
interaction was statistically significant on the additive scale (RERI = 0.49; 95% CI = 0.03, 
0.96), suggesting antagonism between low intake of ω-3/ω-6 and high risk TNF-α genotype.  
 
4.4 Discussion 
 In this population-based follow-up study of women with breast cancer, we observed 
reduced hazards of 16-34% for all-cause mortality after 15 years of follow-up with 
consumption of higher levels, compared to the lowest level, of long-chain ω-3 fatty acids 
(DPA, DHA, and EPA). Similarly, higher intake of tuna and other baked/broiled fish was 
associated with 25-34% decreased all-cause mortality (and an imprecise 19% reduction in 
breast cancer-specific mortality in association with tuna intake only).  We found little 
evidence for interaction between ω-3 and ω-6, or between PUFAs and most genotypes 
considered in three related pathways. 
 Our population-based results are consistent with one previous study on PUFA and/or 
fish intake in relation to survival among women with breast cancer that is relatively 
comparable to our own [339].  Patterson and colleagues [339] examined marine food sources 
of EPA and DHA in the WHEL study, and reported reductions of 28% for recurrence and 
41% for all-cause mortality. The study methods for the WHEL study differ from ours in that 
only marine ω-3 sources were assessed using repeated 24-hour recalls after varying lengths 
of time since diagnosis among a convenience sample of breast cancer survivors; whereas, we 
considered marine and other dietary PUFA sources that were assessed using a 101-item FFQ 
administered within three months of diagnosis to a population-based sample of women newly 
diagnosed with breast cancer.  The robustness of the results across studies, despite the 
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methodological differences in our LIBCSP study and the WHEL study, support the 
possibility of long-chain ω-3 as a potential risk reduction strategy for breast cancer survivors.   
Further research is needed to confirm these findings. 
 Our reported results for long-chain ω-3 fatty acids (DPA, DHA, EPA), total ω-6, LA, 
AA, and the ratio of ω-3/ω-6 are consistent with the biologic mechanism of a PUFA-induced 
cytotoxic environment via lipid peroxidation, and the potential benefit of this environment on 
reducing apoptosis and cell growth in cancer cells [155, 256].  Long-chain ω-3 fatty acids 
contain more double bonds within the fatty acid chain compared to ALA and ω-6.  These 
double bonds provide additional opportunities for lipid peroxidation and thus could help to 
better promote a cytotoxic environment within the cell. Consequently, this cytotoxic 
environment could provide a beneficial environment for women with breast cancer. 
 Our results for ALA intake, which suggest a modest increase in the rate of overall 
death, are not consistent with a biologic hypothesis via inflammatory pathways.  This 
discrepancy may reflect the foods that are contributing to high ALA intake in our Long 
Island population; namely, we observed that the foods containing butter and fried foods are 
contributing to high ALA intake. This similarity between ALA and ω-6 intake in terms of 
foods contributing to high intake, may explain the potentially spurious increased rate of 
overall death observed for greater intake of ALA.  Additionally, the in vivo conversion of 
ALA into long-chain ω-3 PUFAs is inefficient in populations with high ω-6 [150], which 
may possibly explain the modest increase in the overall rate of death observed here. 
 We observed an additive interaction for low intake of ω-3/ω-6 and high risk TNF-α 
genotype with all-cause mortality, which could be due to chance.  However, the variant TNF-
α allele is thought to increase activity [402], and TNF-α indirectly increases cellular levels of 
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AA by inducing phospholipase A2 (PLA2) activity in human tumor cells [205, 206].  Thus, 
the antagonism observed for low intake of ω-3/ω-6 in combination with potential for 
increased TNF-α activity (high risk genotype) is consistent with biology, but requires 
confirmation by others.   
 This prospective, population-based study has multiple strengths.  We are the first to 
examine the potential relation between PUFA intake and breast cancer survival, while 
simultaneously considering both ω-3 and ω-6 PUFAs.  Additionally, we examined multiple 
ω-3 (e.g., ALA, DPA, DHA, and EPA) and ω-6 (e.g., LA, AA) subtypes in relation to all-
cause mortality.  Consideration of non-marine sources of PUFAs may be critical for some 
U.S. populations that consume low amounts of fish [146].  We are also the first to examine 
the interaction between ω-3/ω-6 ratio and genetic susceptibility in inflammation, oxidative 
stress, and estrogen metabolism in relation to all-cause mortality; identification of high risk 
subgroups defined by genotype could aid in tailoring risk reduction strategies. 
 However, our follow-up study also has limitations. Despite our relatively large 
sample size, effect estimates for the associations with breast cancer-specific mortality were 
imprecise for both the 5-year and 15-year follow-up periods.  We were able to capture dietary 
intake close to the time of diagnosis, and thus this exposure window may be more relevant 
for the 5-year follow period, given the more pronounced effect estimates observed for this 
time period. However, the imprecision for all breast cancer-specific estimates, regardless of 
the time period, is likely to be due to PUFA measurement error. For example, it is possible 
that a one-time baseline FFQ measurement of diet may not accurately reflect dietary intake 
throughout the 15-year period following diagnosis.  One recent study compared pre-diagnosis 
versus post-diagnosis dietary intake, and reported dietary increases in oily fish and fish oil 
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consumption post breast cancer diagnosis [420]. However, this repeated measure study 
enrolled women 9-15 months after diagnosis, and asked them to concurrently recall dietary 
intake one year prior to diagnosis as well as changes in diet following diagnosis; thus, the 
reported changes in dietary intake are subject to errors in recall.  Nonetheless, it is possible 
that the estimates of long-chain ω-3 PUFA intake in our study population are conservative.  
Further, long-chain ω-3 PUFA levels differ by fish species, with tuna being among the 
highest [419]. Thus, future, larger studies should consider repeated PUFA measurements 
(self-reported intake of specific fish species, fish oil, and/or biomarkers) throughout follow-
up to enhance our examination of the potential association between long-chain ω-3 PUFAs 
and breast cancer survival.  
Although we are the first to explore PUFA interactions with multiple genotypes from 
multiple biologic pathways, future studies may want to consider assessing interactions with 
additional genes from these relevant pathways.   In addition, although our study is 
population-based and reflects the racial distribution of the target study population on Long 
Island, which improves external validity, the LIBCSP population includes predominantly 
Caucasian women; therefore, examination of racial differences is not possible.  However, our 
results are generalizable to Caucasian-American women for whom the rates of breast cancer 
remain high [1]. Future studies may consider exploring possible heterogeneity between 
PUFA and survival by race, or by breast cancer tumor subtypes.  
 In conclusion, in our population-based follow-up study of women with breast cancer 
on Long Island, NY, we observed 16-34% reductions in all-cause mortality after 15 years of 
follow-up for high intake of fish, and long-chain ω-3 (DPA, DHA, and EPA), which is 
consistent with laboratory evidence and the one other U.S.-based epidemiologic study 
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considering this issue [339].  Thus, pending additional replication, dietary intake of fish and 
other sources of long-chain ω-3 fatty acids may provide an additional strategy to improve 
survival following breast cancer. 
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Table 4.1 Distributions of intakes of polyunsaturated fatty acid (PUFA) and fish at 
baseline among a population-based sample of women newly diagnosed with breast cancer 
(N=1463), LIBCSP, 1996-1997 
Nutrient/Food Mean SD 
25
th
 
Pct 
50
th
 
Pct 
75
th
 
Pct 
Major PUFA-rich foods contributing 
to high nutrient intake in the LIBCSP 
Nutrient (g/day)       
Total PUFA
a 
8.50 5.83 4.38 7.24 10.92 
Butter, mayonnaise/salad dressings, 
safflower/corn oil, margarine, 
peanuts/peanut butter 
Total ω-3b 0.99 0.69 0.52 0.82 1.26 
Biscuits/muffins, butter, fish, 
mayonnaise/salad dressings, 
safflower/corn oil 
 ALA 0.85 0.67 0.38 0.68 1.10 
Biscuits/muffins, French fries/fried 
potatoes, butter, cookies, 
mayonnaise/salad dressings, 
safflower/corn oil 
 DPA 0.01 0.01 0.01 0.01 0.02 Fish, tuna, chicken, shellfish, beef 
 DHA 0.09 0.10 0.03 0.06 0.12 Fish, tuna, eggs, chicken, shellfish 
 EPA 0.05 0.05 0.01 0.03 0.06 Fish, tuna, shellfish, chicken 
Total ω-6c 7.51 5.26 3.83 6.43 9.73 
Biscuits/muffins, French fries/fried 
potatoes, butter, mayonnaise/salad 
dressings 
 LA 7.44 5.24 3.80 6.35 9.66 
Biscuits/muffins, French fries/fried 
potatoes, butter, mayonnaise/salad 
dressings, safflower/corn oil 
 AA 0.07 0.05 0.04 0.06 0.09 
Eggs, fish, chicken, ham/lunch meats, 
shellfish 
ω-3/ω-6 0.15 0.11 0.11 0.13 0.17 N/A 
Fish (g/day)
d
       
Tuna 8.13 10.61 1.40 4.77 12.40 N/A 
Shell fish 3.30 6.01 0.00 0.00 4.62 N/A 
Other 
(broiled/baked) 
7.88 14.70 0.00 3.85 10.77 N/A 
Note: 
a 
Total PUFA = ALA + DPA + DHA + EPA + LA + AA 
bTotal ω-3 = ALA + DPA + DHA + EPA 
c Total ω-6 = LA + AA 
d 
Cases with null values for tuna (N=343), shell fish (N=750), and other (N=505) are included in calculations. 
SD = standard deviation 
N/A = not applicable 
LIBCSP = Long Island Breast Cancer Study Project 
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Table 4.2 Age- and multivariate
a
-adjusted HRs and 95% CI for the association between dietary PUFA intake and all-cause 
mortality among a population-based sample of women with breast cancer, LIBCSP, 1996/1997 through 2011(an average of 14.7 years 
of follow-up)  
PUFA Covariates 
Q1  Q2  Q3  Q4 
D Co HR  D Co HR 95% CI  D Co HR 95% CI  D Co HR 95% CI 
Total PUFA 
Age 
124 241 
1.00  
128 238 
1.15 0.90,1.47  
110 256 
1.01 0.78,1.31  
123 243 
1.28 0.99,1.64 
Multivariate 1.00  1.12 0.87,1.44  0.97 0.73,1.27  1.16 0.84,1.61 
Total ω-3 
Age 
124 242 
1.00  
116 249 
0.97 0.75,1.25  
124 243 
1.15 0.90,1.48  
121 244 
1.14 0.89,1.46 
Multivariate 1.00  0.93 0.71,1.21  1.07 0.82,1.41  1.00 0.72,1.38 
ALA 
Age 
114 252 
1.00  
129 237 
1.21 0.94,1.55  
121 244 
1.24 0.96,1.61  
121 245 
1.25 0.97,1.62 
Multivariate 1.00  1.18 0.91,1.52  1.18 0.90,1.55  1.14 0.83,1.57 
DPA 
Age 
136 230 
1.00  
131 235 
0.98 0.77,1.25  
99 266 
0.71 0.55,0.92  
119 247 
0.94 0.74,1.21 
Multivariate 1.00  0.93 0.73,1.19  0.66 0.51,0.86  0.84 0.64,1.10 
DHA 
Age 
139 227 
1.00  
130 235 
0.95 0.75,1.21  
105 261 
0.76 0.59,0.98  
111 255 
0.76 0.60,0.98 
Multivariate 1.00  0.93 0.73,1.18  0.73 0.56,0.94  0.71 0.55,0.92 
EPA 
Age 
136 230 
1.00  
131 234 
0.95 0.75,1.21  
102 264 
0.74 0.57,0.96  
116 250 
0.81 0.63,1.04 
Multivariate 1.00  0.93 0.73,1.18  0.70 0.54,0.91  0.75 0.58,0.97 
Total ω-6 
Age 
122 243 
1.00  
124 242 
1.12 0.87,1.43  
112 254 
1.07 0.83,1.38  
127 239 
1.34 1.04,1.72 
Multivariate 1.00  1.10 0.85,1.42  1.04 0.79,1.38  1.27 0.92,1.76 
LA 
Age 
121 244 
1.00  
126 240 
1.15 0.90,1.48  
111 255 
1.07 0.83,1.39  
127 239 
1.36 1.06,1.74 
Multivariate 1.00  1.14 0.88,1.47  1.05 0.79,1.39  1.30 0.94,1.79 
AA 
Age 
122 243 
1.00  
120 247 
1.03 0.80,1.32  
113 252 
0.93 0.72,1.20  
130 236 
1.24 0.97,1.59 
Multivariate 1.00  1.00 0.78,1.30  0.89 0.68,1.16  1.15 0.87,1.52 
ω-3/ω-6 
Age 
124 242 
1.00  
113 252 
0.90 0.70,1.17  
128 238 
0.95 0.75,1.22  
120 246 
0.84 0.66,1.08 
Multivariate 1.00  0.89 0.69,1.14  0.93 0.73,1.19  0.85 0.66,1.09 
Note: 
Co=Cohort N, D=Deaths N, LIBCSP=Long Island Breast Cancer Study Project 
a
 Multivariate-adjusted HRs and 95% CI adjusted age (5-year age group) and total energy intake (kcal/day) 
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Table 4.3 Age- and multivariate
a
-adjusted HRs and 95% CI for the association between fish intake and all-cause mortality among 
a population-based sample of women with breast cancer, LIBCSP, 1996/1997 through 2011(an average of 14.7 years of follow-up)  
PUFA Covariates 
Never Q1 Q2 Q3 Q4 
D Co HR D Co HR 95% CI D Co HR 95% CI D Co HR 95% CI D Co HR 95% CI 
Tuna 
Age 
125 218 
1.00 
86 155 
0.98 0.75,1.29 
84 162 
0.95 0.72,1.26 
78 137 
1.08 0.82,1.44 
112 306 
0.74 0.58,0.96 
Multivariate 1.00 0.98 0.74,1.29 0.93 0.70,1.22 1.06 0.80,1.41 0.71 0.55,0.92 
                     
Shell fish 
Age 
268 482 
1.00 
23 79 
0.72 0.47,1.10 
84 161 
1.00 0.78,1.27 
46 123 
0.80 0.59,1.10 
64 133 
1.10 0.84,1.45 
Multivariate 1.00 0.71 0.46,1.09 0.98 0.76,1.25 0.79 0.57,1.08 1.05 0.79,1.39 
                     
Other fish 
(broiled/baked) 
Age 
319 186 
1.00 
145 75 
0.95 0.73,1.24 
87 50 
0.98 0.72,1.34 
91 250 
0.68 0.53,0.87 
83 177 
0.77 0.60,1.00 
Multivariate 1.00 0.95 0.72,1.24 0.97 0.71,1.33 0.66 0.51,0.85 0.75 0.58,0.97 
Note: 
Co=Cohort N, D=Deaths N, LIBCSP = Long Island Breast Cancer Study Project 
a Multivariate-adjusted HRs and 95% CI adjusted for age (5-year age group), total energy intake (kcal/day). 
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Figure 4.1 Kaplan-Meier survival curves for dietary intake (quartiles) of long-chain ω-3 fatty acids DPA, DHA, and EPA, among 
a population-based sample of women with breast cancer, LIBCSP, 1996/1997 through 2011(an average of 14.7 years of follow-up)  
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Table 4.4 Age- and multivariate
a
-adjusted HRs and 95% CI for the association between dietary PUFA intake and breast cancer-
specific mortality among a population-based sample of women with breast cancer, LIBCSP, 1996/1997 through 2011(an average of 
14.7 years of follow-up)  
PUFA Covariates 
Q1  Q2  Q3  Q4 
D Co HR  D Co HR 95% CI  D Co HR 95% CI  D Co HR 95% CI 
Total PUFA 
Age 
38 327 
1.00  
62 304 
1.67 1.12,2.50  
53 313 
1.40 0.92,2.13  
57 309 
1.59 1.05,2.41 
Multivariate 1.00  1.56 1.03,2.36  1.25 0.80,1.95  1.25 0.74,2.11 
Total ω-3 
Age 
43 323 
1.00  
51 314 
1.18 0.79,1.77  
63 304 
1.53 1.04,2.26  
53 312 
1.29 0.86,1.93 
Multivariate 1.00  1.08 0.71,1.64  1.32 0.87,2.01  0.96 0.57,1.61 
ALA 
Age 
46 320 
1.00  
50 316 
1.13 0.76,1.69  
57 308 
1.32 0.89,1.95  
57 309 
1.32 0.89,1.94 
Multivariate 1.00  1.06 0.71,1.60  1.17 0.77,1.77  1.03 0.64,1.68 
DPA 
Age 
55 311 
1.00  
50 316 
0.91 0.62,1.34  
44 321 
0.76 0.51,1.13  
61 305 
1.10 0.76,1.58 
Multivariate 1.00  0.85 0.58,1.25  0.69 0.46,1.03  0.93 0.63,1.38 
DHA 
Age 
55 311 
1.00  
50 315 
0.92 0.62,1.34  
50 316 
0.86 0.59,1.27  
55 311 
0.96 0.66,1.40 
Multivariate 1.00  0.88 0.58,1.25  0.81 0.55,1.19  0.86 0.59,1.27 
EPA 
Age 
53 313 
1.00  
50 315 
0.95 0.65,1.40  
51 315 
0.91 0.62,1.34  
56 310 
1.02 0.70,1.49 
Multivariate 1.00  0.92 0.62,1.35  0.84 0.57,1.25  0.92 0.63,1.36 
Total ω-6 
Age 
37 328 
1.00  
61 305 
1.68 1.12,2.53  
54 312 
1.48 0.98,2.26  
58 308 
1.67 1.10,2.53 
Multivariate 1.00  1.59 1.05,2.42  1.34 0.86,2.11  1.36 0.81,2.30 
LA 
Age 
37 328 
1.00  
61 305 
1.69 1.12,2.55  
54 312 
1.49 0.98,2.26  
58 308 
1.67 1.10,2.54 
Multivariate 1.00  1.60 1.05,2.43  1.35 0.86,2.11  1.36 0.81,2.29 
AA 
Age 
47 318 
1.00  
48 319 
1.02 0.68,1.53  
52 313 
1.09 0.74,1.62  
63 303 
1.41 0.96,2.06 
Multivariate 1.00  0.98 0.65,1.47  1.01 0.67,1.52  1.22 0.80,1.86 
ω-3/ω-6 
Age 
63 303 
1.00  
44 321 
0.68 0.46,1.00  
53 313 
0.84 0.58,1.21  
50 316 
0.78 0.54,1.13 
Multivariate 1.00  0.65 0.44,0.95  0.79 0.55,1.15  0.79 0.54,1.14 
Note: 
Co=Cohort N, D=Deaths N, LIBCSP=Long Island Breast Cancer Study Project 
a
 Multivariate-adjusted HRs and 95% CI adjusted age (5-year age group) and total energy intake (kcal/day) 
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Table 4.5 Age- and energy-adjusted HRs and 95% CI for competing risks analysis for 
all-cause, breast cancer-specific, other cause mortality, among a population-based sample of 
women with breast cancer, LIBCSP, 1996/1997 (within 5 years of diagnosis) 
LC ω-3 and 
Fish intake 
(g/day) 
All-cause 
mortality 
 
Breast cancer-specific 
mortality 
 
Other cause 
mortality 
D Co HR 95% CI  D Co HR 95% CI  D Co HR 95% CI 
DPA               
 Q1 44 322 1.00   27 322 1.00   17 322 1.00  
 Q2 45 321 0.95 0.62,1.44  26 321 0.86 0.50,1.47  19 321 1.16 0.60,2.26 
 Q3 30 335 0.61 0.38,0.99  23 335 0.70 0.40,1.24  7 335 0.46 0.19,1.13 
 Q4 41 325 0.81 0.51,1.28  29 325 0.80 0.45,1.41  12 325 0.91 0.41,2.01 
DHA               
 Q1 46 320 1.00   29 320 1.00   17 320 1.00  
 Q2 47 318 0.99 0.66,1.48  29 318 0.94 0.56,1.58  18 318 1.06 0.55,2.06 
 Q3 28 338 0.57 0.35,0.92  22 338 0.66 0.37,1.15  6 338 0.39 0.15,0.99 
 Q4 39 327 0.74 0.48,1.15  25 327 0.70 0.40,1.21  14 327 0.90 0.44,1.86 
EPA               
 Q1 43 323 1.00   28 323 1.00   15 323 1.00  
 Q2 50 315 1.10 0.73,1.65  30 315 1.01 0.60,1.69  18 315 1.27 0.65,2.49 
 Q3 29 337 0.63 0.39,1.01  22 337 0.67 0.38,1.17  6 337 0.53 0.21,1.30 
 Q4 38 328 0.76 0.49,1.20  25 328 0.72 0.41,1.26  12 328 0.91 0.43,1.95 
Tuna               
 Never 40 303 1.00   23 303 1.00   17 303 1.00  
 Q1 27 214 0.95 0.58,1.55  16 214 0.98 0.52,1.85  11 214 0.91 0.43,1.94 
 Q2 32 214 1.10 0.69,1.76  24 214 1.38 0.78,2.45  8 214 0.71 0.30,1.64 
 Q3 29 186 1.17 0.72,1.89  20 186 1.31 0.72,2.39  9 186 0.99 0.44,2.24 
 Q4 32 386 0.64 0.40,1.02  22 386 0.69 0.38,1.24  10 386 0.56 0.26,1.23 
Other Fish 
(boiled/baked)               
 Never 62 443 1.00   41 443 1.00   21 443 1.00  
 Q1 32 188 1.22 0.80,1.87  20 188 1.12 0.65,1.91  12 188 1.45 0.71,2.94 
 Q2 13 124 0.74 0.41,1.34  10 124 0.85 0.43,1.70  3 124 0.50 0.15,1.67 
 Q3 24 317 0.54 0.34,0.86  17 317 0.56 0.32,0.98  7 317 0.52 0.22,1.22 
 Q4 29 231 0.81 0.52,1.26  17 231 0.73 0.42,1.29  12 231 1.02 0.50,2.08 
Note: Co=Cohort, D=Deaths, LIBCSP = Long Island Breast Cancer Study Project, LC = long-chain 
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Table 4.6 Age- and multivariate-adjusted hazard ratios (HRs) and 95% confidence 
intervals (CI) for all-cause mortality among a population-based sample of women with breast 
cancer for the interaction between dietary ω-3 and ω-6 intake, LIBCSP, 1996/1997 through 
2011(an average of 14.7 years of follow-up)  
Model 
 Low ω-6 
(< median) 
 High ω-6 
(≥ median) 
 
RERI
b
 95% CI
c
 
 HR 95% CI  HR 95% CI  
Age-adjusted          
High ω-3 (≥ median)  1.00   0.97 0.71, 1.32    
Low ω-3 (< median)  0.82 0.60, 1.11  0.94 0.63, 1.40  0.16 -0.24, 0.55 
Multivariate
a
          
High ω-3 (≥ median)  1.00   0.93 0.68, 1.28    
Low ω-3 (< median)  0.85 0.62, 1.16  0.94 0.63, 1.41  0.17 -0.23, 0.56 
Note: 
a
 Multivariate HRs and 95% CI adjusted for age (5-year age group) and total energy intake (kcal/day) 
b
 RERI (Relative Excess Risk due to Interaction) = HR11 - HR10 - HR01 +1 
c
 95% CI for RERI estimated using Hosmer & Lemeshow  [374] 
LIBCSP = Long Island Breast Cancer Study Project 
 
 
 
  
1
6
5
 
Table 4.7 Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for all-cause mortality for the association with putatively 
functional genetic polymorphisms using dominant model (N=1463) among a population-based sample of women with breast cancer, 
LIBCSP, 1996/1997 through 2011(an average of 14.7 years of follow-up)  
Gene rs# 
Allele 
Substitution. 
No Copies of 
Variant Allele 
N 
≥ 1 Copy of 
Variant Allele 
N 
 No Copies of 
Variant Allele 
 ≥ 1 Copy of 
Variant Allele   
 D HR  D HR 95% CI 
PTGS-2 rs20417 G > C GG 653 GC/CC 377  218 1.00  109 0.85 0.68, 1.07 
PTGS-2 rs5275 T > C TT 463 TC/CC 570  154 1.00  175 0.94 0.76, 1.17 
PPAR-α rs1800206 C > G CC 777 CG/GG 101  258 1.00  30 0.91 0.62, 1.32 
FAS rs2234767 G > A GG 792 GA/AA 238  255 1.00  71 0.91 0.70, 1.18 
FAS rs1800682 G > A GG 274 GA/AA 750  87 1.00  237 1.00 0.78, 1.28 
FASL rs763110 C > T CC 327 CT/TT 708  110 1.00  217 0.89 0.71, 1.12 
TNF-α rs1800629 G > A GG 758 GA/AA 261  236 1.00  85 1.05 0.82, 1.34 
MnSOD rs4880 C > T CC 250 CT/TT 756  76 1.00  240 1.06 0.82, 1.37 
MPO rs2333227 G > A GG 629 GA/AA 386  199 1.00  121 1.00 0.80, 1.26 
CAT rs1001179 C > T CC 614 CT/TT 395  174 1.00  144 1.39 1.11, 1.73 
GPX1 rs1050450 C > T CC 463 CT/TT 550  147 1.00  173 0.98 0.79, 1.22 
GSTM1 deletion deletion present 493 deletion 457  161 1.00  140 0.93 0.74, 1.16 
GSTP1 rs1695 A > G AA 500 AG/GG 499  155 1.00  161 1.06 0.85, 1.32 
GSTT1 deletion deletion present 754 deletion 203  246 1.00  60 0.90 0.68, 1.19 
GSTA1 rs3957356 G > A GG 334 GA/AA 679  108 1.00  213 0.96 0.76, 1.21 
COMT rs4680 G > A GG 280 GA/AA 740  96 1.00  237 0.87 0.68, 1.10 
COMT rs737865 C > T CC 99 CT/TT 903  24 1.00  292 1.40 0.92, 2.12 
CYP17 rs743572 T > C TT 345 TC/CC 656  113 1.00  206 0.94 0.75, 1.19 
LIBCSP = Long Island Breast Cancer Study Population, D=deaths 
 
 
  
1
6
6
 
Table 4.8 Age- and energy-adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs) for all-cause mortality for the 
hypothesized highest risk interaction between ω-3/ω-6 ratio and putatively functional genetic polymorphisms among a population-
based sample of women with breast cancer, LIBCSP, 1996/1997 through 2011(an average of 14.7 years of follow-up)  
Gene rs# 
Allele 
Substitution 
Variant 
allele 
function 
High 
risk 
genotype 
High ω-3/ω-6 
(> median) 
 
Low ω-3/ω-6 
(< median) 
RERI
e
 95% CI
f
 Low 
risk 
 
High 
risk 
 
Low 
risk 
 High 
risk 
HR
a
  HR 95% CI  HR 95% CI  HR
b
 95% CI 
PTGS-2 rs20417 G > C ↓ Inf [399] GG 1.00  1.03 0.74, 1.43  0.87 0.60, 1.26  1.08 0.78, 1.49 0.19 -0.23, 0.61 
PTGS-2 rs5275 T > C ↓ Inf [399] TT 1.00  0.90 0.66, 1.23  0.89 0.66, 1.20  1.02 0.76, 1.37 0.23 -0.17, 0.62 
PPAR-α rs1800206 C > G ↓ Inf [219] CC 1.00  1.64 0.91, 2.97  2.05 0.99, 4.25  1.42 0.79, 2.58 -1.26 -2.90, 0.37 
FAS rs2234767 G > A ↓ Inf [400] GG 1.00  1.35 0.92, 1.98  1.24 0.78, 1.97  1.26 0.86, 1.85 -0.32 -1.00, 0.36 
FAS rs1800682 G > A ↑ Inf [400] GA/AA 1.00  0.92 0.65, 1.32  0.92 0.60, 1.40  0.96 0.67, 1.38 0.12 -0.33, 0.57 
FASL rs763110 C > T ↓ Inf [401] CC 1.00  1.01 0.73, 1.39  0.92 0.70, 1.20  1.22 0.88, 1.70 0.30 -0.17, 0.77 
TNF-α rs1800629 G > A ↑ Inf [402] GA/AA 1.00  0.81 0.56, 1.16  0.89 0.69, 1.15  1.19 0.85, 1.68 0.49 0.03, 0.96 
MnSOD rs4880 C > T ↓ Os [403] CT/TT 1.00  1.41 0.95, 2.10  1.45 0.92, 2.30  1.27 0.85, 1.90 -0.59 -1.37, 0.20 
MPO rs2333227 G > A ↓ Os [404] GA/AA 1.00  1.14 0.83, 1.56  1.12 0.84, 1.47  0.95 0.68, 1.32 -0.30 -1.37, 0.20 
CAT rs1001179 C > T ↑ Os [405] CC 1.00  0.65 0.47, 0.89  0.93 0.67, 1.29  0.70 0.51, 0.95 0.12 -0.24, 0.48 
GPX1 rs1050450 C > T ↑ Os [406] CC 1.00  1.35 0.98, 1.85  1.27 0.94, 1.71  1.05 0.76, 1.44 -0.56 -1.14, 0.02 
GSTM1 deletion deletion ↑ Os [407] present 1.00  1.06 0.77, 1.47  1.00 0.71, 1.39  1.09 0.80, 1.48 0.03 -0.44, 0.49 
GSTP1 rs1695 A > G ↑ Os [408] AA 1.00  0.88 0.64, 1.20  0.93 0.68, 1.26  0.94 0.69, 1.28 0.14 -0.26, 0.54 
GSTT1 deletion deletion ↑ Os [407] present 1.00  1.34 0.90, 2.01  1.43 0.86, 2.38  1.22 0.81, 1.82 -0.56 -1.38, 0.27 
GSTA1 rs3957356 G > A ↑ Os [409] GG 1.00  0.89 0.63, 1.26  0.92 0.71, 1.21  1.09 0.80, 1.49 0.27 -0.16, 0.71 
COMT rs4680 G > A ↑ Os [412] GG 1.00  1.25 0.89, 1.75  1.07 0.83, 1.39  1.14 0.81, 1.61 -0.18 -0.74, 0.38 
COMT rs737865 C > T ↓ Os [410] CT/TT 1.00  1.30 0.68, 2.47  0.90 0.40, 2.02  1.40 0.74, 2.65 0.20 -0.55, 0.95 
CYP17 rs743572 T > C ↑ Es [411] TC/CC 1.00  0.86 0.62, 1.18  0.93 0.64, 1.35  0.88 0.65, 1.20 0.10 -0.32, 0.51 
Note: 
Inf = inflammation, Os = oxidative stress, Es = estrogen, LIBCSP = Long Island Breast Cancer Study Project 
a Hypothesized lowest risk group (referent group) - low risk genotype for PUFA-gene interaction, high ω-3/ω-6 ratio. 
b Hypothesized highest risk group - high risk genotype for PUFA-gene interaction, low ω-3/ω-6 ratio. 
c RERI (Relative Excess Risk Due to Interaction) = HR11 - HR10 - HR01 + HR00 (e.g., RERI for PTGS-2 rs20417 = 1.08 - 0.87 - 1.03 + 1.00 = 0.19). 
d 95% CI for RERI estimated using Hosmer & Lemeshow [374] 
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CHAPTER 5:  
CONCLUSIONS 
 
5.1 Summary of Study Aims and Results 
 The purpose of this dissertation was to examine the impact of dietary intake of 
polyunsaturated fatty acids (PUFAs) and fish (a major source of beneficial PUFAs) and, 
genetic susceptibility in biologically relevant genetic pathways (i.e., inflammation, oxidative 
stress, and estrogen metabolism) on: the risk of developing breast cancer (Aim 1); and 
survival following a new breast cancer diagnosis (Aim 2). To address these aims, data from a 
population-based sample of women residing on Long Island, New York were utilized.   
Previous studies undertaken to address whether PUFAs are associated with the risk of 
developing and dying from breast cancer were limited and inconsistent, when focused on 
populations in the U.S. and other western countries [270, 296, 298, 339]. Thus, the a priori 
study hypothesis was, given that experimental studies suggest that ω-3 PUFAs inhibit 
production of inflammatory eicosanoids from ω-6 PUFA metabolism [155], simultaneous 
consideration of both ω-3 and ω-6 PUFA intake, or interactions with genetic polymorphisms 
in biologically relevant pathways, would facilitate identification of PUFA-breast cancer 
associations in a U.S. population.    
Key dissertation results were as follows.  For Aim 1, a 43% excess risk for 
developing breast cancer was observed among women who consumed high ω-6 and low ω-3 
PUFAs compared to those consuming low ω-6 and high ω-3.  No interactions were observed 
with polymorphisms considered, but odds were elevated for low ω-3/ω-6 ratio across 
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genotypes. Additionally, notable associations with dietary intake of fish or individual PUFA 
subtypes in relation to breast cancer incidence were not observed. 
For Aim 2, key dissertation results included the following. Among a population-based 
sample of women who were newly-diagnosed with their first primary breast cancer, 
reductions in the hazard for all-cause mortality (16-34%) were observed among those 
consuming highest levels of long-chain (LC) ω-3 PUFA (i.e., DPA, DHA, and EPA).  
Additionally, similar hazard reductions were noted among those with high dietary intakes of 
tuna and other fish (broiled or baked).  Interactions between PUFAs and the select genotypes 
considered in relation to all-cause mortality were not observed. 
 
5.2 Summary of Public Health Impact 
 The burden of breast cancer in the U.S. remains high, with approximately 232,000 
new diagnoses and nearly 40,000 deaths per year [1].  Despite this high burden, few easily 
modifiable strategies exist for reducing risk of breast cancer development, or improving 
survival after diagnosis.  Thus, the results from this ancillary study suggest that dietary intake 
of ω-3 may provide an opportunity to reduce breast cancer risk and mortality following 
diagnosis.  Specifically, women who consume unfavorable diets of high ω-6 and low ω-3 
may be at higher risk for developing breast cancer compared to those consuming a more 
favorable diet of low ω-6 and high ω-3.  Additionally, women diagnosed with breast cancer 
may want to consider increasing dietary intake of fish, and consuming more foods that are 
high in LC ω-3 PUFAs.  If confirmed by future investigations, interventions targeted towards 
increasing consumption of LC ω-3 PUFA may be warranted. 
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5.3 Study Strengths 
 This study has a number of strengths. First, the study aims are innovative.  Regarding 
Aim 1, this study is the first to consider an interaction between dietary intake of ω-3 and ω-6 
PUFAs and breast cancer incidence among a U.S. population. Regarding Aim 2, this study is 
the first to identify risk reductions for long-chain ω-3 PUFAs in relation to all-cause 
mortality using a population-based sample in the U.S.  Additionally, this study is also the 
first to examine the interaction between PUFA intake and genetic polymorphisms in multiple 
relevant biologic pathways in a population-based sample for both incidence and survival.  
Another strength of this dissertation is that the major classes of PUFAs (ω-3 and ω-
6), and their individual subtypes (ω-3: ALA, EPA, DPA, DHA; and ω-6: LA, AA) were 
estimated. This approach maximizes the likelihood of improved exposure assessment of the 
PUFA classes, thus facilitating examination of both ω-3 and ω-6 simultaneously.  Fish and 
other marine sources are considered the predominant source of the LC ω-3 [146]. However, 
for many Americans foods other than fish are important contributors to their PUFA intake 
(Tables 3.1 and 4.1). Thus, for this dissertation multiple PUFA subtypes were derived from 
marine and other food sources, to improve measurement of PUFA intake in the LIBCSP 
population.  
To enhance the likelihood of PUFA intake variability in a U.S. population, this 
ancillary study was conducted among women residing on Long Island, New York, a 
population that is reported to have higher fish intake compared to the national estimates from 
the National Health and Nutrition Examination Survey (NHANES) [391]. These NHANES 
findings were confirmed by the LIBCSP data; the LIBCSP reported mean consumption of 8.1 
g/day among cases and 11.9 g/day among controls was higher than the reported mean tuna 
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intake of 5.9 g/day in the general NHANES population sample of the U.S. [392].  It is 
possible, however, that the LIBCSP FFQ estimate are inaccurate, given that the FFQ is 
designed to provide relative rather than absolute intake. Nevertheless, the LIBCSP may be 
one of the ideal populations to examine PUFAs and fish intake in relation to breast cancer 
incidence and mortality in the U.S.  Despite the relatively higher fish consumption in the 
Long Island population compared to the general U.S. population, fish consumption in the 
LIBCSP population was much lower than the fish intake reported among Asian populations 
[146, 391, 392].  However, in the LIBCSP, intake of ω-3 was low relative to ω-6 intake, 
which is consistent with PUFA intake estimates reported for other Western populations [153, 
154]. 
 An additional benefit of the approach used in this dissertation is the population-based 
design of the LIBCSP, where cases in a circumscribed geographic area were ascertained 
within three months of diagnosis (“super-rapid identification”), and controls were incidence-
density sampled. This population-based approach allows for stronger inferences regarding 
breast cancer incidence [373].  Also, to ascertain outcomes for the follow-up study (Aim 2), 
vital status for the population-based cases was determined using the NDI, a standard resource 
for assessing mortality in the U.S., with high sensitivity [358].  
Finally, the LIBCSP is a rich resource with which to address the study aims. Existing 
LIBCSP data available for this dissertation included: FFQ data, which was assessed using a 
validated 101-item Block FFQ [359, 395, 396]; genetic polymorphisms in biologically 
relevant genes; and 15 years post-diagnosis vital status of the population-based cohort of 
women with breast cancer. Thus, the study design was cost-efficient and utilized extant 
resources from a population-based study. 
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5.4 Study Limitations 
 There are several limitations to this study.  The LIBCSP study population includes 
primarily Caucasian and postmenopausal women; therefore examination of potential racial 
differences was not possible.  However, the results are generalizable to the subgroup of 
women who are at high risk for developing breast cancer in the U.S. [1]. 
 For the case-control approach utilized in Aim 1, it is not possible to rule out recall 
bias, where it is possible that cases and controls may differentially recall foods high PUFA 
content.  Also, a single dietary assessment via FFQ may not necessarily reflect diet during 
the etiologically relevant time period for breast cancer development.  Similarly with regard to 
possible measurement error for Aim 2 follow-up approach, a one-time dietary assessment via 
FFQ is unable to assess changes in diet that may have occurred following breast cancer 
diagnosis.  Although, a recent study has reported that intake of oily fish and fish oil increases 
post breast cancer diagnosis [420], thus suggesting that the estimate reported in this 
dissertation for PUFA intake near time of diagnosis may be conservative. 
 Another limitation, relevant for both Aims 1 and 2, is the potential errors associated 
with dietary PUFA assessment via linkage with the USDA database.  It is possible that the 
PUFA content in foods available in the USDA database differs from those actually consumed 
by LIBCSP participants.  This could be due to a variety of reasons, including geographic 
differences in harvesting, storage, processing, and cooking methods [147, 417, 418].  For 
example, the nutrient composition of wild versus farmed fish of the same species differs 
substantially, where the farmed fish tend to contain lower amounts of LC ω-3 PUFAs [421].  
Furthermore, the food sources for various ω-3 PUFA subtypes differ, and thus ω-3 content 
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obtained from these different sources could vary due to differences in food storage.  For 
example, ALA is primarily obtained via vegetable and plant-derived oils, which are prone to 
oxidation due to prolonged storage [417].  Any observed benefit of ALA may be masked due 
to oxidation-induced ALA loss, thus further lowering formation of downstream LC ω-3 
PUFAs resulting from ALA metabolism. However, absolute PUFA measurement error may 
be less of a concern since this dissertation considered PUFA via relative ranking of 
individuals, using quartiles. 
 Another concern regarding PUFA measurement for Aims 1 and 2 is that the parent 
LIBCSP did not include assessment of consumption of different fish species, other than tuna. 
Levels of LC ω-3 PUFA differ by fish species [419].  Tuna, however, is the most common 
fish consumed in the U.S. and is a major food source of LC ω-3 PUFA [391]. Nonetheless, 
exposure assessment would have been improved if the LIBCSP participants had been also 
asked about their consumption of other specific fish species that are also high in LC ω-3 and 
may be commonly consumed in the U.S., such as salmon (rather than grouping all other fish 
species together). Additionally, although LIBCSP participants were queried about their 
cooking practices, the prevalence of fish intake was relatively low, which limits inferences 
regarding the impact of cooking methods due to small sample sizes. However, even with a 
larger sample, more detailed information would be required on factors affecting PUFA 
content (e.g., cooking time, type of oil used if fried, type of fish consumed) in order to more 
accurately assess the impact of different cooking methods on PUFA content, and its 
subsequent relation with breast cancer risk and mortality. 
 Another limitation of this dissertation is the potential for inadequate coverage of 
genes involved in related biologic pathways.  Although key putatively functional SNPs 
 173 
involved in relevant pathways were considered (i.e., inflammation, oxidative stress, estrogen 
metabolism), it remains possible that some PUFA-gene interactions may have been missed 
due to failure to consider other relevant SNPs. For example, genes involved in the in vivo 
metabolism of PUFA, namely LA and ALA (Figure 1.2) may interact with PUFAs to 
influence breast carcinogenesis, given their role in PUFA bioavailability.  The efficiency of 
enzymes involved in this metabolism, in combination with dietary intake of PUFAs could 
influence consequent eicosanoid production. For example, it has been reported that the 
conversion of ALA into LC ω-3 is highly inefficient in populations consuming high ω-6 
[150], thus further hindering the potential benefit derived from ALA consumption.  However, 
a recent dietary intervention conducted among subjects with high ω-6 intake at baseline, 
observed increases in LC ω-3 PUFA plasma concentrations among subjects who lowered 
their ω-6 intake, thus suggesting improved enzyme efficiency in ALA to LC ω-3 PUFA 
metabolism in populations consuming high ω-6 [416].  Thus, consideration of these 
additional genes, in concert with dietary intake of PUFAs, may further elucidate the relation 
between PUFAs and breast cancer. 
 Finally, this dissertation had limited study power to make inferences regarding breast-
cancer specific mortality, because of the low number of deaths due to breast cancer in the 
LIBCSP study population even after 15 years of follow-up.  However, the magnitude of the 
effect estimates for breast cancer-specific mortality was similar to those for all-cause 
mortality, for both 5-year survival as well as the entire 15-year follow-up.  Thus, these 
findings are consistent with the proposed biology of PUFAs when considering the relation 
with breast-cancer specific mortality, though estimates were imprecise. 
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5.5 Future Directions 
 Ideally, future studies, utilizing a cohort approach, should consider measuring 
repeated PUFA exposure assessments, via multiple FFQs, 24-hour recalls, or biomarkers, 
throughout the etiologically relevant periods in order to better capture dietary changes both 
before and after a diagnosis of breast cancer. However, each method of PUFA assessment 
has its strengths and limitations. Repeated FFQs may provide a benefit over repeated 24-hour 
recalls since FFQs typically assess usual intake and have the potential to capture long-term 
changes in dietary habits. Whereas, repeated 24-hour recalls are subject to day-to-day 
variations in intake, and may not accurately assess long-term patterns of intake.  In 
comparison, biomarkers provide an objective measure of PUFA intake.  However, they may 
reflect very different exposure windows depending on the type of biomarker measured 
(adipose tissue, red-blood cells, or serum) [272]. Similar to 24-hour recalls, serum PUFA 
biomarkers provide an objective measure of short-term intake. Adipose tissue biomarkers 
could reflect fat intake up to one year post-biopsy. However, the possibility for selection bias 
due to the invasive procedure of obtaining an adipose tissue sample via needle aspiration 
needs to be considered.  Also, adipose tissue biomarkers are also subject to measurement 
error in the presence of weight changes. Red-blood cell biomarkers reflect up to three months 
of intake, however, issues with membrane degradation due to oxidation during storage have 
been reported [273].  The window of exposure reflected by each PUFA assessment varies; 
thus, consideration needs to be given in order to identify relevant PUFA exposures in relation 
to breast cancer development and prognosis. 
Another consideration of the approach used in this dissertation is the potential 
limitations of a ratio measure of ω-3 and ω-6 in populations with low intake. Future studies 
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with improved power may also want to consider three-level interactions between ω-6, ω-3, 
and genetic polymorphisms in relation to both the risk of developing breast cancer and the 
risk of dying from breast cancer. This alternative approach would better reflect the 
interaction between PUFAs and breast cancer in Aim 1, and perhaps improve the likelihood 
of detecting an interaction with biologically relevant genetic polymorphisms. With regards to 
Aim 2, given the low prevalence of ω-3-rich foods in the U.S., future follow-up studies 
should increase the study sample size to facilitate examination of interactions between the 
exposure for which the effect estimates were strongest in this dissertation (e.g., fish, or LC ω-
3 fatty acids), and genetic polymorphisms. Finally, future studies should include a larger 
sample population to enhance the likelihood of confirming the exploratory findings regarding 
LC ω-3 and breast cancer-specific mortality observed in this dissertation. Also, a larger 
sample size would facilitate examination of: additional genes involved in PUFA metabolism; 
a more detailed consideration of fish cooking methods; and modification by breast cancer 
subtypes and/or race.   
 
5.6 Conclusion 
 Findings from this dissertation indicate that higher consumption of ω-6 fatty acids in 
combination with low ω-3 may increase breast cancer risk compared to those women 
consuming lower ω-6 and higher ω-3.  Increased risks for breast cancer were evident 
regardless of polymorphisms in relevant genes.  Additionally, higher consumption of LC ω-3 
PUFAs following a first-primary diagnosis of breast cancer may reduce risk of mortality. 
Strategies aimed to increase dietary intake of ω-3 relative to ω-6 (e.g., via fish consumption 
or fish oil supplementation) may be warranted, pending confirmation from future studies.  
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APPENDIX: TABLES & FIGURES 
 
Table A.1 Pearson correlation between PUFA subtypes among 1,500 LIBCSP controls 
 
 ALA DPA DHA EPA LA AA 
ALA 1      
DPA 
0.1816 
p<0.0001 
1     
DHA 
0.0745 
p=0.0039 
0.9348 
p<0.0001 
1    
EPA 
0.0645 
p=0.0125 
0.9162 
p<0.0001 
0.9515 
p<0.0001 
1   
LA 
0.8441 
p<0.0001 
0.19488 
p<0.0001 
0.0811 
p=0.0017 
0.0697 
p=0.0069 
1  
AA 
0.3756 
p<0.001 
0.7135 
p<0.0001 
0.5798 
p<0.0001 
0.52051 
p<0.0001 
0.3588 
p<0.0001 
1 
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Table A.2 Pearson correlation between PUFA subtypes among 1,463 LIBCSP cases 
 
 ALA DPA DHA EPA LA AA 
ALA 1      
DPA 
0.1014 
p=0.0001 
1     
DHA 
0.0135 
p=0.6061 
0.9480 
p<0.0001 
1    
EPA 
0.01501 
p=0.5662 
0.9344 
p<0.0001 
0.9730 
p<0.0001 
1   
LA 
0.8237 
p<0.0001 
0.1251 
p<0.0001 
0.0305 
p=0.2431 
0.0324 
p=0.2160 
1  
AA 
0.2948 
p<0.001 
0.7551 
p<0.0001 
0.6307 
p<0.0001 
0.6016 
p<0.0001 
0.3076 
p<0.0001 
1 
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Table A.3 Age- and energy-adjusted ORs and 95% CI for the interaction between total 
PUFA intake (low or high) and genetic variants on breast cancer incidence
 
Co=Controls, Ca=Cases, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374]
Co Ca OR 95% CI Co Ca OR 95% CI
PTGS-2 GC/CC 196 196 1.00 206 181 1.01 0.74, 1.36
rs20417 GG 345 315 0.91 0.71, 1.17 329 338 1.17 0.89, 1.54 0.25 -0.08, 0.59
PTGS-2 TC/CC 305 293 1.00 314 277 1.06 0.82, 1.37
rs5275 TT 235 221 0.98 0.77, 1.26 219 242 1.30 0.99, 1.70 0.25 -0.11, 0.62
PPAR-α GC/GG 39 48 1.00 53 53 0.96 0.54, 1.74
rs18000206 CC 432 383 0.73 0.47, 1.14 413 394 0.88 0.55, 1.40 0.19 -0.34, 0.72
FAS GA/AA 133 123 1.00 118 114 1.19 0.81, 1.73
rs2234767 GG 408 390 1.01 0.76, 1.34 417 402 1.17 0.87, 1.59 -0.02 -0.47, 0.43
FAS GG 138 124 1.00 163 150 1.17 0.83, 1.66
rs1800682 GA/AA 398 384 1.09 0.82, 1.44 372 366 1.29 0.95, 1.75 0.03 -0.40, 0.46
FASL CT/TT 376 351 1.00 348 357 1.25 0.99, 1.59
rs763110 CC 164 165 1.07 0.82, 1.39 187 162 1.07 0.80, 1.42 -0.25 -0.67, 0.16
TNF-α GG 388 379 1.00 396 379 1.13 0.90, 1.43
rs1800629 GA/AA 146 122 0.86 0.65, 1.14 139 139 1.19 0.88, 1.60 0.20 -0.21, 0.60
MnSOD CC 129 112 1.00 130 138 1.39 0.96, 2.01
rs4880 CT/TT 400 382 1.09 0.82, 1.46 398 374 1.25 0.91, 1.72 -0.23 -0.75, 0.28
MPO GG 328 317 1.00 305 312 1.24 0.96, 1.59
rs2333227 GA/AA 206 183 0.93 0.72, 1.19 224 203 1.08 0.83, 1.42 -0.08 -0.46, 0.30
CAT CT/TT 196 200 1.00 184 195 1.19 0.88, 1.62
rs1001179 CC 335 298 0.86 0.67, 1.11 344 316 1.04 0.79, 1.37 -0.01 -0.39, 0.37
GPX1 CT/TT 292 278 1.00 260 272 1.28 0.99, 1.67
rs1050450 CC 242 223 0.98 0.76, 1.25 267 240 1.10 0.85, 1.44 -0.16 -0.55, 0.24
GSTM1 Null 208 243 1.00 235 214 0.89 0.67, 1.18
deletion Present 275 222 0.68 0.53, 0.88 257 271 1.04 0.78, 1.38 0.47 0.18, 0.76
GSTP1 AG/GG 260 226 1.00 272 273 1.33 1.02, 1.75
rs1695 AA 258 270 1.22 0.95, 1.57 251 230 1.23 0.93, 1.63 -0.33 -0.77, 0.12
GSTT1 Null 110 104 1.00 104 99 1.17 0.78, 1.77
deletion Present 381 364 1.01 0.74, 1.37 394 390 1.19 0.86, 1.65 0.01 -0.47, 0.49
GSTA1 GA/AA 340 345 1.00 350 334 1.10 0.86, 1.39
rs3957356 GG 191 156 0.81 0.63, 1.06 181 178 1.13 0.86, 1.50 0.22 -0.13, 0.58
COMT AG/AA 392 358 1.00 405 382 1.21 0.96, 1.53
rs4680 GG 140 146 1.16 0.88, 1.52 127 134 1.32 0.97, 1.79 -0.05 -0.53, 0.43
COMT CC 60 53 1.00 50 46 1.17 0.67, 2.05
rs737865 CT/TT 471 445 1.06 0.71, 1.57 481 458 1.22 0.81, 1.84 0.00 -0.64, 0.63
CYP17 TT 185 168 1.00 190 177 1.17 0.85, 1.61
rs743572 TC/CC 339 330 1.07 0.82, 1.38 329 326 1.24 0.93, 1.65 0.00 -0.41, 0.41
Low intake High intake
95% CIRERIGene Genotype
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Table A.4 Age- and energy-adjusted ORs and 95% CI for the interaction between total 
ω-3 intake (low or high) and genetic variants on breast cancer incidence 
 
Co=Controls, Ca=Cases, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374]
Co Ca OR 95% CI Co Ca OR 95% CI
PTGS-2 GC/CC 207 181 1.00 195 196 1.08 0.79, 1.46
rs20417 GG 337 323 1.10 0.85, 1.42 337 330 1.04 0.79, 1.36 -0.14 -0.53, 0.25
PTGS-2 TC/CC 317 274 1.00 302 296 1.05 0.81, 1.35
rs5275 TT 225 229 1.16 0.91, 1.49 229 234 1.09 0.83, 1.42 -0.12 -0.51, 0.26
PPAR-α GC/GG 48 57 1.00 44 44 0.76 0.42, 1.37
rs18000206 CC 426 377 0.72 0.48, 1.09 419 400 0.73 0.47, 1.12 0.24 -0.22, 0.70
FAS GA/AA 127 113 1.00 124 125 1.07 0.73, 1.55
rs2234767 GG 418 385 1.04 0.78, 1.39 407 407 1.04 0.76, 1.42 -0.07 -0.50, 0.37
FAS GG 165 145 1.00 136 129 1.02 0.72, 1.44
rs1800682 GA/AA 380 352 1.08 0.83, 1.42 390 398 1.10 0.83, 1.46 0.00 -0.40, 0.40
FASL CT/TT 351 329 1.00 373 379 1.01 0.79, 1.27
rs763110 CC 194 172 0.94 0.73, 1.22 157 155 0.97 0.72, 1.30 0.02 -0.33, 0.38
TNF-α GG 391 358 1.00 393 400 1.03 0.81, 1.29
rs1800629 GA/AA 153 142 1.02 0.78, 1.34 132 119 0.91 0.66, 1.23 -0.14 -0.53, 0.25
MnSOD CC 133 125 1.00 126 125 0.99 0.69, 1.43
rs4880 CT/TT 404 369 0.99 0.74, 1.31 394 387 0.97 0.72, 1.31 -0.01 -0.41, 0.39
MPO GG 305 304 1.00 328 325 0.91 0.71, 1.17
rs2333227 GA/AA 233 194 0.84 0.65, 1.07 197 192 0.89 0.68, 1.18 0.15 -0.16, 0.46
CAT CT/TT 349 296 1.00 193 195 0.87 0.64, 1.18
rs1001179 CC 187 200 0.80 0.62, 1.03 330 318 0.82 0.62, 1.09 0.15 -0.15, 0.46
GPX1 CT/TT 262 231 1.00 278 285 0.97 0.74, 1.26
rs1050450 CC 274 265 0.92 0.72, 1.18 247 232 0.89 0.68, 1.18 0.01 -0.32, 0.33
GSTM1 Null 239 214 1.00 204 243 1.25 0.94, 1.67
deletion Present 259 249 1.08 0.84, 1.40 273 244 0.93 0.70, 1.22 -0.41 -0.84, 0.02
GSTP1 AG/GG 275 257 1.00 257 242 0.93 0.71, 1.22
rs1695 AA 256 231 0.97 0.76, 1.25 253 269 1.06 0.81, 1.38 0.16 -0.18, 0.49
GSTT1 Null 107 101 1.00 107 102 0.94 0.63, 1.42
deletion Present 397 367 0.98 0.72, 1.33 378 387 1.00 0.72, 1.40 0.08 -0.33, 0.49
GSTA1 GA/AA 355 323 1.00 335 356 1.07 0.84, 1.36
rs3957356 GG 185 172 1.03 0.80, 1.34 187 162 0.88 0.66, 1.16 -0.23 -0.60, 0.15
COMT AG/AA 418 365 1.00 379 375 1.02 0.81, 1.29
rs4680 GG 124 134 1.20 0.90, 1.59 143 146 1.07 0.80, 1.44 -0.15 -0.59, 0.29
COMT CC 56 46 1.00 54 53 1.11 0.64, 1.95
rs737865 CT/TT 484 443 1.12 0.74, 1.70 468 460 1.11 0.72, 1.71 -0.12 -0.77, 0.52
CYP17 TT 192 175 1.00 183 170 0.95 0.69, 1.30
rs743572 TC/CC 336 311 1.01 0.78, 1.30 332 345 1.06 0.80, 1.40 0.10 -0.25, 0.46
95% CIGene Genotype
High intake Low intake
RERI
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Table A.5 Age- and energy-adjusted ORs and 95% CI for the interaction between ALA 
intake (low or high) and genetic variants on breast cancer incidence 
 
Co=Controls, Ca=Cases, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374]
Co Ca OR 95% CI Co Ca OR 95% CI
PTGS-2 GC/CC 209 182 1.00 193 195 1.06 0.78, 1.43
rs20417 GG 335 337 1.15 0.90, 1.48 339 316 0.97 0.74, 1.27 -0.24 -0.64, 0.16
PTGS-2 TC/CC 316 280 1.00 303 290 0.97 0.76, 1.25
rs5275 TT 226 238 1.17 0.91, 1.49 228 225 1.01 0.77, 1.32 -0.13 -0.51, 0.24
PPAR-α GC/GG 48 59 1.00 44 42 0.67 0.37, 1.21
rs18000206 CC 424 383 0.70 0.47, 1.06 421 394 0.67 0.44, 1.03 0.30 -0.12, 0.71
FAS GA/AA 125 119 1.00 126 119 0.91 0.62, 1.32
rs2234767 GG 419 395 0.99 0.74, 1.32 406 397 0.93 0.68, 1.26 0.03 -0.35, 0.42
FAS GG 163 143 1.00 138 131 1.00 0.71, 1.41
rs1800682 GA/AA 382 367 1.12 0.86, 1.47 388 383 1.05 0.79, 1.39 -0.08 -0.49, 0.33
FASL CT/TT 354 351 1.00 370 357 0.89 0.70, 1.12
rs763110 CC 190 166 0.88 0.68, 1.14 161 161 0.91 0.69, 1.22 0.14 -0.19, 0.47
TNF-α GG 390 366 1.00 394 392 0.96 0.76, 1.21
rs1800629 GA/AA 154 148 1.02 0.78, 1.34 131 113 0.83 0.61, 1.14 -0.15 -0.53, 0.23
MnSOD CC 132 129 1.00 127 121 0.91 0.63, 1.31
rs4880 CT/TT 403 379 0.99 0.74, 1.31 395 377 0.89 0.66, 1.20 0.00 -0.39, 0.38
MPO GG 311 314 1.00 322 315 0.87 0.68, 1.12
rs2333227 GA/AA 227 198 0.86 0.67, 1.10 203 188 0.83 0.63, 1.09 0.09 -0.21, 0.40
CAT CT/TT 185 206 1.00 195 189 0.78 0.58, 1.06
rs1001179 CC 350 304 0.78 0.61, 1.01 329 310 0.76 0.57, 1.00 0.19 -0.09, 0.47
GPX1 CT/TT 270 271 1.00 282 279 0.88 0.68, 1.14
rs1050450 CC 265 239 0.90 0.70, 1.15 244 224 0.83 0.63, 1.09 0.05 -0.26, 0.36
GSTM1 Null 236 218 1.00 207 239 1.14 0.86, 1.52
deletion Present 260 260 1.09 0.85, 1.40 272 233 0.84 0.63, 1.11 -0.39 -0.80, 0.02
GSTP1 AG/GG 277 264 1.00 255 255 0.87 0.66, 1.13
rs1695 AA 252 240 1.01 0.79, 1.29 257 260 0.96 0.74, 1.26 0.09 -0.24, 0.42
GSTT1 Null 109 104 1.00 105 99 0.90 0.60, 1.35
deletion Present 392 377 1.00 0.73, 1.35 383 377 0.93 0.67, 1.29 0.04 -0.37, 0.44
GSTA1 GA/AA 354 338 1.00 336 341 0.95 0.75, 1.21
rs3957356 GG 185 171 0.97 0.75, 1.26 187 163 0.83 0.63, 1.10 -0.09 -0.44, 0.25
COMT AG/AA 415 380 1.00 382 360 0.92 0.73, 1.15
rs4680 GG 127 133 1.11 0.84, 1.47 140 147 1.04 0.77, 1.39 0.01 -0.40, 0.42
COMT CC 55 45 1.00 55 54 1.08 0.62, 1.89
rs737865 CT/TT 485 458 1.15 0.76, 1.75 467 445 1.06 0.69, 1.63 -0.18 -0.83, 0.47
CYP17 TT 191 187 1.00 184 158 0.79 0.57, 1.08
rs743572 TC/CC 334 315 0.95 0.74, 1.23 334 341 0.94 0.71, 1.24 0.20 -0.11, 0.51
95% CIGene Genotype
High intake Low intake
RERI
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Table A.6 Age- and energy-adjusted ORs and 95% CI for the interaction between DPA 
intake (low or high) and genetic variants on breast cancer incidence 
 
Co=Controls, Ca=Cases, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374]
Co Ca OR 95% CI Co Ca OR 95% CI
PTGS-2 GC/CC 208 200 1.00 194 177 0.89 0.67, 1.20
rs20417 GG 321 328 1.06 0.82, 1.35 353 325 0.90 0.70, 1.17 -0.05 -0.39, 0.30
PTGS-2 TC/CC 303 291 1.00 316 279 0.87 0.68, 1.10
rs5275 TT 224 238 1.09 0.86, 1.40 230 225 0.96 0.74, 1.23 -0.01 -0.35, 0.34
PPAR-α GC/GG 40 57 1.00 52 44 0.58 0.33, 1.03
rs18000206 CC 425 395 0.65 0.42, 1.00 420 382 0.60 0.39, 0.93 0.37 0.01, 0.74
FAS GA/AA 135 107 1.00 116 131 1.34 0.93, 1.93
rs2234767 GG 395 420 1.33 1.00, 1.78 430 372 1.02 0.76, 1.37 -0.65 -1.24, -0.06
FAS GG 395 420 1.00 430 372 0.83 0.59, 1.16
rs1800682 GA/AA 135 107 1.05 0.80, 1.37 116 131 0.93 0.70, 1.23 0.06 -0.30, 0.41
FASL CT/TT 361 354 1.00 363 354 0.95 0.76, 1.18
rs763110 CC 169 175 1.07 0.83, 1.39 182 152 0.80 0.61, 1.05 -0.22 -0.58, 0.15
TNF-α GG 407 392 1.00 377 366 0.95 0.77, 1.17
rs1800629 GA/AA 118 131 1.18 0.88, 1.57 167 130 0.76 0.58, 1.01 -0.36 -0.78, 0.05
MnSOD CC 118 126 1.00 141 124 0.79 0.55, 1.12
rs4880 CT/TT 404 388 0.90 0.68, 1.21 394 368 0.83 0.62, 1.11 0.14 -0.20, 0.48
MPO GG 299 318 1.00 334 311 0.83 0.66, 1.05
rs2333227 GA/AA 225 204 0.86 0.67, 1.10 205 182 0.78 0.60, 1.02 0.09 -0.21, 0.39
CAT CT/TT 176 191 1.00 204 204 0.87 0.65, 1.16
rs1001179 CC 346 326 0.87 0.67, 1.12 333 288 0.75 0.57, 0.98 0.01 -0.31, 0.33
GPX1 CT/TT 289 292 1.00 263 258 0.92 0.72, 1.17
rs1050450 CC 236 227 0.97 0.76, 1.24 273 236 0.82 0.64, 1.04 -0.07 -0.39, 0.26
GSTM1 Null 203 243 1.00 240 214 0.71 0.54, 0.93
deletion Present 281 249 0.75 0.58, 0.97 251 244 0.76 0.59, 0.99 0.30 0.04, 0.57
GSTP1 AG/GG 263 237 1.00 269 262 1.02 0.79, 1.32
rs1695 AA 249 278 1.25 0.98, 1.60 260 222 0.89 0.69, 1.16 -0.38 -0.78, 0.02
GSTT1 Null 108 112 1.00 106 91 0.79 0.53, 1.17
deletion Present 384 387 0.97 0.72, 1.31 391 367 0.85 0.62, 1.16 0.09 -0.29, 0.46
GSTA1 GA/AA 349 347 1.00 341 332 0.93 0.74, 1.15
rs3957356 GG 173 171 1.02 0.78, 1.32 199 163 0.78 0.60, 1.01 -0.17 -0.52, 0.18
COMT AG/AA 401 390 1.00 396 350 0.85 0.69, 1.05
rs4680 GG 123 133 1.10 0.83, 1.46 144 147 0.98 0.74, 1.29 0.03 -0.37, 0.43
COMT CC 58 45 1.00 52 54 1.30 0.75, 2.26
rs737865 CT/TT 466 470 1.33 0.88, 2.01 486 433 1.10 0.73, 1.67 -0.53 -1.35, 0.28
CYP17 TT 198 174 1.00 177 171 1.05 0.77, 1.41
rs743572 TC/CC 316 339 1.22 0.94, 1.58 352 317 0.96 0.74, 1.25 -0.30 -0.72, 0.12
95% CIGene Genotype
High intake Low intake
RERI
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Table A.7 Age- and energy-adjusted ORs and 95% CI for the interaction between DHA 
intake (low or high) and genetic variants on breast cancer incidence 
 
Co=Controls, Ca=Cases, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374]
Co Ca OR 95% CI Co Ca OR 95% CI
PTGS-2 GC/CC 205 204 1.00 197 173 0.87 0.65, 1.16
rs20417 GG 325 324 0.99 0.77, 1.27 349 329 0.93 0.73, 1.20 0.07 -0.26, 0.40
PTGS-2 TC/CC 303 304 1.00 316 266 0.82 0.65, 1.04
rs5275 TT 225 225 0.98 0.77, 1.25 229 238 1.02 0.80, 1.30 0.21 -0.10, 0.53
PPAR-α GC/GG 39 53 1.00 53 48 0.66 0.37, 1.17
rs18000206 CC 428 398 0.67 0.43, 1.04 417 379 0.65 0.42, 1.01 0.32 -0.08, 0.73
FAS GA/AA 134 108 1.00 117 130 1.35 0.94, 1.94
rs2234767 GG 397 418 1.29 0.97, 1.73 428 374 1.06 0.79, 1.42 -0.59 -1.16, -0.01
FAS GG 144 152 1.00 157 122 0.73 0.52, 1.01
rs1800682 GA/AA 386 375 0.93 0.71, 1.22 384 375 0.92 0.70, 1.21 0.27 -0.04, 0.57
FASL CT/TT 352 360 1.00 372 348 0.90 0.73, 1.12
rs763110 CC 178 169 0.93 0.72, 1.20 173 158 0.88 0.68, 1.15 0.05 -0.29, 0.38
TNF-α GG 408 397 1.00 376 361 0.98 0.80, 1.20
rs1800629 GA/AA 120 125 1.09 0.82, 1.45 165 136 0.84 0.64, 1.09 -0.23 -0.63, 0.17
MnSOD CC 119 126 1.00 140 124 0.84 0.59, 1.20
rs4880 CT/TT 404 388 0.92 0.69, 1.23 394 368 0.88 0.65, 1.17 0.12 -0.23, 0.47
MPO GG 299 320 1.00 334 309 0.86 0.69, 1.08
rs2333227 GA/AA 266 200 0.84 0.66, 1.08 204 186 0.84 0.65, 1.08 0.14 -0.17, 0.44
CAT CT/TT 178 195 1.00 202 200 0.89 0.67, 1.18
rs1001179 CC 346 320 0.84 0.65, 1.09 333 294 0.79 0.61, 1.03 0.06 -0.25, 0.38
GPX1 CT/TT 287 292 1.00 265 258 0.94 0.74, 1.20
rs1050450 CC 238 224 0.94 0.73, 1.20 271 239 0.86 0.68, 1.10 -0.02 -0.34, 0.31
GSTM1 Null 204 231 1.00 239 226 0.82 0.63, 1.07
deletion Present 281 253 0.79 0.61, 1.02 251 240 0.83 0.64, 1.08 0.23 -0.06, 0.52
GSTP1 AG/GG 262 236 1.00 270 263 1.07 0.84, 1.38
rs1695 AA 249 276 1.25 0.98, 1.60 260 224 0.94 0.73, 1.22 -0.38 -0.79, 0.03
GSTT1 Null 106 111 1.00 108 92 0.82 0.56, 1.21
deletion Present 387 380 0.94 0.70, 1.27 388 374 0.91 0.67, 1.24 0.15 -0.23, 0.52
GSTA1 GA/AA 349 345 1.00 341 334 0.98 0.79, 1.22
rs3957356 GG 174 170 1.00 0.77, 1.30 198 164 0.83 0.64, 1.07 -0.16 -0.51, 0.20
COMT AG/AA 400 389 1.00 397 351 0.90 0.73, 1.10
rs4680 GG 127 133 1.07 0.81, 1.42 140 147 1.05 0.80, 1.38 0.08 -0.32, 0.48
COMT CC 60 43 1.00 50 56 1.54 0.89, 2.67
rs737865 CT/TT 465 471 1.42 0.94, 2.15 487 432 1.22 0.81, 1.86 -0.74 -1.67, 0.20
CYP17 TT 211 170 1.00 164 175 1.32 0.98, 1.78
rs743572 TC/CC 304 344 1.40 1.09, 1.81 364 312 1.05 0.81, 1.35 -0.68 -1.19, -0.16
95% CIGene Genotype
High intake Low intake
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 183 
Table A.8 Age- and energy-adjusted ORs and 95% CI for the interaction between EPA 
intake (low or high) and genetic variants on breast cancer incidence 
 
Co=Controls, Ca=Cases, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374]
Co Ca OR 95% CI Co Ca OR 95% CI
PTGS-2 GC/CC 208 205 1.00 194 172 0.88 0.66, 1.18
rs20417 GG 324 323 1.01 0.79, 1.30 350 330 0.93 0.73, 1.20 0.04 -0.30, 0.37
PTGS-2 TC/CC 304 301 1.00 315 269 0.84 0.66, 1.06
rs5275 TT 227 228 1.00 0.78, 1.28 227 235 1.02 0.79, 1.30 0.18 -0.15, 0.50
PPAR-α GC/GG 39 55 1.00 53 46 0.62 0.35, 1.10
rs18000206 CC 427 396 0.65 0.42, 1.01 418 381 0.63 0.40, 0.97 0.36 -0.02, 0.74
FAS GA/AA 131 110 1.00 120 128 1.23 0.86, 1.77
rs2234767 GG 402 416 1.22 0.91, 1.63 423 376 1.02 0.76, 1.37 -0.43 -0.96, 0.10
FAS GG 152 145 1.00 149 129 0.88 0.63, 1.23
rs1800682 GA/AA 380 381 1.06 0.81, 1.39 390 369 0.98 0.75, 1.29 0.04 -0.33, 0.41
FASL CT/TT 366 361 1.00 358 347 0.96 0.78, 1.19
rs763110 CC 167 168 1.03 0.79, 1.33 184 159 0.86 0.66, 1.11 -0.13 -0.49, 0.23
TNF-α GG 407 396 1.00 377 362 0.96 0.78, 1.18
rs1800629 GA/AA 123 124 1.04 0.78, 1.39 162 137 0.85 0.65, 1.12 -0.15 -0.54, 0.24
MnSOD CC 117 123 1.00 142 127 0.85 0.60, 1.21
rs4880 CT/TT 408 389 0.92 0.69, 1.23 390 367 0.88 0.66, 1.18 0.11 -0.24, 0.47
MPO GG 295 315 1.00 338 314 0.86 0.69, 1.08
rs2333227 GA/AA 234 204 0.83 0.65, 1.06 196 182 0.85 0.65, 1.10 0.16 -0.14, 0.46
CAT CT/TT 190 191 1.00 190 204 1.04 0.78, 1.38
rs1001179 CC 336 323 0.95 0.74, 1.23 343 291 0.82 0.63, 1.06 -0.17 -0.54, 0.20
GPX1 CT/TT 292 288 1.00 260 262 1.00 0.79, 1.27
rs1050450 CC 237 227 0.98 0.77, 1.26 272 236 0.87 0.68, 1.11 -0.12 -0.46, 0.23
GSTM1 Null 210 231 1.00 233 226 0.87 0.66, 1.13
deletion Present 276 252 0.83 0.64, 1.07 256 241 0.84 0.64, 1.09 0.14 -0.17, 0.45
GSTP1 AG/GG 259 239 1.00 273 260 1.02 0.79, 1.31
rs1695 AA 254 272 1.18 0.92, 1.51 255 228 0.95 0.73, 1.22 -0.26 -0.64, 0.13
GSTT1 Null 108 110 1.00 106 93 0.84 0.57, 1.25
deletion Present 386 379 0.96 0.71, 1.29 389 375 0.92 0.68, 1.25 0.12 -0.26, 0.50
GSTA1 GA/AA 356 351 1.00 334 328 0.98 0.79, 1.21
rs3957356 GG 170 162 0.99 0.76, 1.28 202 172 0.85 0.66, 1.09 -0.12 -0.47, 0.24
COMT AG/AA 398 389 1.00 399 351 0.88 0.71, 1.08
rs4680 GG 130 130 1.01 0.76, 1.34 137 150 1.08 0.82, 1.42 0.19 -0.20, 0.59
COMT CC 61 46 1.00 49 53 1.43 0.83, 2.48
rs737865 CT/TT 466 464 1.34 0.90, 2.02 486 439 1.19 0.79, 1.78 -0.59 -1.45, 0.27
CYP17 TT 201 172 1.00 174 173 1.15 0.85, 1.55
rs743572 TC/CC 317 341 1.26 0.97, 1.63 351 315 1.02 0.79, 1.32 -0.39 -0.83, 0.06
95% CIGene Genotype
High intake Low intake
RERI
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Table A.9 Age- and energy-adjusted ORs and 95% CI for the interaction between total 
ω-6 intake (low or high) and genetic variants on breast cancer incidence 
 
Co=Controls, Ca=Cases, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374]
Co Ca OR 95% CI Co Ca OR 95% CI
PTGS-2 GC/CC 197 192 1.00 205 185 1.08 0.80, 1.46
rs20417 GG 343 308 0.92 0.71, 1.18 331 345 1.24 0.94, 1.63 0.24 -0.11, 0.59
PTGS-2 TC/CC 302 287 1.00 317 283 1.11 0.86, 1.42
rs5275 TT 237 216 0.97 0.75, 1.24 217 247 1.38 1.05, 1.80 0.31 -0.07, 0.68
PPAR-α GC/GG 42 45 1.00 50 56 1.24 0.69, 2.24
rs18000206 CC 427 375 0.82 0.53, 1.28 418 402 1.03 0.65, 1.63 -0.03 -0.71, 0.64
FAS GA/AA 134 124 1.00 117 114 1.23 0.85, 1.79
rs2234767 GG 406 379 0.99 0.75, 1.32 419 413 1.23 0.91, 1.66 0.00 -0.46, 0.46
FAS GG 136 117 1.00 165 157 1.28 0.90, 1.81
rs1800682 GA/AA 399 380 1.12 0.84, 1.49 371 370 1.38 1.01, 1.89 -0.01 -0.47, 0.44
FASL CT/TT 374 347 1.00 350 361 1.29 1.02, 1.63
rs763110 CC 165 158 1.03 0.79, 1.34 186 169 1.14 0.86, 1.51 -0.17 -0.59, 0.24
TNF-α GG 389 371 1.00 395 387 1.20 0.96, 1.51
rs1800629 GA/AA 144 119 0.87 0.66, 1.15 141 142 1.24 0.93, 1.67 0.17 -0.25, 0.59
MnSOD CC 127 110 1.00 132 140 1.41 0.98, 2.04
rs4880 CT/TT 401 373 1.07 0.80, 1.43 397 383 1.31 0.96, 1.80 -0.17 -0.68, 0.34
MPO GG 329 306 1.00 304 323 1.35 1.05, 1.73
rs2333227 GA/AA 204 183 0.97 0.75, 1.25 226 203 1.13 0.86, 1.48 -0.19 -0.60, 0.22
CAT CT/TT 198 193 1.00 182 202 1.32 0.97, 1.78
rs1001179 CC 332 294 0.89 0.69, 1.15 347 320 1.11 0.84, 1.45 -0.10 -0.51, 0.31
GPX1 CT/TT 297 272 1.00 255 278 1.41 1.08, 1.83
rs1050450 CC 236 218 1.01 0.79, 1.30 273 245 1.16 0.89, 1.50 -0.26 -0.68, 0.16
GSTM1 Null 205 236 1.00 238 221 0.93 0.70, 1.24
deletion Present 277 219 0.68 0.52, 0.88 255 274 1.09 0.82, 1.45 0.49 0.19, 0.79
GSTP1 AG/GG 261 224 1.00 271 275 1.38 1.05, 1.80
rs1695 AA 256 261 1.20 0.94, 1.54 253 239 1.30 0.99, 1.73 -0.27 -0.73, 0.18
GSTT1 Null 108 101 1.00 106 102 1.22 0.81, 1.83
deletion Present 382 357 1.00 0.73, 1.36 393 397 1.25 0.90, 1.73 0.03 -0.45, 0.51
GSTA1 GA/AA 338 336 1.00 352 343 1.16 0.91, 1.47
rs3957356 GG 192 154 0.81 0.63, 1.06 180 180 1.20 0.90, 1.58 0.23 -0.14, 0.59
COMT AG/AA 392 348 1.00 405 392 1.30 1.03, 1.63
rs4680 GG 139 145 1.19 0.90, 1.57 128 135 1.37 1.01, 1.86 -0.11 -0.61, 0.39
COMT CC 59 52 1.00 51 47 1.18 0.67, 2.06
rs737865 CT/TT 471 435 1.03 0.69, 1.53 481 468 1.26 0.84, 1.91 0.06 -0.56, 0.68
CYP17 TT 186 163 1.00 189 182 1.28 0.93, 1.76
rs743572 TC/CC 337 324 1.09 0.84, 1.42 331 332 1.32 0.99, 1.75 -0.05 -0.48, 0.38
95% CIGene Genotype
Low intake High intake
RERI
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Table A.10 Age- and energy-adjusted ORs and 95% CI for the interaction between LA 
intake (low or high) and genetic variants on breast cancer incidence 
 
Co=Controls, Ca=Cases, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374]
Co Ca OR 95% CI Co Ca OR 95% CI
PTGS-2 GC/CC 197 191 1.00 205 186 1.09 0.81, 1.48
rs20417 GG 344 307 0.92 0.71, 1.18 330 346 1.26 0.95, 1.65 0.24 -0.11, 0.60
PTGS-2 TC/CC 302 286 1.00 317 284 1.12 0.87, 1.44
rs5275 TT 238 215 0.96 0.75, 1.23 216 248 1.40 1.07, 1.83 0.32 -0.06, 0.70
PPAR-α GC/GG 41 45 1.00 51 56 1.20 0.67, 2.17
rs18000206 CC 429 373 0.80 0.51, 1.25 416 404 1.02 0.64, 1.63 0.03 -0.62, 0.67
FAS GA/AA 133 124 1.00 118 114 1.22 0.84, 1.77
rs2234767 GG 408 377 0.98 0.74, 1.30 417 415 1.24 0.92, 1.67 0.04 -0.41, 0.49
FAS GG 137 117 1.00 164 157 1.30 0.92, 1.84
rs1800682 GA/AA 399 378 1.12 0.85, 1.50 371 372 1.41 1.03, 1.92 -0.02 -0.48, 0.45
FASL CT/TT 374 345 1.00 350 363 1.31 1.04, 1.66
rs763110 CC 166 158 1.03 0.79, 1.34 185 169 1.16 0.88, 1.54 -0.18 -0.60, 0.25
TNF-α GG 389 370 1.00 395 388 1.22 0.97, 1.53
rs1800629 GA/AA 145 118 0.86 0.65, 1.14 140 143 1.27 0.95, 1.71 0.20 -0.22, 0.62
MnSOD CC 128 110 1.00 131 140 1.45 1.00, 2.09
rs4880 CT/TT 401 371 1.07 0.80, 1.44 397 385 1.34 0.97, 1.83 -0.19 -0.71, 0.34
MPO GG 330 306 1.00 303 323 1.37 1.06, 1.76
rs2333227 GA/AA 204 181 0.96 0.75, 1.24 226 205 1.15 0.88, 1.51 -0.18 -0.59, 0.23
CAT CT/TT 199 192 1.00 181 203 1.35 1.00, 1.83
rs1001179 CC 332 293 0.90 0.70, 1.16 347 321 1.13 0.86, 1.48 -0.12 -0.54, 0.30
GPX1 CT/TT 297 272 1.00 255 278 1.42 1.09, 1.84
rs1050450 CC 237 216 1.00 0.78, 1.28 272 247 1.18 0.91, 1.53 -0.24 -0.66, 0.18
GSTM1 Null 206 236 1.00 237 221 0.94 0.71, 1.26
deletion Present 277 218 0.68 0.52, 0.88 255 275 1.11 0.84, 1.47 0.49 0.19, 0.79
GSTP1 AG/GG 262 222 1.00 270 277 1.42 1.08, 1.86
rs1695 AA 257 261 1.21 0.94, 1.56 252 239 1.34 1.01, 1.77 -0.29 -0.76, 0.17
GSTT1 Null 108 100 1.00 106 103 1.25 0.83, 1.88
deletion Present 383 357 1.00 0.74, 1.37 392 397 1.27 0.92, 1.76 0.02 -0.48, 0.51
GSTA1 GA/AA 338 335 1.00 352 344 1.17 0.92, 1.48
rs3957356 GG 193 153 0.81 0.62, 1.05 179 181 1.22 0.92, 1.62 0.24 -0.13, 0.61
COMT AG/AA 393 347 1.00 404 393 1.32 1.05, 1.66
rs4680 GG 139 144 1.19 0.90, 1.57 128 136 1.40 1.03, 1.89 -0.11 -0.61, 0.40
COMT CC 59 52 1.00 51 47 1.18 0.68, 2.07
rs737865 CT/TT 472 433 1.02 0.69, 1.52 480 470 1.28 0.85, 1.93 0.08 -0.55, 0.70
CYP17 TT 186 161 1.00 189 184 1.32 0.96, 1.81
rs743572 TC/CC 338 324 1.10 0.85, 1.43 330 332 1.35 1.02, 1.79 -0.07 -0.51, 0.37
95% CIGene Genotype
Low intake High intake
RERI
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Table A.11 Age- and energy-adjusted ORs and 95% CI for the interaction between AA 
intake (low or high) and genetic variants on breast cancer incidence 
Co=Controls, Ca=Cases, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374]   
Co Ca OR 95% CI Co Ca OR 95% CI
PTGS-2 GC/CC 184 188 1.00 218 189 0.89 0.67, 1.20
rs20417 GG 351 338 0.95 0.74, 1.22 323 315 1.00 0.76, 1.30 0.15 -0.17, 0.48
PTGS-2 TC/CC 298 306 1.00 321 264 0.83 0.65, 1.06
rs5275 TT 236 223 0.91 0.71, 1.16 218 240 1.11 0.86, 1.43 0.37 0.05, 0.68
PPAR-α GC/GG 48 46 1.00 44 55 1.31 0.74, 2.33
rs18000206 CC 418 403 0.97 0.63, 1.49 427 374 0.92 0.59, 1.42 -0.36 -1.14, 0.42
FAS GA/AA 125 135 1.00 126 103 0.79 0.55, 1.14
rs2234767 GG 410 393 0.88 0.66, 1.16 415 399 0.92 0.69, 1.24 0.26 -0.07, 0.59
FAS GG 134 130 1.00 167 144 0.92 0.66, 1.30
rs1800682 GA/AA 397 395 1.04 0.78, 1.37 373 355 1.04 0.78, 1.40 0.08 -0.29, 0.45
FASL CT/TT 361 373 1.00 363 335 0.93 0.74, 1.16
rs763110 CC 174 157 0.86 0.66, 1.12 177 170 0.98 0.75, 1.28 0.19 -0.14, 0.53
TNF-α GG 379 389 1.00 405 369 0.93 0.75, 1.15
rs1800629 GA/AA 151 128 0.83 0.63, 1.09 134 133 1.02 0.77, 1.37 0.27 -0.09, 0.62
MnSOD CC 132 127 1.00 127 123 1.05 0.73, 1.50
rs4880 CT/TT 395 382 1.00 0.75, 1.32 403 374 1.01 0.75, 1.36 -0.03 -0.45, 0.38
MPO GG 329 306 1.00 304 323 1.21 0.95, 1.53
rs2333227 GA/AA 199 206 1.12 0.87, 1.44 231 180 0.88 0.68, 1.15 -0.44 -0.85, -0.03
CAT CT/TT 187 208 1.00 193 187 0.90 0.67, 1.21
rs1001179 CC 338 304 0.80 0.62, 1.02 341 310 0.86 0.66, 1.12 0.16 -0.15, 0.47
GPX1 CT/TT 261 278 1.00 291 272 0.93 0.72, 1.19
rs1050450 CC 265 237 0.85 0.67, 1.09 244 226 0.93 0.71, 1.20 0.14 -0.17, 0.45
GSTM1 Null 223 232 1.00 220 225 1.04 0.79, 1.36
deletion Present 267 247 0.88 0.68, 1.13 265 246 0.95 0.72, 1.24 0.03 -0.32, 0.38
GSTP1 AG/GG 259 268 1.00 273 231 0.86 0.66, 1.11
rs1695 AA 258 239 0.89 0.70, 1.14 251 261 1.06 0.82, 1.38 0.31 0.00, 0.62
GSTT1 Null 100 90 1.00 114 113 1.17 0.79, 1.75
deletion Present 396 391 1.10 0.80, 1.51 379 363 1.12 0.81, 1.56 -0.15 -0.65, 0.36
GSTA1 GA/AA 330 350 1.00 360 329 0.91 0.73, 1.14
rs3957356 GG 195 167 0.81 0.63, 1.05 177 167 0.95 0.72, 1.24 0.23 -0.09, 0.54
COMT AG/AA 384 369 1.00 413 371 0.99 0.80, 1.23
rs4680 GG 143 149 1.09 0.83, 1.43 124 131 1.15 0.85, 1.54 0.07 -0.36, 0.49
COMT CC 49 55 1.00 61 44 0.68 0.39, 1.18
rs737865 CT/TT 478 454 0.85 0.57, 1.28 474 449 0.89 0.59, 1.35 0.37 -0.03, 0.76
CYP17 TT 189 177 1.00 186 168 1.01 0.74, 1.37
rs743572 TC/CC 327 336 1.09 0.85, 1.41 341 320 1.04 0.79, 1.36 -0.06 -0.45, 0.32
95% CIGene Genotype
Low intake High intake
RERI
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Table A.12 Age- and multivariate-adjusted hazard ratios (HRs) and 95% confidence 
intervals (CI) for all-cause mortality among a population-based sample of women with breast 
cancer for the multiplicative interaction between dietary ω-3 and ω-6 intake, LIBCSP, 
1996/1997 through 2011(an average of 14.7 years of follow-up)  
Model 
 Low ω-6 
(< median) 
 High ω-6 
(> median) 
 
LRT 
χ2c 
p 
value 
 HR 95% CI  HR 95% CI  
Age-adjusted          
High ω-3 (> median)  1.00   1.00     
Low ω-3 (< median)  0.82 0.60, 1.11  0.97 0.71, 1.34  0.58 0.45 
Multivariate
a
          
High ω-3 (> median)  1.00   1.00     
Low ω-3 (< median)  0.85 0.62, 1.16  1.01 0.73, 1.41  0.61 0.43 
Note: 
a
 Multivariate ORs and 95% CI adjusted for age (5-year age group) and total energy intake (kcal/day) 
b
 RERI (Relative Excess Risk due to Interaction) = HR11 - HR10 - HR01 +1 
c
 95% CI for RERI estimated using Hosmer & Lemeshow  [374] 
LIBCSP = Long Island Breast Cancer Study Project 
  
1
8
8
 
Table A.13 Age- and energy-adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs) for all-cause mortality for the 
hypothesized highest risk multiplicative interaction between ω-3/ω-6 ratio and putatively functional genetic polymorphisms among a 
population-based sample of women with breast cancer, LIBCSP, 1996/1997 through 2011(an average of 14.7 years of follow-up)  
Gene rs# 
Allele 
Substitution 
Variant 
allele 
function 
High 
risk 
genotype 
High ω-3/ω-6 
(≥ median) 
 
Low ω-3/ω-6 
(< median) 
 
LRT 
χ2c 
p 
value 
Low 
risk 
 
High 
risk 
 
Low 
risk 
 
High 
risk 
 
HR
a
  HR 95% CI  HR  HR 95% CI  
PTGS-2 rs20417 G > C ↓ Inf [399] GG 1.00  1.03 0.74, 1.43  1.00  1.25 0.90, 1.73  0.70 0.40 
PTGS-2 rs5275 T > C ↓ Inf [399] TT 1.00  0.90 0.66, 1.23  1.00  1.14 0.84, 1.55  1.16 0.28 
PPAR-α rs1800206 C > G ↓ Inf [219] CC 1.00  1.64 0.91, 2.97  1.00  0.70 0.42, 1.14  4.86 0.03 
FAS rs2234767 G > A ↓ Inf [400] GG 1.00  1.35 0.92, 1.98  1.00  1.02 0.71, 1.46  1.09 0.30 
FAS rs1800682 G > A ↑ Inf [400] GA/AA 1.00  0.92 0.65, 1.32  1.00  1.05 0.75, 1.47  0.25 0.62 
FASL rs763110 C > T ↓ Inf [401] CC 1.00  1.01 0.73, 1.39  1.00  1.34 0.97, 1.85  1.47 0.23 
TNF-α rs1800629 G > A ↑ Inf [402] GA/AA 1.00  0.81 0.56, 1.16  1.00  1.33 0.95, 1.88  3.94 0.05 
MnSOD rs4880 C > T ↓ Os [403] CT/TT 1.00  1.41 0.95, 2.10  1.00  0.88 0.62, 1.23  3.19 0.07 
MPO rs2333227 G > A ↓ Os [404] GA/AA 1.00  1.14 0.83, 1.56  1.00  0.85 0.62, 1.18  1.56 0.21 
CAT rs1001179 C > T ↑ Os [405] CC 1.00  0.65 0.47, 0.89  1.00  0.75 0.55, 1.02  0.43 0.51 
GPX1 rs1050450 C > T ↑ Os [406] CC 1.00  1.35 0.98, 1.85  1.00  0.83 0.61, 1.13  4.68 0.03 
GSTM1 deletion deletion ↑ Os [407] present 1.00  1.06 0.77, 1.47  1.00  1.09 0.79, 1.50  0.01 0.91 
GSTP1 rs1695 A > G ↑ Os [408] AA 1.00  0.88 0.64, 1.20  1.00  1.02 0.75, 1.39  0.43 0.51 
GSTT1 deletion deletion ↑ Os [407] present 1.00  1.34 0.90, 2.01  1.00  0.85 0.57, 1.26  2.50 0.11 
GSTA1 rs3957356 G > A ↑ Os [409] GG 1.00  0.89 0.63, 1.26  1.00  1.18 0.86, 1.62  1.38 0.24 
COMT rs4680 G > A ↑ Os [412] GG 1.00  1.25 0.89, 1.75  1.00  1.06 0.76, 1.49  0.44 0.51 
COMT rs737865 C > T ↓ Os [410] CT/TT 1.00  1.30 0.68, 2.47  1.00  1.56 0.90, 2.69  0.18 0.67 
CYP17 rs743572 T > C ↑ Es [411] TC/CC 1.00  0.86 0.62, 1.18  1.00  0.95 0.68, 1.32  0.19 0.66 
Note: 
Inf = inflammation, Os = oxidative stress, Es = estrogen, LIBCSP = Long Island Breast Cancer Study Project 
a Hypothesized lowest risk group (referent group) - low risk genotype for PUFA-gene interaction, high ω-3/ω-6 ratio. 
b Hypothesized highest risk group - high risk genotype for PUFA-gene interaction, low ω-3/ω-6 ratio. 
c LRT χ2 calculated using nested models for the multiplicative interaction . 
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Table A.14 Age- and energy-adjusted HRs and 95% CI for the interaction between PUFA 
intake (low or high) and genetic variants on all-cause mortality 
D=deaths, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374] 
 
D HR 95% CI D HR 95% CI
PTGS-2 GC/CC 69 1.00 40 0.63 0.42, 0.96
rs20417 GG 100 0.86 0.63, 1.18 118 1.00 0.72, 1.39 0.51 0.17, 0.85
PTGS-2 TC/CC 99 1.00 76 0.89 0.64, 1.23
rs5275 TT 71 0.93 0.68, 1.26 83 1.00 0.72, 1.38 0.19 -0.21, 0.58
PPAR-α GC/GG 17 1.00 13 0.66 0.31, 1.40
rs18000206 CC 131 0.88 0.53, 1.46 127 0.86 0.51, 1.45 0.32 -0.21, 0.85
FAS GA/AA 37 1.00 34 0.96 0.59, 1.58
rs2234767 GG 131 1.17 0.81, 1.69 124 1.12 0.76, 1.66 -0.01 -0.55, 0.53
FAS GG 41 1.00 46 0.97 0.62, 1.51
rs1800682 GA/AA 125 0.98 0.69, 1.39 112 0.96 0.65, 1.41 0.02 -0.46, 0.50
FASL CT/TT 113 1.00 104 0.92 0.69, 1.25
rs763110 CC 55 1.06 0.77, 1.47 55 1.16 0.81, 1.65 0.17 -0.31, 0.65
TNF-α GG 124 1.00 112 0.92 0.68, 1.23
rs1800629 GA/AA 39 0.90 0.63, 1.29 46 1.09 0.76, 1.58 0.28 -0.19, 0.75
MnSOD CC 33 1.00 43 0.97 0.61, 1.56
rs4880 CT/TT 128 1.07 0.73, 1.57 112 1.07 0.71, 1.61 0.02 -0.50, 0.54
MPO GG 104 1.00 95 0.98 0.71, 1.35
rs2333227 GA/AA 59 0.97 0.70, 1.33 62 0.98 0.70, 1.37 0.03 -0.41, 0.47
CAT CT/TT 70 1.00 74 1.08 0.76, 1.54
rs1001179 CC 92 0.75 0.55, 1.03 82 0.70 0.49, 0.98 -0.14 -0.56, 0.29
GPX1 CT/TT 89 1.00 84 1.05 0.76, 1.46
rs1050450 CC 74 1.12 0.82, 1.52 73 1.04 0.74, 1.45 -0.13 -0.61, 0.35
GSTM1 Null 74 1.00 66 1.07 0.75, 1.52
deletion Present 78 1.11 0.80, 1.52 83 1.12 0.79, 1.58 -0.06 -0.55, 0.44
GSTP1 AG/GG 75 1.00 86 1.08 0.76, 1.52
rs1695 AA 88 1.05 0.77, 1.43 67 0.91 0.63, 1.30 -0.22 -0.70, 0.25
GSTT1 Null 32 1.00 28 0.93 0.54, 1.58
deletion Present 123 1.03 0.70, 1.52 123 1.05 0.70, 1.58 0.09 -0.44, 0.62
GSTA1 GA/AA 111 1.00 102 0.99 0.73, 1.34
rs3957356 GG 53 1.05 0.76, 1.46 55 1.02 0.72, 1.45 -0.03 -0.50, 0.45
COMT AG/AA 110 1.00 117 1.11 0.82, 1.48
rs4680 GG 55 1.37 0.99, 1.89 41 1.05 0.71, 1.55 -0.42 -1.01, 0.16
COMT CC 15 1.00 9 0.72 0.31, 1.67
rs737865 CT/TT 147 1.26 0.74, 2.14 145 1.26 0.73, 2.17 0.28 -0.38, 0.94
CYP17 TT 59 1.00 54 0.82 0.55, 1.22
rs743572 TC/CC 104 0.79 0.58, 1.09 102 0.84 0.59, 1.18 0.22 -0.15, 0.59
Low intake High intake
95% CIRERIGene Genotype
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Table A.15 Age- and energy-adjusted HRs and 95% CI for the interaction between ω-3 
intake (low or high) and genetic variants on all-cause mortality 
D=deaths, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374] 
 
D HR 95% CI D HR 95% CI
PTGS-2 GC/CC 46 1.00 63 1.29 0.86, 1.94
rs20417 GG 117 1.48 1.06, 2.09 101 1.15 0.79, 1.67 -0.64 -1.31, 0.03
PTGS-2 TC/CC 80 1.00 95 1.04 0.74, 1.44
rs5275 TT 83 1.16 0.85, 1.58 71 0.93 0.65, 1.31 -0.27 -0.76, 0.21
PPAR-α GC/GG 15 1.00 15 1.31 0.62, 2.75
rs18000206 CC 130 1.30 0.76, 2.22 128 1.10 0.62, 1.94 -0.51 -1.56, 0.55
FAS GA/AA 29 1.00 42 1.48 0.90, 2.45
rs2234767 GG 131 1.58 1.06, 2.37 124 1.33 0.86, 2.05 -0.73 -1.59, 0.12
FAS GG 51 1.00 36 0.83 0.53, 1.30
rs1800682 GA/AA 109 0.93 0.67, 1.30 128 0.89 0.63, 1.27 0.13 -0.30, 0.56
FASL CT/TT 101 1.00 116 0.99 0.74, 1.34
rs763110 CC 60 1.24 0.90, 1.71 50 1.06 0.73, 1.53 -0.18 -0.70, 0.34
TNF-α GG 114 1.00 122 0.95 0.71, 1.28
rs1800629 GA/AA 45 1.06 0.75, 1.49 40 0.96 0.66, 1.41 -0.04 -0.54, 0.46
MnSOD CC 39 1.00 37 0.96 0.61, 1.54
rs4880 CT/TT 117 1.11 0.77, 1.59 123 1.03 0.70, 1.51 -0.04 -0.57, 0.49
MPO GG 96 1.00 103 0.98 0.71, 1.34
rs2333227 GA/AA 64 1.08 0.78, 1.48 57 0.87 0.61, 1.25 -0.18 -0.64, 0.28
CAT CT/TT 77 1.00 67 0.85 0.59, 1.21
rs1001179 CC 80 0.63 0.46, 0.86 94 0.66 0.47, 0.92 0.18 -0.15, 0.52
GPX1 CT/TT 81 1.00 92 0.98 0.71, 1.36
rs1050450 CC 78 1.12 0.82, 1.53 69 0.96 0.67, 1.37 -0.14 -0.60, 0.33
GSTM1 Null 71 1.00 69 0.82 0.57, 1.17
deletion Present 77 1.00 0.72, 1.38 84 0.95 0.68, 1.34 0.14 -0.28, 0.55
GSTP1 AG/GG 86 1.00 75 0.83 0.59, 1.16
rs1695 AA 70 0.82 0.60, 1.13 85 0.90 0.64, 1.25 0.25 -0.12, 0.61
GSTT1 Null 32 1.00 28 0.85 0.50, 1.46
deletion Present 119 1.04 0.70, 1.54 127 0.95 0.62, 1.46 0.06 -0.46, 0.58
GSTA1 GA/AA 108 1.00 105 0.85 0.63, 1.15
rs3957356 GG 51 0.90 0.65, 1.26 57 1.02 0.71, 1.45 0.26 -0.16, 0.69
COMT AG/AA 112 1.00 115 0.90 0.67, 1.21
rs4680 GG 48 1.10 0.78, 1.54 48 1.09 0.75, 1.56 0.09 -0.41, 0.59
COMT CC 11 1.00 13 0.90 0.39, 2.04
rs737865 CT/TT 145 1.39 0.75, 2.57 147 1.32 0.70, 2.49 0.03 -0.79, 0.84
CYP17 TT 58 1.00 55 1.00 0.68, 1.48
rs743572 TC/CC 101 0.95 0.69, 1.32 105 0.85 0.60, 1.21 -0.11 -0.57, 0.35
95% CIGene Genotype
High intake Low intake
RERI
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Table A.16 Age- and energy-adjusted HRs and 95% CI for the interaction between ALA 
intake (low or high) and genetic variants on all-cause mortality 
D=deaths, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374] 
 
D HR 95% CI D HR 95% CI
PTGS-2 GC/CC 47 1.00 62 1.17 0.78, 1.75
rs20417 GG 118 1.37 0.98, 1.93 100 1.11 0.76, 1.60 -0.44 -1.04, 0.16
PTGS-2 TC/CC 80 1.00 95 1.01 0.73, 1.40
rs5275 TT 85 1.14 0.84, 1.55 69 0.91 0.64, 1.29 -0.24 -0.72, 0.23
PPAR-α GC/GG 16 1.00 14 1.08 0.51, 2.28
rs18000206 CC 129 1.17 0.70, 1.98 129 1.02 0.58, 1.76 -0.24 -1.11, 0.64
FAS GA/AA 32 1.00 39 1.34 0.82, 2.20
rs2234767 GG 130 1.47 1.00, 2.17 125 1.25 0.83, 1.90 -0.56 -1.32, 0.21
FAS GG 48 1.00 39 0.80 0.51, 1.24
rs1800682 GA/AA 112 0.89 0.63, 1.25 125 0.88 0.62, 1.27 0.20 -0.21, 0.60
FASL CT/TT 108 1.00 109 0.93 0.69, 1.25
rs763110 CC 55 1.15 0.83, 1.59 55 1.08 0.76, 1.53 0.00 -0.49, 0.49
TNF-α GG 114 1.00 122 0.93 0.69, 1.24
rs1800629 GA/AA 48 1.06 0.76, 1.48 37 0.93 0.62, 1.37 -0.06 -0.55, 0.44
MnSOD CC 43 1.00 33 0.80 0.50, 1.27
rs4880 CT/TT 116 1.00 0.71, 1.42 124 0.96 0.66, 1.38 0.15 -0.30, 0.61
MPO GG 97 1.00 102 0.96 0.70, 1.31
rs2333227 GA/AA 65 1.07 0.78, 1.47 56 0.86 0.60, 1.23 -0.18 -0.63, 0.28
CAT CT/TT 77 1.00 67 0.86 0.60, 1.22
rs1001179 CC 83 0.65 0.48, 0.89 91 0.64 0.46, 0.89 0.13 -0.21, 0.48
GPX1 CT/TT 83 1.00 69 0.95 0.68, 1.31
rs1050450 CC 78 1.09 0.80, 1.49 90 0.95 0.67, 1.35 -0.09 -0.54, 0.36
GSTM1 Null 72 1.00 68 0.77 0.54, 1.10
deletion Present 78 0.95 0.69, 1.31 83 0.94 0.66, 1.32 0.21 -0.18, 0.61
GSTP1 AG/GG 89 1.00 72 0.77 0.55, 1.08
rs1695 AA 71 0.81 0.59, 1.10 84 0.86 0.62, 1.19 0.28 -0.07, 0.64
GSTT1 Null 33 1.00 27 0.82 0.48, 1.40
deletion Present 119 1.02 0.69, 1.50 127 0.94 0.62, 1.43 0.10 -0.40, 0.60
GSTA1 GA/AA 106 1.00 107 0.91 0.67, 1.23
rs3957356 GG 55 1.02 0.74, 1.42 53 0.96 0.67, 1.37 0.03 -0.42, 0.48
COMT AG/AA 114 1.00 113 0.92 0.68, 1.23
rs4680 GG 48 1.18 0.84, 1.66 48 1.04 0.72, 1.48 -0.06 -0.58, 0.45
COMT CC 10 1.00 14 1.02 0.44, 2.33
rs737865 CT/TT 148 1.51 0.79, 2.87 144 1.39 0.72, 2.71 -0.13 -1.07, 0.81
CYP17 TT 61 1.00 52 1.00 0.67, 1.48
rs743572 TC/CC 100 0.96 0.70, 1.32 106 0.84 0.60, 1.19 -0.11 -0.57, 0.35
95% CIGene Genotype
High intake Low intake
RERI
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Table A.17 Age- and energy-adjusted HRs and 95% CI for the interaction between DPA 
intake (low or high) and genetic variants on all-cause mortality 
D=deaths, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374] 
 
D HR 95% CI D HR 95% CI
PTGS-2 GC/CC 46 1.00 63 1.70 1.15, 2.52
rs20417 GG 101 1.41 1.00, 2.00 117 1.56 1.10, 2.21 -0.56 -1.29, 0.18
PTGS-2 TC/CC 76 1.00 99 1.47 1.07, 2.02
rs5275 TT 71 1.16 0.84, 1.61 83 1.32 0.96, 1.81 -0.31 -0.89, 0.26
PPAR-α GC/GG 14 1.00 16 1.69 0.82, 3.49
rs18000206 CC 117 1.23 0.71, 2.15 141 1.50 0.86, 2.64 -0.42 -1.58, 0.75
FAS GA/AA 24 1.00 47 1.68 1.02, 2.78
rs2234767 GG 123 1.47 0.95, 2.28 132 1.75 1.12, 2.74 -0.40 -1.24, 0.44
FAS GG 40 1.00 47 1.24 0.81, 1.91
rs1800682 GA/AA 107 0.98 0.68, 1.41 130 1.24 0.86, 1.79 0.02 -0.52, 0.57
FASL CT/TT 97 1.00 120 1.26 0.95, 1.67
rs763110 CC 50 1.15 0.81, 1.61 60 1.47 1.06, 2.04 0.06 -0.51, 0.63
TNF-α GG 105 1.00 131 1.30 0.99, 1.70
rs1800629 GA/AA 39 1.07 0.74, 1.55 46 1.31 0.92, 1.87 -0.06 -0.65, 0.53
MnSOD CC 27 1.00 49 1.94 1.21, 3.12
rs4880 CT/TT 114 1.49 0.98, 2.27 126 1.67 1.10, 2.55 -0.76 -1.71, 0.19
MPO GG 89 1.00 110 1.29 0.97, 1.73
rs2333227 GA/AA 55 1.01 0.72, 1.41 66 1.26 0.91, 1.75 -0.04 -0.56, 0.48
CAT CT/TT 58 1.00 86 1.47 1.04, 2.06
rs1001179 CC 85 0.82 0.59, 1.14 89 0.91 0.64, 1.28 -0.38 -0.92, 0.16
GPX1 CT/TT 83 1.00 90 1.18 0.87, 1.61
rs1050450 CC 60 0.95 0.68, 1.32 87 1.34 0.98, 1.82 0.20 -0.27, 0.68
GSTM1 Null 72 1.00 68 1.03 0.74, 1.44
deletion Present 63 0.84 0.60, 1.18 98 1.33 0.98, 1.82 0.46 0.02, 0.90
GSTP1 AG/GG 68 1.00 93 1.18 0.85, 1.63
rs1695 AA 76 0.90 0.65, 1.25 79 1.21 0.87, 1.69 0.13 -0.33, 0.59
GSTT1 Null 28 1.00 32 1.61 0.97, 2.70
deletion Present 111 1.23 0.81, 1.87 135 1.50 0.98, 2.28 -0.35 -1.18, 0.48
GSTA1 GA/AA 100 1.00 113 1.23 0.93, 1.62
rs3957356 GG 44 0.97 0.68, 1.38 64 1.33 0.96, 1.83 0.13 -0.39, 0.65
COMT AG/AA 110 1.00 117 1.14 0.87, 1.49
rs4680 GG 36 0.93 0.64, 1.36 60 1.50 1.09, 2.07 0.43 -0.11, 0.97
COMT CC 9 1.00 15 1.32 0.58, 3.02
rs737865 CT/TT 130 1.45 0.74, 2.86 162 1.98 1.00, 3.89 0.20 -0.73, 1.14
CYP17 TT 51 1.00 62 1.32 0.90, 1.93
rs743572 TC/CC 90 0.89 0.63, 1.26 116 1.20 0.85, 1.69 -0.01 -0.53, 0.51
95% CIGene Genotype
High intake Low intake
RERI
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Table A.18 Age- and energy-adjusted HRs and 95% CI for the interaction between DHA 
intake (low or high) and genetic variants on all-cause mortality 
D=deaths, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374] 
 
D HR 95% CI D HR 95% CI
PTGS-2 GC/CC 49 1.00 60 1.48 1.01, 2.18
rs20417 GG 96 1.27 0.90, 1.80 122 1.47 1.05, 2.06 -0.28 -0.92, 0.35
PTGS-2 TC/CC 83 1.00 92 1.26 0.93, 1.71
rs5275 TT 62 0.98 0.71, 1.37 92 1.28 0.95, 1.73 0.04 -0.45, 0.53
PPAR-α GC/GG 14 1.00 16 1.48 0.71, 3.05
rs18000206 CC 115 1.16 0.67, 2.03 143 1.41 0.81, 2.46 -0.23 -1.25, 0.79
FAS GA/AA 21 1.00 50 1.88 1.13, 3.16
rs2234767 GG 124 1.64 1.03, 2.61 131 1.87 1.17, 2.98 -0.66 -1.64, 0.33
FAS GG 42 1.00 45 1.16 0.76, 1.78
rs1800682 GA/AA 103 0.93 0.65, 1.34 134 1.20 0.84, 1.71 0.11 -0.40, 0.62
FASL CT/TT 100 1.00 117 1.16 0.88, 1.52
rs763110 CC 45 1.01 0.71, 1.44 65 1.48 1.08, 2.03 0.31 -0.22, 0.84
TNF-α GG 105 1.00 131 1.29 0.99, 1.67
rs1800629 GA/AA 36 1.06 0.72, 1.54 49 1.30 0.92, 1.82 -0.05 -0.63, 0.54
MnSOD CC 34 1.00 42 1.34 0.85, 2.11
rs4880 CT/TT 104 1.12 0.76, 1.65 136 1.40 0.96, 2.05 -0.06 -0.69, 0.57
MPO GG 87 1.00 112 1.30 0.98, 1.73
rs2333227 GA/AA 54 1.03 0.73, 1.44 67 1.24 0.90, 1.71 -0.09 -0.61, 0.44
CAT CT/TT 56 1.00 88 1.48 1.06, 2.08
rs1001179 CC 84 0.83 0.59, 1.17 90 0.91 0.65, 1.27 -0.41 -0.96, 0.14
GPX1 CT/TT 80 1.00 93 1.18 0.87, 1.60
rs1050450 CC 60 0.96 0.69, 1.34 87 1.32 0.97, 1.80 0.18 -0.29, 0.66
GSTM1 Null 67 1.00 73 1.05 0.75, 1.47
deletion Present 63 0.86 0.61, 1.22 98 1.34 0.98, 1.84 0.43 -0.01, 0.87
GSTP1 AG/GG 67 1.00 94 1.20 0.87, 1.65
rs1695 AA 74 0.93 0.67, 1.29 81 1.19 0.86, 1.65 0.06 -0.41, 0.53
GSTT1 Null 25 1.00 35 1.76 1.05, 2.95
deletion Present 109 1.32 0.86, 2.04 137 1.58 1.02, 2.43 -0.51 -1.42, 0.40
GSTA1 GA/AA 99 1.00 114 1.17 0.89, 1.54
rs3957356 GG 42 0.90 0.63, 1.30 66 1.33 0.97, 1.83 0.26 -0.23, 0.76
COMT AG/AA 109 1.00 118 1.10 0.84, 1.43
rs4680 GG 34 0.87 0.59, 1.28 62 1.52 1.11, 2.08 0.55 0.02, 1.07
COMT CC 9 1.00 15 1.11 0.48, 2.54
rs737865 CT/TT 128 1.31 0.67, 2.57 164 1.78 0.91, 3.50 0.36 -0.42, 1.15
CYP17 TT 52 1.00 61 1.19 0.82, 1.72
rs743572 TC/CC 88 0.83 0.59, 1.17 118 1.14 0.82, 1.59 0.12 -0.35, 0.59
95% CIGene Genotype
High intake Low intake
RERI
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Table A.19 Age- and energy-adjusted HRs and 95% CI for the interaction between EPA 
intake (low or high) and genetic variants on all-cause mortality 
D=deaths, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374] 
 
D HR 95% CI D HR 95% CI
PTGS-2 GC/CC 51 1.00 58 1.41 0.96, 2.07
rs20417 GG 92 1.17 0.83, 1.64 126 1.50 1.08, 2.09 -0.07 -0.66, 0.51
PTGS-2 TC/CC 82 1.00 93 1.31 0.96, 1.77
rs5275 TT 61 0.96 0.69, 1.33 93 1.35 1.00, 1.83 0.09 -0.40, 0.58
PPAR-α GC/GG 13 1.00 17 1.87 0.90, 3.87
rs18000206 CC 116 1.30 0.73, 2.30 142 1.61 0.90, 2.86 -0.55 -1.83, 0.72
FAS GA/AA 23 1.00 48 1.97 1.19, 3.26
rs2234767 GG 120 1.61 1.03, 2.52 135 1.92 1.22, 3.01 -0.66 -1.64, 0.32
FAS GG 40 1.00 47 1.23 0.80, 1.89
rs1800682 GA/AA 102 0.93 0.65, 1.34 135 1.28 0.89, 1.84 0.12 -0.41, 0.65
FASL CT/TT 95 1.00 122 1.29 0.98, 1.70
rs763110 CC 48 1.11 0.78, 1.57 62 1.55 1.12, 2.14 0.15 -0.42, 0.72
TNF-α GG 103 1.00 133 1.34 1.03, 1.74
rs1800629 GA/AA 36 1.03 0.71, 1.51 49 1.38 0.98, 1.95 0.01 -0.58, 0.60
MnSOD CC 29 1.00 47 1.68 1.05, 2.67
rs4880 CT/TT 107 1.28 0.85, 1.93 133 1.62 1.08, 2.43 -0.34 -1.12, 0.44
MPO GG 85 1.00 114 1.39 1.04, 1.86
rs2333227 GA/AA 54 1.05 0.74, 1.47 67 1.31 0.94, 1.82 -0.13 -0.68, 0.42
CAT CT/TT 57 1.00 87 1.44 1.03, 2.02
rs1001179 CC 80 0.77 0.54, 1.07 94 0.95 0.68, 1.33 -0.25 -0.77, 0.26
GPX1 CT/TT 80 1.00 93 1.18 0.87, 1.59
rs1050450 CC 58 0.89 0.64, 1.25 89 1.40 1.03, 1.91 0.34 -0.13, 0.80
GSTM1 Null 64 1.00 76 1.18 0.85, 1.66
deletion Present 64 0.92 0.65, 1.31 97 1.42 1.04, 1.96 0.32 -0.16, 0.80
GSTP1 AG/GG 69 1.00 92 1.16 0.85, 1.60
rs1695 AA 70 0.85 0.61, 1.18 85 1.26 0.91, 1.74 0.25 -0.20, 0.69
GSTT1 Null 26 1.00 34 1.64 0.98, 2.74
deletion Present 106 1.22 0.80, 1.88 140 1.56 1.02, 2.40 -0.30 -1.12, 0.52
GSTA1 GA/AA 97 1.00 116 1.32 1.00, 1.74
rs3957356 GG 41 1.00 0.69, 1.44 67 1.37 1.00, 1.87 0.05 -0.49, 0.59
COMT AG/AA 107 1.00 120 1.19 0.91, 1.55
rs4680 GG 34 0.93 0.63, 1.37 62 1.54 1.12, 2.12 0.42 -0.13, 0.97
COMT CC 11 1.00 13 1.04 0.46, 2.33
rs737865 CT/TT 123 1.22 0.66, 2.26 169 1.74 0.94, 3.22 0.48 -0.24, 1.21
CYP17 TT 50 1.00 63 1.29 0.89, 1.88
rs743572 TC/CC 88 0.86 0.61, 1.22 118 1.21 0.86, 1.70 0.06 -0.44, 0.56
95% CIGene Genotype
High intake Low intake
RERI
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Table A.20 Age- and energy-adjusted HRs and 95% CI for the interaction between ω-6 
intake (low or high) and genetic variants on all-cause mortality 
D=deaths, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374] 
 
D HR 95% CI D HR 95% CI
PTGS-2 GC/CC 65 1.00 44 1.27 0.85, 1.91
rs20417 GG 99 1.43 1.01, 2.02 119 1.17 0.80, 1.71 -0.53 -1.18, 0.12
PTGS-2 TC/CC 94 1.00 81 0.95 0.69, 1.32
rs5275 TT 71 1.04 0.77, 1.42 83 0.94 0.66, 1.33 -0.05 -0.49, 0.38
PPAR-α GC/GG 15 1.00 15 1.18 0.56, 2.48
rs18000206 CC 128 1.19 0.69, 2.03 130 1.10 0.62, 1.94 -0.27 -1.19, 0.66
FAS GA/AA 36 1.00 35 0.89 0.55, 1.46
rs2234767 GG 127 1.13 0.77, 1.64 128 1.07 0.71, 1.61 0.05 -0.45, 0.56
FAS GG 38 1.00 49 0.90 0.57, 1.40
rs1800682 GA/AA 123 0.98 0.70, 1.36 114 0.91 0.63, 1.30 0.04 -0.42, 0.50
FASL CT/TT 110 1.00 107 0.97 0.72, 1.30
rs763110 CC 53 1.23 0.89, 1.70 57 1.05 0.73, 1.49 -0.15 -0.67, 0.36
TNF-α GG 120 1.00 116 0.98 0.73, 1.31
rs1800629 GA/AA 38 1.17 0.83, 1.64 47 0.89 0.60, 1.31 -0.26 -0.79, 0.27
MnSOD CC 33 1.00 43 0.95 0.59, 1.52
rs4880 CT/TT 123 1.12 0.79, 1.59 117 1.01 0.70, 1.46 -0.06 -0.59, 0.47
MPO GG 100 1.00 99 0.93 0.68, 1.27
rs2333227 GA/AA 58 1.01 0.73, 1.38 63 0.88 0.62, 1.26 -0.05 -0.49, 0.39
CAT CT/TT 65 1.00 79 0.80 0.56, 1.13
rs1001179 CC 92 0.62 0.45, 0.84 82 0.63 0.45, 0.88 0.22 -0.10, 0.54
GPX1 CT/TT 85 1.00 88 0.83 0.60, 1.15
rs1050450 CC 73 0.95 0.70, 1.30 74 0.96 0.68, 1.35 0.17 -0.22, 0.57
GSTM1 Null 71 1.00 69 0.84 0.59, 1.20
deletion Present 77 1.04 0.75, 1.43 84 0.94 0.66, 1.33 0.06 -0.37, 0.49
GSTP1 AG/GG 74 1.00 87 0.87 0.62, 1.23
rs1695 AA 84 0.89 0.65, 1.22 71 0.89 0.64, 1.23 0.13 -0.26, 0.52
GSTT1 Null 32 1.00 28 0.99 0.58, 1.69
deletion Present 119 1.13 0.75, 1.71 127 1.01 0.64, 1.58 -0.11 -0.71, 0.49
GSTA1 GA/AA 106 1.00 107 0.89 0.66, 1.20
rs3957356 GG 53 1.00 0.72, 1.38 55 0.97 0.68, 1.38 0.07 -0.37, 0.52
COMT AG/AA 106 1.00 121 0.80 0.60, 1.08
rs4680 GG 54 0.93 0.66, 1.32 42 1.13 0.80, 1.60 0.40 -0.06, 0.86
COMT CC 14 1.00 10 1.18 0.52, 2.69
rs737865 CT/TT 143 1.66 0.88, 3.15 149 1.50 0.77, 2.89 -0.34 -1.44, 0.76
CYP17 TT 56 1.00 57 1.06 0.72, 1.57
rs743572 TC/CC 102 0.99 0.72, 1.37 104 0.86 0.60, 1.23 -0.19 -0.68, 0.30
95% CIGene Genotype
Low intake High intake
RERI
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Table A.21 Age- and energy-adjusted HRs and 95% CI for the interaction between LA 
intake (low or high) and genetic variants on all-cause mortality 
D=deaths, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374] 
 
D HR 95% CI D HR 95% CI
PTGS-2 GC/CC 66 1.00 43 1.32 0.88, 1.99
rs20417 GG 99 1.46 1.03, 2.07 119 1.20 0.82, 1.76 -0.58 -1.25, 0.09
PTGS-2 TC/CC 95 1.00 80 0.97 0.70, 1.35
rs5275 TT 71 1.05 0.77, 1.43 83 0.95 0.67, 1.35 -0.07 -0.52, 0.37
PPAR-α GC/GG 15 1.00 15 1.19 0.56, 2.49
rs18000206 CC 129 1.18 0.69, 2.03 129 1.11 0.63, 1.96 -0.26 -1.18, 0.67
FAS GA/AA 37 1.00 34 0.93 0.57, 1.53
rs2234767 GG 127 1.15 0.78, 1.68 128 1.10 0.73, 1.67 0.02 -0.50, 0.55
FAS GG 38 1.00 49 0.91 0.58, 1.42
rs1800682 GA/AA 124 0.97 0.70, 1.36 113 0.92 0.64, 1.32 0.04 -0.43, 0.50
FASL CT/TT 110 1.00 107 0.97 0.72, 1.31
rs763110 CC 54 1.22 0.88, 1.69 56 1.07 0.75, 1.52 -0.13 -0.64, 0.38
TNF-α GG 120 1.00 116 0.98 0.73, 1.31
rs1800629 GA/AA 39 1.16 0.82, 1.63 46 0.91 0.62, 1.33 -0.23 -0.76, 0.29
MnSOD CC 33 1.00 43 0.95 0.59, 1.52
rs4880 CT/TT 124 1.11 0.78, 1.58 116 1.02 0.70, 1.47 -0.05 -0.57, 0.48
MPO GG 101 1.00 98 0.94 0.69, 1.29
rs2333227 GA/AA 58 1.01 0.74, 1.39 63 0.90 0.63, 1.28 -0.06 -0.50, 0.38
CAT CT/TT 66 1.00 78 0.81 0.57, 1.15
rs1001179 CC 92 0.62 0.45, 0.84 82 0.64 0.46, 0.89 0.21 -0.12, 0.53
GPX1 CT/TT 85 1.00 88 0.84 0.61, 1.16
rs1050450 CC 74 0.95 0.70, 1.29 73 0.97 0.69, 1.37 0.19 -0.21, 0.58
GSTM1 Null 72 1.00 68 0.87 0.61, 1.23
deletion Present 77 1.05 0.76, 1.45 84 0.95 0.67, 1.35 0.04 -0.40, 0.47
GSTP1 AG/GG 75 1.00 86 0.89 0.64, 1.26
rs1695 AA 84 0.90 0.66, 1.23 71 0.90 0.65, 1.25 0.11 -0.29, 0.50
GSTT1 Null 32 1.00 28 0.99 0.58, 1.69
deletion Present 120 1.12 0.74, 1.70 126 1.02 0.65, 1.60 -0.10 -0.70, 0.50
GSTA1 GA/AA 107 1.00 106 0.91 0.68, 1.23
rs3957356 GG 53 1.01 0.73, 1.39 55 0.98 0.68, 1.40 0.06 -0.39, 0.51
COMT AG/AA 106 1.00 121 0.81 0.60, 1.08
rs4680 GG 55 0.92 0.64, 1.31 41 1.15 0.82, 1.62 0.42 -0.03, 0.88
COMT CC 15 1.00 9 1.35 0.58, 3.13
rs737865 CT/TT 143 1.80 0.92, 3.53 149 1.64 0.82, 3.27 -0.52 -1.78, 0.75
CYP17 TT 56 1.00 57 1.06 0.72, 1.58
rs743572 TC/CC 103 0.98 0.71, 1.36 103 0.87 0.61, 1.24 -0.17 -0.66, 0.31
95% CIGene Genotype
Low intake High intake
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Table A.22 Age- and energy-adjusted HRs and 95% CI for the interaction between AA 
intake (low or high) and genetic variants on all-cause mortality 
D=deaths, RERI=Relative Excess Risk due to Interaction 
95% CI for RERI estimated using Hosmer & Lemeshow [374] 
 
D HR 95% CI D HR 95% CI
PTGS-2 GC/CC 60 1.00 49 1.33 0.90, 1.96
rs20417 GG 97 1.54 1.11, 2.15 121 1.11 0.78, 1.58 -0.76 -1.46, -0.07
PTGS-2 TC/CC 92 1.00 83 0.98 0.72, 1.35
rs5275 TT 67 1.12 0.83, 1.51 87 0.90 0.64, 1.25 -0.21 -0.66, 0.25
PPAR-α GC/GG 13 1.00 17 0.89 0.43, 1.84
rs18000206 CC 129 1.03 0.62, 1.72 129 0.97 0.57, 1.63 0.05 -0.66, 0.75
FAS GA/AA 42 1.00 29 1.34 0.82, 2.17
rs2234767 GG 114 1.53 1.03, 2.29 141 1.21 0.79, 1.85 -0.66 -1.46, 0.14
FAS GG 34 1.00 53 0.66 0.42, 1.02
rs1800682 GA/AA 121 0.83 0.60, 1.15 116 0.80 0.57, 1.13 0.31 -0.04, 0.67
FASL CT/TT 103 1.00 114 0.83 0.62, 1.10
rs763110 CC 53 1.06 0.77, 1.46 57 1.04 0.74, 1.47 0.15 -0.30, 0.60
TNF-α GG 110 1.00 126 0.80 0.61, 1.06
rs1800629 GA/AA 45 0.85 0.59, 1.21 40 1.02 0.72, 1.45 0.38 -0.06, 0.81
MnSOD CC 40 1.00 36 1.24 0.79, 1.97
rs4880 CT/TT 113 1.33 0.92, 1.93 127 1.10 0.74, 1.61 -0.48 -1.17, 0.21
MPO GG 91 1.00 108 0.90 0.67, 1.21
rs2333227 GA/AA 62 1.00 0.72, 1.37 59 0.88 0.63, 1.22 -0.01 -0.44, 0.42
CAT CT/TT 67 1.00 77 0.78 0.55, 1.10
rs1001179 CC 85 0.63 0.47, 0.86 89 0.59 0.43, 0.83 0.18 -0.14, 0.50
GPX1 CT/TT 87 1.00 86 1.00 0.73, 1.37
rs1050450 CC 68 1.17 0.87, 1.59 79 0.94 0.67, 1.31 -0.24 -0.72, 0.24
GSTM1 Null 61 1.00 79 0.76 0.54, 1.07
deletion Present 84 0.94 0.69, 1.29 77 0.95 0.69, 1.31 0.25 -0.14, 0.64
GSTP1 AG/GG 75 1.00 86 0.72 0.52, 1.00
rs1695 AA 76 0.77 0.57, 1.04 79 0.85 0.61, 1.17 0.36 0.02, 0.69
GSTT1 Null 24 1.00 36 0.82 0.48, 1.39
deletion Present 122 1.05 0.72, 1.52 124 0.93 0.63, 1.38 0.07 -0.45, 0.58
GSTA1 GA/AA 100 1.00 113 0.83 0.63, 1.11
rs3957356 GG 55 0.93 0.67, 1.29 53 0.97 0.69, 1.36 0.21 -0.21, 0.63
COMT AG/AA 106 1.00 121 0.88 0.67, 1.17
rs4680 GG 49 1.15 0.82, 1.61 47 1.03 0.73, 1.45 0.00 -0.51, 0.50
COMT CC 13 1.00 11 0.80 0.36, 1.81
rs737865 CT/TT 141 1.31 0.71, 2.42 151 1.23 0.66, 2.30 0.12 -0.63, 0.86
CYP17 TT 51 1.00 62 0.84 0.57, 1.24
rs743572 TC/CC 104 0.84 0.61, 1.15 102 0.82 0.58, 1.14 0.14 -0.25, 0.52
95% CIGene Genotype
Low intake High intake
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Table A.23 Multiple comparisons adjustment via FDR for statistically significant (p<0.05) 
multivariate-adjusted associations (Aim 1a) 
PUFA/ 
Fish 
Comparison p Rank Weight
a
 
FDR 
p value
b Significant
c
 
ω-6 Q3 vs Q1 0.0154 1 0.01754 0.000877193 no 
LA Q3 vs Q1 0.0179 2 0.03509 0.001754386 no 
ALA Q3 vs Q1 0.0226 3 0.05263 0.002631579 no 
PUFA Q3 vs Q1 0.0324 4 0.07018 0.003508772 no 
ω-3 Q2 vs Q1 0.0377 5 0.08772 0.004385965 no 
Other fish Q2 vs never 0.0483 6 0.10526 0.005263158 no 
Note: 
a 
Weight = rank/57, where 57 represents the total number of comparisons for Aim 1a 
b 
FDR p = weight*0.05 
c 
If p ≤ FDR p-value then “yes”, otherwise “no”  
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Table A.24 Multiple comparisons adjustment via FDR for statistically significant (p<0.05) 
multivariate-adjusted associations for individual PUFA-gene interactions (Aim 1b) 
PUFA Gene Comparison p Rank Weight
a
 
FDR 
p value
b
 
Significant
c 
ω-6 GSTM1 Low, high risk 0.003 1 0.00185 9.25926E-05 no 
LA GSTM1 Low, high risk 0.003 2 0.0037 0.000185185 no 
PUFA GSTM1 Low, high risk 0.0033 3 0.00556 0.000277778 no 
ratio FASL Low, high risk 0.0057 4 0.00741 0.00037037 no 
DHA CYP17 High, high risk 0.0096 5 0.00926 0.000462963 no 
LA GPX1 High, low risk 0.0096 6 0.01111 0.000555556 no 
ω-6 GPX1 High, low risk 0.011 7 0.01296 0.000648148 no 
LA GSTP1 High, low risk 0.011 8 0.01481 0.000740741 no 
DPA GSTM1 Low, low risk 0.0141 9 0.01667 0.000833333 no 
LA MPO High, low risk 0.0142 10 0.01852 0.000925926 no 
ratio FAS rs2234767 Low, low risk 0.0147 11 0.02037 0.001018519 no 
ratio COMT rs4680 Low, low risk 0.0154 12 0.02222 0.001111111 no 
LA PTGS2 rs5275 High, high risk 0.0165 13 0.02407 0.001203704 no 
ratio GPX1 Low, low risk 0.0174 14 0.02593 0.001296296 no 
ω-6 MPO High, low risk 0.0183 15 0.02778 0.001388889 no 
LA COMT rs4680 High, low risk 0.0183 16 0.02963 0.001481481 no 
ω-6 GSTP1 High, low risk 0.0197 17 0.03148 0.001574074 no 
DPA PPAR Low, high risk 0.0227 18 0.03333 0.001666667 no 
LA FASL High, low risk 0.024 19 0.03519 0.001759259 no 
ω-6 PTGS2 rs5275 High, high risk 0.0249 20 0.03704 0.001851852 no 
DPA GSTM1 High, high risk 0.0257 21 0.03889 0.001944444 no 
ω-6 COMT rs4680 High, low risk 0.0262 22 0.04074 0.002037037 no 
ratio FAS rs1800682 Low, high risk 0.0264 23 0.04259 0.00212963 no 
LA COMT rs4680 High, high risk 0.0301 24 0.04444 0.002222222 no 
LA FAS rs1800682 High, high risk 0.0303 25 0.0463 0.002314815 no 
DPA CAT Low, high risk 0.0329 26 0.04815 0.002407407 no 
ω-6 FASL High, low risk 0.0338 27 0.05 0.0025 no 
ratio COMT rs4680 High, high risk 0.0365 28 0.05185 0.002592593 no 
EPA PPAR Low, high risk 0.0376 29 0.0537 0.002685185 no 
PUFA GSTP1 High, low risk 0.0377 30 0.05556 0.002777778 no 
LA CYP17 High, high risk 0.0391 31 0.05741 0.00287037 no 
ω-6 COMT rs4680 High, high risk 0.04 32 0.05926 0.002962963 no 
ω-6 FAS rs1800682 High, high risk 0.0404 33 0.06111 0.003055556 no 
LA GSTP1 High, high risk 0.0432 34 0.06296 0.003148148 no 
DPA GSTM1 Low, high risk 0.0455 35 0.06481 0.003240741 no 
DPA PPAR High, high risk 0.0474 36 0.06667 0.003333333 no 
ratio GSTM1 High, high risk 0.0475 37 0.06852 0.003425926 no 
ALA CAT Low, high risk 0.0486 38 0.07037 0.003518519 no 
LA MnSOD High, low risk 0.0486 39 0.07222 0.003611111 no 
Note: 
a 
Weight = rank/540, where 540 represents the total number of comparisons for Aim 1b interactions 
b 
FDR p = weight*0.05 
c 
If p ≤ FDR p-value then “yes”, otherwise “no”  
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Table A.25 Multiple comparisons adjustment via FDR for statistically significant (p<0.05) 
additive interactions (RERI) for PUFA-gene interactions (Aim 1b) 
PUFA Gene p Rank Weight
a
 
FDR 
p value
b Significant
c
 
ω-6 GSTM1 0.0014 1 0.0056 0.000277778 no 
PUFA GSTM1 0.0015 2 0.0111 0.000555556 no 
LA GSTM1 0.0015 3 0.0167 0.000833333 no 
DHA CYP17 0.0107 4 0.0222 0.001111111 no 
DPA GSTM1 0.0247 5 0.0278 0.001388889 no 
DPA FAS rs2234767 0.0296 6 0.0333 0.001666667 no 
AA MPO 0.0340 7 0.0389 0.001944444 no 
ratio FASL 0.0425 8 0.0444 0.002222222 no 
DPA PPAR 0.0462 9 0.0500 0.0025 no 
DHA FAS rs2234767 0.0462 10 0.0556 0.002777778 no 
AA GSTP1 0.0476 11 0.0611 0.003055556 no 
Note: 
a 
Weight = rank/180, where 180 represents the total number of RERIs for Aim 1b 
b 
FDR p = weight*0.05 
c 
If p ≤ FDR p-value then “yes”, otherwise “no”  
 
 201 
Table A.26 Multiple comparisons adjustment via FDR for statistically significant (p<0.05) 
multivariate-adjusted associations (Aim 2a) 
PUFA/ 
Fish 
Comparison p Rank Weight
a
 
FDR 
p value
b Significant
c
 
Other fish Q3 vs never 0.0012 1 0.01754 0.00088 no 
DPA Q3 vs Q1 0.0023 2 0.03509 0.00175 no 
EPA Q3 vs Q1 0.007 3 0.05263 0.00263 no 
DHA Q4 vs Q1 0.0086 4 0.07018 0.00351 no 
Tuna Q4 vs never 0.0106 5 0.08772 0.00439 no 
DHA Q3 vs Q1 0.0141 6 0.10526 0.00526 no 
Other fish Q4 vs never 0.0289 7 0.12281 0.00614 no 
EPA Q4 vs Q1 0.0294 8 0.14035 0.00702 no 
Note: 
a 
Weight = rank/57, where 57 represents the total number of comparisons for Aim 2a 
b 
FDR p = weight*0.05 
c 
If p ≤ FDR p-value then “yes”, otherwise “no”  
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Table A.27 Multiple comparisons adjustment via FDR for statistically significant (p<0.05) 
gene associations according to a dominant model (Aim 2b) 
Gene p Rank Weight
a
 
FDR 
p value
b Significant
c
 
CAT 0.0035 1 0.0556 0.0028 no 
Note: 
a 
Weight = rank/18, where 18 represents the total number of comparisons for Aim 2b 
b 
FDR p = weight*0.05 
c 
If p ≤ FDR p-value then “yes”, otherwise “no”  
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Table A.28 Multiple comparisons adjustment via FDR for statistically significant (p<0.05) 
multivariate-adjusted associations for individual PUFA-gene interactions (Aim 2c) 
PUFA Gene Comparison p Rank Weight
a
 
FDR 
p-value
b Significant
c
 
LA GSTT1 High, low risk 0.0006 1 0.00185 9.25926E-05 no 
AA CAT High, high risk 0.0019 2 0.0037 0.000185185 no 
ω-6 CAT Low, high risk 0.0022 3 0.00556 0.000277778 no 
LA CAT Low, high risk 0.0025 4 0.00741 0.00037037 no 
ω-3 CAT High, high risk 0.0033 5 0.00926 0.000462963 no 
AA CAT Low, high risk 0.0033 6 0.01111 0.000555556 no 
EPA FAS rs2234767 Low, high risk 0.0046 7 0.01296 0.000648148 no 
DPA MnSOD Low, low risk 0.0061 8 0.01481 0.000740741 no 
LA GSTT1 High, high risk 0.0063 9 0.01667 0.000833333 no 
ω-6 CAT High, high risk 0.0064 10 0.01852 0.000925926 no 
ALA CAT High, high risk 0.0065 11 0.02037 0.001018519 no 
ratio CAT High, high risk 0.0066 12 0.02222 0.001111111 no 
EPA COMT rs4680 Low, high risk 0.0075 13 0.02407 0.001203704 no 
LA CAT High, high risk 0.0081 14 0.02593 0.001296296 no 
EPA FAS rs2234767 Low, low risk 0.0083 15 0.02778 0.001388889 no 
EPA FASL Low, high risk 0.0083 16 0.02963 0.001481481 no 
ALA CAT Low, high risk 0.0088 17 0.03148 0.001574074 no 
DHA FAS rs2234767 Low, high risk 0.0088 18 0.03333 0.001666667 no 
DHA COMT rs4680 Low, high risk 0.0096 19 0.03519 0.001759259 no 
DPA COMT rs4680 Low, high risk 0.0135 20 0.03704 0.001851852 no 
ω-3 CAT Low, high risk 0.014 21 0.03889 0.001944444 no 
DPA FAS rs2234767 Low, high risk 0.014 22 0.04074 0.002037037 no 
DPA PTGS2 rs20417 Low, low risk 0.0141 23 0.04259 0.00212963 no 
DHA FASL Low, high risk 0.0148 24 0.04444 0.002222222 no 
AA PTGS2 rs20417 Low, high risk 0.0151 25 0.0463 0.002314815 no 
DHA FAS rs2234767 Low, low risk 0.016 26 0.04815 0.002407407 no 
DPA MnSOD Low, high risk 0.0168 27 0.05 0.0025 no 
EPA MnSOD Low, high risk 0.0202 28 0.05185 0.002592593 no 
Note: 
a 
Weight = rank/540, where 540 represents the total number of comparisons for Aim 2c interactions 
b 
FDR p = weight*0.05 
c 
If p ≤ FDR p-value then “yes”, otherwise “no”  
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Table A.28 (cont.) Multiple comparisons adjustment via FDR for statistically significant 
(p<0.05) multivariate-adjusted associations for individual PUFA-gene interactions (Aim 2c) 
PUFA Gene Comparison p Rank Weight
a
 
FDR 
p-value
b Significant
c
 
DPA FASL Low,high risk 0.0221 29 0.0537 0.002685185 no 
ratio CAT Low,high risk 0.0223 30 0.05556 0.002777778 no 
DHA CAT Low, low risk 0.0227 31 0.05741 0.00287037 no 
EPA MPO Low, low risk 0.0248 32 0.05926 0.002962963 no 
ω-3 FAS rs2234767 High,high risk 0.0264 33 0.06111 0.003055556 no 
DPA CAT Low, low risk 0.0278 34 0.06296 0.003148148 no 
EPA PTGS2 rs20417 Low,high risk 0.0288 35 0.06481 0.003240741 no 
EPA MnSOD Low, low risk 0.0297 36 0.06667 0.003333333 no 
EPA GSTM1 Low,high risk 0.0299 37 0.06852 0.003425926 no 
EPA TNFa Low, low risk 0.0304 38 0.07037 0.003518519 no 
DHA GSTT1 Low, low risk 0.031 39 0.07222 0.003611111 no 
EPA GPX1 Low,high risk 0.0315 40 0.07407 0.003703704 no 
ω-3 PTGS2 rs20417 High,high risk 0.0337 41 0.07593 0.003796296 no 
EPA CAT Low, low risk 0.0346 42 0.07778 0.003888889 no 
DPA PTGS2 rs20417 Low,high risk 0.0365 43 0.07963 0.003981481 no 
DHA FAS rs2234767 High,high risk 0.0367 44 0.08148 0.004074074 no 
AA FAS rs2234767 Low,high risk 0.0368 45 0.08333 0.004166667 no 
PUFA CAT High,high risk 0.0375 46 0.08519 0.004259259 no 
EPA FAS rs2234767 High,high risk 0.0376 47 0.08704 0.004351852 no 
DPA PTGS2 rs5275 Low, low risk 0.0382 48 0.08889 0.004444444 no 
DHA GSTT1 Low,high risk 0.0397 49 0.09074 0.004537037 no 
EPA GSTT1 Low,high risk 0.0407 50 0.09259 0.00462963 no 
DPA FAS rs2234767 Low, low risk 0.0414 51 0.09444 0.004722222 no 
EPA GSTA1 Low, low risk 0.0471 52 0.0963 0.004814815 no 
AA GSTP1 Low, low risk 0.0488 53 0.09815 0.004907407 no 
DPA COMT rs737865 Low,high risk 0.0491 54 0.1 0.005 no 
Note: 
a 
Weight = rank/540, where 540 represents the total number of comparisons for Aim 2c interactions 
b 
FDR p = weight*0.05 
c 
If p ≤ FDR p-value then “yes”, otherwise “no”  
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Table A.29 Multiple comparisons adjustment via FDR for statistically significant (p<0.05) 
additive interactions (RERI) for PUFA-gene interactions (Aim 2c) 
PUFA Gene p Rank Weight
a
 
FDR 
p value
b Significant
c
 
PUFA PTGS2 rs20417 0.00755 1 0.00556 0.00028 no 
AA PTGS2 rs20417 0.03335 2 0.01111 0.00056 no 
AA GSTP1 0.03519 3 0.01667 0.00083 no 
DPA GSTM1 0.03848 4 0.02222 0.00111 no 
ratio TNFa 0.03859 5 0.02778 0.00139 no 
DHA COMT rs4680 0.04166 6 0.03333 0.00167 no 
Note: 
a 
Weight = rank/180, where 180 represents the total number of RERIs for Aim 2c 
b 
FDR p = weight*0.05 
c 
If p ≤ FDR p-value then “yes”, otherwise “no”  
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Table A.30 Age-adjusted ORs and 95% CIs for the potential association between PUFA and breast cancer incidence stratified by 
supplement use 
 
 
Co Ca OR Co Ca OR 95% CI Co Ca OR 95% CI Co Ca OR 95% CI
Yes 144 124 1.00 142 158 1.32 0.95, 1.84 121 133 1.34 0.95, 1.89 133 116 1.07 0.75, 1.51
No 86 96 1.00 102 106 0.99 0.66, 1.48 134 134 0.98 0.67, 1.43 128 129 1.02 0.69, 1.50
Yes 131 117 1.00 146 162 1.26 0.90, 1.76 138 140 1.16 0.82, 1.64 125 112 1.02 0.71, 1.46
No 95 103 1.00 104 110 0.97 0.66, 1.43 124 131 1.02 0.70, 1.48 127 121 0.94 0.65, 1.38
Yes 141 129 1.00 135 144 1.17 0.83, 1.63 134 147 1.22 0.87, 1.71 130 111 0.96 0.67, 1.35
No 87 89 1.00 106 119 1.12 0.75, 1.66 133 134 1.04 0.71, 1.53 124 123 1.04 0.70, 1.54
Yes 119 132 1.00 126 127 0.90 0.63, 1.28 147 127 0.79 0.56, 1.11 148 145 0.89 0.63, 1.24
No 115 123 1.00 126 108 0.79 0.55, 1.13 103 122 1.15 0.79, 1.66 106 112 1.04 0.72, 1.51
Yes 125 123 1.00 118 122 1.04 0.73, 1.49 145 125 0.88 0.62, 1.24 152 161 1.05 0.75, 1.46
No 114 133 1.00 134 110 0.71 0.50, 1.02 103 120 1.02 0.70, 1.47 99 102 0.89 0.61, 1.30
Yes 128 111 1.00 125 131 1.19 0.84, 1.70 129 133 1.19 0.84, 1.70 158 156 1.11 0.79, 1.56
No 115 125 1.00 122 111 0.79 0.55, 1.15 117 122 0.99 0.69, 1.42 96 107 1.03 0.71, 1.51
Yes 144 126 1.00 141 153 1.26 0.90, 1.76 126 140 1.33 0.95, 1.87 129 112 1.04 0.73, 1.47
No 85 97 1.00 104 97 0.87 0.58, 1.30 131 145 1.06 0.73, 1.55 130 126 0.96 0.65, 1.41
Yes 144 127 1.00 142 151 1.23 0.88, 1.71 124 141 1.35 0.96, 1.91 130 112 1.02 0.72, 1.45
No 85 97 1.00 104 96 0.86 0.57, 1.29 131 146 1.07 0.73, 1.57 130 126 0.96 0.65, 1.41
Yes 133 133 1.00 130 140 1.07 0.76, 1.50 141 147 1.04 0.74, 1.45 136 111 0.83 0.59, 1.18
No 118 110 1.00 107 120 1.27 0.88, 1.84 99 114 1.27 0.87, 1.86 126 121 1.10 0.76, 1.58
Yes 132 124 1.00 132 142 1.15 0.82, 1.62 135 119 0.90 0.63, 1.28 141 146 1.02 0.72, 1.44
No 117 128 1.00 116 125 0.99 0.69, 1.42 122 114 0.83 0.58, 1.20 95 98 0.88 0.60, 1.29
PUFA
Supplement 
use
Q1 Q2 Q3
PUFA
ω-3
ALA
DPA
DHA
EPA
ω-6
LA
AA
ω-3/ω-6
Q4 LRT 
p
0.49
0.79
0.81
0.77
0.93
0.25
0.21
0.44
0.49
0.50
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Table A.31 Age-adjusted ORs and 95% CIs for the potential association between PUFA and breast cancer incidence stratified by 
menopausal status 
 
 
 
Co Ca OR Co Ca OR 95% CI Co Ca OR 95% CI Co Ca OR 95% CI
Premenopausal 90 79 1.00 118 114 1.15 0.77, 1.72 136 130 1.13 0.76, 1.66 143 134 1.16 0.79, 1.71
Postmenopausal 274 252 1.00 239 271 1.26 0.99, 1.61 224 248 1.25 0.97, 1.60 216 206 1.08 0.84, 1.40
Premenopausal 98 80 1.00 114 125 1.35 0.91, 2.00 142 130 1.16 0.79, 1.70 133 122 1.17 0.79, 1.72
Postmenopausal 262 249 1.00 248 273 1.16 0.91, 1.48 217 238 1.17 0.90, 1.50 226 217 1.03 0.80, 1.33
Premenopausal 91 82 1.00 122 110 1.04 0.70, 1.55 134 140 1.22 0.83, 1.79 140 125 1.07 0.72, 1.57
Postmenopausal 267 241 1.00 240 275 1.27 0.99, 1.62 227 241 1.19 0.93, 1.53 219 220 1.13 0.87, 1.45
Premenopausal 111 110 1.00 129 97 0.75 0.51, 1.09 124 126 1.02 0.71, 1.46 124 123 1.00 0.70, 1.45
Postmenopausal 247 249 1.00 234 246 1.05 0.82, 1.35 233 243 1.05 0.82, 1.36 239 239 1.02 0.80, 1.32
Premenopausal 126 115 1.00 132 101 0.86 0.60, 1.24 128 128 1.09 0.76, 1.55 101 113 1.19 0.82, 1.72
Postmenopausal 228 249 1.00 227 231 0.90 0.70, 1.16 233 236 0.94 0.73, 1.21 265 261 0.94 0.73, 1.21
Premenopausal 131 116 1.00 118 95 0.93 0.64, 1.35 133 133 1.13 0.80, 1.60 105 113 1.19 0.82, 1.72
Postmenopausal 225 227 1.00 244 254 1.02 0.79, 1.32 227 228 1.01 0.78, 1.31 257 268 1.05 0.81, 1.35
Premenopausal 89 83 1.00 117 105 1.01 0.68, 1.51 139 138 1.10 0.75, 1.61 142 131 1.07 0.73, 1.58
Postmenopausal 275 253 1.00 239 263 1.22 0.96, 1.56 220 259 1.33 1.04, 1.71 219 202 1.05 0.81, 1.35
Premenopausal 88 83 1.00 117 104 0.99 0.66, 1.48 140 139 1.08 0.74, 1.59 142 131 1.06 0.72, 1.57
Postmenopausal 276 257 1.00 239 256 1.17 0.92, 1.50 219 261 1.33 1.04, 1.71 219 203 1.04 0.80, 1.34
Premenopausal 102 100 1.00 132 115 0.87 0.59, 1.26 113 117 1.04 0.71, 1.53 140 125 0.91 0.63, 1.32
Postmenopausal 255 259 1.00 227 258 1.12 0.88, 1.44 253 244 0.96 0.75, 1.22 218 216 1.00 0.78, 1.30
Premenopausal 133 126 1.00 134 143 1.15 0.82, 1.62 129 89 0.72 0.50, 1.04 91 99 1.09 0.74, 1.59
Postmenopausal 222 226 1.00 231 235 1.01 0.78, 1.31 230 251 1.05 0.81, 1.36 270 265 0.93 0.73, 1.20
0.47
0.08
0.41
0.53
0.72
0.65
0.66
Q4 LRT 
p
0.95
0.85
0.76
EPA
ω-6
LA
AA
ω-3/ω-6
PUFA
ω-3
ALA
DPA
DHA
PUFA Model
Q1 Q2 Q3
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Table A.32 Age-adjusted ORs and 95% CI for potential association between PUFA intake 
and breast cancer according to breast cancer tumor subtype 
PUFA 
 
Controls 
N 
 
ER+ or PR+ vs. 
all controls  
ER-/PR- vs. 
all controls 
  N OR 95% CI  N OR 95% CI 
PUFA 
Q1  375  185 1.00   42 1.00  
Q2  375  202 1.17 0.91, 1.49  57 1.35 0.89, 2.07 
Q3  375  193 1.13 0.88, 1.46  66 1.57 1.03, 2.38 
Q4  375  180 1.09 0.85, 1.41  40 0.95 0.60, 1.51 
ω-3 
Q1  375  168 1.00   42 1.00  
Q2  375  227 1.37 1.07, 1.75  57 1.36 0.89, 2.07 
Q3  375  189 1.19 0.92, 1.54  60 1.43 0.94, 2.17 
Q4  375  176 1.11 0.86, 1.44  46 1.09 0.70, 1.70 
ALA 
Q1  375  173 1.00   36 1.00  
Q2  375  207 1.22 0.95, 1.56  62 1.72 1.11, 2.66 
Q3  375  203 1.24 0.97, 1.60  59 1.64 1.06, 2.54 
Q4  375  177 1.09 0.84, 1.41  48 1.33 0.84, 2.11 
DPA 
Q1  375  188 1.00   61 1.00  
Q2  375  184 1.01 0.78, 1.29  47 0.77 0.51, 1.16 
Q3  375  184 1.02 0.79, 1.31  48 0.79 0.52, 1.18 
Q4  375  204 1.15 0.90, 1.47  49 0.80 0.54, 1.20 
DHA 
Q1  375  191 1.00   58 1.00  
Q2  375  179 0.94 0.73, 1.21  44 0.76 0.50, 1.15 
Q3  375  191 1.01 0.78, 1.29  57 0.98 0.66, 1.46 
Q4  375  199 1.03 0.80, 1.32  46 0.79 0.53, 1.20 
EPA 
Q1  375  181 1.00   60 1.00  
Q2  375  188 1.02 0.79, 1.31  41 0.68 0.45, 1.04 
Q3  375  181 1.01 0.78, 1.30  56 0.93 0.63, 1.38 
Q4  375  210 1.15 0.90, 1.47  48 0.80 0.53, 1.20 
ω-3 
Q1  375  189 1.00   42 1.00  
Q2  375  188 1.06 0.82, 1.36  55 1.31 0.85, 2.01 
Q3  375  206 1.20 0.93, 1.53  68 1.62 1.07, 2.45 
Q4  375  177 1.05 0.81, 1.35  40 0.95 0.60, 1.51 
LA 
Q1  375  191 1.00   42 1.00  
Q2  375  185 1.03 0.80, 1.33  55 1.31 0.85, 2.01 
Q3  375  207 1.19 0.93, 1.52  68 1.62 1.07, 2.45 
Q4  375  177 1.04 0.80, 1.34  40 0.95 0.60, 1.51 
AA 
Q1  375  188 1.00   51 1.00  
Q2  375  201 1.09 0.85, 1.39  57 1.12 0.74, 1.67 
Q3  375  189 1.03 0.80, 1.32  47 0.92 0.60, 1.40 
Q4  375  182 1.04 0.81, 1.33  50 0.98 0.64, 1.48 
ω3/ω6 
Q1  375  172 1.00   55 1.00  
Q2  375  218 1.30 1.02, 1.67  46 0.84 0.55, 1.27 
Q3  375  180 1.01 0.78, 1.30  49 0.89 0.59, 1.35 
Q4  375  190 1.01 0.79, 1.31  55 1.01 0.67, 1.51 
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Table A.33 Age-adjusted HRs and 95% CIs for the potential association between PUFA 
and all-cause mortality stratified by supplement use 
 
 
 
 
 
HR HR 95% CI HR 95% CI HR 95% CI
No 1.00 1.31 0.83, 2.07 1.17 0.75, 1.83 1.24 0.80, 1.92
Yes 1.00 1.08 0.69, 1.68 1.06 0.67, 1.69 1.48 0.94, 2.32
No 1.00 0.90 0.57, 1.42 1.11 0.72, 1.71 1.09 0.72, 1.65
Yes 1.00 1.28 0.82, 2.01 1.23 0.77, 1.95 1.22 0.75, 1.98
No 1.00 1.03 0.65, 1.61 1.24 0.80, 1.93 1.06 0.69, 1.64
Yes 1.00 1.23 0.78, 1.94 1.32 0.84, 2.07 1.31 0.81, 2.10
No 1.00 1.51 1.02, 2.24 0.64 0.39, 1.03 0.96 0.62, 1.50
Yes 1.00 0.63 0.41, 0.97 0.65 0.41, 1.01 0.68 0.44, 1.04
No 1.00 1.35 0.92, 1.99 0.75 0.48, 1.19 0.78 0.50, 1.24
Yes 1.00 0.64 0.41, 1.00 0.74 0.48, 1.14 0.57 0.37, 0.88
No 1.00 1.13 0.77, 1.67 0.64 0.41, 1.00 0.73 0.46, 1.14
Yes 1.00 0.68 0.43, 1.08 0.82 0.53, 1.26 0.69 0.45, 1.07
No 1.00 1.22 0.77, 1.95 1.28 0.82, 2.00 1.30 0.84, 2.01
Yes 1.00 1.13 0.72, 1.76 1.06 0.66, 1.70 1.60 1.02, 2.50
No 1.00 1.23 0.77, 1.95 1.28 0.82, 1.99 1.30 0.84, 2.01
Yes 1.00 1.22 0.78, 1.91 1.10 0.68, 1.77 1.67 1.07, 2.63
No 1.00 1.02 0.66, 1.59 0.95 0.61, 1.50 1.24 0.81, 1.89
Yes 1.00 1.04 0.67, 1.60 0.77 0.49, 1.21 0.95 0.60, 1.51
No 1.00 1.02 0.67, 1.54 1.00 0.66, 1.50 0.76 0.48, 1.21
Yes 1.00 0.63 0.40, 1.00 0.75 0.48, 1.17 0.60 0.38, 0.93
0.02
0.19
0.19
0.29
0.14
0.22
0.26
0.43
0.001
0.01
PUFA
Supplement 
Use
Q1 Q2 Q3 Q4 LRT 
p
PUFA
ω-3
ALA
DPA
DHA
ω-3/ω-6
EPA
ω-6
LA
AA
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Table A.34 Age-adjusted HRs and 95% CIs for the potential association between PUFA 
and all-cause mortality stratified by menopausal status 
 
 
 
HR HR 95% CI HR 95% CI HR 95% CI
Premenopausal 1.00 1.33 0.68, 2.60 1.52 0.80, 2.90 1.60 0.85, 3.00
Postmenopausal 1.00 1.12 0.86, 1.47 0.93 0.70, 1.24 1.20 0.90, 1.59
Premenopausal 1.00 1.56 0.78, 3.13 1.98 1.02, 3.87 1.97 1.01, 3.84
Postmenopausal 1.00 0.91 0.69, 1.19 1.03 0.78, 1.36 1.01 0.77, 1.34
Premenopausal 1.00 1.44 0.72, 2.89 2.06 1.09, 3.89 1.65 0.85, 3.19
Postmenopausal 1.00 1.16 0.89, 1.53 1.08 0.81, 1.44 1.17 0.88, 1.55
Premenopausal 1.00 1.14 0.64, 2.01 0.75 0.41, 1.37 1.27 0.74, 2.17
Postmenopausal 1.00 0.94 0.72, 1.22 0.69 0.52, 0.92 0.88 0.67, 1.17
Premenopausal 1.00 1.11 0.64, 1.94 0.79 0.45, 1.41 1.09 0.63, 1.88
Postmenopausal 1.00 0.90 0.69, 1.18 0.74 0.56, 0.99 0.70 0.53, 0.93
Premenopausal 1.00 1.18 0.67, 2.09 0.93 0.54, 1.63 1.14 0.65, 2.01
Postmenopausal 1.00 0.89 0.68, 1.16 0.70 0.52, 0.93 0.76 0.58, 1.01
Premenopausal 1.00 1.15 0.58, 2.28 1.51 0.80, 2.85 1.63 0.87, 3.05
Postmenopausal 1.00 1.11 0.85, 1.46 1.00 0.75, 1.33 1.26 0.95, 1.67
Premenopausal 1.00 1.16 0.59, 2.30 1.51 0.80, 2.85 1.62 0.86, 3.02
Postmenopausal 1.00 1.16 0.88, 1.51 1.00 0.75, 1.34 1.28 0.97, 1.70
Premenopausal 1.00 0.86 0.46, 1.62 1.17 0.65, 2.11 1.40 0.80, 2.45
Postmenopausal 1.00 1.07 0.81, 1.41 0.87 0.66, 1.17 1.18 0.89, 1.57
Premenopausal 1.00 1.06 0.63, 1.78 0.69 0.37, 1.30 1.27 0.74, 2.19
Postmenopausal 1.00 0.84 0.62, 1.13 1.00 0.76, 1.31 0.78 0.58, 1.03
ω-3/ω-6
EPA
ω-6
LA
AA
PUFA
ω-3
ALA
DPA
DHA
LRT 
p
PUFA Model
Q1 Q2 Q3 Q4
0.13
0.09
0.09
0.11
0.01
0.08
0.02
0.03
0.17
0.13
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Table A.35 Age-adjusted HRs and 95% CIs for the potential association between PUFA 
and all-cause mortality stratified by hormone therapy treatment 
 
 
HR HR 95% CI HR 95% CI HR 95% CI
No 1.00 0.96 0.52, 1.78 1.21 0.68, 2.17 1.23 0.66, 2.29
Yes 1.00 1.14 0.76, 1.70 0.99 0.65, 1.50 1.20 0.79, 1.81
No 1.00 0.89 0.48, 1.66 1.12 0.63, 1.99 1.08 0.60, 1.96
Yes 1.00 0.94 0.62, 1.42 1.10 0.74, 1.65 1.09 0.72, 1.65
No 1.00 0.86 0.47, 1.60 1.12 0.63, 2.02 1.03 0.56, 1.87
Yes 1.00 1.03 0.69, 1.55 1.12 0.74, 1.70 1.20 0.80, 1.80
No 1.00 1.15 0.65, 2.06 0.71 0.37, 1.35 0.88 0.48, 1.62
Yes 1.00 0.85 0.56, 1.29 0.66 0.44, 1.00 0.97 0.65, 1.45
No 1.00 0.79 0.43, 1.44 0.76 0.42, 1.37 0.66 0.36, 1.21
Yes 1.00 0.88 0.58, 1.32 0.79 0.52, 1.19 0.79 0.53, 1.18
No 1.00 0.81 0.44, 1.49 0.75 0.42, 1.34 0.66 0.36, 1.20
Yes 1.00 0.83 0.55, 1.25 0.69 0.46, 1.06 0.83 0.56, 1.23
No 1.00 1.12 0.60, 2.10 1.33 0.73, 2.41 1.43 0.76, 2.68
Yes 1.00 1.07 0.71, 1.62 1.10 0.74, 1.66 1.23 0.81, 1.86
No 1.00 1.24 0.66, 2.33 1.38 0.75, 2.53 1.53 0.81, 2.89
Yes 1.00 1.12 0.74, 1.68 1.11 0.74, 1.66 1.24 0.82, 1.87
No 1.00 1.00 0.58, 1.72 0.45 0.24, 0.87 0.93 0.51, 1.70
Yes 1.00 1.20 0.78, 1.84 1.07 0.70, 1.65 1.25 0.82, 1.92
No 1.00 0.60 0.32, 1.13 0.77 0.44, 1.35 0.54 0.31, 0.95
Yes 1.00 0.89 0.58, 1.35 0.92 0.61, 1.38 0.88 0.58, 1.34
0.40
0.69
0.63
0.02
0.14
0.34
0.87
0.54
0.20
0.64
PUFA
Hormone 
Therapy
Q1 Q2 Q3 Q4 LRT 
p
PUFA
ω-3
ALA
DPA
DHA
ω-3/ω-6
EPA
ω-6
LA
AA
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Table A.36 Age-adjusted HRs and 95% CIs for the potential association between PUFA 
and all-cause mortality stratified by chemotherapy treatment 
 
 
 
HR HR 95% CI HR 95% CI HR 95% CI
No 1.00 0.88 0.58, 1.34 0.89 0.58, 1.38 0.92 0.58, 1.44
Yes 1.00 1.58 0.91, 2.75 1.37 0.80, 2.33 1.64 0.95, 2.84
No 1.00 0.82 0.54, 1.24 0.86 0.56, 1.34 0.81 0.51, 1.28
Yes 1.00 1.10 0.62, 1.95 1.66 1.01, 2.74 1.54 0.92, 2.55
No 1.00 0.89 0.59, 1.36 0.91 0.58, 1.43 0.82 0.52, 1.30
Yes 1.00 1.20 0.69, 2.09 1.71 1.03, 2.83 1.59 0.96, 2.62
No 1.00 0.89 0.57, 1.37 0.58 0.37, 0.92 1.02 0.66, 1.56
Yes 1.00 0.99 0.60, 1.63 0.82 0.49, 1.36 0.94 0.57, 1.54
No 1.00 0.85 0.54, 1.31 0.87 0.56, 1.35 0.71 0.45, 1.11
Yes 1.00 0.80 0.48, 1.31 0.67 0.41, 1.11 0.79 0.49, 1.26
No 1.00 0.77 0.49, 1.19 0.64 0.41, 1.00 0.75 0.48, 1.17
Yes 1.00 0.87 0.52, 1.45 0.86 0.53, 1.41 0.78 0.48, 1.26
No 1.00 0.95 0.62, 1.46 0.95 0.61, 1.47 1.07 0.68, 1.67
Yes 1.00 1.40 0.80, 2.45 1.51 0.90, 2.55 1.56 0.90, 2.70
No 1.00 1.01 0.66, 1.53 0.93 0.59, 1.45 1.09 0.70, 1.70
Yes 1.00 1.49 0.85, 2.62 1.61 0.95, 2.73 1.62 0.93, 2.82
No 1.00 0.92 0.60, 1.43 0.65 0.41, 1.03 1.06 0.68, 1.65
Yes 1.00 1.30 0.79, 2.14 1.08 0.63, 1.83 1.23 0.73, 2.08
No 1.00 0.84 0.53, 1.34 0.91 0.59, 1.40 0.65 0.42, 1.02
Yes 1.00 0.73 0.45, 1.20 0.74 0.45, 1.22 1.04 0.65, 1.68
0.24
0.06
0.04
0.15
0.05
0.02
0.01
0.01
0.33
0.40
PUFA Chemo
Q1 Q2 Q3 Q4 LRT 
p
PUFA
ω-3
ALA
DPA
DHA
ω-3/ω-6
EPA
ω-6
LA
AA
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Table A.37 Age-adjusted HRs and 95% CIs for the potential association between PUFA 
and all-cause mortality stratified by radiation treatment 
 
 
HR HR 95% CI HR 95% CI HR 95% CI
No 1.00 0.89 0.52, 1.53 0.81 0.46, 1.43 1.32 0.79, 2.21
Yes 1.00 1.28 0.85, 1.93 1.26 0.84, 1.89 1.10 0.70, 1.72
No 1.00 0.68 0.39, 1.20 1.14 0.67, 1.93 1.13 0.68, 1.91
Yes 1.00 1.12 0.73, 1.71 1.16 0.77, 1.74 1.04 0.68, 1.61
No 1.00 0.80 0.47, 1.39 1.05 0.61, 1.81 1.16 0.69, 1.96
Yes 1.00 1.14 0.75, 1.74 1.26 0.83, 1.91 1.08 0.70, 1.66
No 1.00 1.14 0.67, 1.93 0.73 0.42, 1.27 0.95 0.56, 1.60
Yes 1.00 0.81 0.53, 1.23 0.65 0.42, 1.00 0.94 0.62, 1.43
No 1.00 1.01 0.59, 1.70 0.75 0.44, 1.28 0.75 0.44, 1.28
Yes 1.00 0.73 0.48, 1.12 0.79 0.52, 1.20 0.74 0.49, 1.12
No 1.00 1.06 0.64, 1.78 0.73 0.42, 1.27 0.74 0.43, 1.27
Yes 1.00 0.66 0.43, 1.01 0.69 0.46, 1.04 0.76 0.51, 1.14
No 1.00 0.90 0.51, 1.59 0.91 0.52, 1.59 1.41 0.84, 2.36
Yes 1.00 1.27 0.84, 1.92 1.37 0.91, 2.06 1.16 0.73, 1.82
No 1.00 0.98 0.56, 1.71 0.91 0.52, 1.59 1.44 0.86, 2.42
Yes 1.00 1.32 0.87, 2.01 1.40 0.93, 2.10 1.19 0.75, 1.88
No 1.00 1.22 0.70, 2.12 1.06 0.59, 1.91 1.19 0.67, 2.13
Yes 1.00 1.04 0.69, 1.56 0.73 0.47, 1.11 1.13 0.75, 1.72
No 1.00 0.71 0.41, 1.22 0.80 0.47, 1.36 0.91 0.55, 1.50
Yes 1.00 0.82 0.53, 1.26 0.81 0.54, 1.22 0.68 0.45, 1.04
ω-3/ω-6
EPA
ω-6
LA
AA
PUFA
ω-3
ALA
DPA
DHA
LRT 
p
PUFA Radiation 
Q1 Q2 Q3 Q4
0.09
0.05
0.05
0.25
0.18
0.04
0.08
0.19
0.26
0.24
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Table A.38 Models for adjusting for total energy intake 
Model Covariates Interpretation 
Age-adjusted only age Adding PUFAs to your current diet  
Model 1: 
Multivariate 
adjustment 
age 
total energy 
Substituting PUFAs for any other source 
of energy 
Model 2: 
Standard multivariate 
adjustment 
Set 1: 
age 
total energy 
protein 
carbohydrates 
Substituting PUFAs for any other fat or 
alcohol 
Set 2: 
age 
total energy 
protein 
carbohydrates 
alcohol 
Substituting PUFAs for any other fat 
Model 3: 
Standard multivariate 
adjustment 
Set 1: 
age 
total energy 
protein 
carbohydrates 
non-saturated fats 
Substituting PUFAs for saturated fats or 
alcohol 
Set 2: 
age 
total energy 
protein 
carbohydrates 
non-saturated fats 
alcohol 
Substituting PUFAs for saturated fats 
Model 4: 
Standard multivariate 
adjustment 
Set 1: 
age 
total energy 
protein 
carbohydrates 
saturated fats 
Substituting PUFAs for non-saturated fats 
or alcohol 
Set 2: 
age 
total energy 
protein 
carbohydrates 
saturated fats 
alcohol 
Substituting PUFAs for non-saturated fats 
Adapted from [387] 
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Table A.39 Comparison of different energy adjustment methods (no alcohol adjustment) 
for breast cancer incidence 
 
Interpretation: 
Age-adjusted: Adding PUFAs to your current diet 
Model 1: Substituting PUFAs for any other source of energy 
Model 2: Substituting PUFAs for any other fat or alcohol 
Model 3: Substituting PUFAs for saturated fats or alcohol 
Model 4: Substituting PUFAs for non-saturated fats or alcohol 
 
 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age-adjusted 1.00 1.20 0.98, 1.47 1.15 0.93, 1.41 1.05 0.85, 1.29
Model 1 1.00 1.25 1.01, 1.54 1.23 0.98, 1.54 1.20 0.92, 1.58
Model 2 1.00 1.25 1.01, 1.54 1.21 0.96, 1.53 1.15 0.85, 1.56
Model 3 1.00 1.25 1.01, 1.54 1.21 0.96, 1.53 1.15 0.85, 1.56
Model 4 1.00 1.25 1.01, 1.54 1.23 0.97, 1.55 1.19 0.87, 1.62
Age-adjusted 1.00 1.11 0.91, 1.37 1.23 1.00, 1.51 1.04 0.84, 1.28
Model 1 1.00 1.15 0.93, 1.42 1.31 1.05, 1.63 1.18 0.91, 1.55
Model 2 1.00 1.14 0.92, 1.41 1.29 1.03, 1.62 1.14 0.84, 1.55
Model 3 1.00 1.14 0.92, 1.41 1.29 1.03, 1.63 1.14 0.83, 1.57
Model 4 1.00 1.14 0.92, 1.41 1.29 1.02, 1.62 1.13 0.83, 1.53
ω-3
ω-6
Q4
PUFA Model
Q1 Q2 Q3
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Table A.40 Comparison of different energy adjustment methods (alcohol adjustment) for 
breast cancer incidence 
 
Interpretation: 
Age-adjusted: Adding PUFAs to your current diet 
Model 1: Substituting PUFAs for any other source of energy 
Model 2: Substituting PUFAs for any other fat 
Model 3: Substituting PUFAs for saturated fats 
Model 4: Substituting PUFAs for non-saturated fats 
 
 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age-adjusted 1.00 1.20 0.98, 1.47 1.15 0.93, 1.41 1.05 0.85, 1.29
Model 1 1.00 1.25 1.01, 1.55 1.24 0.99, 1.55 1.21 0.92, 1.58
Model 2 1.00 1.25 1.01, 1.54 1.22 0.97, 1.54 1.17 0.86, 1.59
Model 3 1.00 1.25 1.01, 1.54 1.22 0.97, 1.54 1.17 0.86, 1.59
Model 4 1.00 1.25 1.01, 1.54 1.23 0.97, 1.55 1.19 0.87, 1.63
Age-adjusted 1.00 1.11 0.91, 1.37 1.23 1.00, 1.51 1.03 0.84, 1.28
Model 1 1.00 1.15 0.94, 1.42 1.32 1.06, 1.64 1.19 0.91, 1.55
Model 2 1.00 1.15 0.93, 1.42 1.30 1.04, 1.64 1.16 0.85, 1.59
Model 3 1.00 1.15 0.93, 1.42 1.30 1.03, 1.64 1.15 0.83, 1.58
Model 4 1.00 1.14 0.93, 1.41 1.29 1.02, 1.63 1.13 0.82, 1.55
ω-3
ω-6
Q4
PUFA Model
Q1 Q2 Q3
 217 
Table A.41 Comparison of different energy adjustment methods (no alcohol adjustment) 
for breast cancer survival 
 
Interpretation: 
Age-adjusted: Adding PUFAs to your current diet 
Model 1: Substituting PUFAs for any other source of energy 
Model 2: Substituting PUFAs for any other fat or alcohol 
Model 3: Substituting PUFAs for saturated fats or alcohol 
Model 4: Substituting PUFAs for non-saturated fats or alcohol 
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Table A.42 Comparison of different energy adjustment methods (alcohol adjustment) for 
breast cancer survival 
 
Interpretation: 
Age-adjusted: Adding PUFAs to your current diet 
Model 1: Substituting PUFAs for any other source of energy 
Model 2: Substituting PUFAs for any other fat 
Model 3: Substituting PUFAs for saturated fats 
Model 4: Substituting PUFAs for non-saturated fats 
 
 
 
  
2
1
9
 
Table A.43 Sensitivity analyses examining PUFA adjustment for breast cancer incidence 
PUFA 
 
Covariates included in model: 
 Q1  Q2  Q3  Q4 
  OR  OR 95% CI  OR 95% CI  OR 95% CI 
ω-3 
 Age  1.00  1.20 0.98, 1.47  1.15 0.93, 1.41  1.05 0.85, 1.29 
 Age, energy  1.00  1.25 1.01, 1.54  1.23 0.98, 1.54  1.20 0.92, 1.58 
 Age, energy, ω-6  1.00  1.17 0.93, 1.48  1.08 0.82, 1.43  1.07 0.76, 1.50 
 Age, energy, LA, AA  1.00  1.17 0.92, 1.48  1.09 0.82, 1.45  1.07 0.75, 1.52 
 Age, energy, ω-6, LA, AA  1.00  1.17 0.92, 1.48  1.09 0.82, 1.45  1.07 0.75, 1.52 
ω-6 
 Age  1.00  1.11 0.91, 1.37  1.23 1.00, 1.51  1.04 0.84, 1.28 
 Age, energy  1.00  1.15 0.93, 1.42  1.31 1.05, 1.63  1.18 0.91, 1.55 
 Age, energy, ω-3  1.00  1.09 0.86, 1.38  1.25 0.96, 1.64  1.16 0.83, 1.63 
 Age, energy, ALA, DPA, DHA, EPA  1.00  1.05 0.82, 1.34  1.17 0.88, 1.56  1.07 0.75, 1.53 
 Age, energy, ω-3, ALA, DPA, DHA, EPA  1.00  1.05 0.82, 1.35  1.20 0.89, 1.60  1.11 0.78, 1.60 
 
 
 
  
2
2
0
 
Table A.44 Sensitivity analyses examining PUFA adjustment for breast cancer survival 
PUFA 
 
Covariates included in model: 
 Q1  Q2  Q3  Q4 
  HR  HR 95% CI  HR 95% CI  HR 95% CI 
ω-3 
 Age  1.00  0.97 0.75, 1.25  1.15 0.90, 1.48  1.14 0.89, 1.46 
 Age, energy  1.00  0.93 0.71, 1.21  1.07 0.82, 1.41  1.00 0.72, 1.38 
 Age, energy, ω-6  1.00  0.90 0.68, 1.20  1.01 0.73, 1.41  0.85 0.57, 1.28 
 Age, energy, LA, AA  1.00  0.90 0.67, 1.21  1.00 0.71, 1.41  0.83 0.55, 1.26 
 Age, energy, ω-6, LA, AA  1.00  0.92 0.68, 1.23  1.02 0.73, 1.45  0.85 0.56, 1.29 
ω-6 
 Age  1.00  0.97 0.75, 1.25  1.15 0.90, 1.48  1.14 0.89, 1.46 
 Age, energy  1.00  0.93 0.71, 1.21  1.07 0.82, 1.41  1.00 0.72, 1.38 
 Age, energy, ω-3  1.00  1.12 0.84, 1.49  1.06 0.76, 1.49  1.37 0.92, 2.04 
 Age, energy, ALA, DPA, DHA, EPA  1.00  1.02 0.75, 1.38  0.98 0.69, 1.38  1.26 0.83, 1.91 
 Age, energy, ω-3, ALA, DPA, DHA, EPA  1.00  1.02 0.75, 1.39  0.97 0.68, 1.39  1.23 0.80, 1.88 
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Table A.45 Power for PUFA/Fish intake & Incidence (Aim 1a)  
 
Exposure 
Detectable 
OR 
Power (%) for three different proportions of 
exposed controls 
0.25 0.33 0.50 
Total ω-3, Fish intake, or the 
PUFA ratio 
0.5 >99% >99% >99% 
0.6 >99% >99% >99% 
0.7 98% 99% >99% 
Total ω-6 
1.4 99% 99% >99% 
1.7 >99% >99% >99% 
2.0 >99% >99% >99% 
Note: 
n = 1481 cases and 1518 controls with FFQ data available  
 
Power presented for a range of: (1) exposure levels for PUFAs (based on considering intake 
categorized as quartiles (0.25), tertiles (0.33) or as a dichotomous variable (0.5); and (2) 
minimum ORs for ω-3 (0.5-0.7) and for ω-6 (1.4-2.0), which is consistent with previously 
published effect estimates [422]. 
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Table A.46 Power for PUFA-gene interactions & incidence (Aim 1b) 
Prevalence of exposure 
θ* = 2 
OR(x,y) = 
2.1 
θ = 3 
OR(x,y) = 
3.2 
θ = 0.5 
OR(x,y) = 
0.53 
θ = 0.3 
OR(x,y) = 
0.32 
Variant 
Genotype 
ω-3 or 
PUFA 
ratio 
Power Power Power Power 
0.10 
0.25 66% 98% 47% 84% 
0.33 73% 99% 56% 91% 
0.50 77% 99% 66% 97% 
0.25 
0.25 90% >99% 77% 99% 
0.33 94% >99% 86% >99% 
0.50 96% >99% 93% >99% 
0.40 
0.25 93% >99% 86% >99% 
0.33 96% >99% 93% >99% 
0.50 98% >99% 97% >99% 
Note: 
n = 1067 cases and 1110 controls with genotyping and PUFA estimates 
 
Power presented for a range of: (1) exposure levels for PUFAs (ω-3 fatty acids, or the ratio of 
ω-3 to ω-6 fatty acids), based on considering PUFAs categorized as quartiles (0.25), tertiles 
(0.33) or as a dichotomous variable (0.5); (2) genotype prevalence (= minor allele 
frequencies (MAF from 0.10 to 0.40)); and (3) plausible minimum detectable ORs for the 
joint effect of PUFAs and genotype (2.1 and 3.2, or 0.53 and 0.32) [344, 422]. 
 
*θ (departure from multiplicativity) = OR (x,y)/ [OR(x)*OR(y)], where OR(x)=the odds ratio 
for genotype relative to low risk exposure to factor y; OR(y)=the odds ratio for factor y 
relative to the low risk genotype; OR(x,y)=the hypothesized OR for persons with the high 
risk genotype and exposure.  
 
 223 
Table A.47 Power for PUFA/Fish intake & Survival (Aim 2a) 
All-cause mortality 
Exposure 
Detectable 
HR 
Power for 3 different proportions of exposed 
breast cancer cases 
0.25 0.33 0.50 
Total ω-3, fish or the 
PUFA ratio 
0.5 >99% >99% >99% 
0.6 95% 98% >99% 
0.7 75% 83% 89% 
Total ω-6 
1.4 88% 92% 94% 
1.7 >99% >99% >99% 
2.0 >99% >99% >99% 
Breast cancer-specific mortality 
Exposure 
Detectable 
HR 
Power for 3 different proportions of exposed 
breast cancer cases 
0.25 0.33 0.50 
Total ω-3, fish or the 
PUFA ratio 
0.5 89% 94% 97% 
0.6 70% 79% 86% 
0.7 45% 53% 60% 
Total ω-6 
1.4 60% 66% 69% 
1.7 96% 98% 98% 
2.0 >99% >99% >99% 
Note: 
n = 1481 cases with LIBCSP FFQ responses 
 
Power presented for a range of: (1) exposure levels for PUFA intake (based on considering 
intake categorized as quartiles (0.25), tertiles (0.33) or as a dichotomous variable (0.5); and 
(2) minimum detectable HR for ω-3 (0.5-0.7) and ω-6 (1.4-2.0) fatty acids.  We have 
assumed the outcome includes 436 overall deaths (199 breast cancer-specific deaths) over an 
average of 12.7 years of follow-up.  Power will be better than illustrated here when we 
consider PUFA intake as a continuous variable. 
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Table A.48 Power for Genotypes & Survival (Aim 2b) 
All-cause mortality 
Detectable 
HR 
 Power (%) for 3 different proportions of variant genotypes 
0.10 0.25 0.40 
2.0 >99% >99% >99% 
1.7 89% >99% >99% 
1.5 64% 90% 95% 
Breast cancer-specific mortality 
Detectable 
HR 
Power (%) for 3 different proportions of variant genotypes 
0.10 0.25 0.40 
2.0 89% 99% 99% 
1.7 63% 88% 93% 
1.5 38% 64% 72% 
Note: 
n= 1067 cases with LIBCSP with available DNA 
Power presented for a range of: (1) genotype prevalence (= minor allele frequencies (MAF 
from 0.10 to 0.40)); and (2) minimum detectable HR ranging from 1.3 - 2.0. We have 
assumed the outcome to include 314 overall deaths (144 breast cancer-specific deaths) over 
an average of 12.7 years of follow-up. 
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Table A.49 Age- and multivariate-adjusted ORs and 95% CI for the association between dietary fish intake (by various cooking 
methods) and breast cancer incidence 
 
Note: 
Multivariate ORs and 95% CI adjusted for matching factor (5-year age group), energy intake (kcal/day), and NSAID use (aspirin, 
acetaminophen, ibuprofen) 
Co=Controls, Ca=Cases 
 
Co Ca OR Co Ca OR 95% CI Co Ca OR 95% CI Co Ca OR 95% CI
Age-adjusted 1.00 0.94 0.76, 1.16 1.06 0.86, 1.30 1.09 0.80, 1.47
Multivariate 1.00 0.85 0.68, 1.05 1.00 0.80, 1.24 0.98 0.72, 1.35
Age-adjusted 1.00 0.93 0.76, 1.15 0.89 0.73, 1.08 0.96 0.69, 1.33
Multivariate 1.00 0.88 0.71, 1.09 0.86 0.70, 1.05 0.86 0.61, 1.22
Age-adjusted 1.00 1.01 0.81, 1.27 1.02 0.85, 1.22 0.95 0.75, 1.21
Multivariate 1.00 0.93 0.73, 1.17 0.91 0.76, 1.10 0.88 0.68, 1.12
Age-adjusted 1.00 1.17 0.94, 1.46 1.06 0.88, 1.26 1.17 0.92, 1.48
Multivariate 1.00 1.09 0.86, 1.37 0.98 0.81, 1.18 1.14 0.89, 1.47
Age-adjusted 1.00 0.79 0.52, 1.22 0.82 0.54, 1.24 1.02 0.56, 1.85
Multivariate 1.00 0.78 0.50, 1.21 0.75 0.49, 1.16 0.87 0.46, 1.67
Grilled/BBQ
Pan Fried
Broiled
Baked
Microwaved
Method Model
Never < 1 serving per month 1-3 servings per month > 1 per week
821 807
774 782
248 213
246 228
241 232
291 260
94 96
78
562 540
534 490
1235 1205
218 205
226 238
49 38
441 429
474 460
52 42 21 23
77
195 185
176 195
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Table A.50 Age- and multivariate-adjusted HRs and 95% CI for the association between dietary fish intake (by various cooking 
methods) and all-cause mortality 
 
Note: 
Multivariate HRs and 95% CI adjusted for age (5-year age group) and energy intake (kcal/day) 
Co=Cohort, D=deaths
D Co HR D Co HR 95% CI D Co HR 95% CI D Co HR 95% CI
Age-adjusted 1.00 0.76 0.56, 1.04 0.79 0.59, 1.05 0.82 0.55, 1.22
Multivariate 1.00 0.76 0.56, 1.04 0.78 0.58, 1.04 0.80 0.53, 1.19
Age-adjusted 1.00 1.01 0.77, 1.33 1.27 1.00, 1.61 1.10 0.74, 1.63
Multivariate 1.00 1.01 0.77, 1.32 1.24 0.98, 1.57 1.07 0.72, 1.59
Age-adjusted 1.00 1.00 0.75, 1.33 0.79 0.63, 0.99 0.77 0.58, 1.03
Multivariate 1.00 1.00 0.75, 1.32 0.79 0.63, 0.99 0.75 0.56, 1.01
Age-adjusted 1.00 0.95 0.72, 1.25 0.93 0.75, 1.17 1.06 0.80, 1.39
Multivariate 1.00 0.94 0.71, 1.24 0.93 0.74, 1.16 1.04 0.79, 1.37
Age-adjusted 1.00 0.84 0.45, 1.56 0.74 0.41, 1.35 0.79 0.39, 1.60
Multivariate 1.00 0.85 0.45, 1.59 0.74 0.41, 1.35 0.78 0.39, 1.57
8 15
50
59 126
74 121
123 306
145 315
11 31
65 140
71 167
10 28
191 349
162 328
399 806
> 1 per week
300 507
248 534
49 164
65 163
57 175
96 164
26 70
27
Method Model
Never < 1 serving per month 1-3 servings per month
Grilled/BBQ
Pan Fried
Broiled
Baked
Microwaved
  
2
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Figure A.1 Dose-response between total PUFA intake (g/day) and the age-adjusted log-odds of breast cancer in the LIBCSP 
 
 
 
Note: Line represents women 54-59 years old 
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Figure A.2 Dose-response between total ω-3 intake (g/day) and the age-adjusted log-odds of breast cancer in the LIBCSP 
 
 
 
Note: Line represents women 54-59 years old 
 
 
 
  
2
2
9
 
Figure A.3 Dose-response between total ω-6 intake (g/day) and the age-adjusted log-odds of breast cancer in the LIBCSP 
 
 
 
Note: Line represents women 54-59 years old 
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Figure A.4 Kaplan-Meier Survival curves for total PUFA, total ω-3, total ω-6, and ω-3/ω-
6 intake (quartiles) and all-cause mortality  
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Figure A.5 Kaplan-Meier Survival curves for ALA, DPA, DHA, and EPA intake 
(quartiles) and all-cause mortality  
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Figure A.6 Kaplan-Meier Survival curves for LA and AA intake (quartiles) and all-cause 
mortality  
 
 
 
LA 
AA 
  
2
3
3
 
Figure A.7 Dose-response between total PUFA intake (g/day) and the age-adjusted difference in log-hazards of all-cause mortality 
among women with breast cancer in the LIBCSP 
 
 
 
Note: Line represents women 54-59 years old 
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Figure A.8 Dose-response between total ω-3 intake (g/day) and the age-adjusted difference in log-hazards of all-cause mortality 
among women with breast cancer in the LIBCSP 
 
 
 
Note: Line represents women 54-59 years old 
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Figure A.9 Dose-response between total ω-6 intake (g/day) and the age-adjusted difference in log-hazards of all-cause mortality 
among women with breast cancer in the LIBCSP 
 
 
 
Note: Line represents women 54-59 years old 
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